11/17/99

```
=> d his

     (FILE 'HOME' ENTERED AT 07:56:44 ON 18 NOV 1999)

     FILE 'REGISTRY' ENTERED AT 07:58:07 ON 18 NOV 1999
                E AL-OBEIDI F.      0
                E SAFAR P           0
                E LEBL M            0
                E OSTREM            0
                E STIERANDOVA       0
                E STROP P           0
                E WALSER A          0

     FILE 'USPATFULL' ENTERED AT 08:06:07 ON 18 NOV 1999
L1             0 S FACATOR (3A) "XA" (3A) INHIBITOR
L2             0 S TRP-CHG-ARG-LEU PRO
```

(7 last space

```
FILE 'HOME' ENTERED AT 16:01:32 ON 08 NOV 2002

=> index chemistry pharmacology bioscience patents polymers
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA,
       CADLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI,
       COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK,
       INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 16:02:03 ON 08 NOV 2002

108 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (Xa (s)(inhibitor or inhibition)) and peptide and arginine
           1   FILE AGRICOLA
           3   FILE BABS
          14   FILE BIOTECHNO
           1   FILE CABA
          37   FILE CAPLUS
           1   FILE CEN
           0*  FILE FEDRIP
  26 FILES SEARCHED...
           1   FILE INVESTEXT
           3   FILE JICST-EPLUS
           9   FILE PASCAL
           1   FILE PROMT
          33   FILE SCISEARCH
           1   FILE ADISALERTS
  46 FILES SEARCHED...
           2   FILE BIOBUSINESS
          21   FILE BIOSIS
           3   FILE CANCERLIT
           6   FILE DDFU
          20   FILE DRUGU
  61 FILES SEARCHED...
          25   FILE EMBASE
           7   FILE ESBIOBASE
           5   FILE IFIPAT
           4   FILE LIFESCI
          29   FILE MEDLINE
           1   FILE PHIN
           1   FILE SYNTHLINE
           3   FILE TOXCENTER
         614   FILE USPATFULL
          14   FILE USPAT2
           1   FILE AQUASCI
           1   FILE BIOTECHABS
           1   FILE BIOTECHDS
  79 FILES SEARCHED...
           1   FILE VETU
           1   FILE WPIDS
           1   FILE WPINDEX
           0*  FILE CASREACT
  93 FILES SEARCHED...
          49   FILE EUROPATFULL
         347   FILE PCTFULL

  36 FILES HAVE ONE OR MORE ANSWERS,  109 FILES SEARCHED IN STNINDEX

L1    QUE (XA (S)(INHIBITOR OR INHIBITION)) AND PEPTIDE AND ARGININE
```

=> file hits
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.24	4.45

FILE 'USPATFULL' ENTERED AT 16:06:37 ON 08 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Univentio

FILE 'EUROPATFULL' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 WILA Verlag Muenchen (WILA)

FILE 'CAPLUS' ENTERED AT 16:06:37 ON 08 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:06:37 ON 08 NOV 2002

FILE 'EMBASE' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'BIOSIS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'DRUGU' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'USPAT2' ENTERED AT 16:06:37 ON 08 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 16:06:37 ON 08 NOV 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 ACS

FILE 'ESBIOBASE' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'IFIPAT' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

```
FILE 'BABS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
Licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'JICST-EPLUS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'CANCERLIT' ENTERED AT 16:06:37 ON 08 NOV 2002

FILE 'BIOBUSINESS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'CASREACT' ENTERED AT 16:06:37 ON 08 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 NOV 2002

FILE 'CABA' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CEN' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'INVESTEXT' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'PROMT' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PHIN' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SYNTHLINE' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 Prous Science

FILE 'AQUASCI' ENTERED AT 16:06:37 ON 08 NOV 2002
(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'VETU' ENTERED AT 16:06:37 ON 08 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

=> s l1
L2          614 FILE USPATFULL
L3          367 FILE PCTFULL
L4           80 FILE EUROPATFULL
L5           37 FILE CAPLUS
L6           29 FILE MEDLINE
L7           25 FILE EMBASE
L8           23 FILE STNGUIDE
L9           21 FILE BIOSIS
L10          20 FILE DRUGU
L11          14 FILE BIOTECHNO
L12          14 FILE USPAT2
L13           9 FILE PASCAL
L14           9 FILE TOXCENTER
```

```
L15             7 FILE ESBIOBASE
L16             8 FILE IFIPAT
L17             8 FILE WPIDS
L18             4 FILE LIFESCI
L19             3 FILE BABS
L20             3 FILE JICST-EPLUS
L21             3 FILE CANCERLIT
L22             2 FILE BIOBUSINESS
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'XA (S)(INHIBITOR'
L23             2 FILE CASREACT
L24             1 FILE AGRICOLA
L25             1 FILE CABA
L26             1 FILE CEN
L27             1 FILE INVESTEXT
L28             1 FILE PROMT
L29             1 FILE ADISALERTS
L30             1 FILE PHIN
L31             1 FILE SYNTHLINE
L32             1 FILE AQUASCI
L33             1 FILE BIOTECHDS
L34             1 FILE VETU

TOTAL FOR ALL FILES
L35          1306 L1

=> s l35 and (selectivity or specificity) and analogue#
L36            98 FILE USPATFULL
L37            81 FILE PCTFULL
L38            17 FILE EUROPATFULL
L39             0 FILE CAPLUS
L40             1 FILE MEDLINE
L41             1 FILE EMBASE
L42             2 FILE SCISEARCH
L43             2 FILE BIOSIS
L44             0 FILE DRUGU
L45             0 FILE BIOTECHNO
L46             1 FILE USPAT2
L47             1 FILE PASCAL
L48             0 FILE TOXCENTER
L49             1 FILE ESBIOBASE
L50             0 FILE IFIPAT
L51             0 FILE WPIDS
L52             1 FILE LIFESCI
L53             0 FILE BABS
L54             0 FILE JICST-EPLUS
L55             0 FILE CANCERLIT
L56             0 FILE BIOBUSINESS
L57             0 FILE CASREACT
L58             0 FILE AGRICOLA
L59             0 FILE CABA
L60             0 FILE CEN
L61             0 FILE INVESTEXT
L62             0 FILE PROMT
L63             1 FILE ADISALERTS
L64             0 FILE PHIN
L65             0 FILE SYNTHLINE
L66             0 FILE AQUASCI
L67             0 FILE BIOTECHDS
L68             0 FILE VETU

TOTAL FOR ALL FILES
L69           207 L35 AND (SELECTIVITY OR SPECIFICITY) AND ANALOGUE#

=> s L69 factor (w) Xa
```

```
MISSING OPERATOR 'L69  FACTOR'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L69 and (factor (w  Xa
L70          96 FILE USPATFULL
L71          71 FILE PCTFULL
L72          17 FILE EUROPATFULL
L73           6 FILE CAPLUS
L74           1 FILE MEDLINE
L75           1 FILE EMBASE
L76           2 FILE SCISEARCH
L77           2 FILE BIOSIS
L78           0 FILE DRUGU
L79           0 FILE BIOTECHNO
L80           1 FILE USPAT2
L81           1 FILE PASCAL
L82           0 FILE TOXCENTER
L83           1 FILE ESBIOBASE
L84           0 FILE IFIPAT
L85           0 FILE WPIDS
L86           1 FILE LIFESCI
L87           0 FILE BARS
L88           0 FILE JICST-EPLUS
L89           0 FILE CANCERLIT
L90           0 FILE BIOBUSINESS
L91           0 FILE CASREACT
L92           0 FILE AGRICOLA
L93           0 FILE CABA
L94           0 FILE CEN
L95           0 FILE INVESTEXT
L96           0 FILE PROMT
L97           1 FILE ADISALERTS
L98           0 FILE PHIN
L99           0 FILE SYNTHLINE
L100          0 FILE AQUASCI
L101          0 FILE BIOTECHDS
L102          0 FILE VETU

TOTAL FOR ALL FILES
L103        195 L69 AND (FACTOR (W) XA)

=> dup rem l103
DUPLICATE IS NOT AVAILABLE IN 'INVESTEXT, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L103
L104         189 DUP REM L103 (6 DUPLICATES REMOVED)

=> d l104 1-189 ibib abs

L104 ANSWER 1 OF 189  USPATFULL
ACCESSION NUMBER:         2003:272301  USPATFULL
TITLE:                    Compositions and methods for the therapy and diagnosis
                          of colon cancer
INVENTOR(S):              Stolk, John A., Bothell, WA, UNITED STATES
                          Xu, Jiangchun, Bellevue, WA, UNITED STATES
                          Chenault, Ruth A., Seattle, WA, UNITED STATES
                          Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S):       Corixa Corporation, Seattle, WA, UNITED STATES, 98104
                          (U.S. corporation)

                               NUMBER         KIND     DATE
                          --- ------------- ------ --------
PATENT INFORMATION:       US 2002150922      A1    20021017
APPLICATION INFO.:        US 2001-998599     A1    20011116  (9)
```

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267911P	20 10206 (60)
	US 2000-252022P	20001120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 9239

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L104 ANSWER 2 OF 189 USPATFULL
ACCESSION NUMBER: 2002:272761 USPATFULL
TITLE: Directed evolution of novel binding proteins
INVENTOR(S): Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150881	A1	20021017
APPLICATION INFO.:	US 2001-781988	A1	20010214 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED Continuation of Ser. No. US 1995-415902, filed on 3 Apr 1995, PATENTED Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1998-US3731	19980301

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC, 20001
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 19646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage genetic package, are introduced into a genetic

package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 3 OF 189 USPATFULL
ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 4 OF 189 USPATFULL
ACCESSION NUMBER: 2002:242791 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer
INVENTOR(S): Ping, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Jacrist, Heather, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 20020131971 A1 20020919
APPLICATION INFO.: US 2001-839529 A1 20011228 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-920800, filed on 31 Jul 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-301281P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223293P	20000803 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 5083
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 5 OF 189 USPATFULL
ACCESSION NUMBER: 2002:221957 USPATFULL
TITLE: Use of dendroaspin as a scaffold for non-dendroaspin domains
INVENTOR(S): Lu, Xinjie, London, UNITED KINGDOM
Kakkar, Vijay Vir, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020120102	A1	20020829
APPLICATION INFO.:	US 2001-773054	A1	20010205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-2625	20000205

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP, Suite 3400, Four Embarcadero Center, San Francisco, CA, 94111-4187
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of dendroaspin as a scaffold for one or more non-wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-binding amino acid sequence other than RGD which contains aspartic acid (D) or glutamic acid (E).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 6 OF 189 USPATFULL
ACCESSION NUMBER: 2002:221918 USPATFULL
TITLE: Antibody conjugate formulations for selectively

Inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents,The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020119153	A1	20020829
APPLICATION INFO.:	US 2001-998831	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-561109, filed on 28 Apr 2000, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shelley P.M. Fussey, WILLIAMS, MORGAN & AMERSON, P.C., Suite 250, 7676 Hillmont, Houston, TX, 77040
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 10502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 7 OF 139 USPATFULL
ACCESSION NUMBER: 2002:231099 USPATFULL
TITLE: Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
INVENTOR(S): Hanson, Stephen R., Stone Mountain, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020119144	A1	20020829
APPLICATION INFO.:	US 2002-117837	A1	20020408 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-666224, filed on 21 Sep 2000, GRANTED, Pat. No. US 6376242		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-154929P	19990921 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
LINE COUNT: 262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations

comprising such agents are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 8 OF 189 USPATFULL
ACCESSION NUMBER: 2003:236239 USPATFULL
TITLE: Arrays of proteins and methods of use thereof
INVENTOR(S): Wagner, Peter, Belmont, CA, UNITED STATES
Ault-Riche, Dana, Palo Alto, CA, UNITED STATES
Nock, Steffen, Redwood City, CA, UNITED STATES
Itin, Christian, Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003110933	A1	20030815
APPLICATION INFO.:	US 2003-113964	A1	20030329 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-353215, filed on 14 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-115455, filed on 14 Jul 1998, GRANTED, Pat. No. US 6406921
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Cyomyx, 36101 Research Road, Hayward, CA, 94545
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Protein arrays for the parallel, in vitro screening of biomolecular activity are provided. Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different proteins, such as different members of a single protein family, are immobilized on one or more organic thinfilms on the substrate surface. The protein arrays are particularly useful in drug development, proteomics, and clinical diagnostics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 9 OF 189 USPATFULL
ACCESSION NUMBER: 2002:195971 USPATFULL
TITLE: Pharmaceutical combinations
INVENTOR(S): Brearley, Christopher John, Sandwich, UNITED KINGDOM
Butler, Paul, Sandwich, UNITED KINGDOM
Chahwala, Suresh Babubhai, Sandwich, UNITED KINGDOM
Chopp, Michael, Sandwich, UNITED KINGDOM
Krams, Michael, Sandwich, UNITED KINGDOM
Looby, Michael, Sandwich, UNITED KINGDOM
MacIntyre, Fiona, Sandwich, UNITED KINGDOM
McElroy, Andrew Brian, Sandwich, UNITED KINGDOM
McHarg, Aileen Dorothy, Sandwich, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048179	A1	20020725
APPLICATION INFO.:	US 2001-969271	A1	20011001 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-25479	20001017
	US 2000-253847P	20001129 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pfizer Inc., 20th Floor, 235 East 42nd Street, New York, NY, 10017-5703
NUMBER OF CLAIMS: 49

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 9819
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates, inter alia, to methods of treating pathophysiological conditions involving neutrophils, comprising administering to a patient in need of such treatment a combination therapy comprising at least one Neutrophil Inhibitory Factor (NIF) and at least one other agent that protects neurons from toxic insult, inhibits the inflammatory reaction after brain damage or promotes cerebral reperfusion (i.e. neuroprotective or thrombolytic/fibrinolytic agents), or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 10 OF 189 USPATFULL
ACCESSION NUMBER: 2002:171946 USPATFULL
TITLE: Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020090695	A1	20020711
APPLICATION INFO.:	US 2001-958718	A1	20010517 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US31917, filed on 21 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-166751P	19991122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 12006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human KTPI polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KTPI polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human KTPI polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 11 OF 189 USPATFULL
ACCESSION NUMBER: 2002:37526 USPATFULL
TITLE: Profiling of protease **specificity** using combinatorial fluorogenic substrate libraries
INVENTOR(S): Harris, Jennifer L., San Diego, CA, UNITED STATES
Backes, Bradley J., San Diego, CA, UNITED STATES
Ellman, Jonathan A., Oakland, CA, UNITED STATES
Craik, Charles S., San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020022243	A1	20020221
APPLICATION INFO.:	US 2001-866132	A1	20010525 (9)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2000-189274P	20000602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2990	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is presented for the preparation and use of fluorogenic **peptide** substrates that allows for the configuration of general substrate libraries to rapidly identify the primary and extended **specificity** of enzymes, such as proteases. The substrates contain a fluorogenic-leaving group, such as 7-amino-4-carbamoylmethyl-coumarin (ACC). Substrates incorporating the ACC leaving group show comparable kinetic profiles as those with the traditionally used 7-amino-4-methyl-coumarin (AMC) leaving group. The bifunctional nature of ACC allows for the efficient production of single substrates and substrate libraries using solid-phase synthesis techniques. The approximately 3-fold increased quantum yield of ACC over AMC permits reduction in enzyme and substrate concentrations. As a consequence, a greater number of substrates can be tolerated in a single assay, thus enabling an increase in the diversity space of the library. Soluble positional protease substrate libraries of 137,180 and 6,859 members, possessing amino acid diversity at the P4-P3-P2-P1 and P4-P3-P2 positions, respectively, were constructed. Employing this screening method the substrate **specificities** of a diverse array of proteases were profiled, including the serine proteases thrombin, plasmin, **factor Xa**, uPA, tPA, granzyme B, trypsin, chymotrypsin, human neutrophil elastase, and the cysteine proteases papain and cruzain. The resulting profiles create a pharmacophoric portrayal of the proteases allowing for the design of selective substrates and potent **inhibitors**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 12 OF 189 USPATFULL

ACCESSION NUMBER:	2002:32572 USPATFULL		
TITLE:	Bicyclic sulfonyl amino **inhibitors** of **factor Xa**		
INVENTOR(S):	Li, Wenhao, South San Francisco, CA, UNITED STATES Marlowe, Charles K., Redwood City, CA, UNITED STATES Scarborough, Robert M., Half Moon Bay, CA, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019394	A1	20020214
APPLICATION INFO.:	US 2001-816781	A1	20010326 (9)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-191715P	20000324 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON, DC, 20036-5869		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1514		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of formulae I or Ia: ##STR1##

including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian **factor Xa** is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 13 OF 189 USPATFULL
ACCESSION NUMBER: 2002:290789 USPATFULL
TITLE: Arrays of proteins and methods of use thereof
INVENTOR(S): Wagner, Peter, Belmont, CA, United States
Ault-Riche, Dana, Palo Alto, CA, United States
Nock, Steffen, Redwood City, CA, United States
Itin, Christian, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Cyomyx, Incorporated, Hayward, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475808	B1	20021105
APPLICATION INFO.:	US 1999-353215		19990714 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-115455, filed on 14 Jul 1998		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chin, Christopher L.
LEGAL REPRESENTATIVE: Hager, Alicia J., Heinkel, Gregory L.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 3339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Protein arrays for the parallel, in vitro screening of biomolecular activity are provided. Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different proteins, such as different members of a single protein family, are immobilized on one or more organic thinfilms on the substrate surface. The protein arrays are particularly useful in drug development, proteomics, and clinical diagnostics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 14 OF 189 USPATFULL
ACCESSION NUMBER: 2002:283394 USPATFULL
TITLE: N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
INVENTOR(S): Klingler, Otmar, Rodgau, GERMANY, FEDERAL REPUBLIC OF
Zoller, Gerhard, Schoneck, GERMANY, FEDERAL REPUBLIC OF
Defossa, Elisabeth, Idstein, GERMANY, FEDERAL REPUBLIC OF
Al-Obeidi, Fahad A., Tucson, AZ, United States
Walser, Armin, Tucson, AZ, United States
Ostrem, James, Tucson, AZ, United States
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6472562	B1	20021029
APPLICATION INFO.:	US 2000-697188		20001027 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-19951715	19991027

PRIORITY INFORMATION: EP 1999-121623 19991030
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kumar, Shailendra
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2134
AB The present invention relates to compounds of the formula I, ##STR1##

in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible **inhibitors** of the blood clotting enzymes **factor Xa** and/or factor VIIa and can in general be applied in conditions in which an undesired activity of **factor Xa** and/or factor VIIa is present or for the cure or prevention of conditions in which an **inhibition** of **factor Xa** and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

L104 ANSWER 15 OF 189 USPATFULL
ACCESSION NUMBER: 2002:167884 USPATFULL
TITLE: Antibody conjugate kits for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6416758	B1	20020709
APPLICATION INFO.:	US 2000-561526		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 10439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR1) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 16 OF 189 USPATFULL
ACCESSION NUMBER: 2002:144294 USPATFULL

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6417131	B1	20020618
APPLICATION INFO.:	US 1999-453608		19991203 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998 Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now patented, Pat. No. US 5916910		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Reiter, Stephen E., Foley & Lardner
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 17 OF 189 USPATFULL
ACCESSION NUMBER: 2002:143940 USPATFULL
TITLE: Cancer treatment methods using antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Pan, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406693	B1	20020618
APPLICATION INFO.:	US 1999-351543		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110608P	19981202 (60)
	US 1998-92672P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ansari, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure s.; 8 Drawing Page s.

LINE COUNT: 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 18 OF 189 USPATFULL
ACCESSION NUMBER: 2002:89262 USPATFULL
TITLE: Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
INVENTOR(S): Hanson, Stephen R., Stone Mountain, GA, United States
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6376242	B1	20020423	
APPLICATION INFO.:	US 2000-666224		20000921	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-154929P	19990921 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Davis, Ruth A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 19 OF 189 USPATFULL
ACCESSION NUMBER: 2002:91487 USPATFULL
TITLE: .beta.-sheet mimetics and methods relating to the use thereof
INVENTOR(S): Qabar, Maher N., Redmond, WA, United States
McMillan, Michael K., Bellevue, WA, United States
Hahn, Michael F., Kirkland, WA, United States
Tulinsky, John E., Seattle, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Mathew, Cessymol, Bellevue, WA, United States
PATENT ASSIGNEE(S): Mil-pumetics Ltd., Bellevue, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 6372744	B1	20020416
APPLICATION INFO.:	US 2000-501052		20000209 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-22934, filed on 12 Feb 1998, now patented, Pat. No. US 6117996 Continuation-in-part of Ser. No. US 1997-797915, filed on 12 Feb 1997, now abandoned Continuation-in-part of Ser. No. US 682420, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47067P	19970519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 4223
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB .beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 20 OF 189 USPATFULL
ACCESSION NUMBER: 2001:19060 USPATFULL
TITLE: Antibody conjugate compositions for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342221	B1	20020129
APPLICATION INFO.:	US 2000-561108		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 11442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous

immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 21 OF 189 USPATFULL
ACCESSION NUMBER: 2002:19058 USPATFULL
TITLE: Antibody compositions for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6343218	B1	20020129
APPLICATION INFO.:	US 2000-561500		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 20
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 10403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 22 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002077267 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): NUCLEIC ACID MOLECULES ENCODING A TRANSMEMBRAN SERINE PROTEASE 9, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON
TITLE (FRENCH): MOLECULES D'ACIDE NUCLEIQUE CODANT UNE SERINE PROTEASE TRANSMEMBRANAIRE 9, POLYPEPTIDES CODES ET PROCEDES FONDES SUR CES DERNIERS
INVENTOR(S): MADISON, Edwin, L.; ONG, Edgar, O.
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., for all designates States except US; MADISON, Edwin, L., for US only; ONG, Edgar, O., for US only
AGENT: SEIDMAN, Stephanie, L.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002077267	A2	20021003
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD		

MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH
GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN
TD TG

APPLICATION INFO.: WO 2000-US9611 A 20000407
PRIORITY INFO.: US 1999-60/128,279,2 19990407
US 1999-60/128,291,2 19990407

ABEN Provided herein are type II transmembrane serine protease 9 (MTSP9) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domains are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP9 are provided.

ABFR La presente invention concerne des polypeptides de serines proteases transmembranaires 9 (MTSP9), les formes zymogenes et activees de ces polypeptides ainsi que les formes monocatenaires et bicatenaires du domaine protease. Des procedes d'utilisation de ces polypeptides pour identifier des composes qui modulent l'activite protease d'une MTSP9 sont egalement presentees.

L104 ANSWER 23 OF 189 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2000077263 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): NUCLEIC ACID MOLECULES ENCODING SERINE PROTEASE CVSP14, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON
TITLE (FRENCH): MOLECULES D'ACIDE NUCLEIQUE CODANT LA SERINE PROTEASE CVSP14, POLYPEPTIDES CODES ET PROCEDES
INVENTOR(S): MADISON, Edwin, L.; YEH, Jiunn Chern
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., for all designates States except US; MADISON, Edwin, L., for US only; YEH, Jiunn-Chern, for US only
AGENT: SEIDMAN, Stephanie, L.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000077263	A2	20001003

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US9089 A 20000320
PRIORITY INFO.: US 2001-60/278,166 20010322

ABEN Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provides. The polypeptides also serve as tumor markers.

ABFR L'invention porte sur des polypeptides appeles polypeptides CVSP14 qui presente l'activite de la protease sous forme d'une chaine unique ou sous une forme activee a deux chaines. L'invention porte egalement sur des procedes utilisant ces polypeptides pour identifier des composes qui modulent l'activite de la protease. Les polypeptides de cette invention peuvent egalement etre utilises comme marqueurs tumoraux.

L104 ANSWER 24 OF 189 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2000077155 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): KERATINOCYTE GROWTH FACTOR-2

TITLE (FRENCH): FACTEUR DE CROISSANCE DES KERATINOCYTES-2
INVENTOR(S): RUBEN, Steven, M.; JIMENEZ, Pablo; DUAN, D., Roxanne; RAMPY, Mark, A.; MENDRICK, Donna; ZHANG, Jun; NI, Jian; MOORE, Paul, A.; COLEMAN, Timothy, A.; GRUBER, Joachim, R.; DILLON, Patrick, J.; GENTZ, Reiner, L.
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., for all designates States except US; RUBEN, Steven, M., for US only; JIMENEZ, Pablo, for US only; DUAN, D., Roxanne, for US only; RAMPY, Mark, A., for US only; MENDRICK, Donna, for US only; ZHANG, Jun, for US only; NI, Jian, for US only; MOORE, Paul, A., for US only; COLEMAN, Timothy, A., for US only; GRUBER, Joachim, R., for US only; DILLON, Patrick, J., for US only; GENTZ, Reiner, L., for US only
AGENT: STEFFE, Eric, K.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2003077155	A2	20030918
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2003-US101	A	20020104
PRIORITY INFO.:	US 2001-60/259,853		20010108
	US 2001-60/286,368		20010426
	US 2001-60/331,169		20011109

ABEN This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as KGF-2 also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

ABFR La presente invention concerne des polynucleotides, des polypeptides codes par ces polynucleotides nouvellement identifies, l'utilisation de ces polynucleotides et polypeptides, ainsi que la production de ces polynucleotides et polypeptides. Plus precisement, le polypeptide de la presente invention est un facteur de croissance des keratinocytes, parfois signale ci-dessous sous le nom generique de ≤ KGF-2 ≥ et egalement connu sous le nom generique de facteur de croissance des fibroblastes 12 (FGF-12). La presente invention concerne egalement l'utilisation therapeutique du KGF-2 pour promouvoir ou accelerer la cicatrisation. La presente invention concerne egalement de nouvelles formes mutantes du KGF-2 presentant une activite amelioree, une plus grande stabilite, un meilleur rendement ou une meilleure solubilite.

L104 ANSWER 25 OF 189 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001US1979 PCTFULL ED 20020118 EW 200239
TITLE (ENGLISH): EXPRESSION PROFILES AND METHODS OF USE
TITLE (FRENCH): PROFILS D'EXPRESSION ET METHODES D'UTILISATION
INVENTOR(S): WAN, Jackson; WANG, Yixin
PATENT ASSIGNEE(S): ORTHO-CLINICAL DIAGNOSTICS, INC.

AGENT: PELTO, Don
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002074979	A1	20020926
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US8456	A	20020320
PRIORITY INFO.:	US 2001-60/276,947		20010320

ABEN The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms. The present invention further relates to protein expression profiles, algorithms to generate protein expression profiles, microarrays comprising protein-capture agents that bind proteins comprising protein expression profiles, methods of using protein expression profiles and microarrays, and business methods directed to the use of protein expression profiles, microarrays, and algorithms.

ABFR La presente invention concerne des profils d'expression genetiques, des algorithmes permettant de produire des profils d'expression genetiques, des jeux ordonnees de microechantillons contenant des sequences d'acide nucleique representant des profils d'expression genetiques, des methodes d'utilisation des profils d'expression genetiques et des jeux ordonnees de microechantillons, et des techniques commerciales destinees a l'utilisation des profils d'expression genetiques, des jeux ordonnees de microechantillons et des algorithmes. L'invention concerne en outre des profils d'expression de proteines, des algorithmes permettant de produire des des profils d'expression de proteines, des jeux ordonnees de microechantillons comprenant des agents de capture de proteines qui se lient a des proteines comprenant des profils d'expression, des methodes d'utilisation des profils d'expression de proteines et des jeux ordonnees de microechantillons, et des techniques commerciales destinees a l'utilisation des profils d'expression de proteines, des jeux ordonnees de microechantillons et des algorithmes.

L104 ANSWER 26 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002074929 PCTFULL ED 20021010 EW 200239
TITLE (ENGLISH): EVOLVING NEW MOLECULAR FUNCTION
TITLE (FRENCH): EVOLUTION D'UNE NOUVELLE FONCTION MOLECULAIRE
INVENTOR(S): LIU, David, R.; GARTNER, Zev, J.; KANAN, Matthew, W.
PATENT ASSIGNEE(S): PRESIDENT AND FELLOWS OF HARVARD COLLEGE, for all designates States except US; LIU, David, R., for US only; GARTNER, Zev, J., for US only; KANAN, Matthew, W., for US only
AGENT: SHAIR, Karoline, K., M.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002074929	A2	20020926
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR		

	CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
	IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
	MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
	SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH
	GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD
	RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
	NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN
	TD TG
APPLICATION INFO.:	WO 2002-US6546 A 20020219
PRIORITY INFO.:	US 2001-60/277,081 20010319
	US 2001-60/277,094 20010319
	US 2001-60/306,691 20010720
	US 2002-10/101,030 20020319

ABEN Nature evolves biological molecules such as proteins through iterated rounds of diversification, selection, and amplification. The present invention provides methods, compositions, and systems for synthesizing, selecting, amplifying, and evolving non-natural molecules based on nucleic acid templates. The sequence of a nucleic acid template is used to direct the synthesis of non-natural molecules such as unnatural polymers and small molecules. Using this method combinatorial libraries of these molecules can be prepared and screened. Upon selection of a molecule, its encoding nucleic acid template may be amplified and/or evolved to yield the same molecule of the present invention allow for the amplification and evolution of non-natural molecules in a manner analogous to the amplification of natural biopolymer such as polynucleotides and protein.

ABFR La nature fait evoluer les molecules biologiques telles que les proteines en les soumettant a des cycles repetes de diversification, selection et amplification. La presente invention se rapporte a des procedes, des compositions et des systemes permettant de synthetiser, selectionner, amplifier et faire evoluer des molecules artificielles basees sur des modeles d'acides nucleiques. La sequence d'un modele d'acide nucleique est utilisee pour diriger la synthese de molecules artificielles, telles que des polymeres et de petites molecules artificielles. Cette methode permet la preparation et le criblage de bibliotheques combinatoires de ces molecules. Lors de la selection d'une molecule, il est possible d'amplifier et/ou de faire evoluer son modele d'acide nucleique codant de maniere a produire la meme molecule ou des molecules associees aux fins d'un nouveau criblage. Les methodes et les compositions de la presente invention permettent l'amplification et l'evolution de molecules artificielles d'une maniere **analogue** a l'amplification des biopolymeres naturels du type polynucleotides et proteines.

L104 ANSWER 27 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	2001072786 PCTFULL ED 20020927 EW 200238
TITLE (ENGLISH):	NUCLEIC ACID MOLECULES ENCODING A TRANSMEMBRANE SERINE PROTEASE 7, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON
TITLE (FRENCH):	MOLECULES D'ACIDES NUCLEIQUES CODANT POUR UNE SERINE PROTEASE TRANSMEMBRANAIRE 7, POLYPEPTIDES CODES ET PROCEDES ASSOCIES
INVENTOR(S):	MADISON, Edwin, L.; ONG, Edgar, O.
PATENT ASSIGNEE(S):	CORVAS INTERNATIONAL, INC., for all designates States except US; MADISON, Edwin, L., for US only; ONG, Edgar, O., for US only
AGENT:	SEIDMAN, Stephanie, L.
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 2001072786	A2	20011004

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR

CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH
GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN
TD TG

APPLICATION INFO.: WO [illegible]-US[illegible] A [illegible]
PRIORITY INFO.: US [illegible]-60,275,642 [illegible]

ABEN Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymigen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP7 are provided.

ABFR La presente invention concerne des polypeptides de serine protease transmembranaire 7 (MTSP7) de type II. L'invention concerne egalement des proenzymes et des formes activees de ces polypeptides ainsi que des formes simple chaine et double chaine du domaine protease. Cette invention concerne egalement des procedes consistant a utiliser les polypeptides pour identifier les composes qui modulent l'activite protease d'une MTSP7.

L104 ANSWER 28 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002072024 PCTFULL ED 20020927 EW 200238
TITLE (ENGLISH): TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, COMPOSITIONS, USES AND THE LIKE RELATING THERETO
TITLE (FRENCH): PROTEINES TRANSGENIQUES OBTENUES A PARTIR DE SYSTEMES MULTIGENIQUES, PROCEDES, COMPOSITIONS, UTILISATIONS ET **ANALOGUES** APPARENTES
INVENTOR(S): COOPER, Julian, D; O'SICKEY, Tanya, K; BUTLER, Stephen, P
PATENT ASSIGNEE(S): PROGENETICS LLC, for all designates States except US; COOPER, Julian, D; O'SICKEY, Tanya, K; BUTLER, Stephen, P
AGENT: CRAWFORD, Robert, J.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002072024	A2	20020919

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US7540 A 20020311
PRIORITY INFO.: US 2001-60/274,993 20010312

ABEN A non-human transgenic mammalian animal, as described above, contains one or more exogenous double stranded DNA sequence(s) stably integrated into the genome of the animal, which comprises trans-acting regulatory units controlling expression of DNA sequences encoding proteins to be secreted into the milk of transgenic mammals. The DNA sequence of the trans-regulatory gene encodes transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed in a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins

which require specialized propeptides for proper post-translational processing is also described.

ABFR L'invention porte sur un animal mammalien transgenique comprenant une ou plusieurs sequences exogenes d'ADN double brin integrees de maniere stable dans le genome de l'animal et des motifs de repetition regulateurs transactivateurs regulant l'expression des sequences d'ADN codant de proteines a secreter dans le lait des mammiferes transgeniques. La sequence d'ADN du gene transregulateur code des proteines d'activation transcriptionnelles qui ne sont pas secretees, mais fabriquees de maniere reguler dans le temps et de maniere specifique du tissu mammaire. La sequence d'ADN contenant la proteine a secreter dans le lait est construite sur une sequence genique separee sous la regulation d'un promoteur minimal et d'un domaine de liaison de transactivation. Les mammiferes transgeniques sont de preference des porcs, des vaches, des moutons, des chevres et des lapins. L'invention porte egalement sur une composition apparentee et sur un procede de fabrication de proteines transgeniques qui ont besoin de propeptides specialises pour un traitement post-translationnel correct(.)

L104 ANSWER 29 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002063017 PCTFULL ED 20020807 EW 200233
TITLE (ENGLISH): INTEGRIN-BINDING CHIMERAS
TITLE (FRENCH): CHIMERES POUVANT SE LIER A L'INTEGRINE
INVENTOR(S): LU, Xinjie; KAKKAR, Vijay, Vir
PATENT ASSIGNEE(S): TRIGEN LIMITED, for all designates States except US; LU, Xinjie, for US only; KAKKAR, Vijay, Vir, for US only
AGENT: HARRISON GODDARD FOOTE
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002063017	A2	20020815
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-GB500	A	20020205
PRIORITY INFO.:	US 2001-60/267,234		20010205

ABEN Products which contain two interlinked functional moieties of which one is an integrin-binding protein (e.g. a snake venom protein) or a homologue thereof. The products comprise a first portion which is an integrin-binding protein, a homologue thereof having a binding activity or a fragment of either which has integrin-binding activity, and, ligated to the first portion, a second portion which has a different function.

ABFR L'invention concerne des produits qui contiennent deux fragments fonctionnels entrelaces dont l'un est une proteine de liaison a l'integrine (p. ex. une proteine du venin du serpent) ou un homologue de ladite proteine. Les produits comprennent une premiere partie qui est une proteine de liaison a l'integrine, un homologue de ladite proteine ayant une activite de liaison, ou un fragment de l'un ou l'autre ayant une activite de liaison a l'integrine; et une seconde partie liee a la premiere partie et ayant une fonction differente.

L104 ANSWER 30 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002057278 PCTFULL ED 20020731 EW 200230
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND

ACCEPTOR

TITLE (FRENCH): INHIBITEURS DE LA SERINE PROTEASE COMPRENANT UN ACCEPTEUR DE LIAISON HYDROGENE

INVENTOR(S): DEADMAN, John, Joseph; SPENCER, John; GREENIDGE, Paulette, Angela; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; SCULLY, Michael, Finbarr

PATENT ASSIGNEE(S): TRIGEN LIMITED, for all designated States except US; DEADMAN, John, Joseph, for US only; SPENCER, John, for US only; GREENIDGE, Paulette, Angela, for US only; GOODWIN, Christopher, Andrew, for US only; KAKKAR, Vijay, Vir, for US only; SCULLY, Michael, Finbarr, for US only

AGENT: HARRISON GODDARD FOOTE

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002057273	A1	20020725

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-GB324 A 20020118

PRIORITY INFO.: GB 2001-0101937.9 20010120
US 2001-60/267,172 20010206

ABEN Compounds, useful as protease inhibitors, of the formula (I): where: Ar is a ring or ring system, for example a benzene ring, and may be substituted by one or more moieties in addition to X and LJ; X is a functional group which is a hydrogen-bond acceptor, e.g. a nitro or boronate group BY<sp>1</sp>Y<sp>2</sp>; L is a linker, most preferably (CR<sp>5</sp>R<sp>6</sp>)-S-; J is a moiety containing a basic nitrogen atom but not containing an amino acid residue, preferably amidino, guanidino, amino, carboxamido, hydroxylamino, or imidazolyl, or an N-substituted **analogue** thereof.

ABFR L'invention concerne des composes utilises comme inhibiteurs de protease representes par la formule (I). Dans cette formule, Ar represente un noyau ou un systeme cyclique, par exemple, un noyau benzenique, et peut etre substitue par au moins une fraction en plus de X et LJ; X represente un groupe fonctionnel accepteur de liaison hydrogene, par exemple, un groupe nitro ou boronate BY<sp>1</sp>Y<sp>2</sp>; L represente un liant, de preference (CR<sp>5</sp>R<sp>6</sp>)-S-; J represente une fraction contenant un atome d'azote basique mais ne contenant pas de residu d'acide amine, et contenant de preference amidino, guanidino, amino, carboxamido, hydroxylamino, ou imidazolyl, ou un **analogue** de ceux-ci substitue par un N.

L104 ANSWER 31 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002042336 PCTFULL EP 20020610 EW 200222

TITLE (ENGLISH): FGF-AFFINITY CHROMATOGRAPHY

TITLE (FRENCH.): CHROMATOGRAPHIE D'AFFINITE AVEC FGF
INVENTOR(S.): MCKEEHAN, Wallace, L.; LUO, Yongde
PATENT ASSIGNEE S : THE TEXAS A & M UNIVERSITY SYSTEM
AGENT: REBLE, Raymond, J.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002042336	A2	20020530

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US43817	A	20011121
PRIORITY INFO.:	US 2000-60/252,275		20001121
	US 2001-60/277,785		20010321
	US 2001-60/305,613		20010716
	US 2001-60/325,502		20010928

ABEN The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoagulant heparan sulfate onto an affinity matrix and separating the non-bound material from the bound material. The affinity matrix is made of a fibroblast growth factor immobilized on a support. The invention also relates to a method and composition for neutralizing anticoagulant catalyzed by heparin, a heparin mimic, or a heparin derivative, by contacting heparin, a heparin mimic, or a heparin derivative with a fibroblast growth factor.

ABFR L'invention concerne un procede et un dispositif servant a isoler de l'heparine anticoagulante ou du sulfate d'heparane par fixation de l'heparine anticoagulante ou du sulfate d'heparane anticoagulant sur une matrice d'affinite et separation du materiau non fixe et du materiau fixe. Cette matrice d'affinite est constituee par un facteur de croissance de fibroblastes immobilise sur un support. Elle concerne egalement un procede et une composition servant a neutraliser l'anticoagulation catalysee par heparine, un **analogue** d'heparine ou un derive d'heparine, par mise en contact d'heparine, d'un **analogue** d'heparine ou d'un derive d'heparine avec un facteur de croissance de fibroblastes.

L104 ANSWER 32 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002040654 PCTFULL ED 20020611 EW 200221
TITLE (ENGLISH): POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN SECRETED FROM LYMPHOID CELLS LSI-01
TITLE (FRENCH): POLYNUCLEOTIDE CODANT POUR UNE NOUVELLE SERPINE HUMAINE (LSI-01) SECRETEE A PARTIR DES CELLULES LYMPHOIDES
INVENTOR(S): CHEN, Jian; FEDER, John, N.; NELSON, Thomas; SEILER, Steven; BASSOLINO, Donna, A; CHENEY, Daniel, L.; DUCLOS, Frank
PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY, for all designates States except US; CHEN, Jian, for US only; FEDER, John, N., for US only; NELSON, Thomas, for US only; SEILER, Steven, for US only; BASSOLINO, Donna, A, for US only; CHENEY, Daniel, L., for US only; DUCLOS, Frank, for US only
AGENT: BRISTOL-MYERS SQUIBB COMPANY
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002039994	A2	20020523
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US43965	A	20011114
PRIORITY INFO.:	US 2000-604248,434		20001114
	US 2000-604397,610		20001221
	US 2001-604382,745		20010410

ABEN The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention furtherrelates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseas and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ABFR La presente invention concerne des nouveaux polynucleotides codant pour des polypeptides LSI 01, des fragments et des homologues desdits polypeptides. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps et des methodes de recombinaison et des methodes synthetiques destinees a la production de ces polypeptides. Ladite invention se rapporte en outre a des methodes diagnostiques et therapeutiques permettant d'appliquer ces nouveaux polypeptides LSI-01 au diagnostic, au traitement et/ou a la prevention de maladies et/ou de troubles divers associes auxdits polypeptides. Elle porte enfin sur des methodes de criblage destinees a identifier des agonistes et des antagonistes des polynucleotides et des polypeptides susmentionnes.

L104 ANSWER 33 OF 189 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER:	2002039997 PCTFULL ED 20020610 EW 200221
TITLE (ENGLISH):	ACE-2 MODULATING COMPOUNDS AND METHODS OF USE THEREOF
TITLE (FRENCH):	COMPOSES MODULANT ACE-2 ET PROCEDES D'UTILISATION ASSOCIES
INVENTOR(S):	ACTON, Susan, L.; OCAIN, Timothy, D.; GOULD, Alexandra, E.; DALES, Natalie, A.; GUAN, Bing; BROWN, James, A.; PATANE, Michael; KADAMBI, Vivek, J.; SOLOMON, Michael; STRICKER-KRONGRAD, Alain
PATENT ASSIGNEE(S):	MILLENNIUM PHARMACEUTICALS, INC., for all designates States except US; ACTON, Susan, L., for US only; OCAIN, Timothy, D., for US only; GOULD, Alexandra, E., for US only; DALES, Natalie, A., for US only; GUAN, Bing, for US only; BROWN, James, A., for US only; PATANE, Michael, for US only; KADAMBI, Vivek, J., for US only; SOLOMON, Michael, for US only; STRICKER-KRONGRAD, Alain, for US only
AGENT:	HANLEY, Elizabeth, A.
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

	NUMBER	KIND	DATE
	WO 2002039497	A2	20020523
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD		

	MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2 01-US45713 A 20011031
PRIORITY INFO.:	US 2 00-244704,216 20001101 US 2 001-09 870,382 20011529 US 2 001-60 371,741 20011019

ABEN ACE-2 modulating compounds for the treatment of body disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

ABFR L'invention concerne des composes modulant ACE-2, destines au traitement de problemes de poids. L'invention concerne egalement des procedes d'utilisation de ces composes et des compositions pharmaceutiques contenant lesdits composes.

L104 ANSWER 34 OF 189 PCTFULL COPYRIGHT 2003 Univentic

ACCESSION NUMBER:	2002:032446 PCTFULL ED 20020515 EW 200217
TITLE (ENGLISH):	PHARMACEUTICAL COMBINATIONS
TITLE (FRENCH):	COMBINAISONS PHARMACEUTIQUES
INVENTOR(S):	BREARLEY, Christopher, John; BUTLER, Paul; CHAHWALA, Suresh, Babubhai; CHOPP, Michael; KRAMS, Michael; LOOBY, Michael; MACINTYRE, Fion; MCELROY, Andrew, Brian; MCHARG, Aileen, Dorothy
PATENT ASSIGNEE(S):	PFIZER LIMITED, for GB only; PFIZER INC., for all designates States except GB US; BREARLEY, Christopher, John, for US only; BUTLER, Paul, for US only; CHAHWALA, Suresh, Babubhai, for US only; CHOPP, Michael, for US only; KRAMS, Michael, for US only; LOOBY, Michael, for US only; MACINTYRE, Fion, for US only; MCELROY, Andrew, Brian, for US only; MCHARG, Aileen, Dorothy, for US only
AGENT:	WOOD, David, J.
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 2002032446	A2	20020425

DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2001-IB1936 A 20011015
PRIORITY INFO.:	GB 2000-0025473.9 20001017

ABEN This invention relates, inter alia, to methods of treating pathophysiological conditions involving neutrophils, comprising administering to a patient in need of such treatment a combination therapy comprising at least one Neutrophil Inhibitory Factor (NIF) and at least one other agent that protects neurons from toxic insult, inhibits the inflammatory reaction after brain damage or promotes cerebral reperfusion i.e. neuroprotective or thrombolytic/fibrinolytic agents), or a pharmaceutically acceptable salt thereof.

ABFR La presente invention concerne notamment des methodes de traitement d'etats pathophysiologiques impliquant des polynucleaires neutrophiles, lesquelles methodes consistent a administrer a un patient necessitant un tel traitement une polytherapie comportant au moins un facteur inhibiteur des polynucleaires neutrophiles (NIF) et au moins un autre agent qui protege les neurones d'une attaque toxique, inhibe la reaction

inflammatoire suite a une lesion cerebrale, ou favorise une reperfusion cerebrale c'est-a-dire des agents neuroprotecteurs ou thrombolytiques / fibrinolytiques), ou un sel pharmaceutiquement acceptable.

L104 ANSWER 85 OF 189 POTFULL COPYRIGHT 2 00 Univentio
ACCESSION NUMBER: 20020290?2 POTFULL ED 2?020617 EW 200215
TITLE (ENGLISH): WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TITLE (FRENCH): MANIPULATION DE CELLULE ENTIERE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT PAR REPETITION
INVENTOR(S): SHORT, Jay, M.; FU, Pengcheng; LATTERICH, Martin; WEI, Jing; LEVIN, Michael
PATENT ASSIGNEE(S): DIVERSA CORPORATION, for all designates States except US; SHORT, Jay, M., for US only; FU, Pengcheng, for US only; LATTERICH, Martin, for US only; WEI, Jing, for US only; LEVIN, Michael, for US only
AGENT: EINHORN, Gregory, P.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002029032	A2	20020411
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US31094	A	20011001
PRIORITY INFO.:	US 2000-09/677,584		20000930
	US 2001-60/274,702		20010309
	US 2001-PCT/US01/19367		20010614

ABEN An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. In one embodiment, this invention provides a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. This invention also provides a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, this conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. This invention also provides a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products. This invention provides novel methods for determining polypeptide profiles, and protein expression variations, which methods are applicable to all sample types disclosed herein. The

present
invention provides methods of simultaneously identifying and quantifying individual proteins in complex protein mixtures. Additionally this invention
provides methods for cellular and metabolic engineering of new and modified
phenotypes by using on-line or real-time metabolic
flux analysis.

ABFR L'invention concerne des procedes de transformation cellulaire, d'evolution dirigee et de criblage utiles pour produire de nouveaux organismes transgeniques possedant des proprietes voulues. Dans une forme de realisation, l'invention concerne un procede de production d'organisme transgenique, tel qu'un microbe ou une plante, comportant une pluralite de caracteristiques
activables de maniere differenciee. L'invention concerne aussi un procede de remaniement de genes et de voies geniques par l'introduction de sequences regulatrices, tels des promoteurs, qui peuvent etre activees chez un hote voulu et sont ainsi capables de conferer une capacite d'activation a une nouvelle
voie genique apres introduction de celle-ci dans un hote voulu; par exemple, une nouvelle voie genique artificielle, produite sur la base
de modeles de progeniteurs derives de microbes, qui peut etre activee dans une cellule vegetale. Cette invention concerne aussi un procede de production de nouveaux organismes hotes possedant une expression accrue de caracteristiques voulues, de genes recombines et de produits geniques; de nouveaux procedes servant a determiner des profils de polypeptides et des variations d'expression de proteines, ces procedes pouvant etre appliques a tous les types d'echantillons decrits; des procedes permettant d'identifier et de quantifier simultanement des proteines individuelles dans des melanges complexes de proteines. De plus, l'invention concerne des procedes de mise au point cellulaire et metabolique de nouveaux phenotypes modifies utilisant une analyse de flux metabolique ≤ en ligne ≥ ou ≤ en temps reel ≥.

L104 ANSWER 36 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	2002026781 PCTFULL ED 20020701 EW 200214
TITLE (ENGLISH):	IGE RECEPTOR ANTAGONISTS
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR D'IGE
INVENTOR(S):	LOWMAN, Henry B.; REYNOLDS, Mark E.; NAKAMURA, Gerald R.; STAROVASNIK, Melissa A.
PATENT ASSIGNEE(S):	GENENTECH, INC., for all designates States except US; LOWMAN, Henry B., for US only; REYNOLDS, Mark E., for US only; NAKAMURA, Gerald R., for US only; STAROVASNIK, Melissa A., for US only
AGENT:	SVOBODA, Craig G.
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 2002026781	A2	20020404
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US30299	A 20010926

PRIORITY INFO.: US 2000-61/235,958 20000926
US 2001-60/278,143 20010326

ABEN The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated FcεRI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides compositions, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

ABFR L'invention concerne de nouveaux composes se liant a un recepteur de haute affinite pour l'immunoglobuline E (IgE), designe par FcεRI, ainsi que des procedes d'identification et de preparation de tels composes. Sous des aspects particuliers, l'invention concerne le traitement de troubles occasionnes par IgE, traitement utilisant les nouveaux composes de l'invention. L'invention concerne en outre des compositions, telles que des compositions pharmaceutiques, renfermant les nouveaux composes, ainsi que leur utilisation en recherche et dans des methodes de diagnostic, therapeutiques et prophylactiques.

L104 ANSWER 37 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1179541 EUROPATFULL EW 200207 FS OS
TITLE: Compositions and methods for cancer treatment by selectively inhibiting VEGF.
Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF.
Compositions et procedes de traitment du cancer par l'inhibition selective du VEGF.
INVENTOR(S): The designation of the inventor has not yet been filed
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Office of General Council, 201 West 7th Street, Austin, Texas 78701, US
PATENT ASSIGNEE NO: 266341
AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT Pettenkoferstrasse 20-22, 80336 Muenchen, DE
AGENT NUMBER: 61531
OTHER SOURCE: EPPA2002015 EP 1179541 A1 0214
SOURCE: Wila-EPS-2002-H07-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1179541	A1	20020213

'OFFENLEGUNGS' DATE: 20020213
APPLICATION INFO.: EP 2001-125811 20000426
PRIORITY APPLN. INFO.: US 1999-131432 19990426
RELATED DOC. INFO.: EP 9301939 DIV

L104 ANSWER 38 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 994893 EUROPATFULL EW 200201 PS PS
TITLE: SELECTIVE **FACTOR XA** **INHIBITORS** CONTAINING A FUSED AZEPINONE STRUCTURE.
SELEKTIVE INHIBITOREN DES FAKTORS X, EINE AZEPINONSTRUKTUR ENTHALTEND.
INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE.
INVENTOR(S): SCARBOROUGH, Robert, M., 2544 Belmont Canyon Road, Belmont, CA 94002, US
PATENT ASSIGNEE(S): COR THERAPEUTICS, INC., 256 East Grand Avenue, Suite 80, South San Francisco, CA 94080, US
PATENT ASSIGNEE NO: 1193100
AGENT: Doireau, Marc et al., Cabinet Dres 6, avenue de Messine, 75008 Paris, FR
AGENT NUMBER: 44329
OTHER SOURCE: EPPB1000031 EP 0994893 B1 0062
SOURCE: Wila-EPR-2002-H01-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 994893	B1	20020102
'OFFENLEGUNGS' DATE:		20000426
APPLICATION INFO.:	EP 1998-939911	19980811
PRIORITY APPLN. INFO.:	US 1997-92316	19970811
	US 1997-907779	19970811
RELATED DOC. INFO.:	WO 98-US16704	980811 INTAKZ
	WO 9907730	990218 INTPNR
REFERENCE PAT. INFO.:	WO 97-05160 A	

REF. NON-PATENT-LIT.: J A ROBL ET AL.: "Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 15, 1994, pages 1795-1800, XP000196079 Amsterdam J A ROBL ET AL.: "Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY., vol. 39, 1996, pages 494-502, XP000749701 EASTON US

L104 ANSWER 39 OF 189 USPATFULL DUPLICATE 1
ACCESSION NUMBER: 2001:150554 USPATFULL
TITLE: PROTEASE INHIBITOR **PEPTIDES**
INVENTOR(S): WHITE, R. TYLER, FREMONT, CA, United States
DAMM, DEBORAH, REDWOOD CITY, CA, United States
LESIKAR, DAVID D., PALO ALTO, CA, United States
MCFADDEN, KATHLEEN, MOUNTAIN VIEW, CA, United States
GARRICK, BRETT L., PALO ALTO, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001020003	A1	20010906
	US 6376648	B2	20020423
APPLICATION INFO.:	US 1999-234874	A1	19990121 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: FOLEY & LARDNER, 3000 K STREET NW, SUITE 500, WASHINGTON, DC, 200075109
NUMBER OF CLAIMS: 79
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 51 Drawing Page's
LINE COUNT: 4113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Analogues** of the Kunitz Protease **Inhibitor** (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, **Xa**, XIa, and XIIa. Pharmaceutical compositions containing the KPI **analogues**, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these **analogues** and systems for expression of the **peptides** of the invention are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 40 OF 189 USPATFULL
ACCESSION NUMBER: 2001:91439 USPATFULL
TITLE: HIGH THROUGHPUT METHOD FOR FUNCTIONALLY CLASSIFYING PROTEINS IDENTIFIED USING A GENOMICS APPROACH
INVENTOR(S): PANTOLIANO, MICHAEL W., AVONDALE, PA, United States
SALEMME, F. RAYMOND, YARDLEY, PA, United States
CARVER, THEODORE E., JR., THORNDALE, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001003648	A1	20010614
APPLICATION INFO.:	US 1998-190128	A1	19981112 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-651248	19971112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE KESSLER GOLDSTEIN AND FOX, SUITE 600, 1100 NEW YORK AVENUE NW, WASHINGTON, DC, 200053934
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for functionally classifying a protein that is capable of unfolding due to a thermal change. The method comprises screening one or more of a multiplicity of different molecules for their ability to shift the thermal unfolding curve of the protein, wherein a shift in the thermal unfolding curve indicates that the molecule binds to the protein or affects the stability in a measurable way; generating an activity spectrum for the protein wherein the activity spectrum reflects a set of molecules, from the multiplicity of molecules, that shift the thermal unfolding curve, of the protein and therefore are ligands that bind to the protein, comparing the activity spectrum for the protein to one or more functional reference spectrum lists; and classifying the protein according to the set of molecules in the multiplicity of different molecules that shift the thermal unfolding curve of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 41 OF 189 USPATFULL
ACCESSION NUMBER: 2001:235319 USPATFULL
TITLE: Kallikrein-binding "Kunitz domain" proteins and

analogues thereof

INVENTOR(S): Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States

PATENT ASSIGNEE S.: Dyax Corp., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333402	B1	20011225
APPLICATION INFO.:	US 1999-421097		19991019 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-208264, filed on 10 Mar 1994, now patented, Pat. No. US 6057287
Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Achutamurthy, Ponnathapu
ASSISTANT EXAMINER: Pak, Yong
LEGAL REPRESENTATIVE: Yankwich, Leon R., Zwicker, Kenneth P., Maravic-Magovcevic, Ivana
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 3154
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 42 OF 189 USPATFULL
ACCESSION NUMBER: 2001:196603 USPATFULL
TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312694	B1	20011106
APPLICATION INFO.:	US 1999-351457		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1,2,3,4
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 9243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to

aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 43 OF 189 USPATFULL
ACCESSION NUMBER: 2001:191342 USPATFULL
TITLE: Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil P., San Diego, CA, United States
Wang, Tingmin, San Marcos, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274627	B1	20010814
APPLICATION INFO.:	US 1999-416619		19991012 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E.Foley & Lardner		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2173		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents (e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 44 OF 189 USPATFULL
ACCESSION NUMBER: 2001:86465 USPATFULL
TITLE: .beta.-sheet mimetics and use thereof as inhibitors of biologically active **peptides** or proteins
INVENTOR(S): Hahn, Michael, Kirkland, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Eguchi, Masakatsu, Bellevue, WA, United States
Kim, Hwa-Ok, Redmond, WA, United States
Beatman, Jr., Patrick Douglas, Issaquah, WA, United States
PATENT ASSIGNEE(S): Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6245764	B1	20010612
APPLICATION INFO.:	US 1998-9665		19980120 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-726073, filed on 2 Oct

1996, now abandoned Continuation-in-part of Ser. No. US 1996-624690, filed on 28 Mar 1996, now abandoned Continuation-in-part of Ser. No. US 1995-549036, filed on 27 Oct 1995, now abandoned Continuation-in-part of Ser. No. US 1995-410819, filed on 24 Mar 1995, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed .beta.-sheet mimetics and methods relating to the same for imparting or stabilizing the .beta.-sheet structure of a **peptide**, protein or molecule. In one aspect, .beta.-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and Factor X inhibitors. In one embodiment, the .beta.-sheet mimetic is a thrombin inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 45 OF 189 USPATFULL
ACCESSION NUMBER: 2001:82499 USPATFULL
TITLE: Immunoassays for catalytically-active, serine proteases
INVENTOR(S.: Mann, Kenneth G., Shelburne, VT, United States
Williams, Brady, St. Paul, MN, United States
Tracy, Russell P., Essex Junction, VT, United States
PATENT ASSIGNEE(S): University of Vermont and State Agriculatural College, Burlington, VT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6242178	B1	20010605
APPLICATION INFO.:	US 1999-333646		19990307 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-252506, filed on 30 Sep 1998, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for detecting and/or quantifying catalytically-active, serine proteases in a biological fluid are disclosed. The methods are useful for measuring the active enzymes of the coagulation/fibrinolytic system and evaluating the system or components of the system as indicative of thrombosis-related disorders. The methods involve the combined use of halomethyl ketone probes having broad **specificity** for catalytically-active serine proteases and immunological reagents specific for serine proteases of particular types. The halomethyl ketone probes are active site specific; they are only incorporated into catalytically-active serine proteases. An antibody is used to provide **specificity** for the particular type of serine protease. By the combined active-site-**specificity** of the halomethyl ketone probes and the type-**specificity** of the antibody, the catalytically-active fraction of a particular serine protease is determined.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 46 OF 189 USPATFULL
ACCESSION NUMBER: 2001:43957 USPATFULL
TITLE: Methods of determining endogenous thrombin potential ETP) and thrombin substrates for use in said methods
INVENTOR(S): Hemker, Hendrik Coenraad, Tongerstraat 41, NL-6211 LM Maastricht, Netherlands
Rijkers, Dirk Thomas Sigurd, Eindhoven, Netherlands
Tesser, Godefridus Ignatius, Nijmegen, Netherlands
PATENT ASSIGNEE(S): Hemker, Hendrik Coenraad, Maastricht, Netherlands (non-U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6207399	B1	20010327	
	WO 9621740		19960718	
APPLICATION INFO.:	US 1997-860808		19970905	(8)
	WO 1996-NL18		19960110	
			19970905	PCT 371 date
			19970905	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-43	19950110

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: Tung, Mary Beth
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 3996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining the endogenous thrombin potential of a sample having a total anticoagulant activity of or equivalent to at least 0.07 U ISH/ml, includes using a thrombin substrate or a salt thereof that is soluble in the sample to determine the ETP of the sample. Suitable thrombin substrate include those of the formula P-Val-Xaa-S, in which P is an amino protective group, that is non-aromatic and polar, Val is a valine residue attached via a **peptide** bond to Xaa, Xaa is an amino acid residue comprising a terminal guanidino group or ureido group separated by at least 2 carbon atoms from the **peptide** backbond the amino acid residue is attached to S and S is a signal group such as a chromophore that can be enzymatically hydrolyzed. Other substrates include substrates comprising the structure Xaa-Pipecolyl-Yaa-S or Xaa-Pro-Yaa-S, wherein Xaa represents D-Phenylalanine, D-Tryptophan or D-Tyrosine, Pro represents proline, Yaa is an amino acid residue other than **arginine** and S is a signal marker can also be used. The substrates Boc-Gly-Val-Arg-pNA and H-Glu-Gly-Gly-Val-Arg-pNA are also applicable. Furthermore ETP determination methods can be improved by addition of hydroxylamine to the sample to circumvent defibrination of the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 47 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001096551 PCTFULL ED 20020836
TITLE (ENGLISH): WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TITLE (FRENCH): INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT REPETITION

INVENTOR(S): SHORT, Jay, M.
PATENT ASSIGNEE(S): DIVERSA CORPORATION; SHORT, Jay, M.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001096551	A2	20011220

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US19367 A 20010614
PRIORITY INFO.: US 2000-09/594,459 20000614
US 2000-09/677,594 20000930

ABEN An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

ABFR L'invention porte sur des procedes de transformation cellulaire, d'evolution dirigee et de criblage en vue de creer de nouveaux organismes transgeniques aux proprietes souhaitees. En variante, cette invention porte sur un procede de generation d'un organisme transgenique tel qu'un microbe ou une plante presentant une pluralite de caracteristiques pouvant etre activees de maniere differentielle. L'invention porte aussi sur un procede permettant de restructurer des genes et des mecanismes d'action genetiques par l'introduction de sequences regulatrices telles que des promoteurs pouvant agir dans un hote determine, ce qui confere une operabilite a un nouveau mecanisme d'action genetique lorsqu'il est introduit dans un hote determine. Par exemple, un nouveau mecanisme d'action genetique artificiel, genere a partir de gabarits de progeniteurs derives de microbes, peut etre utilise dans une cellule vegetale. L'invention porte en outre sur de nouveaux organismes hotes dont les caracteristiques souhaitees, les genes de recombinaison et les produits geniques ont une expression accrue.

L104 ANSWER 48 OF 139 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20010994332 PCTFULL ED 20020826
TITLE (ENGLISH): PROFILING OF PROTEASE **SPECIFICITY** USING COMBINATORIAL FLUOROGENIC SUBSTRATE LIBRARIES
TITLE (FRENCH): PROFILAGE DES PARTICULARITES D'ENZYMES A L'AIDE DE BIBLIOTHEQUES COMBINATOIRES DE SUBSTRATS FLUOROGENES
INVENTOR(S): HARRIS, Jennifer, L.; BACKES, Bradley, J.; ELLMAN, Jonathan, A.; CRAIK, Charles, S.
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; HARRIS, Jennifer, L.; BACKES, Bradley, J.; ELLMAN, Jonathan, A.; CRAIK, Charles, S.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001094332	A1	20011213

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US17265 A 20010525
PRIORITY INFO.: US 2000-61/209,174 20000602
US 2001-09/866,132 20010525

ABEN Fluorogenic **peptide** substrates allow for the configuration of general substrate libraries to rapidly identify the primary and extended **specificity** of enzymes, such as proteases. The substrates contain a fluorogenic-leaving group, such as 7-amino-4-carbamoylmethyl-coumarin (ACC). Substrates incorporating the ACC leaving group show comparable kinetic profiles as those with the traditionally used 7-amino-4-methyl-coumarin (AMC) leaving group. The bifunctional nature of ACC allows for the efficient production of single substrates and substrate libraries using solid-phase synthesis techniques. The approximately 3-fold increased quantum yield of ACC over AMC permits reduction in enzyme and substrate concentrations, so that a greater number of substrates can be tolerated in a single assay, thus enabling an increase in the diversity space of the library. Employing this screening method, the substrate **specificities** of a diverse array of proteases were profiled, including serine proteases and cysteine proteases.

ABFR L'invention porte sur des substrats de **peptides** fluorogenes servant a creer des bibliotheques de substrats generaux permettant d'identifier rapidement les particularites primaires et etendues d'enzymes, telles que des proteases. Les substrats contiennent un groupe partant fluorogene tel qu'un groupe 7-amino-4-carbamoylmethyl-coumarine (ACC). Les substrats contenant le groupe partant ACC presentent des profils cinetiques comparables a ceux du groupe partant 7-amino-4-methyl-coumarine (AMC) utilise couramment. La nature bifonctionnelle de l'ACC permet de produire efficacement differents substrats et bibliotheques de substrats a l'aide de techniques de synthese en phase solide. Le rendement quantique sensiblement triple de l'ACC par rapport a l'AMC permet de reduire la concentration des enzymes et des substrats, d'ou un plus grand nombre de substrats par essai et la possibilite d'accroitre l'espace pour divers de la bibliotheque. Avec ce procede de criblage, on a pu profiler les particularites d'un reseau divers de proteases dont des proteases de serine et de cysteine.

L104 ANSWER 49 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001087842 PCTFULL ED 20020326
TITLE (ENGLISH): SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE
TITLE (FRENCH): PYRIDONES ARYLE ET HETEROARYLE POLYCYCLIQUES SUBSTITUEES UTILISEES POUR L'INHIBITION SELECTIVE DE LA CASCADE DE COAGULATION
INVENTOR(S : SOUTH, Michael, S.; ZENG, Qingping; RUEPPEL, Melvin, L.; HAMME, Ashton, T., II
PATENT ASSIGNEE(S): PHARMACIA CORPORATION; SOUTH, Michael, S.; ZENG, Qingping; RUEPPEL, Melvin, L.; HAMME, Ashton, T., II
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001087842	A1	20011122

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ
TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI
CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US17893 A 20000629
PRIORITY INFO.: US 1999-141,574,P 19990629

ABEN The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds of the formula (I) useful as inhibitors of serine protease of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

ABFR L'invention concerne des composes de pyridone aryle et heteroaryle polycycliques substitues de formule (I) utiles comme inhibiteurs de la serine protease de la cascade de coagulation, ainsi que des composes, des compositions et des methodes destines a la therapie anticoagulante pour le traitement et la prevention d'une pluralite d'etats thrombotiques tels que les coronaropathies et les affections vasculaires cerebrales.

L104 ANSWER 51 OF 139 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001-081581 PCTFULL ED 20020826
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF ACNE VULGARIS
TITLE (FRENCH): COMPOSITIONS ET PROCEDES POUR LA THERAPIE ET LE DIAGNOSTIC DE L'ACNE VULGAIRE
INVENTOR(S): SKEIKY, Yasir, A., W.; PERSING, David, H.; MITCHAM, Jennifer, L.; WANG, Siqing, Steven; BHATIA, Ajay; L'MAISONNEUVE, Jean-Francois; ZHANG, Yanni; JEN, Shyuan; CARTER, Darrick
PATENT ASSIGNEE(S): CORIXA CORPORATION; SKEIKY, Yasir, A., W.; PERSING, David, H.; MITCHAM, Jennifer, L.; WANG, Siqing, Steven; BHATIA, Ajay; L'MAISONNEUVE, Jean-Francois; ZHANG, Yanni; JEN, Shyuan; CARTER, Darrick
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001081581	A2	20011101

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US10865 A 20010402
PRIORITY INFO.: US 2000-60/194,047 20000402
US 2000-60/203,841 20000512
US 2000-60/214,747 20000627

ABEN Compositions and methods for the therapy and diagnosis of acne vulgaris and other related conditions are disclosed. Compositions may comprise one or more Propionibacterium acnes proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antibody that binds a Propionibacterium acnes protein, antigen presenting cell that expresses a Propionibacterium acnes protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and/or treatment of acne.

ABFR L'invention concerne les compositions et les procedes pour la therapie et le diagnostic de l'acne vulgaire et d'autres etats apparentes. Les compositions peuvent comprendre une ou plusieurs proteines de Propionibacterium acnes, des fractions immunogenes de celles-ci, ou des polynucleotides qui codent de telles fractions. Selon une

variante, une composition therapeutique peut comprendre un anticorps qui fixe une proteine de Propionibacterium acnes, une cellule presentant un antigene qui exprime une proteine de Propionibacterium acnes, ou une cellule T qui agit specifiquement sur les cellules exprimant une telle proteine. De telles compositions peuvent etre utilisees, par exemple, pour la prevention et/ou le traitement de l'acne.

L104 ANSWER 51 OF 189 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2001072729 PCTFULL EP 2 028 822
TITLE (ENGLISH): BICYCLIC SULFONYL AMINO **INHIBITORS** OF **FACTOR Xa**
TITLE (FRENCH): INHIBITEURS AMINOSULFONYLES BICYCLIQUES DU FACTEUR XA
INVENTOR(S): LI, Wenhao; MARLOWE, Charles, K.; SCARBOROUGH, Robert, M.
PATENT ASSIGNEE(S): CIR THERAPEUTICS, INC.; LI, Wenhao; MARLOWE, Charles, K.; SCARBOROUGH, Robert, M.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001072729	A1	20011004

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US9375 A 20010326
PRIORITY INFO.: US 2000 60/191,715 20000324
ABEN Novel compounds of formulae (I) or (Ia), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian **factor Xa** is described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro orin vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
ABFR L'invention concerne les composes de formule (I) ou (Ia), ainsi que leurs isomeres, sels, hydrates, solvates et derives pro-medicamenteux pharmaceutiquement acceptables, lesdits composes ayant une activite contre le facteur XA mammifere. L'invention concerne egelement des compositions contenant de tels composes. Les composes et compositions selon l'invention servent au traitement et a la prevention in vitro et in vivo de maladies mammiferes caracterisees par la presence de thromboses indesirables.

L104 ANSWER 52 OF 189 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2001072295 PCTFULL EP 2028822
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
TITLE (FRENCH): COMPOSITIONS ET METHODES POUVANT TRAITER OU DIAGNOSTIQUER LE CANCER DU POUMON
INVENTOR(S): REED, Steven, G.; LODES, Michael, J.; MOHAMATH, Raodoh; SECRIST, Heather; BENSON, Darin, R.; INDIRIAS, Carol, Yoseph; HENDERSON, Robert, A.; FLING, Steven, P.; ALGATE, Paul, A.; ELLIOT, Mark; MANNION, Jane; KALOS, Michael, D.
PATENT ASSIGNEE(S): CORIXA CORPORATION; REED, Steven, G.; LODES, Michael, J.; MOHAMATH, Raodoh; SECRIST, Heather; BENSON, Darin, R.; INDIRIAS, Carol, Yoseph; HENDERSON, Robert, A.; FLING, Steven, P.; ALGATE, Paul, A.; ELLIOT, Mark; MANNION, Jane; KALOS, Michael, D.
DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001072795	A2	20011004
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US40991	A	20010329
PRIORITY INFO.:	US 2000-09/538,337		20000329
	US 2000-09/588,937		20000605
	US 2000-09/640,978		20000817
	US 2000-60/234,517		20000922
	US 2000-09/704,512		20001101
	US 2000-09/738,973		20001214

ABEN Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

ABFR L'invention concerne des compositions et des methodes pouvant traiter ou diagnostiquer le cancer, notamment le cancer du poumon. Des compositions exemplaires contiennent un ou plusieurs polypeptides de tumeur broncho-pulmonaire, des parties immunogenes desdits polypeptides, des polynucleotides codant ces polypeptides, une cellule antigenique exprimant ces polypeptides, et des lymphocytes T specifiques de cellules exprimant ces polypeptides. Les compositions de l'invention sont utiles, par exemple, pour diagnostiquer, prevenir et/ou traiter des maladies, notamment le cancer du poumon.

L104 ANSWER 53 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001063090 PCTFULL ED 20020822
TITLE (ENGLISH): BCMP-7 AS MARKER FOR DIAGNOSIS OF BREAST CANCER
TITLE (FRENCH): BCMP 7 EN TANT QUE MARQUEUR POUR LE DIAGNOSTIC DU CANCER DU SEIN
INVENTOR(S): BOYD, Robert, Simon; STAMPS, Alasdair, Craig; TERRETT, Jonathan, Alexander; TYSON, Kerry, Louise
PATENT ASSIGNEE(S): OXFORD GLYCOSCIENCES (UK) LTD.; BOYD, Robert, Simon; STAMPS, Alasdair, Craig; TERRETT, Jonathan, Alexander; TYSON, Kerry, Louise
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001063090	A1	20010830
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-GB734	A	20010221
PRIORITY INFO.:	GB 2000-00048 6.5		20000225

ABEN The present invention provides the use of a protein found in breast cancer cell membranes, known as BCMP 7, in the diagnosis, screening, treatment and prophylaxis of breast cancer, as well as compositions

comprising BCMP 7, including vaccines and antibodies that are immunospecific for BCMP 7.

ABFR La presente invention concerne l'utilisation d'une proteine presente dans des membranes cellulaires de cancer du sein, connue en tant que BCMP 7, dans le diagnostic, le criblage, le traitement et la prophylaxie du cancer du sein. L'invention concerne egalement des compositions contenant BCMP 7 et des vaccins et anticorps immunospecifiques a BCMP 7.

L104 ANSWER 54 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001062095 PCTFULL ED 20010830
TITLE (ENGLISH): PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR
TITLE (FRENCH): FORMES PROTEGEES D'AGENTS PHARMACOLOGIQUEMENT ACTIFS ET UTILISATIONS CORRESPONDANTES
INVENTOR(S): LAI, Ching-San; WANG, Tingmin; VASSILEV, Vassil, P.
PATENT ASSIGNEE(S): MEDINOX, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001062095	A1	20010830
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US5977	A	20010223
PRIORITY INFO.:	US 2000-09/516,043		20000225

ABEN In accordance with the present invention, there are provided conjugates of dithiocarbamates ("DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein.

ABFR La presente invention se rapporte a des conjugues de dithiocarbamates ("DC") et a des agents pharmacologiquement actifs (par exemple, des AINS). Lesdits conjugues fournissent une nouvelle classe d'agents pharmacologiquement actifs (par exemple, d'agents anti-inflammatoires) qui provoquent une apparition bien moindre d'effets secondaires en raison des effets protecteurs conferes par la modification des agents pharmacologiquement actifs decrits ci-dessus.

L104 ANSWER 55 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001057010 PCTFULL ED 20020827
TITLE (ENGLISH): USE OF DENDROASPIN AS A VEHICLE FOR NON-DENDROASPIN DOMAINS
TITLE (FRENCH): UTILISATION DE DENDROASPINE EN TANT QU'EXCIPIENT POUR DOMAINES EXEMPTS DE DENDROASPINE
INVENTOR(S): LU, Xinjie; KAKKAR, Vijay, Vir
PATENT ASSIGNEE(S): TRIGEN LIMITED
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001057010	A2	20010809
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG		

CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-GB4[illegible] A 20010205
PRIORITY INFO.: GB 2000-[illegible].625.2 20000207

ABEN The use of dendroaspin as a scaffold for one or more non wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-binding amino acid sequence other than RGD which contains aspartic acid (D) or glutamic acid (E).

ABFR L'invention concerne l'utilisation de dendroaspine en tant que structure pour au moins un domaine de dendroaspine qui n'est pas du type sauvage, la structure de dendroaspine etant modifiee du fait que le motif endogene RGD a ete elimine ou remplace (i) par une sequence d'acides amines ne possedant pas d'activite de liaison aux integrines ou (ii) par une sequence d'acides amines se liant aux integrines qui differe de RGD et renferme de l'acide aspartique (D) ou de l'acide glutamique (E).

L104 ANSWER 56 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001057194 PCTFULL ED 20020927
TITLE (ENGLISH): NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, THE ENCODED PROTEINS AND METHODS BASED THEREON
TITLE (FRENCH): MOLECULES D'ACIDES NUCLEIQUES CODANT POUR DES PROTEASES A SERINE TRANSMEMBRANAIRES, PROTEINES CODEES ET PROCEDES ASSOCIES
INVENTOR(S): MADISON, Edwin, L.; ONG, Edgar, O.; YEH, Jiunn-chern
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC.; MADISON, Edwin, L.; ONG, Edgar, O.; YEH, Jiunn-chern
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001057194	A2	20010809
DESIGNATED STATES	AE AG AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US3471	A	20010202
PRIORITY INFO.:	US 2000-60/179,980		20000203
	US 2000-60/183,540		20000218
	US 2000-60/213,124		20000620
	US 2000-60/220,970		20000726
	US 2000-09/667,986		20000908
	US 2000-60/234,640		20000922

ABEN Provided herein are polypeptides that include the protease domain of a type II transmembrane serine protease (MTSP) as a single chain. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP are provided. Also provided are MTSPs designated MTSP3 and MTSP4 and a form of an MTSP designated MTSP6.

ABFR L'invention concerne des polypeptides comportant un domaine de protease du type de protease a serine transmembranaire de type II (MTSP) sous forme d'une chaine unique. Elle concerne aussi des procedes utilisant des polypeptides afin d'identifier des composes qui modulent l'activite protease d'une MTSP. Elle concerne encore des MTSP de designation MTSP3 et MTSP4 ainsi qu'une forme de MTSP de designation MTSP6.

L104 ANSWER 57 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001056208 PCTFULL ED 20020927
TITLE (ENGLISH): NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TITLE (FRENCH): ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS
INVENTOR(S): ROSEN, Craig, A.; BARASH, Steven, C.; RUBEN, Steven, M.

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; RUBEN, Craig, A.; BARASH, Steven, C.; RUBEN, Steven, M.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001056205	A1	20010802

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US1337	A	20010117
PRIORITY INFO.:	US 2000-60/176,065		20000131
	US 2000-60/180,628		20000204
	US 2000-60/184,664		20000224
	US 2000-60/186,350		20000302
	US 2000-60/189,874		20000316
	US 2000-60/190,076		20000317
	US 2000-60/198,123		20000417
	US 2000-60/205,515		20000519
	US 2000-60/209,467		20000607
	US 2000-60/214,886		20000628
	US 2000-60/215,135		20000630
	US 2000-60/216,647		20000707
	US 2000-60/216,880		20000707
	US 2000-60/217,487		20000711
	US 2000-60/217,496		20000711
	US 2000-60/218,290		20000714
	US 2000-60/220,963		20000726
	US 2000-60/220,964		20000726
	US 2000-60/225,757		20000814
	US 2000-60/225,270		20000814
	US 2000-60/225,447		20000814
	US 2000-60/225,267		20000814
	US 2000-60/225,758		20000814
	US 2000-60/225,268		20000814
	US 2000-60/224,513		20000814
	US 2000-60/224,513		20000814
	US 2000-60/225,752		20000814
	US 2000-60/225,213		20000814
	US 2000-60/225,266		20000814
	US 2000-60/225,214		20000814
	US 2000-60/226,378		20000818
	US 2000-60/226,[illegible]		20000820
	US 2000-60/227,182		20000820
	US 2000-60/226,681		20000820
	US 2000-60/227,003		20000823
	US 2000-60/228,424		20000830
	US 2000-60/229,344		20000901
	US 2000-60/229,343		20000901
	US 2000-60/229,387		20000901
	US 2000-60/229,645		20000901
	US 2000-60/229,513		20000901
	US 2000-60/229,519		20000901
	US 2000-60/236,438		20000927
	US 2000-60/236,467		20000927
	US 2000-60/231,413		20000908
	US 2000-60/232,990		20000908
	US 2000-60/231,414		20000908
	US 2000-60/231,244		20000908
	US 2000-60/232,081		20000908

US 2000-60/231,240 20000908
US 2000-60/231,248 20000908
US 2000-60/231,469 20000912
US 2000-60/232,471 20000914
US 2000-60/232,344 20000914
US 2000-60/232,4 20000914
US 2000-60/232,347 20000914
US 2000-60/232,363 20000914
US 2000-60/232,364 20000914
US 2000-60/232,365 20000914
US 2000-60/232,344 20000914
US 2000-60/234,223 20000921
US 2000-60/234,274 20000921
US 2000-60/234,447 20000925
US 2000-60/234,445 20000925
US 2000-60/235,434 20000926
US 2000-60/235,434 20000927
US 2000-60/235,936 20000927
US 2000-60/236,304 20000928
US 2000-60/236,327 20000928
US 2000-60/236,373 20000928
US 2000-60/236,368 20000928
US 2000-60/236,367 20000929
US 2000-60/237,039 20001002
US 2000-60/237,038 20001002
US 2000-60/237,040 20001002
US 2000-60/237,037 20001002
US 2000-60/236,802 20001002
US 2000-60/239,937 20001013
US 2000-60/239,935 20001013
US 2000-60/241,785 20001020
US 2000-60/241,804 20001020
US 2000-60/240,360 20001020
US 2000-60/241,787 20001020
US 2000-60/241,803 20001020
US 2000-60/241,771 20001020
US 2000-60/241,786 20001020
US 2000-60/241,806 20001020
US 2000-60/244,617 20001101
US 2000-60/246,474 20001102
US 2000-60/246,532 20001106
US 2000-60/246,476 20001108
US 2000-60/246,526 20001102
US 2000-60/246,475 20001108
US 2000-60/246,535 20001108
US 2000-60/246,528 20001103
US 2000-60/246,527 20001108
US 2000-60/246,477 20001108
US 2000-60/246,611 20001105
US 2000-60/246,610 20001105
US 2000-60/246,612 20001102
US 2000-60/246,609 20001105
US 2000-60/246,478 20001105
US 2000-60/246,524 20001104
US 2000-60/246,523 20001104
US 2000-60/248,094 20001117
US 2000-60/248,201 20001117
US 2000-60/248,112 20001117
US 2000-60/248,110 20001117
US 2000-60/248,111 20001117
US 2000-60/248,201 20001117
US 2000-60/248,114 20001117
US 2000-60/248,204 20001117
US 2000-60/248,213 20001117
US 2000-60/249,212 20001117

US 2000-60/249,207 20001117
US 2000-60/249,248 20001117
US 2000-60/249,244 20001117
US 2000-60/249,287 20001117
US 2000-60/249,214 20001117
US 2000-60/249,264 20001117
US 2000-60/249,209 20001117
US 2000-60/249,300 20001117
US 2000-60/249,265 20001117
US 2000-60/250,991 20001201
US 2000-60/251,160 20001201
US 2000-60/256,719 20001205
US 2000-60/251,930 20001205
US 2000-60/251,999 20001205
US 2000-60/251,479 20001206
US 2000-60/251,969 20001208
US 2000-60/251,956 20001208
US 2000-60/251,968 20001208
US 2000-60/251,999 20001208
US 2000-60/251,989 20001208
US 2000-60/254,097 20001211
US 2001-60/259,675 20010105

ABEN The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ABFR La presente invention se rapporte a de nouvelles proteines. Plus specifiquement, elle se rapporte a des molecules d'acides nucleiques isolees codant pour de nouveaux polypeptides. Elle se rapporte a de nouveaux polypeptides et a des anticorps qui se lient a ces polypeptides. L'invention se rapporte a des vecteurs, a des cellules hotes et a des procedes de synthese et de recombinaison pour la production de polynucleotides et/ou de polypeptides humains et d'anticorps. L'invention se rapporte a des methodes diagnostiques et therapeutiques permettant de diagnostiquer, de traiter, de prevenir et/ou de pronostiquer des troubles associes a ces nouveaux polypeptides. L'invention se rapporte en outre a des procedes de criblage permettant d'identifier des agonistes et des antagonistes des polynucleotides et des polypeptides decrits ci-dessus. Elle se rapporte enfin a des procedes et/ou a des compositions permettant d'inhiber ou de favoriser la production et la fonction desdits polypeptides.

L104 ANSWER 58 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20010510067 PCTFULL ED 20020807
TITLE (ENGLISH): MULTIPLE INACTIVATED BLOOD FACTOR ANTICOAGULANT COMPOSITION
TITLE (FRENCH): COMPOSITION ANTICOAGULANTE A FACTEURS SANGUINS INACTIVES MULTIPLES
INVENTOR(S): JOHNSON, Richard, C.; LUNDBLAD, Roger
PATENT ASSIGNEE(S): BAXTER INTERNATIONAL INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 20010510067	A1	20010719

DESIGNATED STATES AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC

NL PT SE TR
APPLICATION INFO.: WO 2000-US34124 A 20001220
PRIORITY INFO.: US 1999-60/171,921 19991223
US 2000-09/741,239 20001219

ABEN An anticoagulant composition is provided which comprises at least two inactivated blood factors in a pharmaceutically acceptable carrier, such inactivated blood factors being present in a therapeutically effective dosage. Methods for utilizing such anticoagulant compositions comprising providing to a patient a coagulation inhibiting amount thereof are also provided, as are methods for the preparation of such compositions.

ABFR La presente invention concerne une composition anticoagulante comprenant au moins deux facteurs sanguins inactives dans un vecteur acceptable du point de vue pharmaceutique, les facteurs sanguins inactives de ce type etant presents en un dosage efficace du point de vue pharmaceutique. Cette invention concerne egalement des procedes d'utilisation des compositions anticoagulantes de l'invention, comprenant l'administration a un patient d'une quantite desdites compositions permettant d'inhiber la coagulation, ainsi que des procedes de preparation de ces compositions.

L104 ANSWER 59 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001049675 PCTFULL ED 20020927
TITLE (ENGLISH): DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS
TITLE (FRENCH): DIHYDROBENZOPYRANNES, DIHYDROBENZOTHIOPYRANNES ET TETRAHYDROQUINOLINES DESTINES AU TRAITEMENT DES TROUBLES INDUITS PAR COX-2
INVENTOR(S): ROGIER, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, John, J.
PATENT ASSIGNEE(S): PHARMACIA CORPORATION; ROGIER, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, John, J.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001049675	A1	20010712
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US34525	A	20001219
PRIORITY INFO.:	US 2000-60/174,381		20000103

ABEN A class of dihydrobenzopyrans, dihydrobenzothiopyrans, tetrahydroquinolines, tetrahydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I) wherein X, A1, A2, A3, A4, R, R'', R1 and R2 are as described in the specification.

ABFR L'invention concerne une categorie de dihydrobenzopyrannes, dihydrobenzothiopyrannes, tetrahydroquinolines, tetrahydronaphthalenes et leurs **analogues**, destines a etre utilises dans le traitement des troubles induits par la cyclooxygenase-2. Les composes presentant un interet particulier sont representes par la formule (I), ou X, A1, A2, A3, A4, R, R'', R1 et R2 sont tels que definis dans le descriptif.

L104 ANSWER 60 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001036458 PCTFULL ED 20020906
TITLE (ENGLISH): KUNITZ-TYPE PROTEASE INHIBITOR POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
TITLE (FRENCH): POLYNUCLEOTIDES INHIBITEURS DE PROTEASE DU TYPE DE

KUNITZ, POLYPEPTIDES ET ANTICORPS

INVENTOR(S): RUBEN, Steven, M.; NI, Jian

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; RUBEN, Steven, M.; NI, Jian

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001 34486	A2	20010517
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US31417	A	20001110
PRIORITY INFO.:	US 1999-164,711		19991102

ABEN The present invention relates to novel human KTPI polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human KTPI polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human KTPI polypeptides.

ABFR

L104 ANSWER 61 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001033611 PCTFULL ED 20020926

TITLE (ENGLISH): N GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM

TITLE (FRENCH): N GUANIDINOALKYLAMIDES, LEUR PREPARATION, LEUR UTILISATION, ET PREPARATIONS PHARMACEUTIQUES RENFERMANT CEUX-CI

INVENTOR(S): KLINGLER, Otmar; ZOLLER, Gerhard; DEFOSSA, Elisabeth; AL-OBEIDI, Fahad; WALSER, Armin; OSTREM, James

PATENT ASSIGNEE(S): AVENTIS PHARMA DEUTSCHLAND GMBH

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001033611	A1	20010510
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000 EP10345	A	20001018
PRIORITY INFO.:	EP 1999-121623.9		19991030

ABEN The present invention relates to compounds of formula (I), in which A, L, Y and k have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible **inhibitors** of the blood clotting enzymes **factor Xa** and/or factor VIIa and can in general be applied in conditions in which an undesired activity of **factor Xa** and/or factor VIIa is present or for the cure or prevention of which an **inhibition** of **factor Xa** and/or factor VIIa is intended. The invention furthermore relates to processes for the

preparation of compounds of the formula I , their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

ABFR

L104 ANSWER 62 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001027141 PCTFULL ED 20020920
TITLE (ENGLISH): **INHIBITORS** OF **FACTOR XA** HAVING AN **ARGININE** OR **ARGININE** ALDEHYDE MIMIC
TITLE (FRENCH): INHIBITEURS DU FACTEUR XA POSSEDANT UNE **ARGININE** OU UN **ANALOGUE** DE L' **ARGININE**
INVENTOR(S): TEMPLE, Joseph, Edward; BRUNCK, Terence, Kevin; LEVY, Odile, Esther; TAMURA, Susan, Y.
PATENT ASSIGNEE(S): NOVAS INTERNATIONAL, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001027141	A1	20010419
DESIGNATED STATES	CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US27615	A	20001006
PRIORITY INFO.:	US 1999-09/414,903		19991008

ABEN Peptidyl aldehydes having an **arginine** or **arginine** mimic at P3 which are selective **inhibitors** of certain serine proteases, including **factor Xa**, are described. These compounds are useful in prevention and treatment of conditions characterized by abnormal thrombosis in mammals.

ABFR

L104 ANSWER 63 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001025413 PCTFULL ED 20020920
TITLE (ENGLISH): USE OF A CONTEXT-DEPENDENT FUNCTIONAL ENTITY TO ENHANCE THE EFFICACY OF AN AGENT
TITLE (FRENCH): EFFICACITE ACCRUE D'UN AGENT GRACE A L'UTILISATION D'UNE ENTITE FONCTIONNELLE DEPENDANT DU CONTEXTE
INVENTOR(S): HOUSTON, L., L.
PATENT ASSIGNEE(S): NUVAS, LLC; HOUSTON, L., L.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001025413	A1	20010412
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD AL AZ TM UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US27794	A	20001004
PRIORITY INFO.:	US 1999-09/411,067		19991004

ABEN The present invention relates to a method of enhancing the efficacy of one or more agents in a subject by administering the agent or agents and a context-dependent functional entity to the subject, wherein a context-dependent functional entity includes a substructure with thrombogenic potential operably linked to a selective recognition domain, and interacts with a function-forming context expressed by a cell or tissue in the subject. The invention also relates to a method of treating a pathologic condition in a subject by administering to the subject a therapeutic agent and a context-dependent functional entity. The invention further relates to a pharmaceutical composition, which

contains an agent and a context-dependent functional entity in a pharmaceutically acceptable form. The invention further provides a **peptide** having the amino acid sequence Pro-Arg-Lys-Leu-Tyr-Asp (SEQ ID NO: 1).

ABFR

L104 ANSWER 64 OF 189 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 20010211299 PCTFULL ED 20030810
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS
TITLE (FRENCH): PROCEDES ET COMPOSITIONS DE TRAITEMENT DES PATHOLOGIES APPARENTEES AUX PLAQUETTES
INVENTOR(S): HANSON, Stephen, R.
PATENT ASSIGNEE(S): EMORY UNIVERSITY
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 0101211299	A2	20010809
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US26781	A	20000421
PRIORITY INFO.:	US 1999-60/154,929		19990421

ABEN The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

ABFR

L104 ANSWER 65 OF 189 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 20010211163 PCTFULL ED 20030820
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS
TITLE (FRENCH): PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES LIES AUX PLAQUETTES AU MOYEN D'AGENTS INHIBITEURS DE TRAJET DE MPL
INVENTOR(S): HANSON, Stephen, R.
PATENT ASSIGNEE(S): EMORY UNIVERSITY
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 0101211163	A2	20010809
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US26025	A	20000421
PRIORITY INFO.:	US 1999-60/154,929		19990421

ABEN The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

ABFR

L104 ANSWER 66 OF 189 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 20010183046 PCTFULL ED 20030828
TITLE (ENGLISH): OVARIAN TUMOR SEQUENCES AND METHODS OF USE THEREFOR
TITLE (FRENCH): SEQUENCES DE TUMEURS OVARIENNES ET PROCEDES D'UTILISATION CORRESPONDANTS
INVENTOR(S): XU, Jiangchun; STOLK, John, A.
PATENT ASSIGNEE(S): ORIXA CORPORATION; XU, Jiangchun; STOLK, John, A.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 2001019046	A2 20010315	
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU		
	CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN		
	IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK		
	MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM		
	TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD		
	SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY		
	DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG		
	CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US24127	A 20000901	
PRIORITY INFO.:	US 1999-09/394,374	19990911	
	US 2000-09/541,778	20000501	
	US 2000-09/640,173	20000815	
	US 2000-09/656,668	20000907	

ABEN Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Polypeptides and polynucleotides as provided herein may further be used for the detection and monitoring of ovarian cancer.

ABFR

L104 ANSWER 67 OF 189 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2001012336 PCTFULL ED 20020828

TITLE (ENGLISH): CRYSTAL OF A TRUNCATED PROTEIN CONSTRUCT CONTAINING A COAGULATION FACTOR VIII C2 DOMAIN IN THE PRESENCE OR ABSENCE OF A BOUND LIGAND AND METHODS OF USE THEREOF

TITLE (FRENCH): CRISTAL DE PRODUIT DE RECOMBINAISON PROTEIQUE TRONQUE RENFERMANT UN DOMAINE C2 DU FACTEUR DE COAGULATION VIII, AVEC OU SANS LIGAND LIE, ET PROCEDES D'UTILISATION

INVENTOR(S): STODDARD, Barry, L.; PRATT, Kathleen; FUJIKAWA, Kazuo; DAVIE, Earl, W.

PATENT ASSIGNEE(S): FRED HUTCHINSON CANCER RESEARCH CENTER; UNIVERSITY OF WASHINGTON; STODDARD, Barry, L.; PRATT, Kathleen; FUJIKAWA, Kazuo; DAVIE, Earl, W.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001012336	A1	20010222
DESIGNATED STATES	AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US21226	A	20000811
PRIORITY INFO.:	US 1999-09/149,907		19990813

ABEN A detailed three-dimensional structure for the C-terminal C2 domain of blood coagulation factor VIII is disclosed. The novel truncated factor VIII constructs which were designed so as to omit a significant portion of the flexible full length protein are also part of the present invention. In addition, the crystals of the protein, both in the presence and absence of bound ligands are also included. Furthermore, methods of identifying antagonists of the human factor VIII protein which can be used to inhibit coagulation or to stabilize and activate factor VIII mutants are also disclosed. Furthermore, methods of identifying variations of the C2 domain sequence and structure that can be incorporated into intact factor VIII for the purpose of administration to hemophiliac patients who are immunoreactive against wild type factor VIII are disclosed.

ABFR

L104 ANSWER 68 OF 189 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2001010992 PCTFULL ED 20020828

TITLE (ENGLISH): FVIIa ANTAGONISTS
TITLE (FRENCH): ANTAGONISTE DU FVIIa
INVENTOR(S): DENNIS, Mark, S.
PATENT ASSIGNEE(S): GENENTECH, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001010892	A2	20010215

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US21296	A	20000804
PRIORITY INFO.:	US 1999-60/147,617		19990806
	US 1999-60/150,315		19990823

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a **peptide** compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
ABFR

L104 ANSWER 69 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001003735 PCTFULL ED 20020828
TITLE (ENGLISH): CANCER TREATMENT USING ANGIOPOIETINS TARGETED TO AMINOPHOSPHOLIPIDS
TITLE (FRENCH): TRAITEMENT ANTICANCEREUX DANS LEQUEL SONT UTILISEES DES ANGIOPOIETINES CIBLANT DES AMINOPHOSPHOLIPIDES
INVENTOR(S): THORPE, Philip, E.
PATENT ASSIGNEE(S): MAINE MEDICAL CENTER RESEARCH INSTITUTE; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THORPE, Philip, E.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001003735	A1	20010119

DESIGNATED STATES: AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.:	WO 2000-US18779	A	20000711
PRIORITY INFO.:	US 1999-60/143,742		19990713

ABEN Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention particularly provides therapeutic constructs and conjugates that bind to aminophospholipids and contain angiopoietins, and various methods of specifically delivering angiopoietins to the stably-expressed aminophospholipids of tumor blood vessels, thereby exerting anti-tumor effects.
ABFR

L104 ANSWER 70 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001001749 PCTFULL ED 20020828
TITLE (ENGLISH): FVIIa ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DE FVIIa
INVENTOR(S): DENNIS, Mark, S.; EIGENBROT, Charles; LAZARUS, Robert, A.

PATENT ASSIGNEE(S): GENENTECH, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001001749	A2	20010111
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000 US18364	A	20000630
PRIORITY INFO.:	US 1999 60/141,811		19990702

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a **peptide** compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
ABFR

L104 ANSWER 71 OF 189 PCTFULL COPYRIGHT 2000 Univentio
ACCESSION NUMBER: 2001001150 PCTFULL ED 20020809
TITLE (ENGLISH): DIAGNOSTIC TEST FOR THROMBOTIC OR THROMBOEMBOLIC DISEASE
TITLE (FRENCH): EXAMEN DIAGNOSTIQUE POUR LA THROMBOSE OU LA THROMBOEMBOLIE
INVENTOR(S): MORRIS, Timothy, A.
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; MORRIS, Timothy, A.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001001150	A2	20010104
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US17877	A	20000630
PRIORITY INFO.:	US 1999-60/141,734		19990630

ABEN Thrombotic or thromboembolic disease is detected or monitored by determining the presence or amount B in a physiological sample.
ABFR

L104 ANSWER 72 OF 189 PCTFULL COPYRIGHT 2000 Univentio
ACCESSION NUMBER: 2001000667 PCTFULL ED 20020606
TITLE (ENGLISH): ANTI-THROMBIN **PEPTIDE** FROM ANOPHELES ALBIMANUS SALIVARY GLAND
TITLE (FRENCH): NOUVEAU **PEPTIDE** ANTI-THROMBINE
INVENTOR(S): VALENZUELA, Jesus, G.; RIBEIRO, Jose; FRANCISCHETTI, Ivo
PATENT ASSIGNEE(S): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; VALENZUELA, Jesus, G.; RIBEIRO, Jose; FRANCISCHETTI, Ivo

DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001006867	A2	20010104
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US18078	A	20000629
PRIORITY INFO.:	US 1999-141,423		19990629

ABEN The DNA and amino acid sequences are disclosed for a novel anti-thrombin **peptide**, anophelin, one embodiment of which was isolated form the salivary glands of the mosquito Anopheles albimanus. Also disclosed are anti-thrombotic therapeutic applications of anophelin.
ABFR

L104 ANSWER 73 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 802986 EUROPATFULL EW 200138 FS PS STA R
TITLE: METHODS OF DETERMINING ENDOGENOUS THROMBIN POTENTIAL (ETP) AND THROMBIN SUBSTRATES FOR USE IN SAID METHODS.
VERFAHREN ZUM NACHWEIS DES ENDOGENEN THROMBIN-POTENTIALS UND THROMBIN SUBSTRATE ZUR VERWENDUNG IN DIESEN VERFAHREN.
PROCEDES POUR LA DETERMINATION DU POTENTIEL THROMBINE ENDOGENE (ETP), ET SUBSTRATS POUR THROMBINE UTILISES DANS CES PROCEDES.
INVENTOR(S): HEMKER, Hendrik, Coenraad, Tongersestraat 41, NL-6211 LM Maastricht, NL;
BIJKERK, Dirk, Thomas, Sigurd, Arieslaan 13, NL-5632 AS Eindhoven, NL;
TESSER, Godefriedus, Ignatius, Kronenburgersingel 64, NL-6511 AT Nijmegen, NL
PATENT ASSIGNEE(S): Hemker, Hendrik Coenraad, Tongersestraat 41, NL-6211 LM Maastricht, NL
PATENT ASSIGNEE NO: 1277390
AGENT: de Bruijn, Leendert C. et al., Nederlandsch Octrooibureau P.O. Box 29720, 2502 LS Den Haag, NL
AGENT NUMBER: 19641
OTHER SOURCE: EEPB2001043 EP 0802986 B1 0031
SOURCE: Wila-EPS-2001-H38-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Verpeffentlichung in Englisch
DESIGNATED STATES: R CH; R DE; R ES; R FR; R GB; R IT; R LI; R NL
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 802986	B1	20010919
'OFFENLEGUNGS' DATE:			19971029
APPLICATION INFO.:	EP 1996-902067		19960110
PRIORITY APPLN. INFO.:	EP 1995-200043		19950110
RELATED DOC. INFO.:	WO 96-NL18	960110	INTAKZ
	WO 962740	960718	INTPNR
REFERENCE PAT. INFO.:	EP 290410 A		EP 420332 A
	WO 96-01899 A		US 4214049 A
	US 4247484 A		

REF. NON-PATENT-LIT.: THROMBOSIS AND HAEMOSTASIS, vol. 70, no. 4, 1993, STUTTGART DE, pages 617-624, XP000967560 H.C. HEMKER ET AL.: "Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential" cited in the application THROMBOSIS RESEARCH, vol. 74, no. 5-6, 15 September 1994, WASHINGTON US, pages 491-499, XP002000516 D.T. RICKERS ET AL.: "Design and synthesis of thrombin substrates with modified kinetic parameters" THROMBOSIS AND HAEMOSTASIS, vol. 74, no. ., July 1995, STUTTGART DE, pages 134-138, XP000194941 H.C. HEMKER ET AL.: "Thrombin generation in plasma: its assessment via the endogenous thrombin potential" Biochemistry, vol.34, p.3750, (1995) J.Med.Chem., vol.38, p.1145, (1995) J.Med.Chem., vol.37, p.3879, (1994) J.Med.Chem., vol.39, p.4527, (1996) Structure, vol.4, p.1353-1362, (1996) J.Med.Chem., vol.39, p.4531, (1996)

L104 ANSWER 74 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 692025 EUROPATFULL EW 200142 FS PS STA R
TITLE: YEAST CELLS ENGINEERED TO PRODUCE PHEROMONE SYSTEM PROTEIN SURROGATES, AND USES THEREFOR.
HEFE ZELLEN SO KONSTRUIERT, DASS SIE PROTEINSURROGATE DES PHEROMENSYSTEMS PRODUZIEREN UND ANWENDUNGEN DAFUER.
CELLULES DE LEVURE TRAITEES POUR PRODUIRE DES SUBSTITUTS DE PROTEINES DU SYSTEME DE PHEROMONES, ET LEURS EMPLOIS.
INVENTOR(S): POWLRES, Dana, Merriman 90 Green Street, Apartment 2, New York, NY 10013, US;
BROACH, Jim 360 East 88th Street, Apartment 2A, New York, NY 10128, US;
MANFREDI, John 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
KLEIN, Christine 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
MURPHY, Andrew, J., 17 Windsor Place, Montclair, NJ 07043, US;
PAUL, Jeremy, 197 Route 9W, Palisades, NY 10964, US;
TRUEHEART, Joshua, 212 South Broadway, South Nyack, NY 10960, US
PATENT ASSIGNEE(S): Cadus Pharmaceutical Corporation, 7th floor, 180 Varick Street, New York, NY 10128, US
PATENT ASSIGNEE NO: 1860560
AGENT: Price, Vincent Andrew et al., FRY HEATH & SPENCE The Old College 53 High Street, Horley Surrey RH6 7BN, GB
AGENT NUMBER: 79513
OTHER SOURCE: REPB200105: EP 0692025 B1 0068
SOURCE: Wila EPB-2001-H42-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 692025	B1	20011017
'OFFENLEGUNGS' DATE:			19960117
APPLICATION INFO.:	EP 1994-912382		19940323
PRIORITY APPLN. INFO.:	US 1993-41431		19930331
	US 1994-190329		19940131
RELATED DOC. INFO.:	WO 94-US3143	940323	INTAKZ

WO 9423025 941013 INTPNR

REFERENCE PAT. INFO.: WO 92-05244 A

REF. NON-PATENT-LIT.: SCIENCE vol. 251, October 1991, LANCASTER, PA US pages 121 - 123 KLIM KING ET AL. 'Control of yeast mating signal transduction by a mammalian beta2-adrenergic receptor and Gs alpha subunit' CELL vol. 66, 20 September 1991, CAMBRIDGE, MA US pages 1197 - 1206 D. J. LEW ET AL. 'Isolation of three novel human cyclins by rescue of G. cyclin (Cln) function in yeast' CELL vol. 66, 17 May 1991, CAMBRIDGE, MA US pages 691 - 699 YUE XIONG ET AL. 'Human D-type cyclin' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 89, October 1992, WASHINGTON US pages 9413 - 9414 M. WITHEWAY ET AL. 'Dominant negative selection of heterologous genes: Isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell cycle arrest' JOURNAL OF CELLULAR BIOCHEMISTRY vol. 18B, February 1994 page 224 J. MANFREDI ET AL. 'Autocrine stimulation of yeast through human G-coupled receptors' A. KOFF ET AL.,: 'HUMAN CYCLIN E, A NEW CYCLIN THAT INTERACTS WITH TWO MEMBERS OF THE CDC2 GENE FAMILY' CELL vol. 66, 1991, pages 1217 - 1228 D.A. HUGHES ET AL.,: 'COMPLEMENTATION OF BYR1 IN FISSION YEAST BY MAMMALIAN MAP KINASE REQUIRES COEXPRESSION OF RAF KINASE' NATURE vol. 364, 1993, pages 394 - 352

L104 ANSWER 75 OF 189 USPATFULL

ACCESSION NUMBER: 2000:164081 USPATFULL

TITLE: Tissue factor methods and compositions for coagulation and tumor treatment

INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
King, Steven W., Foothill Ranch, CA, United States
Gao, Boning, Dallas, TX, United States

PATENT ASSIGNEE(S): Board Of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6156321		20001205	
APPLICATION INFO.:	US 1999-9800		19980120	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35900P	19970102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1,3
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 7503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa or FVIIa

activators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 76 OF 189 USPATFULL
ACCESSION NUMBER: 2001:137821 USPATFULL
TITLE: Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
King, Steven W., Foothill Ranch, CA, United States
Gac, Boning, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232739		20010517
APPLICATION INFO.:	US 1998-9456		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35920P	19970122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1,3
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 7436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 77 OF 189 USPATFULL
ACCESSION NUMBER: 2001:137819 USPATFULL
TITLE: Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
King, Steven W., Foothill Ranch, CA, United States
Gac, Boning, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232729		20010517
APPLICATION INFO.:	US 1998-9017		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)

US 1997-862058P 19970127 (60)
US 1997-35923P 19970122 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 7496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 78 OF 189 USPATFULL
ACCESSION NUMBER: 2000:131912 USPATFULL
TITLE: Serine protease inhibitors
INVENTOR(S): Green, Donovan St. Clair, London, United Kingdom
Elgendy, Said Mohammed Anwr Ahmed, London, United Kingdom
Patel, Geeta, London, United Kingdom
Scully, Michael Finbar, Essex, United Kingdom
Goodwin, Christopher Andrew, Avon, United Kingdom
Kakkar, Vijay Vir, Hants, United Kingdom
Deadman, John Joseph, Surrey, United Kingdom
PATENT ASSIGNEE(S): Trigen Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6127349		20001003	
	WO 9625427		19960822	
APPLICATION INFO.:	US 1998-894120		19980330	(8)
	WO 1996-GB352		19960215	
			19980330	PCT 371 date
			19980330	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-2985	19950216

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
LINE COUNT: 2442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to **peptide** inhibitors of serine proteases, especially thrombin, in which the P1-P2 natural amide linkage is replaced by another bond. Exemplary thrombin inhibitors have the formula: X-(aa.sup.3)-(aa.sup.2)-.psi.-(aa.sup.1)-Z wherein X is H or a substituent on the N-terminal amino group, aa.sup.3 is a hydrophobic amino acid, aa.sup.23 is Pro, aa.sup.1 is Arg or an Arg

analgoue, Z is --COOH or a heteroatom acid group and .psi. is a non-amide linkage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 79 OF 189 USPATFULL
ACCESSION NUMBER: 2001:101539 USPATFULL
TITLE: Methods for regulating transcription factors
INVENTOR(S): Qasar, Maher N., Redmond, WA, United States
McMillan, Michael K., Bellevue, WA, United States
Mahn, Michael S., Kirkland, WA, United States
Tulinsky, John E., Seattle, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Mathew, Jessymol, Bellevue, WA, United States
PATENT ASSIGNEE(S): Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117896		20000912
APPLICATION INFO.:	US 1998-22934		19980212 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, now abandoned And a continuation-in-part of Ser. No. US 692420		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47067P	19970519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 4591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB .beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 80 OF 189 USPATFULL
ACCESSION NUMBER: 2000:102075 USPATFULL
TITLE: Yeast cells engineered to produce pheromine system protein surrogates, and uses therefor
INVENTOR(S): Fowlkes, Dana Merriman, New York, NY, United States
Broach, Jim, New York, NY, United States
Manfredi, John, New York, NY, United States
Klein, Christine, New York, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, Palisades, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PATENT ASSIGNEE(S): Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6130042		20000908

APPLICATION INFO.: US 1994-322137 19941013 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-309313, filed on 21 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190325, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, Lauro, Esq., Peter C., Kara, Catherine J.
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential **peptide** modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 81 OF 189 USPATFULL
ACCESSION NUMBER: 2000:87702 USPATFULL
TITLE: Prothrombin derivatives
INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Schlokat, Uwe, Orth/Donau, Austria
Mitterer, Artur, Orth/Donau, Austria
Falkner, Falko-Gunter, Orth/Donau, Austria
Eibl, Johann, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6086871		20000711	
	WO 9641868		19961227	
APPLICATION INFO.:	US 1998-952967		19980126	(3)
	WO 1996-AT105		19960612	
			19980126	PCT 371 date
			19980126	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1995-1005	19950613

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Saucha, Tekchand
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new prothrombin mutants or derivatives thereof which comprise one or more changes in their protein sequence as compared to natural protein, are either inactive or have an activity of approximately 10% at the most, preferably approximately 0.25% at the most, of the natural protein and which have a binding capacity relative

to natural ligands, natural or synthetic anticoagulants, substantially corresponding to that of the natural protein. Furthermore, the use of mutated prothrombin mutants or derivatives, respectively, as pharmaceutical preparations is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 82 OF 189 USPATFULL
ACCESSION NUMBER: 2001:87745 USPATFULL
TITLE: Thrombin inhibitors based on the amino acid sequence of hirudin
INVENTOR(S): DiMaio, John, Montreal, Canada
Konishi, Yasuo, Kirkland, Canada
Ni, Feng, Pierrefonds, Canada
Steinmetzer, Torsten, Jena, Germany, Federal Republic of
PATENT ASSIGNEE(S): The National Research Council of Canada, Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060451		20000509
APPLICATION INFO.:	US 1995-406142		19950320 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-302245, filed on 9 Sep 1994, now abandoned which is a continuation of Ser. No. US 960425		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 3086
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and acidic character of amino acids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-acetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 carbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of D-configuration. The compounds are useful in the treatment of thrombotic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 83 OF 189 USPATFULL
ACCESSION NUMBER: 2000:54070 USPATFULL
TITLE: Kallikrein-binding "Kunitz domain" proteins and **analogues** thereof
INVENTOR(S): Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
PATENT ASSIGNEE(S): Dyax Corp., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057287		20000502
APPLICATION INFO.:	US 1994-209364		19940310 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Yelsa, Bennett
LEGAL REPRESENTATIVE: Yankwich, Leon R., Zwicker, Kenneth P.
NUMBER OF CLAIMS: -
EXEMPLARY CLAIM: -
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 8827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to Kunitz domain proteins that bind to, and preferably inhibit, one or more kallikreins, and to therapeutic, diagnostic, and purification use of these proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 94 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000064946 PCTFULL ED 20020515
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR CANCER TREATMENT BY SELECTIVELY INHIBITING VEGF
TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE TRAITEMENT DU CANCER PAR INHIBITION SELECTIVE DE VEGF
INVENTOR(S): THORPE, Philip, E.; BREKKEN, Rolf, A.
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000064946	A2	20001102
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US11367	A	20000428
PRIORITY INFO.:	US 1999-60/131,432		19990428

ABEN Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their **specificity**. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

ABFR L'invention concerne des anticorps qui inhibent specifiquement le VEGF se liant a un seul (VEGFR2) des deux recepteurs VEGF. Les anticorps inhibent efficacement l'angiogenese et induisent aussi efficacement une regression de tumeur, tout en presentant une securite accrue du fait de leur specificite. L'invention concerne par conséquent de nouvelles compositions a base d'anticorps, ainsi que des procedes et des protocoles combines pour traiter le cancer et d'autres maladies angiogeniques. Elle concerne egalement des compositions d'immunoconjugues et de promedicaments ainsi que des procedes interessants faisant appel aux nouveaux anticorps pour le VEGF.

L104 ANSWER 85 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20000663243 PCTFULL ED 20020515
TITLE (ENGLISH): DERIVATIVES OF THE B OR Z DOMAIN FROM STAPHYLOCOCCAL PROTEIN A (SPA) INTERACTING WITH AT LEAST ONE DOMAIN OF HUMAN FACTOR VIII
TITLE (FRENCH): DERIVES DU DOMAINE B OU Z D'UNE PROTEINE STAPHYLOCOCCIQUE A (SPA) AYANT UNE INTERACTION AVEC AU MOINS UN DOMAINE DU FACTEUR VIII HUMAIN
INVENTOR(S): LJUNGQVIST, Charlotta; NORD, Karin; NYGREN, Per-Ake; UHLEN, Mathias
PATENT ASSIGNEE(S): PHARMACIA & UPJOHN AB; LJUNGQVIST, Charlotta; NORD, Karin; NYGREN, Per-Ake; UHLEN, Mathias
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000063243	A1	20001026
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-SE732	A	20000417
PRIORITY INFO.:	SE 1999-9901379-9		19990419

ABEN The present invention relates to modified polypeptides which are derivatives of the B domain or Z domain from staphylococcal protein A (SPA), wherein between 1 and 20 amino acid residues of the said B or Z domain have been substituted by other amino acid residues, said substitution being made without substantial loss of the basic structure and stability of the said B or Z domain, and said substitution resulting in interaction capacity of the said polypeptide with at least one domain of human Factor VIII protein.

ABFR La presente invention porte sur des polypeptides modifies qui sont des derives du domaine B ou Z de la proteine staphylococcique A (SPA), et dans lesquels entre 1 et 20 restes d'acides amines de ce domaine B ou Z ont ete substitues par d'autres restes d'acides amines, cette substitution se faisant pratiquement sans perte de la structure basique et de la stabilite du domaine B ou Z, et conferant au polypeptide une capacite d'interaction avec au moins un domaine de la proteine du Factor VIII humain.

L104 ANSWER 86 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20003661789 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS AND REAGENTS FOR DETERMINING ENZYME SUBSTRATE **SPECIFICITY**, AND USES RELATED THERETO
TITLE (FRENCH): PROCEDES ET REACTIFS SERVANT A DETERMINER LA SPECIFICITE DE SUBSTRATS ENZYMATIQUES ET UTILISATIONS CORRESPONDANTES
INVENTOR(S): BACHOVCHIN, William
PATENT ASSIGNEE(S): TRUSTEES OF TUFTS COLLEGE; BACHOVCHIN, William
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE

WO 2000061789 A1 20001019

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US9497 A 20000410

PRIORITY INFO.: US 1999-60/128,471 19990409

ABEN The invention provides a method for determining a preferred amino acid sequence motif for an active site an associated substrate **specificity** subsites of an enzyme. In the method of the invention, an enzyme is contacted with an oriented degenerate **peptide** library, certain **peptides** within the library which are substrates for the enzyme are bound by the enzyme, and bound **peptide**/enzyme complexes are separated from unbound **peptides**. The bound **peptides** are released from the enzyme and are sequenced. A preferred amino acid sequence motif for the active site and associated **specificity** subsites is determined based upon the relative abundance of different amino acids residues at each degenerate position. The invention also provides **peptides, peptide** analogs, and other small molecules which have a variety of uses and can be derived from the present invention.

ABFR L'invention concerne un procede permettant de determiner un motif prefere de sequence d'acides amines pour un site actif d'une enzyme et ses sous-sites de specificite associes. Selon le procede de l'invention, on met en contact une enzyme avec une banque de **peptides** degeneres orientes, certains **peptides** de la banque etant des substrats pour l'enzyme qui s'y lie, puis on separe les complexes **peptide**/enzyme lies et non lies. Les **peptides** lies sont liberes de l'enzyme puis sequences. On determine un motif prefere de sequence d'acides amines pour le site actif et ses sous-sites de specificite associes en fonction de l'abondance relative des differents residus d'acides amines a chaque position degeneree. L'invention concerne egalement des **peptides**, des **analogues** peptidiques et d'autres petites molecules convenant pour de nombreuses utilisations et pouvant etre derives de l'invention.

L104 ANSWER 87 OF 139 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2000061782 PCTFULL ED 20020515

TITLE (ENGLISH): ECOTINE DERIVATIVES

TITLE (FRENCH): DERIVES D'ECOTINE

INVENTOR(S): CRAIK, Charles, S.; FLETTERICK, Robert, J.; LUNDBLAD, Roger, L.; SCHWARZ, Hans, P.

PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; CRAIK, Charles, S.; FLETTERICK, Robert, J.; LUNDBLAD, Roger, L.; SCHWARZ, Hans, P.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000061782	A1	20001019

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US9773 A 20010312

PRIORITY INFO.: US 1999-09/289,990 19990412

ABEN This invention provides a class binding proteins that specifically bind to and modulate (e.g. enhance) the activity of polypeptides having a chymotrypsin fold (e.g. serine proteases). The binding proteins are based on the structure of ecotin. It was discovered that modification of the amino or carboxyl terminus and/or randomization of one or more of loops 50s, 60s, 80s or 100s will provide an ecotin variant library from which can be selected binding molecules (e.g. protease modulators) specific to virtually any serine protease. Depending on the ecotin variant and the target serine protease, the modulator can act as a serine protease inhibitor or as a serine protease activator. Specific agonists (enhancers) of Factor IXa are disclosed.

ABFR L'invention concerne une classe de proteines de liaison qui se lient specifiquement aux polypeptides comprenant un enroulement de chymotrypsine (p. ex. protease a serine) et modulent (p. ex. renforcent) l'activite de ceux-ci. Ces proteines de liaison reposent sur une structure ecotine. On a decouvert que la modification du terminus amino ou carboxyle et/ou la randomisation d'une ou plusieurs boucles selectionnees dans les boucles 50, 60, 80 ou 100 permet d'obtenir une banque de mutants d'ecotine a partir de laquelle des molecules de liaison (p. ex. modulateurs de protease) specifiques de pratiquement n'importe quelle protease a serine peuvent etre selectionnees. Selon le mutant d'ecotine et la protease a serine cible, le modulateur peut avoir une action d'inhibiteur de protease a serine ou d'activateur de protease a serine. L'invention concerne egalement des agonistes (renforcateurs-facilitateurs) du facteur IX.

L104 ANSWER 88 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 20020515196 PCTFULL ED 20020515

TITLE (ENGLISH): PROTAMINE FRAGMENT COMPOSITIONS AND METHODS OF USE

TITLE (FRENCH): COMPOSITIONS CONTENANT DES FRAGMENTS DE PROTAMINE ET PROCEDES D'UTILISATION

INVENTOR(S): YANG, Victor, C.; BYRN, Youngro

PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF MICHIGAN; YANG, Victor, C.; BYRN, Youngro

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002056196	A1	20020921

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI

FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US6876 A 20000315

PRIORITY INFO.: US 1999-60/124,873 19990317

ABEN Provided are bioactive, low toxicity protamine fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing heparin and reducing post-operative bleeding. Improved protamine fragment-insulin solutions and methods for treating diabetes are also provided.

ABFR L'invention concerne des fragments de protamine bioactifs de faible toxicite, des compositions, des combinaisons, des trousses et des procedes d'utilisation de ces composants dans diverses formes de realisation, y compris pour neutraliser l'heparine et reduire un saignement postoperatoire. L'invention concerne egalement des solutions ameliorees contenant des fragments de protamine-insuline et des methodes de traitement du diabete.

L104 ANSWER 89 OF 189 PCTFULL COPYRIGHT 2001 Univentio

ACCESSION NUMBER: 2000053210 PCTFULL ED 20020515

TITLE (ENGLISH): METHODS OF TREATMENT AND PREVENTION OF RESTENOSIS

TITLE (FRENCH): METHODES DE TRAITEMENT ET DE PREVENTION DE LA RESTENOSE

INVENTOR(S): ROSEN, Craig, A.; NI, Jian; WANG, Mingsheng; SHI, Y., Eric

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; LONG ISLAND JEWISH MEDICAL CENTER; ROSEN, Craig, A.; NI, Jian; WANG, Mingsheng; SHI, Y., Eric

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000053210	A1	20000914

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US6279 A 20000313

PRIORITY INFO.: US 1999-09/266,404 19990311

ABEN The present invention describes methods of treating or preventing restenosis, vascular injury, and vascular disease in a subject by administering TIMP-4. The inventors have surprisingly found that TIMP-4 has an important role in the accumulation of the extracellular matrix in a vessel wall and as such facilitates the healing process of an injured vessel. Also provided by the present invention is a method of inhibiting migration of smooth muscle cells, such as vascular smooth muscle cells, by introducing to the cell an amount of TIMP-4 effective to inhibit the migration, as well as inhibiting extracellular matrix degradation of a vessel, such as an artery, vein or capillary, by introducing TIMP-4 to the vessel.

ABFR La presente invention concerne des methodes de traitement ou de prevention de la restenose, d'une lesion vasculaire, et d'une maladie vasculaire chez un sujet, en lui administrant la TIMP-4.

Les inventeurs ont decouvert avec surprise que la TIMP-4 jouait un role important dans
l'accumulation de la matrice extracellulaire dans la paroi d'une veine, facilitant ainsi le
processus de regeneration d'une veine lesee. En outre, cette invention concerne une methode
d'inhibition de la migration des cellules du muscle lisse, comme par exemple les cellules du muscle
lisse vasculaire, en introduisant dans la cellule une quantite efficace de TIMP-4 pour inhiber la
migration, cette methode inhibant egalement la degradation de la matrice extracellulaire d'une
veine, telle qu'une artere ou un capillaire, en introduisant la TIMP-4 dans la veine.

L104 ANSWER 90 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000052034 PCTFULL ED 20020215
TITLE (ENGLISH): INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
TITLE (FRENCH): INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT D'INFECTIONS VIRALES
INVENTOR(S): SHAPIRO, Leland
PATENT ASSIGNEE(S): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000052034	A2	20000908
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US5558	A	20000303
PRIORITY INFO.:	US 1999-60/123,167		19990305
	US 1999-60/137,795		19990603

ABEN A novel method of treating and preventing viral infection is provided. In particular a method
of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which
consists of administering to a subject suffering or about to suffer from viral infection a
therapeutically effective amount of a compound having a serine protease inhibitory or serpin
activity. Among compounds are α1-antitrypsin (AAT), **peptide** derivatives from the
carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such
compounds. The preferred viral infections include retroviral infection such as human
immunodeficiency virus (HIV) infection.

ABFR L'invention concerne une nouvelle methode de traitement et de prevention d'une infection
virale. L'invention concerne, en particulier, une methode destinee a combattre une infection virale
favorisee par une activite de serine proteolytique 'SP', consistant a administrer a un sujet
souffrant ou susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace
d'un compose presentant une activite d'inhibition de serine protease ou serpin. Parmi les composes

se trouvent l'antitrypsine α1 AAT., des derives peptidiques de l'extremite carboxyterminale
de l'AAT, et des composes synthetiques artificiels imitant l'action de ces composes. Parmi les
infections virales preferees se trouvent les infections retrovirales telles que l'infection du virus
de l'immunodeficience humaine (VIH).

L104 ANSWER 91 OF 189 BOTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000162625 BOTFULL ED 20020513
TITLE (ENGLISH): INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF HERPES VIRUSES
TITLE (FRENCH): INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT DE VIRUS DE L'HERPES
INVENTOR(S): SHAPIRO, Leland
PATENT ASSIGNEE(S): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000051625	A1	20000908
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US5557	A	20000303
PRIORITY INFO.:	US 1999-60/123,167		19990305
	US 1999-60/153,942		19990915

ABEN Novel compositions and methods of treating and preventing a viral infection are provided. A
method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed,
which involves administering to a subject suffering or about to suffer from a viral infection a
therapeutically effective amount of a substance having serine protease inhibitory activity or serpin
activity. Among the substances found to be useful are α1-antitrypsin (AAT), **peptide**
derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such
substances. The invention is particularly well suited for checking a viral infection mediated by
members of herpesviridae family.

ABFR L'invention concerne de nouvelles compositions et methodes de traitement et de prevention d'une
infection virale. L'invention concerne une methode visant a bloquer une infection virale favorisee
par une activite proteolytique de serine (SP), consistant a administrer a un sujet souffrant ou
susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace d'une
substance presentant une activite d'inhibition de serine protease ou serpin. Parmi les substances
utiles se trouvent l'antitrypsine α1 (AAT), des derives peptidiques de l'extremite
carboxyterminale de l'AAT et des medicaments synthetiques imitant l'action de ces substances.
L'invention est particulierement appropriee dans le depistage d'une infection virale a mediation de
membres de la famille des Herpesviridae.

L104 ANSWER 92 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: [illegible] PCTFULL ED 20020515
TITLE (ENGLISH): ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS
TITLE (FRENCH): DERIVES DE PYRIMIDINE A SUBSTITUTION ARYLE ET HETEROCYCLYLE EN TANT QU'ANTICOAGULANTS
INVENTOR(S): DAVEY, David, D.; PHILLIPS, Gary, B.
PATENT ASSIGNEE(S): BERLEX LABORATORIES, INC.; DAVEY, David, D.; PHILLIPS, Gary, B.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001033944	A1	20010515
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US08537	A	19990203
PRIORITY INFO.:	US 1998-09/205,493		19981204

ABEN This invention is directed to aryl and heterocyclyl substituted pyrimidine derivatives selected from formulae (I), (II) and (III), wherein Z1, Z2, R1, R2, R3, R4, R5 and R6 are defined herein. These compounds are useful as anti-coagulants.

ABFR L'invention concerne des derives de pyrimidine a substitution aryle et heterocyclyle choisis parmi les formules (I), (II) et (III), dans lesquelles Z1, Z2, R1, R2, R3, R4, R5 et R6 sont definis dans le descriptif. Ces composes sont utiles en tant qu'anticoagulants.

L104 ANSWER 93 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20000024718 PCTFULL ED 20020515
TITLE (ENGLISH): SERINE PROTEASE INHIBITOR
TITLE (FRENCH): INHIBITEUR DE LA SERINE PROTEASE
INVENTOR(S): TIMMERS, Cornelis, Marius; REWINKEL, Johannes, Bernardus, Maria
PATENT ASSIGNEE(S): AKZO NOBEL N.V.; TIMMERS, Cornelis, Marius; REWINKEL, Johannes, Bernardus, Maria
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000024718	A1	20000504
DESIGNATED STATES	AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-EP7826	A	19991014
PRIORITY INFO.:	EP 1998-98203559.4		19981022

ABEN The invention relates to a serine protease inhibitor having formula I, in which J is H, R1, R1-C(=O)-, R1-C(=S)-, R1-SO2-, R3OOC-(CHR2)p-, (R2a, R2b)N-CO-(CHR2)p- or Het-CO-(CHR2)p-; D is an amino-acid of the formula -NH-CHR1-C(=O)-, -NR4-CH[(CH2)qC(=O)OR1]-C(=O)-, -NR4-CH[(CH2)qC(=O)NR2a,

R2b)-C(O)-, -NR4-CH[CH2-qC O)Het]-C(O -, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq or D 3-Piq; E is
-NR2-CH2 or the fragment ..., optionally substituted with (1-6C.alkyl, (1-6C)alkoxy or benzyloxy; R1
is selected from (1-12C.alkyl, (2-12C)alkenyl, (2-12C.alkynyl, (3-12C)cycloalkyl and
(3-12C)cycloalkyl(1-6C)alkylene, which groups may optionally be substituted with (3-12C)cycloalkyl,
(1-6C)alkoxy, oxo, OH, CF3 or halogen, and from (6-14C.aryl, (7-15C)aralkyl, (8-16C)aralkenyl and
(14-20C)(bisaryl)alkyl, whereby the aryl groups may optionally be substituted with (1-6C)alkyl,
(3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF3 or halogen; R2, R2a and R2b are each independently selected
from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and
(3-6C)cycloalkyl(1-4C)alkylene, which can each be optionally substituted with (3-6C)cycloalkyl,
(1-6C)alkoxy, CF3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl whereby the aryl groups may
optionally be substituted with (1-6C)alkyl, (3-6C)cycloalkyl,
(1-6C)alkoxy, CF3 or halogen; R3 is
defined for R2 or Het-(1-6C)alkyl; R4 is H or (1-3C)alkyl; X and Y are CH or N with the proviso that
they are not both N; Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms
selected from O, N and S; m is 1 or 2; p is 1, 2 or 3; q is 1, 2 or 3; t is 2, 3 or 4; or a prodrug;
or a pharmaceutically acceptable addition salt and/or solvate thereof and its use in therapy and
manufacture of a medicament for treating or preventing thrombin-mediated and thrombin-associated
diseases.

ABFR L'invention concerne un inhibiteur de la serine protease ayant la formule (I), dans laquelle J
est H, R1, R1-O-C(O)-, R1-C(O)-, R1-SO2-, R3OOC-(CHR2)p-, (R2a, R2b)N-CO-(CHR2)p- ou
Het-CO-(CHR2)p-; D est un acide amine de formule NH-CHR1-C(O)-,
-NR4-CH[(CH2)qC(O)OR1]-C(O)-,
NR4-CH[(CH2)qC(O)N(R2a,R2b)]-C(O)-, NR4-CH[(CH2)qC(O)Het]-C(O)-,
D 1-Tiq, D-3-Tiq, D-Atc, Aic,
D-1-Piq ou D 3-Piq; E est NR2-CH2- ou le fragment, facultativement remplace par (1-6C)alkyle,
(1-6C)alcoxy ou benzyloxy; R1 choisi dans (1-12C)alkyle, (2-12C)alcenyle, (2-12C)alkynyle,
(3-12C)cycloalkyle et (3-12C)cycloalkyle(1-6C)alkylene, groupes qui peuvent facultativement etre
remplaces par (3-12C)cycloalkyle, (1-6C)alcoxy, oxo, OH, CF3 ou halogene, et dans (6-14C)aryle,
(7-15C)aralkyle, (8-16C)aralcenyle et (14-20C)(bisaryle)alkyle, les groupes aryle pouvant
facultativement etre remplaces par (1-6C)alkyle, (3-12C)cycloalkyle, (1-6C)alcoxy, OH, CF3 ou
halogene; R2, R2a et R2b sont, chacun, choisis de maniere independante dans H, (1-8C)alkyle,
(3-8C)alcenyle, (3-8C)alkynyle, (3-8C)cycloyalkyle et (3-6C)cycloalkyle(1-4C)alkylene, qui peuvent,
chacun, etre facultativement remplaces par (3-6C)cycloalkyle, (1-6C)alcoxy, CF3 ou halogene, et dans
(6-14C)aryle et (7-15C)aralkyle, les groupes aryle pouvant etre facultativement remplaces par
(1-6C)alkyle, (3-6C)cycloalkyle, (1-6C)alcoxy, CF3 ou halogene; R3 est tel que defini pour R2 ou
Het (1-6C)alkyle; R4 est H ou (1-3C)alkyle; X et Y sont CH ou N, a condition qu'ils ne soient pas
tous deux N; Het est 4-, 5- or 6-heterocycle ramifie contenant au moins

un heteroatome choisi dans
O, N et S; m est egal a 1 ou 2; p a 1, 2 ou 3; q a 1, 2 ou 3,; t a 2, 3
ou 4; un promedicament; une
adjonction de sel et/ou de solvate pharmaceutiquement acceptable(s) de
celui-ci, ainsi que son
utilisation en therapie et pour la fabrication d'un medicament pour
traiter ou prevenir des maladies
induites par la thrombine ou associees a celle-ci.

L104 ANSWER 94 OF 169 POTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000 22160 POTFULL ED 20020515
TITLE (ENGLISH): METHODS FOR ASSESSING COMPLEMENT ACTIVATION
TITLE (FRENCH): METHODE D'EVALUATION DE L'ACTIVATION DU COMPLEMENT
INVENTOR(S): HUGLI, Tony, E.; STOUGHTON, Roland, B.
PATENT ASSIGNEE(S): CELL ACTIVATION, INC.; THE SCRIPPS RESEARCH INSTITUTE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000022160	A1	20000420
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US24150	A	19991015
PRIORITY INFO.:	US 1998-09/173,579		19981015
	US 1999-09/245,829		19990205

ABEN Methods for measuring i(in vivo) activation of the lectin pathway by measuring mannan-binding
serine protease activity (MASP) are provided. The methods are accomplished by measuring C3a and C4a
levels in i(in vitro) activated EDTA plasma. In particular, the increase in C3a and/or C4a as a
function of time is an indicator of the amount of activated MASP in EDTA plasma. Methods are also
provided for measuring the alternate and classical pathways of complement activation, exclusive of
the lectin pathway, and thereby disorders associated therewith. To perform such measurements, Futhan
or other serine protease inhibitor is added to blood or plasma, containing a divalent metal ion
chelator, and C3a and C4a are measured.

ABFR L'invention se rapporte a des methodes permettant d'evaluer l'activation i(in vivo) de la voie
de la lectine par mesure de l'activite de la serine protease se fixant a la mannane (MASP). Ces
methodes consistent a mesurer les taux de C3a et de C4a dans du plasma d'EDTA active i(in vitro). En
particulier, l'accroissement de C3a et/ou C4a en fonction du temps est un indicateur de la quantite
de MASP activee dans le plasma d'EDTA. L'invention se rapporte egalement a des methodes permettant
de mesurer les voies classiques et autres de l'activation du complement, a l'exclusion de la voie de
la lectine, et permettant par consequent d'evaluer les troubles associes. Pour permettre ces
mesures, on ajoute un inhibiteur de serine protease de type Futhan ou **analogue** a du sang ou du
plasma contenant un agent de chelation des ions metalliques bivalents et l'on mesure les taux de C3a

et de Cia.

L104 ANSWER 95 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000004382 PCTFULL ED 20020515
TITLE (ENGLISH): ARRAYS OF PROTEINS AND METHODS OF USE THEREOF
TITLE (FRENCH): GROUPEMENTS DE PROTEINES ET PROCEDES D'UTILISATION DE CEUX-CI
INVENTOR(S): WAGNER, Peter; AULT-RICHE, Dana; NOCK, Steffen; ITIN, Christian
PATENT ASSIGNEE(S): ZYOMYX, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000004382	A1	20000127

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US15971 A 19990714
PRIORITY INFO.: US 1998-09/115,455 19980714

ABEN Protein arrays for the parallel, i(in vitro) screening of biomolecular activity are provided.
Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different
proteins, such as different members of a single protein family, are immobilized on one or more
organic thin films on the substrate surface. The protein arrays are particularly useful in drug
development, proteomics, and clinical diagnostics.

ABFR L'invention concerne des groupements de proteines permettant de mettre en oeuvre un criblage
i(in vitro) en parallele d'activite biomoleculaire. Des procedes d'utilisation des groupements de
proteines sont egalement decrits. Dans les groupements, plusieurs proteines differentes telles que
des membres differents d'une seule famille de proteines, sont immobilisees sur un ou plusieurs films
minces organiques a la surface du substrat. Les groupements de proteines sont particulierement
utiles dans le developpement de medicaments, la proteomique et le diagnostic clinique.

L104 ANSWER 96 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000002587 PCTFULL ED 20020515
TITLE (ENGLISH): CANCER TREATMENT METHODS USING THERAPEUTIC CONJUGATES THAT BIND TO AMINOPHOSPHOLIPIDS
TITLE (FRENCH): PROCEDES DE TRAITEMENT DU CANCER METTANT EN APPLICATION DES CONJUGUES THERAPEUTIQUES SE FIXANT A DES AMINOPHOSPHOLIPIDES
INVENTOR(S): THORPE, Philip, E.; RAN, Sophia
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000002587	A1	20000120

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL

PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU
ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US15668 A 19990712
PRIORITY INFO.: US 1998-60/092,572 19980713
US 1998-60/110,608 19981202

ABEN Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

ABFR On a decouvert que des aminophospholipides, tels que phosphatidylserine et phosphatidylethanolamine, sont des marqueurs specifiques, accessibles et stables de la surface intracavitaire de vaisseaux sanguins tumoraux. L'invention concerne, de ce fait, des produits de recombinaison diagnostiques et therapeutiques ciblant les aminophospholipides et conçus pour intervenir sur la tumeur. Elle concerne en particulier des conjugues d'agents therapeutiques et d'anticorps et des produits de recombinaison se fixant aux aminophospholipides, ainsi que des procedes servant a administrer de facon specifique des agents therapeutiques, y compris des toxines et des coagulants, aux aminophospholipides d'expression stable de vaisseaux sanguins tumoraux, de qui provoque une thrombose, une necrose et une regression de la tumeur.

L104 ANSWER 97 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000002584 PCTFULL ED 20020515
TITLE (ENGLISH): CANCER TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS
TITLE (FRENCH): PROCEDES DE TRAITEMENT DU CANCER REPOSANT SUR L'UTILISATION D'ANTICORPS VIS-A-VIS DES AMINOPHOSPHOLIPIDES
INVENTOR(S): THORPE, Philip, E.; RAN, Sophia
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000002584	A2	20000120

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU
ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US15668 A 19990712
PRIORITY INFO.: US 1998-60/092,572 19980713
US 1998-60/110,608 19981202

ABEN Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression i(in vivo). This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

ABFR L'invention concerne la decouverte surprenante selon laquelle les aminophospholipides, du type phosphatidylserine et phosphatidylethanolamine, sont des marqueurs stables et accessibles a la surface intracavitaire des vaisseaux sanguins de tumeur, et selon laquelle la simple administration d'anticorps vis-a-vis des aminophospholipides suffit a induire la thrombose, la necrose tumorale et la regression tumorale i(in vivo). En consequence, l'invention concerne des procedes reposant sur l'utilisation d'anticorps vis-a-vis des aminophospholipides, et des compositions destinees a etre utilisees pour la destruction specifique des vaisseaux sanguins de tumeur et le traitement des tumeurs solides. Bien que l'invention concerne ainsi plusieurs conjugues et combinaisons d'anticorps, l'utilisation d'anticorps nus ou non conjugues vis-a-vis du type phosphatidylserine est un aspect particulierement important de l'invention, grace a la simplicite et a l'efficacite de l'approche consideree

L104 ANSWER 99 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 930371 EUROPATFULL EW 200051 FS PS
TITLE: IMIDAZO(1,5A)PYRIDINE DERIVED SERINE PROTEASE INHIBITORS.
AUS IMIDAZO-(1,5A)-PYRIDIN STAMMENDE INHIBITOREN VON SERINPROTEASEN.
INHIBITEURS DE SERINE PROTEASE DERIVES DE IMIDAZO(1,5A)PYRIDINE.
INVENTOR(S): OTTENHEYM, Henricus Carl Joseph, Gagelveld 5, 6596 CC Milsbeek, NL;
ADANG, Anton Egbert Peter, Le Sage ten Broeklaan 77, 5615 CR Eindhoven, NL;
PETERS, Jacobus Albertus Maria, Meerval 23, 5345 DB Oss, NL
PATENT ASSIGNEE(S): Akzo Nobel N.V., Velperweg 76, 6824 BM Arnhem, NL
PATENT ASSIGNEE NO: 200754
AGENT: Hogenbirk, Marijke et al., P.O. Box 20, 5340 BH Oss, NL
AGENT NUMBER: 86991
OTHER SOURCE: BEPB2000166 EP 0930371 B1 0019
SOURCE: Wila-EPS-2000-H51-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R

IE; R IT; R LI; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 529031	B1	20001220
'OFFENLEGUNGS' DATE:			19930303
APPLICATION INFO.:	EP 1992-916749		19920803
PRIORITY APPLN. INFO.:	US 1991-739929		19910802
RELATED DOC. INFO.:	WO 92-US6936	920803	INTAMZ
	WO 9213952	920827	INTPNR
REFERENCE PAT. INFO.:	EP 185499 A		EP 119880 A
	WO 91-02750 A		

REF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, (Easton, PA, US), J.M. MARAGANORE et al.: "Design and characterization of Hirulogs: A novel class of Bivalent peptide inhibitors

L104 ANSWER 99 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 529031 EUROPATFULL EW 200021 FS PS
TITLE: IMPROVED INHIBITORS OF THROMBIN.
VERBESSERTE THROMBININHIBITOREN.
INHIBITEURS AMELIORES DE THROMBINE.
INVENTOR(S): MARAGANORE, John, M., 17 Highland Street, Concord, MA 01742, US;
JABLONSKI, Jo-Ann, M., 9 Summer Street, Middleborough, MA 02346, US;
BOURDON, Paul, R., 17 1/2 Vinal Avenue, Sommerville, MA 02143, US
PATENT ASSIGNEE(S): BIOGEN, INC., 14 Cambridge Center, Cambridge Massachusetts 02142, US
PATENT ASSIGNEE NO: 1049451
AGENT: VOSSIUS & PARTNER, Postfach 86 07 67, 81634 Muenchen, DE
AGENT NUMBER: 100311
OTHER SOURCE: BEPBJ0030029 EP 0529031 B1 0026
SOURCE: Wila-EPS-2000-H21-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R MC; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 529031	B1	20000524
'OFFENLEGUNGS' DATE:			19930303
APPLICATION INFO.:	EP 1992-916749		19920803
PRIORITY APPLN. INFO.:	US 1991-739929		19910802
RELATED DOC. INFO.:	WO 92-US6936	920803	INTAMZ
	WO 9213952	920827	INTPNR
REFERENCE PAT. INFO.:	EP 185499 A		EP 119880 A
	WO 91-02750 A		

REF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, (Easton, PA, US), J.M. MARAGANORE et al.: "Design and characterization of Hirulogs: A novel class of Bivalent peptide inhibitors

of thrombin" pages 7095-7101, see abstract, page 7099, left-hand column, lines 21-23 Scand. J. Haematol., vol. 31, 1983, Copenhagen, DK, B.F. HANDELAND et al.: "Simplified assay for antithrombin III activity using chromogenic peptide substrate", pages 427-436, see abstract; page 435, left-hand column, paragraphs 2-3

L104 ANSWER 100 OF 189 BASCAL COPYRIGHT 2012 INIST-CNRS. ALL RIGHTS RESERVED.
ACCESSION NUMBER: 2000-0087254 BASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Design, synthesis and structure-activity relationship of a series of **arginine** aldehyde **factor Xa inhibitors**. Part 1 : Structures based on the (D)-Arg-Gly-Arg tripeptide sequence
AUTHOR: MARLOWE C. K.; SINHA U.; GUNN A. C.; SCARBOROUGH R. M.
CORPORATE SOURCE: COR Therapeutics, Inc., 256 East Grand Avenue, South San Francisco, CA 94080, United States
SOURCE: Bioorganic & medicinal chemistry letters, (2000), 10(1), 13-16, 24 refs.
ISSN: 0960-894X
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United Kingdom
LANGUAGE: English
AVAILABILITY: INIST-22446, 354000081025360040
AN 2000-0087254 PASCAL
CP Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.
AB A series of **arginine** aldehyde **inhibitors** was designed as transition state (TS) **analogues** based on the known **factor Xa** specific substrate Cbz-D-Arg-Gly-Arg-pNA. BnSO.sub.2-(D)Arg-Gly-Arg-H (20) was found to be the most potent and selective **inhibitor** of **factor Xa** and prothrombinase activity in this series.

L104 ANSWER 101 OF 189 USPATFULL
ACCESSION NUMBER: 1999:163933 USPATFULL
TITLE: Human tissue factor related DNA segments polypeptides and antibodies
INVENTOR(S): Edgington, Thomas S., La Jolla, CA, United States
Morrissey, James H., Oklahoma City, OK, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6001978		19991214
APPLICATION INFO.:	US 1997-944806		19970422 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-990079, filed on 29 Apr 1992, now patented, Pat. No. US 5622931 which is a division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Budens, Robert D.
LEGAL REPRESENTATIVE: Fitting, Thomas, Holmes, Emily
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT: 3241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 102 OF 189 USPATFULL
ACCESSION NUMBER: 1999:151192 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5990079		19991123
APPLICATION INFO.:	US 1998-16400		19980130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-263003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5273144		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Degen, Nancy		
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 103 OF 189 USPATFULL
ACCESSION NUMBER: 1999:128513 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5969197		19991019
APPLICATION INFO.:	US 1998-16403		19980130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a		

division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 104 OF 189 USPATFULL
ACCESSION NUMBER: 1999:121300 USPATFULL
TITLE: Factor VII-derived **peptides**
INVENTOR(S): Bakaridassen, Kjell Steinar, Oslo, Norway
Stephens, Poss Wentworth, Copenhagen, Denmark
Orning, Lars, Oslo, Norway
PATENT ASSIGNEE(S): Nycomed Imaging A/S, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5962418		19991005	
	WO 9500541		19950105	
APPLICATION INFO.:	US 1996-564063		19960523	(8)
	WO 1994-GB1315		19940617	
			19960523	PCT 371 date
			19960523	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-13601	19930618
	GB 1994-9939	19940510

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Testa, Hurwitz & Thibeault LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds comprising the amino acid sequences of the formulae (IA): -CVNENGGCEQYCSD-, (IB): -FCLPAFEGRNCE- and/or (IC): -RCHEGYSLLADGVSCT- as well as **peptide** fragments thereof, esters, amides, salts and cyclic derivatives thereof, functional **analogues** thereof and extended **peptide** chains carrying amino acids or **peptides** at the termini of the above sequences or fragments, for use in the prevention or inhibition of

binding of tissue factor to FVII.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 105 OF 189 USPATFULL
ACCESSION NUMBER: 1999:11169 USPATFULL
TITLE: Protease inhibitor **peptides**
INVENTOR(S): White, R. Tyler, Fremont, CA, United States
Damm, Deborah, Redwood City, CA, United States
Lesikar, David D., Palo Alto, CA, United States
McFadden, Kathleen, Mountain View, CA, United States
Garrick, Brett L., Palo Alto, CA, United States
PATENT ASSIGNEE(S): Scios, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863266		19991005
APPLICATION INFO.:	US 1997-829876		19970402 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-436555, filed on 8 May 1995		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Slobodyansky, Elizabeth
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Figure(s); 53 Drawing Page(s)
LINE COUNT: 4412
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Analogues** of the Kunitz Protease **Inhibitor** (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, **Xa**, XIa, and XIIa. Pharmaceutical compositions containing the KPI **analogues**, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these **analogues** and systems for expression of the **peptides** of the invention are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 106 OF 189 USPATFULL
ACCESSION NUMBER: 1999:110297 USPATFULL
TITLE: Basic .alpha.-aminoalkylphosphonate derivatives
INVENTOR(S): Powers, James C., Atlanta, GA, United States
Jackson, Delwin S., Bear, DE, United States
Ni, Liming, Little Canada, MN, United States
PATENT ASSIGNEE(S): Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952307		19990914
APPLICATION INFO.:	US 1997-937840		19970914 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-184296, filed on 21 Jan 1994, now patented, Pat. No. US 5686419		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Deveau, Colton & Marquis
NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1
LINE COUNT: 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptidyl derivatives of diesters of .alpha.-aminoalkylphosphonic acids with basic substituents, their use in inhibiting serine proteases with trypsin-like **specificity** and their roles as anti-inflammatory agents, anticoagulants, and anti-tumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 107 OF 189 USPATFULL
ACCESSION NUMBER: 1999:98793 USPATFULL
TITLE: Modified plasmin precursors with resistance to inhibitors of plasmin
INVENTOR(S): Dawson, Keith Martyn, Cowley, United Kingdom
Gilbert, Richard James, Cowley, United Kingdom
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals, Ltd., Oxford, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5932213		19990803
APPLICATION INFO.:	US 1997-889073		19970707 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-379621, filed on 3 Feb 1995		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-16558	19920804

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Hale and Dorr LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Plasmin precursors are modified so that they exhibit resistance to inhibitors of plasmin. These modified plasmin precursors have fibrinolytic, thrombolytic or antithrombotic properties, which are useful in the treatment of blood clotting diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 108 OF 189 USPATFULL
ACCESSION NUMBER: 1999:72602 USPATFULL
TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5916913		19990629
APPLICATION INFO.:	US 1997-869158		19970604 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1842
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 109 OF 189 USPATFULL
ACCESSION NUMBER: 1999:72590 USPATFULL
TITLE: Imidazo[1,5A]pyridine derived serine protease inhibitors
INVENTOR(S): Peters, Jacobus Albertus Maria, Oss, Netherlands
Ottenheym, Henricus Carl Joseph, Milsbeek, Netherlands
Adang, Anton Egbert Peter, Eindhoven, Netherlands
PATENT ASSIGNEE(S): Akzo Nobel, N.V., Arnhem, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5916898		19990629	
	WO 9639470		19961205	
APPLICATION INFO.:	US 1997-973255		19971202	(8)
	WO 1996-EP2299		19960529	
			19971202	PCT 371 date
			19971202	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-201448	19950602

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Gormley, Mary E.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to an imidazole[1,5a]pyridine derived serine protease inhibitor comprising a unit having general formula (I) ##STR1## wherein R.sub.1 is hydrogen, lower alkyl or an acyl group; R.sub.2 is hydrogen or lower alkyl; R.sub.3 and R.sub.4 are independently hydrogen, lower alkyl or together form .dbd.CH--NR.sub.5 NR.sub.6, R.sub.5 and R.sub.6 being lower alkyl. The compounds are serine protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 110 OF 189 USPATFULL
ACCESSION NUMBER: 1999:63960 USPATFULL
TITLE: **Inhibitors** of **factor Xa**
INVENTOR(S): Brunck, Terence Kevin, San Diego, CA, United States
Webb, Thomas Roy, Encinitas, CA, United States
Sipka, William Charles, San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849877		19990316
APPLICATION INFO.:	US 1993-168964		19931215 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds, their salts and compositions related thereto having activity against mammalian **factor Xa** are disclosed. The novel compounds include **peptide** aldehyde **analogues** having substantial potency and **specificity** as **inhibitors** of mammalian **factor Xa** are further disclosed. The compounds are thought useful as **inhibitors** of **factor xa** in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 111 OF 189 USPATFULL
ACCESSION NUMBER: 1999:17415 USPATFULL
TITLE: Yeast cells engineered to produce pheromone system protein surrogates and uses therefor
INVENTOR(S): Fowlkes, Dana M., Chapel Hill, NC, United States
Broach, Jim, Princeton, NJ, United States
Manfredai, John, Ossining, NY, United States
Klein, Christine, Ossining, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, South Nyack, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PATENT ASSIGNEE(S): Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5876951		19990302
APPLICATION INFO.:	US 1995-461598		19950605 (3)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fetter, James
ASSISTANT EXAMINER: Yucel, Irem
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara, Catherine J.
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 6645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential **peptide** modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 112 OF 189 USPATFULL
ACCESSION NUMBER: 1999:19118 USPATFULL
TITLE: **Arginine** keto-amide enzyme inhibitors
INVENTOR(S): Webb, Thomas Roy, Encinitas, CA, United States
Miller, Todd Anthony, Encinitas, CA, United States
Vlasuk, George Phillip, Carlsbad, CA, United States
Abelman, Matthew Mark, Solana Beach, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869454		19990209
APPLICATION INFO.:	US 1995-462899		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-139300, filed on 18 Oct 1993, now patented, Pat. No. US 5597804 which is a continuation-in-part of Ser. No. US 1992-962301, filed on 16 Oct 1992, now patented, Pat. No. US 5371072
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel **arginine** alpha-keto-amide derivatives, their pharmaceutically acceptable salts and compositions thereof which are useful as antithrombotic agents in mammals and also the use of these compounds as antithrombotic agents. Also, described are methods of using these inhibitors as inhibitors of coagulation proteases and as therapeutic agents for disease states characterized by abnormal thrombus formation and/or disorders of the blood coagulation process. Further described herein are compounds useful as intermediates in the preparation of these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 113 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999064037 PCTFULL ED 20020515
TITLE (ENGLISH): NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES
TITLE (FRENCH): NOUVEAUX AGENTS THERAPEUTIQUES MODULANT LES PROCESSUS ENZYMATIQUES
INVENTOR(S): GRIFFIN, John, H.; JUDICE, J., Kevin
PATENT ASSIGNEE(S): ADVANCED MEDICINE, INC.; GRIFFIN, John, H.; JUDICE, J., Kevin
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

	WO 9964037	A1 19991216
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1999-US12620	A 19990603
PRIORITY INFO.:	US 1998-60/088,448	19980608
	US 1998-60/093,072	19980716

ABEN Novel multi-binding compounds are disclosed that modulate enzymatic processes. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an enzyme, enzyme substrate or enzyme cofactor thereby modulating the biological processes/functions thereof.

ABFR L'invention porte sur de nouveaux composes multi-liants modulant les processus enzymatiques. Lesdits composes comportent de 2-10 ligands unis par covalence dont chacun peut se fixer a une enzyme, a un substrat d'enzyme ou a un cofacteur d'enzyme et modifier par la leurs processus et fonctions biologiques.

L104 ANSWER 114 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	1999063090 PCTFULL ED 20020515
TITLE (ENGLISH):	PROTEASE INHIBITOR **PEPTIDES**
TITLE (FRENCH):	**PEPTIDES** INHIBITEURS DE PROTEASE
INVENTOR(S):	WHITE, R., Tyler; DAMM, Deborah; LESIKAR, David, D.; McFADDEN, Kathleen; GARRICK, Brett, L.; LUCAS, Anne, Bergstrom; POLLITT, N., Stephen; LAM, Andrew, O.
PATENT ASSIGNEE(S):	SCIOS, INC.; WHITE, R., Tyler; DAMM, Deborah; LESIKAR, David, D.; McFADDEN, Kathleen; GARRICK, Brett, L.; LUCAS, Anne, Bergstrom; POLLITT, N., Stephen; LAM, Andrew, O.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9963090	A2	19991209
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US12276	A	19990603
PRIORITY INFO.:	US 1998-60/087,985		19980603

ABEN **Analogues** of the Kunitz Protease **Inhibitor** (KPI) domain of amyloid precursor protein bind to an inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, **Xa**, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogs, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these

analogs and systems for
expression of the **peptides** of the invention are provided.
ABFR L'invention concerne des **analogues** du domaine inhibiteur de
protease de Kunitz (KPI) de la
proteine precurseur amyloide qui se lient aux proteases serines et
inhibent l'activite de ces
proteases, y compris la kallikreine, la plasmine et les facteurs de
coagulation du type VIIa, IXa,
Xa XIa et XIIa. L'invention concerne en outre des compositions
pharmaceutiques renfermant des
analogues de l'inhibiteur KPI, ainsi que des procedes relatifs
a l'utilisation desdites
compositions, utiles pour ameliorer et traiter les etats cliniques lies
a une augmentation de
l'activite de la protease serine, comme par exemple dans le cas des
pertes sanguines inherentes a
une intervention chirurgicale avec circulation extra-corporelle.
L'invention concerne enfin des
sequences d'acides nucleiques codant les **analogues** consideres,
et des systemes permettant d'exprimer
les **peptides** decrits dans l'invention.

L104 ANSWER 115 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999041276 PCTFULL ED 20020515
TITLE (ENGLISH): β-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF
TITLE (FRENCH): IMITATEURS DE BETA FEUILLETS ET PROCEDES LIES A LEUR UTILISATION
INVENTOR(S): QABER, Maher, N.; McMILLIAN, Michael, K.; KAHN, Michael, S.; TULINSKY, John, E.; MATHEW, Jessymol
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; QABER, Maher, N.; McMILLIAN, Michael, K.; KAHN, Michael, S.; TULINSKY, John, E.; MATHEW, Jessymol
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9941276	A1	19990819
DESIGNATED STATES	AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US2891	A	19980212

ABEN β-sheet mimetics and methods relating to the same are disclosed. The β-sheet mimetics
have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and
protein-protein binding interactions. Methods of the invention include administration of a
β-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a
variety of conditions associated with the targeted protease, kinase, transcription factor and/or
protein-protein binding interaction.
ABFR L'invention concerne des imitateurs de β-feuillets et de procedes associes. Les imitateurs
de β-feuillets sont utiles en tant qu'inhibiteurs de protease et de kinase, ainsi que comme
inhibiteurs de facteurs de transcription et d'interaction de liaison proteine-proteine. Les procedes
consistent a administrer un imitateur de β-feuillets ou a utiliser

celui-ci pour fabriquer un
médicament pour le traitement d'une grande variété de pathologies
associées à la protéase, à la
kinase, au facteur de transcription et/ou à l'interaction de liaison
protéine-protéine cibles.

L104 ANSWER 116 OF 199 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999O.6924 PCTFULL ED 20020517
TITLE (ENGLISH): SUBSTITUTED 3-AMINO-2-HYDROXYPHENYLACETAMIDA
DERIVATIVES AS ENZYME INHIBITORS (II)
TITLE (FRENCH): DERIVES DE 3-AMINO-2-HYDROXYPHENYLACETAMIDE SUBSTITUE
UTILISES EN TANT QU'INHIBITEURS (II) D'ENZYME
INVENTOR(S): SEMPLE, Joseph, Edward; LIM-WILBY, Marguerita, S.;
BRUNCK, Terence, K.
PATENT ASSIGNEE S): CORVAS INTERNATIONAL, INC.; SEMPLE, Joseph, Edward;
LIM-WILBY, Marguerita, S.; BRUNCK, Terence, K.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 99-6920	A1	19990618
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US25167	A	19981123
PRIORITY INFO.:	US 1997-08/980,114		19971126
	US 1997-08/979,440		19971126

ABEN The present invention provides **peptide** aldehydes having an
3-amino-2-hydroxyphenyl acetamide
group as part of the **peptide** backbone and an **arginine**
group or analog at P1. These compounds are
potent and specific or inhibitors of thrombin. Their pharmaceutically
acceptable salts,
pharmaceutically acceptable compositions thereof, and methods of using
them as therapeutic agents
for disease states in mammals characterized by abnormal thrombosis are
also described. Also
described are 3-amino-2-hydroxyphenyl-acetamide derivatives having in
history activity towards
proteases of the trypsin/chymotrypsin class.
ABFR La présente invention concerne des aldehydes peptidiques comprenant un
groupe
3-amino-2-hydroxyphenyle acetamide faisant partie du squelette
peptidique et un groupe **arginine** ou
analogue sur P1. Ces composés sont des inhibiteurs puissants
et spécifiques de la thrombine.
L'invention concerne également leurs sels pharmaceutiquement
acceptables, leurs compositions
pharmaceutiquement acceptables, et leurs procédés d'utilisation en tant
qu'agents thérapeutiques
destinés à des états pathologiques chez des mammifères caractérisés par
une thrombose anormale.
L'invention concerne, en outre, des dérivés de 3-amino-2-hydroxyphenyl-
acétamide présentant une
activité connue vis-à-vis de protéases de la catégorie
trypsine/chymotripsine.

L104 ANSWER 117 OF 199 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999O24069 PCTFULL ED 20020110
TITLE (ENGLISH): HIGH THROUGHPUT METHOD FOR FUNCTIONALLY CLASSIFYING

TITLE: PROTEINS IDENTIFIED USING A GENOMICS APPROACH
TITLE (FRENCH): PROCEDE A HAUT RENDEMENT PERMETTANT DE CLASSER FONCTIONNELLEMENT DES PROTEINES IDENTIFIEES PAR UNE METHODE DES GENOMES
INVENTOR(S): PANTOLIANO, Michael, W.; SALEMME, Francis, R.; PETRELLA, Eugenio, C.; CARVER, Theodore, E., Jr.; RHIND, Alexander, W.
PATENT ASSIGNEE(S): 3-DIMENSIONAL PHARMACEUTICALS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9924050	A1	19990520
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US24036	A	19981112
PRIORITY INFO.:	US 1997-60/065,129		19971112

ABEN The present invention provides a method for functionally classifying a protein that is capable of unfolding due to a thermal change. The method comprises screening one or more of a multiplicity of different molecules for their ability to shift the thermal unfolding curve of the protein, wherein a shift in the thermal unfolding curve indicates that the molecule binds to the protein or affects the stability in a measurable way; generating an activity spectrum for the protein wherein the activity spectrum reflects a set of molecules, from the multiplicity of molecules, that shift the thermal unfolding curve, of the protein and therefore are ligands that bind to the protein, comparing the activity spectrum for the protein to one or more functional reference spectrum lists; and classifying the protein according to the set of molecules in the multiplicity of different molecules that shift the thermal unfolding curve of the protein.

ABFR Cette invention a trait a un procede a haut rendement permettant de classer fonctionnellement une proteine capable de se deplier sous l'effet d'un changement d'ordre thermique. Ce procede, qui consiste a cribler l'une, sinon plusieurs, des multiplicites de molecules differentes aux fins de la determination de leur aptitude a decaler la courbe thermique de depliage de la proteine, un decalage de cette courbe indiquant que la molecule se fixe a la proteine ou influe sur sa stabilite de facon mesurable, consiste egalement a generer un spectre d'activite de la proteine, spectre qui correspond a un ensemble de molecules de la proteine, ces molecules etant issues de la multiplicite susmentionnee decalant la courbe thermique de depliage et etant, de ce fait, des ligands qui se fixent a la proteine. On compare ensuite, dans le cadre de ce procede, le spectre d'activite relatif a la proteine a une liste de spectres de reference fonctionnels, sinon a plusieurs, et l'on classe la proteine d'apres l'ensemble de molecules de la multiplicite de molecules differentes qui decalent la courbe thermique de depliage de la proteine.

L104 ANSWER 118 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 915154 EUROPATFULL EW 199919 FS DS
TITLE: Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor.
Hefe Zellen so konstruiert, dass sie Proteinsurrogate des Pheromonsystems produzieren und Anwendungen dafuer.
Cellules de levure traitees pour produire des substituts de proteines du systeme de pheromones, et leurs emplois.
INVENTOR(S): Fowlkes, Duna Merriman, 33 Green Street, Apartment 2, New York, NY 10012, US;
Broach, Jim, 360 East 88th Street, Apartment 2A, New York, NY 10128, US;
Manfredi, John, 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
Klein, Christine, 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
Murphy, Andrew J., 17 Windsor Place, Montclair, NJ 07043, US;
Paul, Jeremy, 197 Route 9W, Palisades, NY 10964, US;
Trueheart, Joshua, 212 South Broadway, South Nyack, NY 10960, US
PATENT ASSIGNEE(S): Cadus Pharmaceuticals, Inc., 7th floor, 180 Varick Street, New York, NY 10014, US
PATENT ASSIGNEE NO: 1860561
AGENT: Price, Vincent Andrew et al, FRY HEATH & SPENCE The Old College 53 High Street, Horley Surrey RH6 7BN, GB
AGENT NUMBER: 79513
OTHER SOURCE: ESP1999034 EP 0915154 A1 990512
SOURCE: Wila-EPS-1999-H19-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 915154	A1	19990512
'OFFENLEGUNGS' DATE:		19990512
APPLICATION INFO.:	EP 1998-203997	19981203
PRIORITY APPLN. INFO.:	US 1997-41431	19970331
	US 1994-190328	19940131
RELATED DOC. INFO.:	EP 6320.05 DIV	

L104 ANSWER 119 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 765333 EUROPATFULL EW 199904 FS PS
TITLE: 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN **ARGININE** MIMIC AS ENZYME INHIBITORS.
3-AMINO-2-OXO-PIPERIDINESSIGSAeUREDERIVATE, DIE EINE ARGININNACHAHMENDE VERBINDUNG, MIT ENZYMINHIBITORISCHEN WIRKUNG ENTHALTEN.
DERIVES D'ACIDE 3-AMINO-2-OXO-PIPERIDINEACETIQUE CONTENANT UN **ANALOGUE** DE L'**ARGININE** UTILISES EN TANT QU'INHIBITEURS D'ENZYME.
INVENTOR(S): SEMPLE, Joseph E., 9711 Caminito Pudregal, San Diego, CA 92131, US;
LEVY, Orlie E., 9278 Avenida Navidad 3, San Diego, CA 92122, US;

NUTT, Ruth F., 4 Colibir Tierra, Santa Fe, New Mexico 87501, US;
RIPKA, William C., 10819 Red Rock Drive, San Diego, CA 92131, US

PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501190

AGENT: VEXHELL & STOLBERG, Patentanwaelte Beselerstrasse 4, 22607 Hamburg, DE

AGENT NUMBER: 100111

OTHER SOURCE: EPB1999036 EP 0765339 B1 990127

SOURCE: Wila-EPS-1999-H04-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 765339	B1	19990127
'OFFENLEGUNGS' DATE:		19970402
APPLICATION INFO.:		19950619
PRIORITY APPLN. INFO.: US 1994-261498		19940617
US 1994-356831		19941213
US 1995-482117		19950607
RELATED DOC. INFO.: WO 95-US7832		950619 INTAKD
WO 9535313		951228 INTPNR
REFERENCE PAT. INFO.: EP 526877 A		FR 2490632 A

REF. NON-PATENT-LIT.: PHARMAZIE, vol.39, no.5, May 1984, BERLIN DD pages 315 - 317 G WAGNER ET AL. 'Synthese von N-alpha-(Tosyl-beta-alanyl)- und N-alpha- (Tosyl-epsilon-aminocapronyl) amidinophenylalanylamiden als stark wirksame thrombininhibitoren' PHARMAZIE, vol.42, no.4, April 1987, BERLIN DD page 268 H VIEWEG ET AL. 'Synthese von N-alpha-(aryl sulphonylglycyl)-3-amidinophenylalaninestern als aktive und relativ spezifische Inhibitoren von Faktor Xa'

L104 ANSWER 120 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 765339 EUROPATFULL EW 199916 FS PS

TITLE: **ARGININE** MIMIC DERIVATIVES AS ENZYME INHIBITORS.
ARGININ AHNLICHE DERIVATE ALS ENZYM-INHIBITOREN.
DERIVES D'**ANALOGUES** DE L'**ARGININE** UTILISES COMME INHIBITEURS D'ENZYME.

INVENTOR(S): LEVY, Odile, Esther, 8273 Avenida Navidad 3, San Diego, CA 92122, US;
TAMURA, Susan, Y., 8997 Gainsborough Avenue, San Diego, CA 92129, US;
NUTT, Ruth, F., 4 Colibir Tierra, Santa Fe, New Mexico 87501, US;
RIPKA, William, C., 10819 Red Rock Drive, San Diego, CA 92131, US

PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US

PATENT ASSIGNEE NO: 1501190

AGENT: VEXHELL & STOLBERG, Patentanwaelte Beselerstrasse 4, 22607 Hamburg, DE

AGENT NUMBER: 100111

OTHER SOURCE: EPB1999024 EP 0765339 B1 990421

SOURCE: Wila-EPS-1999-H16-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 765339	B1	19990421

'OFFENLEGUNGS' DATE: 19970402
APPLICATION INFO.: EP 1995-924618 19950619
PRIORITY APPLN. INFO.: US 1994-261478 19940617
US 1995-487611 19950607
RELATED DOC. INFO.: WO 95-US7799 950619 INTAKC
WO 9539312 951229 INTPNR
REFERENCE PAT. INFO.: EP 526877 A FR 2490632 A
REF. NON-PATENT-LIT.: PHARMAZIE, vol.39, no.5, May 1984, BERLIN DD pages 315 - 317 G WAGNER ET AL. 'Synthese von N-alpha-(Tosyl-beta-alanyl)- und N-alpha- (Tosyl-epsilon-aminocapronyl) amidinophenylalanylamiden als stark wirksame thrombininhibitoren' PHARMAZIE vol. 42, no. 4, April 1987, BERLIN DD, page 263 H VIEWEG ET AL. 'Synthese von N alpha-(arylsulphonylglycyl)-3-amidinophenylalaninestern als aktive und relativ spezifische Inhibitoren von Faktor Xa'

L104 ANSWER 121 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 684830 EUROPATFULL EW 199924 FS PS
TITLE: INHIBITORS OF THROMBOSIS.
INHIBITOREN GEGEN THROMBOSE.
INHIBITEURS DE LA THROMBOSE.
INVENTOR(S): VLASUK, George Phillip, 3014 Garboso Street, Carlsbad, CA 92009, US;
WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA 92024, US;
PEARSON, Daniel Andrew, 149 Beals Road, Bedford, NH 03110, US;
ABELMAN, Matthew Mark, 873 Stevens Avenue, 3312, Solana Beach, CA 92075, US
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US
PATENT ASSIGNEE NO: 1501290
AGENT: Irvine, Jonquil Claire et al, J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
AGENT NUMBER: 74183
OTHER SOURCE: EPB1999035 EP 0684830 B1 990616
SOURCE: Wila-EPS-1999-H24-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 684830	B1	19990616

'OFFENLEGUNGS' DATE: 19951206
APPLICATION INFO.: EP 1994-909429 19940214
PRIORITY APPLN. INFO.: US 1993-17125 19930212

	US 1994-195995	19940211
RELATED DOC. INFO.:	WO 94-US1611	940214 INTAKE
	WO 94-US1611	940214 INTPNR
REFERENCE PAT. INFO.:	WO 93-14777 A	WO 93-15756 A
	US 4999068 A	

L104 ANSWER 122 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT BREVET DELIVRE

ACCESSION NUMBER:	675899 EUROPATFULL EW 199711 FS PS
TITLE:	NOVEL **INHIBITORS** OF **FACTOR XA**. NEUE INHIBITOREN VON FAKTOR XA. NOUVEAUX INHIBITEURS DU FACTEUR XA.
INVENTOR(S):	BRUNCK, Terence Kevin, 4949 Quincy, San Diego, CA 92109, US; WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA 92024, US; RIPKA, William Charles, 10919 Red Rock Drive, San Diego, CA 92024, US
PATENT ASSIGNEE(S):	CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US
PATENT ASSIGNEE NO:	1501290
AGENT:	Viering, Jentschura & Partner, Postfach 22 14 43, 80504 Muenchen, DE
AGENT NUMBER:	100645
OTHER SOURCE:	EPB1999015 EP 0675899 B1 990317
SOURCE:	Wila EPS-1999-H11-T1
DOCUMENT TYPE:	Patent
LANGUAGE:	Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES:	R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE:	EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 675899	B1	19990317
'OFFENLEGUNGS' DATE:		19951011
APPLICATION INFO.:	EP 1994-904466	19931215
PRIORITY APPLN. INFO.:	US 1992-991004	19921215
RELATED DOC. INFO.:	WO 93-US12255	931215 INTAKE
	WO 94113693	940623 INTPNR
REFERENCE PAT. INFO.:	EP 293881 A	EP 295645 A
	WO 93-08211 A	WO 93-12076 A
	US 4883863 A	US 5153176 A

REF. NON-PATENT-LIT.: JOURNAL OF MEDICINAL CHEMISTRY, vol.33, no.1, January 1990, WASHINGTON US pages 86 - 93 R M MCCONNELL ET AL. 'New leupeptin analogues; synthesis and inhibition data' JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol.114, no.8, 8 April 1992, GASTON, PA US pages 3156 - 3157 A M MURPHY ET AL. 'Automated synthesis of peptide C-terminal aldehydes' JOURNAL OF MEDICINAL CHEMISTRY, vol.36, no.8, 16 April 1993, WASHINGTON US pages 1084 - 1089 R M MCCONNELL ET AL. 'Inhibition studies on some serine and thiol proteinases by new leupeptin analogues' Helvetica Chimica Acta, Volume 51, Nr. 5, issued 1968, VON St. GUTTMANN et al., "Synthese des Thyreocalcitonins", pages 1154-1159

L104 ANSWER 123 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 664786 EUROPATFULL EW 199912 FS PS
TITLE: **ARGININE** KETO-AMIDE ENZYME INHIBITORS.
INHIBITOREN DES ARGININ-KETOAMID-ENZYMS.
CETO-AMIDE D'**ARGININE** COMME INHIBITEURS ENZYMATIQUES.
INVENTOR S.: WEBB, Thomas, Roy, 2250 Colony Terrace, Encinitas, CA 92024, US;
MILLER, Todd, Anthony, 1710 South El Camino Real, E-209, Encinitas, CA 92024, US;
VLASUK, George, Phillip, 3014 Garbino Street, Carlsbad, CA 92009, US;
ABELMAN, Matthew, Mark, 878 Stevens Avenue, 3312, Solana Beach, CA 92075, US
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US
PATENT ASSIGNEE NO: 1501290
AGENT: Viering, Jentschura & Partner, Postfach 22 14 43, 80504 Muenchen, DE
AGENT NUMBER: 100645
OTHER SOURCE: EPB19990017 EP 0664786 B1 990324
SOURCE: Wila-EPS-1999-H12-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 664786	B1	19990324
'OFFENLEGUNGS' DATE:		19950802
APPLICATION INFO.:		19931013
PRIORITY APPLN. INFO.:	US 1992-962301	19921016
RELATED DOC. INFO.:	WO 93-US10015	931013 INTAKE
	WO 9408941	940428 INTPNR
REFERENCE PAT. INFO.:	EP 195013 A	WO 92-11850 A
	WO 92-12140 A	US 3966701 A
	US 4161522 A	US 4171299 A
	US 4478745 A	US 5221752 A

REF. NON-PATENT-LIT.: J. AM. CHEM. SOC., vol.112, 1990 pages 7053 - 7054 N. FUSETANI, S. MATSUNAGA 'Cyclotheonamides, Potent Thrombin Inhibitors from a Marine Sponge'

L104 ANSWER 124 OF 189 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2000:433589 BIOSIS
DOCUMENT NUMBER: PREV200000433589
TITLE: Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor.
AUTHOR(S): De Filippis, Vincenzo; Russo, Ilaria; Vindigni, Alessandro; Di Cera, Enrico; Salmaso, Stefano; Fontana, Angelo (1)
CORPORATE SOURCE: (1) Department of Pharmaceutical Sciences, CRIBI Biotechnology Center, Viale G. Colombo 3, 35121, Padua Italy
SOURCE: Protein Science, (Oct., 1999) Vol. 8, No. 10, pp. 2213-2217. print.
ISSN: 0961-8368.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Hirudin is an anticoagulant polypeptide isolated from a medicinal leech that inhibits thrombin with extraordinary potency (Kd = 0.2-1.0 pM) and **selectivity**. Hirudin is composed of a compact N-terminal region (residues 1-47, cross-linked by three disulfide bridges) that binds to the

active site of thrombin, and a flexible C-terminal tail (residues 48-64) that interacts with the exosite I of the enzyme. To minimize the sequence of hirudin able to bind thrombin and also to improve its therapeutic profile, several N-terminal fragments have been prepared as potential anti-coagulants. However, the practical use of these fragments has been impaired by their relatively poor affinity for the enzyme, as given by the increased value of the dissociation constant (Kd) of the corresponding thrombin complexes (Kd = 30-400 nM). The aim of the present study is to obtain a derivative of the N-terminal domain 1-47 of hirudin displaying enhanced inhibitory potency for thrombin compared to the natural product. In this view, we have synthesized an **analogue** of fragment 1-47 of hirudin HM2 in which Val1 has been replaced by tert-butylglycine, Ser2 by Arg, and Tyr3 by beta-naphthylalanine, to give the BugArgNal **analogue**. The results of chemical and conformational characterization indicate that the synthetic **peptide** is able to fold efficiently with the correct disulfide topology (Cys6-Cys14, Cys16-Cys29, Cys22-Cys37), while retaining the conformational properties of the natural fragment. Thrombin **inhibition** data indicate that the effects of amino acid replacements are perfectly additive if compared to the singly substituted **analogues** (De Filippis V, Quarzago D, Vindigni A, Di Cera E, Fontana A, 1998, Biochemistry 37:13507-13515), yielding a molecule that inhibits the fast or slow form of thrombin by 2,670- and 6,813-fold more effectively than the natural fragment, and that binds exclusively at the active site of the enzyme with an affinity (Kd,fast = 15.4 pM, Kd,slow = 220 pM) comparable to that of full-length hirudin (Kd,fast = 0.2 pM, Kd,slow = 5.5 pM). Moreover, BugArgNal displays absolute **selectivity** for thrombin over the other physiologically important serine proteases trypsin, plasmin, **factor Xa**, and tissue plasminogen activator, up to the highest concentration of **inhibitor** tested (10 muM).

L104 ANSWER 125 OF 189 USPATFULL
ACCESSION NUMBER: 1998:157127 USPATFULL
TITLE: **Factor Xa inhibitors**
INVENTOR(S): Al-Obeidi, Fahad, Tucson, AZ, United States
Lebl, Michal, Tucson, AZ, United States
Ostrem, James A., Tucson, AZ, United States
Safar, Pavel, Tucson, AZ, United States
Stierandova, Alena, Tucson, AZ, United States
Strop, Peter, Tucson, AZ, United States
Walser, Armin, Tucson, AZ, United States
PATENT ASSIGNEE(S): Selectide Corporation, Tucson, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849519		19981215
APPLICATION INFO.:	US 1997-947794		19971008 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-428404, filed on 25 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-233054, filed on 26 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 5363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which specifically inhibit **factor Xa** activity. The compounds consist of the structure X.sub.1 -YIR-X.sub.2, wherein X.sub.1 is H, acyl, alkyl, acylalkyl, arylalkyl or one or more amino acids, and X.sub.2 is a

modified C-terminal group, one or more carboxy-protecting groups or one or more amino acids or other substituent, and Y, I and R are tyrosine, isoleucine and **arginine**, respectively, or peptidomimetic or organic structures that possess the same functional activity as Y, I and R, respectively. In addition, the present invention provides a compound having the structure A1-A2-(A3).sub.m --B, where m is 0 or 1. A compound of the invention can be linear or cyclic and can be about 2 and 43 residues in length. A compound of the invention is characterized, in part, in that it exhibits a specific **inhibition** of **factor Xa** activity with a K.sub.i of .ltoreq.100 .mu.M, preferably .ltoreq.2 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of **factor Xa** and of inhibiting blood clotting in vitro and in an individual and methods of detecting **factor Xa** levels or activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 126 OF 189 USPATFULL
ACCESSION NUMBER: 1998:144288 USPATFULL
TITLE: Vascular anticoagulant proteins DNA which codes them, processes for preparing them and their use
INVENTOR(S): Hauptmann, Rudolf, Ebreichsdorf, Austria
Maurer-Fogy, Ingrid, Vienna, Austria
Bodo, Gerhard, Vienna, Austria
Swetly, Peter, Vienna, Austria
Stratowa, Christian, Vienna, Austria
Falkner, Edgar, Kritzendorf, Austria
Adolf, Gunther, Vienna, Austria
Reutelingsperger, Christiaan Maria Peter, Maastricht, Netherlands
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837843		19981117
APPLICATION INFO.:	US 1995-376050		19950123 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-230875, filed on 20 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-868337, filed on 7 Apr 1992, now abandoned which is a division of Ser. No. US 1989-294602, filed on 30 Jan 1989, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3710364	19870328
	DE 1987-3710309	19870329
	DE 1987-3710430	19870328
	DE 1987-3737367	19871104
	WO 1988-EP266	19880326

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 70 Drawing Figure(s); 65 Drawing Page(s)
LINE COUNT: 3930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 127 OF 189 USPATFULL
ACCESSION NUMBER: 1999:144079 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolt, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837679		19981117
APPLICATION INFO.:	US 1996-469301		19960606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-243777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 128 OF 189 USPATFULL
ACCESSION NUMBER: 1998:131542 USPATFULL
TITLE: Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
INVENTOR(S): Rubin, Harvey, Philadelphia, PA, United States
Cooperman, Barry, Penn Valley, PA, United States
Scheenter, Norman, Philadelphia, PA, United States
Plotnick, Michael, Havertown, PA, United States
Wang, Zhi Mei, Philadelphia, PA, United States
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5827662		19981027
APPLICATION INFO.:	US 1996-721268		19960918 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-276936, filed on 19 Jul 1994, now patented, Pat. No. US 5612184 which is a continuation-in-part of Ser. No. US 1994-229286, filed on 18 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-221171, filed on 31 Mar 1994, now patented, Pat. No. US 5723316 And Ser. No. US 1994-221079, filed on 31 Mar 1994, now patented, Pat. No. US 5674708 , each Ser. No. US which		

is a continuation-in-part of Ser. No. US 1993-5908, filed on 15 Jan 1993, now patented, Pat. No. US 5367064 76 Ser. No. US 1991-735335, filed on 24 Jul 1991, now patented, Pat. No. US 5252725 which is a division of Ser. No. US 1989-370704, filed on 23 Jun 1989, now patented, Pat. No. US 5079336

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Moore, William W.
LEGAL REPRESENTATIVE: Law Offices of Jane Massey Licata
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 129 OF 189 USPATFULL
ACCESSION NUMBER: 1998:112054 USPATFULL
TITLE: Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex
INVENTOR(S): Lasters, Ignace, Antwerp, Belgium
De Maeyer, Marc, Groot-Bijgaarden, Belgium
Eipka, William Charles, San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5807989		19980915
APPLICATION INFO.:	US 1993-86328		19930701 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-952801, filed on 25 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-913232, filed on 13 Jul 1992, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 3
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 3750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds derived from BPTI which inhibit factor VIIa-TF complex with an inhibition constant of less than 500 nM, their pharmaceutical compositions, and methods of use. Also disclosed are isolated nucleic acid segments encoding for the compounds, vectors comprising the nucleic acid segment and promoter, transformed host cells, and a method for preparing the compounds using transformed host cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 130 OF 189 USPATFULL
ACCESSION NUMBER: 1998:91815 USPATFULL
TITLE: Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
INVENTOR(S): Fowlkes, Dana M., Chapel Hill, NC, United States

Broach, Jim, Princeton, NJ, United States
Manfredi, John, Ossining, NY, United States
Klein, Christine, Ossining, NY, United States
Murphy, Andrew J., Montclair, NJ, United States
Paul, Jeremy, South Nyack, NY, United States
Trueheart, Joshua, South Nyack, NY, United States
PATENT ASSIGNEE S : Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789184		19980804
APPLICATION INFO.:	US 1995-464581		19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-190328, filed on 31 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ketter, James
ASSISTANT EXAMINER: Yucel, Irem
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara, Catherine J.
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 6731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential **peptide** modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 131 OF 189 USPATFULL
ACCESSION NUMBER: 1998:72722 USPATFULL
TITLE: Process for production of inhibited forms of activated blood factors
INVENTOR(S): King, Robert, Fremont, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770699		19980623
APPLICATION INFO.:	US 1996-774592		19961230 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-330978, filed on 28 Oct 1994, now patented, Pat. No. US 5583571
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing a highly purified preparation of an inhibited

form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 132 OF 189 USPATFULL
ACCESSION NUMBER: 1999:48367 USPATFULL
TITLE: Bovine pancreatic trypsin **inhibitor** derived **inhibitors** of **factor XA**
INVENTOR(S): Lasters, Ignace, Antwerpen, Belgium
De Maeyer, Marc, Groot-Bijgaarden, Belgium
Pipka, William Charles, San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5747449		19980505
APPLICATION INFO.:	US 1993-86630		19930701 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-913232, filed on 13 Jul 1992
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2111
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound derived from BPTI which inhibits **Factor Xa** with an **inhibition** constant less than 50 nM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 133 OF 189 USPATFULL
ACCESSION NUMBER: 1998:39504 USPATFULL
TITLE: **Inhibitors** of **factor Xa**
INVENTOR(S): Brunck, Terence Kevin, San Diego, CA, United States
Webb, Thomas Roy, Encinitas, CA, United States
Pipka, William Charles, San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739112		19980414
APPLICATION INFO.:	US 1995-468115		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-168964, filed on 15 Dec 1993 which is a continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds, their salts and compositions related thereto having activity against mammalian **factor Xa** are disclosed. The novel compounds include **peptide** aldehyde **analogues** having substantial potency and **specificity** as **inhibitors** of mammalian **factor Xa** are further disclosed. The compounds are thought useful as **inhibitors** of **factor Xa** in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 134 OF 189 USPATFULL
ACCESSION NUMBER: 1999:39446 USPATFULL
TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S): Roy, Soumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739101		19980414
APPLICATION INFO.:	US 1995-440814		19950515 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-246978, filed on 20 May 1994, now patented, Pat. No. US 5589363 which is a division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Kubinec, Jeffrey S.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2482		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 135 OF 189 USPATFULL
ACCESSION NUMBER: 1998:12120 USPATFULL
TITLE: Trypsin Inhibitors
INVENTOR(S): Brunck, Terence K., San Diego, CA, United States
Pepe, Michael G., San Diego, CA, United States
Pearson, Daniel A., Solana Beach, CA, United States
Webb, Thomas R., Encinitas, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5714380		19980203
APPLICATION INFO.:	US 1995-465974		19950531 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-11666, filed on 29 Jan 1993, now patented, Pat. No. US 5534498, issued on 9 Jul 1996 which is a continuation-in-part of Ser. No. US		

1992-828388, filed on 30 Jan 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Huff, Sheela J.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds having activity against trypsin are disclosed. Specifically, novel **peptide** aldehyde **analogues** that have substantial potency and **specificity** as inhibitors of mammalian pancreatic trypsin are presented. The compounds are useful in the prevention and treatment of the tissue damage or destruction associated with pancreatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 136 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998098453 PCTFULL ED 20020514
TITLE (ENGLISH): CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR
TITLE (FRENCH): CONJUGUES DE DITHIOCARBAMATES COMPRENANT DES AGENTS PHARMACOLOGIQUEMENT ACTIFS ET UTILISATIONS DESDITS CONJUGUES
INVENTOR(S): LAI, Ching-San
PATENT ASSIGNEE(S): MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9855453	A1	19981210
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US10295	A	19980519
PRIORITY INFO.:	US 1997-8/869,158		19970604

ABEN In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or DC) and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.
ABFR L'invention concerne des conjugues d'accepteurs de monoxyde d'azote (dithiocarbamates ou DC,

par exemple, et des agents pharmacologiquement actifs (AINS, par exemple,. Les conjugues de
l'invention donnent une nouvelle categorie d'agents pharmacologiquement actifs (agents
anti-inflammatoires, par exemple) qui ont une incidence d'effets secondaires beaucoup moindre en
raison de l'effet de protection produit par la modification de ces agents pharmacologiquement
actifs. En outre, les conjugues de l'invention sont plus efficaces que les agents
pharmacologiquement actifs puisse que des cellules ou des tissus places au contact desdits agents
sont proteges contre les effets potentiellement deteriorants de la surproduction de monoxyde d'azote
ainsi induite par la coproduction d'accepteurs de monoxyde d'azote (des dithiocarbamates, par
exemple), a laquelle s'ajoute celle d'un agent libre pharmacologiquement actif lorsque le conjugue
est clive.

L104 ANSWER 137 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998031394 PCTFULL ED 20020514
TITLE (ENGLISH): TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR TREATMENT
TITLE (FRENCH): METHODES ET COMPOSITIONS DE THROMBOPLASTINE TISSULAIRE POUR LE TRAITEMENT DE LA COAGULATION ET DES TUMEURS
INVENTOR(S): THORPE, Philip, E.; KING, Steven, W.; GAO, Boning
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; THORPE, Philip, E.; KING, Steven, W.; GAO, Boning
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9831394	A2	19980723
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US1013	A	19980120
PRIORITY INFO.:	US 1997-60/035,920		19970122
	US 1997-60/036,205		19970117
	US 1997-60/043,427		19970327

ABEN The invention embodies the surprising discovery that Tissue Factor (TF) compositions and
variants thereof specifically localize to the blood vessels within a vascularized tumor following
systemic administration. The invention therefore provides methods and compositions comprising
coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor
treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates
with improved half-life, or in combination with other agents, such as conventional chemotherapeutic
drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa/FVIIa)
or FSVIIa activators.

ABFR La presente invention a trait a la decouverte interessante de la localisation specifique de
compositions de thromboplastine tissulaire (TF) et de variantes de cette derniere dans les vaisseaux

sanguins, a l'interieur d'une tumeur vascularisee, a la suite d'une administration systemique.
L'invention concerne donc des methodes et compositions comprenant une thromboplastine tissulaire
deficiente en coagulants destinee a etre utilisee pour effectuer une coagulation specifique et pour
traiter des tumeurs. Les compositions et methodes de TF de la presente invention peuvent etre
utilisees seules, comme conjugues de TF presentant une demi-vie amelioree; ou en combinaison avec
d'autres agents, tels que des medicaments chimiotherapeutiques, des immunotoxines ciblees, des
coagulants cibles; et/ou en combinaison avec un Facteur VIIa(FVIIa) ou des activateurs de FVIIa.

L104 ANSWER 139 OF 199 PCTFULL COPYRIGHT 2002 Univentic
ACCESSION NUMBER: 1998009987 PCTFULL ED 20020514
TITLE (ENGLISH): LACTAM INHIBITORS OF THROMBIN
TITLE (FRENCH): INHIBITEURS LACTAME DE LA THROMBINE
INVENTOR(S): ST-DENIS, Yves; SIDDIQUI, M., Arshad; CODY, Wayne, Livingston; EDMUNDS, Jeremy, John; PLUMMER, Janet, Samartino
PATENT ASSIGNEE(S): BIOCHEM PHARMA, INC.; ST-DENIS, Yves; SIDDIQUI, M., Arshad; CODY, Wayne, Livingston; EDMUNDS, Jeremy, John; PLUMMER, Janet, Samartino
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9809987	A1	19980312
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US15312	A	19970905
PRIORITY INFO.:	US 1996-60/025,599		19960906
	GB 1996-9618687.9		19960906

ABEN This invention relates to heterocyclic inhibitors of the enzyme thrombin, their preparation,
and pharmaceutical compositions thereof having general formula (I), wherein W, X, Y R1 to R3 are as
defined herein. Also, the invention relates to the use of such compounds and compositions as
anticoagulants and as agents for the treatment and prophylaxis of thrombotic disorders such as
venous thrombosis, pulmonary embolism and arterial thrombosis resulting in acute ischemic events
such as myocardial infarction or cerebral infarction.
ABFR L'invention concerne des inhibiteurs heterocycliques de l'enzyme thrombine, la preparation de
ceux-ci ainsi que des compositions pharmaceutiques contenant ces inhibiteurs possedant la formule
generale (I), dans laquelle W, X, Y, R1 a R3 possedent les notations donnees dans la description. De
meme, l'invention se rapporte a l'utilisation de tels composes et compositions, en tant
qu'anticoagulants et agents destines au traitement et a la prophylaxie de troubles thrombotiques,
tels que la thrombose veineuse, l'embolie pulmonaire et la thrombose arterielle, lesquels
surviennent lors d'accidents ischemiques aigus comme l'infarctus du

myocarde ou l'infarctus
cerebral.

L104 ANSWER 139 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998005333 PCTFULL ED 20020514
TITLE (ENGLISH): USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS
TITLE (FRENCH): UTILISATION DE MIMETIQUES DE FEUILLETS BETA COMME INHIBITEURS DE PROTEASE ET DE KINASE OU COMME INHIBITEURS DE FACTEURS DE TRANSCRIPTION
INVENTOR(S): KAHN, Michael; QABAR, Maher, Nicola; McMILLAN, Michael, Kim; OGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; URBAN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd
PATENT ASSIGNEE(S): MILLENNIUMETICS LTD.; KAHN, Michael; QABAR, Maher, Nicola; McMILLAN, Michael, Kim; OGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; URBAN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9805333	A1	19980212
DESIGNATED STATES	AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US13622	A	19970805
PRIORITY INFO.:	US 1996-8/692,420		19960805
	US 1996-8/729,073		19961002
	US 1997-8/797,919		19970210
	US 1997-60/047,067		19970519

ABEN 'beta'-sheet mimetics and methods relating to the same are disclosed. The 'beta'-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors. Methods of the invention include administration of a 'beta'-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase and/or transcription factor.

ABFR L'invention concerne des mimetiques de feuillets beta et des procedes les concernant. Les mimetiques de feuillets beta sont utiles comme inhibiteurs de protease et de kinase ainsi que comme inhibiteurs de facteurs de transcription. Des procedes de l'invention comprennent l'administration d'un mimetique de feuillets beta ou l'utilisation dudit mimetique pour fabriquer un medicament destine au traitement d'une variete d'etats pathologiques associes a la protease, a la kinase et/ou au facteur de transcription cibles.

L104 ANSWER 140 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998000442 PCTFULL ED 20020514
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE LA SERINE PROTEASE
INVENTOR(S): DEALMAN, John, Joseph; ELGENDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr;

GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir

PATENT ASSIGNEE S : THROMBOSIS RESEARCH INSTITUTE; DEADMAN, John, Joseph; ELSENDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9810442	A1	19980312

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1997-GB1574	A	19970611
PRIORITY INFO.:	GB 1996-9613719.5		19960629

ABEN Bifunctional serine protease inhibitors and methods of preparing boron-containing **peptides** are provided. The serine protease inhibitors comprise a catalytic site-directed moiety, which binds to and inhibits the active site of a serine protease, and an exosite associating moiety, which are joined by a connector moiety. The catalytic site directed moiety and the exosite associating moiety are capable of binding simultaneously to a molecule of the serine protease.

ABFR L'invention concerne des inhibiteurs bifonctionnels de la serine protease et des procedes de preparation de **peptides** contenant du bore. Ces inhibiteurs comprennent une fraction catalytique dirigee qui se lie au site actif d'une serine protease et l'inhibe, et une fraction se liant a un exosite, ces deux fractions etant reunies par une fraction de couplage. La fraction dirigee catalytique et la fraction se liant a un exosite sont capables de se lier simultanement a une molecule de la serine protease.

L104 ANSWER 141 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 918744 EUROPATFULL EW 199803 FS OS

TITLE: Process for selecting candidate drug compounds.
Verfahren zur Auswahl von Kandidat-Drogenverbindungen.
Procede de selection des compositions medicamenteuses potentielles.

INVENTOR(S): Young, Stephen Clinton, 8 Cranbourne Road, Heaton Moor, Stockport, Cheshire SK4 4DL, GB;
Murray, Christopher, 1 Wheatfield Close, Titherington, Macclesfield, Cheshire SK10 2TT, GB

PATENT ASSIGNEE(S): Proteus Molecular Design Limited, Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL, GB

PATENT ASSIGNEE NO: 906234

AGENT: Cockbain, Julian, Dr., Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street, London EC4V 4EL, GB

AGENT NUMBER: 52641

OTHER SOURCE: EGP1998004 EP 0818744 A2 980114

SOURCE: Wila-EPZ-1998-H03-T2a

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 8[illegible]744	A2	19981114
'OFFENLEGUNGS' DATE:			19981114
APPLICATION INFO.:	EP 1997-304413		19970624
PRIORITY APPLN. INFO.:	GB 1996-14302		19960708
	GB 1996-16562		19960807

L104 ANSWER 142 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 703923 EUROPATFULL EW 199841 FS PS
TITLE: FACTOR VII-DERIVED **PEPTIDES**.
FAKTOR VII-**PEPTIDE**.
PEPTIDES DERIVES DU FACTEUR VII.
INVENTOR(S): STEPHENS, Ross Wentworth, Silurveien 19, N-0380 Oslo, NO;
ORNING, Lars, Thomas Heftyes gate 47B, N-0267 Oslo, NO;
SAKARIASSEN, Kjell Steinar, Kygd Alle 33B, N-0262 Oslo, NO
PATENT ASSIGNEE(S): NYCOMED IMAGING AS, Nycoveien 1-2, 0401 Oslo 4, NO
PATENT ASSIGNEE NO: 1564564
AGENT: Matthews, Derek Peter et al, Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street, London EC4V 4EL, GB
AGENT NUMBER: 60131
OTHER SOURCE: EPB1998055 EP 0703923 B1 981007
SOURCE: Wila-EPS-1998-841-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 703923	B1	19981007
'OFFENLEGUNGS' DATE:			19960403
APPLICATION INFO.:	EP 1994 918437		19940617
PRIORITY APPLN. INFO.:	GB 1993-12601		19930618
	GB 1994-9835		19940510
RELATED DOC. INFO.:	WO 94-GB1315		940617 INTAKZ
	WO 9500541		950105 INTPNR
REFERENCE PAT. INFO.:	EP 446747 A		WO 90-03390 A
	WO 93-13804 A		

L104 ANSWER 143 OF 189 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 1998128[illegible] MEDLINE
DOCUMENT NUMBER: 98128[illegible] PubMed ID: 9454596
TITLE: Discovery of a novel, potent, and specific family of **factor Xa inhibitors** via combinatorial chemistry.
AUTHOR: Ostrem J A; al-Obeidi F; Safar P; Safarova A; Stringer S K; Patek M; Cross M T; Spoonamore J; LoCascio J C; Kasireddy P; Thorpe D S; Sepetov N; Lebl M; Wildgoose P; Strop P
CORPORATE SOURCE: Selectide Corporation, Tucson, Arizona 85737, USA.. jim.ostrem@hmrag.com
SOURCE: BIOCHEMISTRY, (1998 Jan 27) 37 (4) 1053-9.

Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199803
ENTRY DATE: Entered STN: 19980319
Last Updated on STN: 20000303
Entered Medline: 19980306

AB A series of low molecular weight **peptide inhibitors** of **factor Xa**, unrelated to any previously described, was identified by screening a combinatorial **peptide** library composed of L-amino acids. The minimal inhibitory sequence is a tripeptide, L-tyrosinyl-L-isoleucyl-L-arginyl, which competitively inhibits the hydrolysis of small chromogenic substrates by **factor Xa** but binds in an orientation which prevents a productive nucleophilic attack by serine 195 of the catalytic triad on the carbonyl carbon of the carboxyterminal **arginine**. The initial leads identified in an octamer combinatorial **peptide** library ranged in potency from 4 to 15 microM. These **peptides** were modified into **peptide** mimetics with a greater than 1000-fold increase in potency while retaining unusual **selectivity** for **factor Xa** over the related serine proteases thrombin, factor VIIa/tissue factor, plasmin, activated protein C, kallikrein, and trypsin. One of the most potent **analogues**, SEL 2711, with a Ki of 0.003 microM for **factor Xa** and 40 microM for thrombin, is active in in vitro and ex vivo coagulation assays, suggesting the potential application of these **inhibitors** in anticoagulant therapy.

L104 ANSWER 144 OF 189 USPATFULL
ACCESSION NUMBER: 97:109871 USPATFULL
TITLE: Methods for coating invasive devices with inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Concord, MA, United States
Fenton, II, John W., Malden Bridge, NY, United States
Kline, Toni, Cambridge, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5691311		19971125
APPLICATION INFO.:	US 1995-439297		19950511 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-834259, filed on 10 Feb 1992, now patented, Pat. No. US 5433940, issued on 18 Jul 1995 which is a continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1990, now patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for

therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 145 OF 189 USPATFULL
ACCESSION NUMBER: 97:104449 USPATFULL
TITLE: Basic .alpha.-aminoalkylphosphonate derivatives
INVENTOR(S): Powers, James C., Atlanta, GA, United States
Bednarek, Bogdan, Wroclaw, Poland
Oleksyszyn, Jozef, Arlington, MA, United States
PATENT ASSIGNEE(S): Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5686419		19971111	
APPLICATION INFO.:	US 1994-184286		19940121	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Deveau, Colton & Marquis
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptidyl derivatives of diesters of .alpha.-aminoalkylphosphonic acids with basic substitutents, their use in inhibiting serine proteases with trypsin-like **specificity** and their roles as anti-inflammatory agents, anticoagulants, and anti-tumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 146 OF 189 USPATFULL
ACCESSION NUMBER: 97:58898 USPATFULL
TITLE: Inhibitor resistant serine proteases
INVENTOR(S): Dawson, Keith Martyn, Cowley, United Kingdom
Gilbert, Richard James, Cowley, United Kingdom
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, Oxford, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5645833		19970708	
	WO 9403614		19940217	
APPLICATION INFO.:	US 1995-379621		19950203	(8)
	WO 1993-GB1632		19930803	
			19950203	PCT 371 date
			19950203	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-16598	19920804

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Hale And Dorr
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 1979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Serine proteases of the chymotrypsin superfamily are modified so that they exhibit resistance to serine protease inhibitors. If such modified serine proteases have fibrinolytic, thrombolytic, antithrombotic or

prothrombotic properties, they are useful in the treatment of blood clotting diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 147 OF 189 USPATFULL
ACCESSION NUMBER: 97:61973 USPATFULL
TITLE: **Peptide** mediated enhancement of thrombolysis methods and compositions
INVENTOR(S): Lawrence, Daniel A., Ann Arbor, MI, United States
Ginsburg, David, Ann Arbor, MI, United States
Shore, Joseph D., Grosse Point Farms, MI, United States
Fay, William P., Ann Arbor, MI, United States
Olson, Steven T., Chicago, IL, United States
Francis-Chmura, Ann Marie, Warren, MI, United States
Eitzman, Daniel T., Ypsilanti, MI, United States
Paielli, Dell, Wyandotte, MI, United States
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
Henry Ford Health System, Detroit, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5639726		19970617	
APPLICATION INFO.:	US 1994-315461		19940930	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 4817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates generally to **peptides** which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using **peptides** which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions useful in clot lysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 148 OF 189 USPATFULL
ACCESSION NUMBER: 97:49542 USPATFULL
TITLE: Activatable fibrinolytic and anti-thrombotic proteins
INVENTOR(S): Dawson, Keith, Marlow, United Kingdom
Edwards, Richard M., Thame, United Kingdom
Forman, Joan M., Oxford, United Kingdom
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5637490		19970610	
	WO 9109119		19910627	
APPLICATION INFO.:	US 1992-814603		19920604	(7)
	WO 1990-GB1912		19901207	
			19920604	PCT 371 date
			19920604	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-27722	19891207

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure s.; 15 Drawing Page(s)
LINE COUNT: 1909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Proteinaceous compounds are activatable by enzymes of the clotting cascade to have fibrinolytic or clot formation **inhibition** activity. For example, a plasminogen **analogue** is activatable to plasmin by thrombin or **Factor Xa**. Fibrinolytic or clot formation **inhibition** activity is therefore directed to the site of clot formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 149 OF 189 USPATFULL
ACCESSION NUMBER: 97:33716 USPATFULL
TITLE: Human tissue factor related DNA segments, polypeptides and antibodies
INVENTOR(S): Edgington, Thomas S., La Jolla, CA, United States
Morrissey, James H., Oklahoma City, OK, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5622931		19970422
APPLICATION INFO.:	US 1992-880079		19920429 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Carlson, K. Cochrane
LEGAL REPRESENTATIVE: Fitting, Thomas
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 3119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 150 OF 189 USPATFULL
ACCESSION NUMBER: 97:31793 USPATFULL
TITLE: Aprotinin analogs
INVENTOR(S): Bj.o slashed.rn, Soren E., Lyngby, Denmark
Norris, Kjeld, Hellerup, Denmark
Diness, Viggo, Charlottenlund, Denmark
N.o slashed.rskov-Lauritsen, Leif, K.o slashed.ge, Denmark
Christensen, Niels D., K.o slashed.benhavn, Denmark

Bregengaard, Claus, Hellerup, Denmark
Norris, Fanny, Hellerup, Denmark
Petersen, Lars C., H.o slashed.rsholm, Denmark
PATENT ASSIGNEE(S) : Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5621078		19970415
APPLICATION INFO.:	US 1995-443977		19950518 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-84718, filed on 23 Jun 1993 which is a continuation-in-part of Ser. No. US 1993-24901, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on 21 Jun 1990, now abandoned , said Ser. No. US 1995-443977, filed on 18 May 1995 which is a continuation-in-part of Ser. No. US 1990-598737, filed on 19 Nov 1990, now patented, Pat. No. US 5373090 And a continuation-in-part of Ser. No. US 1992-827687, filed on 29 Jan 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1987-4601	19870828
	DK 1988-1254	19880426
	DK 1990-2361	19901001
	DK 1991-1118	19910612

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Hobbs, Lisa J.
LEGAL REPRESENTATIVE: Delson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 151 OF 189 USPATFULL
ACCESSION NUMBER: 97:29570 USPATFULL
TITLE: Aprotinin analogs
INVENTOR(S): Bj.o slashed.rn, Soren E., Lyngby, Denmark
Norris, Kjeld, Hellerup, Denmark
Vinss, Viggo, Charlottenlund, Denmark
N.o slashed.rskov-Lauritsen, Leif, K.o slashed.ge, Denmark
Christensen, Niels D., K.o slashed.venhavn, Denmark
Bregengaard, Claus, Hellerup, Denmark
Norris, Fanny, Hellerup, Denmark
Petersen, Lars C., H.o slashed.rsholm, Denmark
PATENT ASSIGNEE(S): Novo Nordisk, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5618918		19970408
APPLICATION INFO.:	US 1995-443976		19950518 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-84718, filed on 23 Jun		

1993 which is a continuation-in-part of Ser. No. US 1993-24905, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on 31 Jun 1990, now abandoned , said Ser. No. US -84718 which is a continuation-in-part of Ser. No. US 1991-599737, filed on 19 Nov 1990, now patented, Pat. No. US 5378090 And a continuation-in-part of Ser. No. US 1992-827697, filed on 29 Jan 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1987-4501	19870929
	DK 1988-2154	19880426
	DK 1990-2361	19901001
	DK 1991-1118	19910621

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Hobbs, Lisa J.
LEGAL REPRESENTATIVE: Nelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 3547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 152 OF 189 USPATFULL
ACCESSION NUMBER: 97:29638 USPATFULL
TITLE: Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
INVENTOR(S): Rubin, Harvey, Philadelphia, PA, United States
Cooperman, Barry, Penn Valley, PA, United States
Schechter, Norman, Philadelphia, PA, United States
Plotnick, Michael, Havertown, PA, United States
Wang, Zhi M., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5613194		19970318
APPLICATION INFO.:	US 1994-276936		19940719 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-229286, filed on 18 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-221078, filed on 31 Mar 1994 And Ser. No. US 1994-221171, filed on 31 Mar 1994 , said Ser. No. US -221078 And Ser. No. US -221171 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-5998, filed on 15 Jan 1993, now abandoned And Ser. No. US 1993-5999, filed on 15 Jan 1993, now patented, Pat. No. US 5367064 , each Ser. No. US - which is a division of Ser. No. US 1991-738336, filed on 24 Jul 1991, now patented, Pat. No. US 5252725 which is a division of Ser. No. US 1989-370704, filed on 23 Jun 1989, now patented, Pat. No. US 5079336
DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Law Offices of Jane Massey Licata
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 153 OF 189 USPATFULL
ACCESSION NUMBER: 97:12570 USPATFULL
TITLE: Process for production of inhibited forms of activated blood factors
INVENTOR(S.: King, Robert, Fremont, CA, United States
PATENT ASSIGNEE(S): DOR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5602233		19970211
APPLICATION INFO.:	US 1995-484558		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-330978, filed on 28 Oct 1994		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 154 OF 189 USPATFULL
ACCESSION NUMBER: 97:7908 USPATFULL
TITLE: N-sulfonylarginine keto-amide compounds
INVENTOR(S : Webb, Thomas R., Encinitas, CA, United States
Miller, Todd A., Encinitas, CA, United States
Vlasuk, George P., Carlsbad, CA, United States
Abelman, Matthew M., Solana Beach, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5597804		19970128
APPLICATION INFO.:	US 1993-139300		19931019 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-962351, filed on 16 Oct 1992, now patented, Pat. No. US 5371072		

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Wityshyn, Michael G.
ASSISTANT EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to N-sulfonyl **arginine** alpha-keto-amide derivatives, their pharmaceutically acceptable salts and compositions thereof which are useful as antithrombotic agents in mammals and also the use of these compounds as antithrombotic agents. Also, disclosed are methods of using these inhibitors in their various embodiments as therapeutic agents for disease states characterized by disorders of the blood coagulation process. Further disclosed are compounds useful as intermediates in the preparation of these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 155 OF 189 USPATFULL
ACCESSION NUMBER: 97:1332 USPATFULL
TITLE: Process for preparing aprotinin and aprotinin analogs in yeast cells
INVENTOR(S): Bj.o slashed.rn, Soren E., Lyngby, Denmark
Norris, Kjeld, Hellerup, Denmark
Diness, Viggo, Charlottenlund, Denmark
N.o slashed.rskov-Lauritsen, Leif, K.o slashed.ge, Denmark
Christensen, Niels D., K.o slashed.venhavn, Denmark
Bregengaard, Claus, Hellerup, Denmark
Norris, Fanny, Hellerup, Denmark
Petersen, Lars C., H.o slashed.rsholm, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5591603		19970107
APPLICATION INFO.:	US 1993-84718		19930623 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-24925, filed on 26 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-466408, filed on 31 Jun 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-598737, filed on 19 Nov 1990, now patented, Pat. No. US 5373090 And a continuation-in-part of Ser. No. US 1992-827687, filed on 29 Jan 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1987-4501	19870828
	DK 1988-0254	19880426
	DK 1990-2361	19901001
	DK 1991-1118	19910612

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Nelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for producing aprotinin and

analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 156 OF 189 EUROPATFULL COPYRIGHT 10 . WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 5089xx EUROPATFULL EW 1xxxxx FS PS
TITLE: ACTIVATABLE FIBRINOLYTIC AND ANTI-THROMBOTIC PROTEINS.
AKTIVIERBARE FIBRINOLYTISCHE UND ANTITHROMBOTISCHE PROTEINE.
PROTEINES FIBRINOLYTIQUES ET ANTITHROMBOTIQUES ACTIVABLES.
INVENTOR(S): DAWSON, Keith Martyn, 80 Barnards Hill, Marlow, Bucks SL7 2NB, GB;
EDWARDS, Richard Mark, 7 Ludlow Drive, Thame, Oxon OX9 3XB, GB;
FORMAN, Joan Mabel, 6 Margaret Road, Oxford OX3 8NG, GB
PATENT ASSIGNEE(S): BRITISH BIOTECH PHARMACEUTICALS LIMITED, Watlington Road, Cowley Oxford, OX4 5LY, GB
PATENT ASSIGNEE NO: 970612
AGENT: Walls, Alan James et al, British Biotech Pharmaceuticals Ltd., Watlington Road, Oxford OX4 5LY, GB
AGENT NUMBER: 37214
OTHER SOURCE: EPB1997047 EP 0502968 B1 970703
SOURCE: Wila-EPS-1997-H30-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 502968	B1	19970703
'OFFENLEGUNGS' DATE:		19920916
APPLICATION INFO.:	EP 1991-900851	19901207
PRIORITY APPLN. INFO.:	GB 1989-27722	19891207
RELATED DOC. INFO.:	WO 90-GB1913	901207 INTAKZ
	WO 9109118	910627 INTPNR

REFERENCE PAT. INFO.:			
EP 211294	A	EP 227933	A
EP 292009	A	EP 297882	A
EP 304013	A	EP 319944	A
EP 323149	A	EP 330709	A
EP 339841	A	WO 89-01036	A
WO 89-06239	A	WO 90-10081	A
WO 90-13640	A	WO 91-15597	A

REF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, American Chemical Society, D.J. Davidson et al.: "plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens", pages 3585-3590 Chemical Abstracts, vol. 103, 1985, Columbus, Ohio, US; J.Y. Chang: "Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate", see page 412 Archives of Biochemistry and Biophysics, vol. 271, no. 2, June 1989, Academic Press, Inc.; J. Whitefliet-Smith et al.: "Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system", pages 390-399 Proc.

Natl. Acad. Sci. USA, vol. 79, October 1982; T. Miyata et al.: "Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine- 601 by threonine in the active site", pages 6132-6136

L104 ANSWER 157 OF 189 USPATFULL
ACCESSION NUMBER: 96:120979 USPATFULL
TITLE: Process for production of inhibited forms of activated blood factors
INVENTOR(S): King, Robert, Fremont, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589572		19961231
APPLICATION INFO.:	US 1995-474042		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-330978, filed on 28 Oct 1994		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 158 OF 189 USPATFULL
ACCESSION NUMBER: 96:120978 USPATFULL
TITLE: Process for production of inhibited forms of activated blood factors
INVENTOR(S): King, Robert, Fremont, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589571		19961231
APPLICATION INFO.:	US 1994-330978		19941028 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fleisher, Mindy
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the

resulting inhibited activated blood factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 159 OF 189 USPATFULL
ACCESSION NUMBER: 96:120775 USPATFULL
TITLE: DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S): Roy, Sumitra, San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589363		19961231
APPLICATION INFO.:	US 1994-246978		19940520 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S., Winter, Daryl B.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2528
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB DNA enclosing a tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.bIII.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 160 OF 189 USPATFULL
ACCESSION NUMBER: 96:113902 USPATFULL
TITLE: Agents affecting thrombosis and hemostasis
INVENTOR(S): Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PATENT ASSIGNEE(S): COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5583107		19961210
APPLICATION INFO.:	US 1994-268003		19940629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Degen, Nancy J.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 141 OF 189 USPATFULL
ACCESSION NUMBER: 96:131466 USPATFULL
TITLE: Directed evolution of novel binding proteins
INVENTOR(S): Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PATENT ASSIGNEE(S): Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571698		19961105
APPLICATION INFO.:	US 1993-57667		19930618 (8)
DISCLAIMER DATE:	20100629		

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 15303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 142 OF 189 USPATFULL
ACCESSION NUMBER: 96:[illegible]694 USPATFULL
TITLE: Trypsin inhibitors
INVENTOR(S): Brunck, Terence K., San Diego, CA, United States

Pepe, Michael G., San Diego, CA, United States
Pearson, Daniel A., Solana Beach, CA, United States
Webb, Thomas R., Encinitas, CA, United States
PATENT ASSIGNEE(S.: Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5594498		19960709
APPLICATION INFO.:	US 1994-11666		19940124 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-828838, filed on 31 Jan 1992, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Marshall, S. G.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds having activity against trypsin are disclosed. Specifically, novel **peptide** aldehyde **analogues** that have substantial potency and **specificity** as inhibitors of mammalian pancreatic trypsin are presented. The compounds are useful in the prevention and treatment of the tissue damage or destruction associated with pancreatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 163 OF 189 USPATFULL
ACCESSION NUMBER: 96:38638 USPATFULL
TITLE: Methods for coating invasive devices with inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Concord, MA, United States
Bourdon, Paul R., Sommerville, MA, United States
Jablonski, Jo-Ann M., Middleborough, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5514409		19960507
APPLICATION INFO.:	US 1995-431678		19950502 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-924549, filed on 31 Jul 1992, now patented, Pat. No. US 5425936, issued on 20 Jun 1995 which is a division of Ser. No. US 1991-652929, filed on 8 Feb 1991, now patented, Pat. No. US 5240913, issued on 31 Aug 1993 which is a continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1990, now patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lusignan, Michael
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to coating invasive devies with novel

biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula: ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unisubstituted, mono-substituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R.sub.1 ' is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R.sub.4 ' is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 8.5; and X, R.sub.2, R.sub.3, R.sub.5, R.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18 .ANG. and 42 .ANG. in length which connects the Y to the ABEAM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 164 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996038470 PCTFULL ED 20020514
TITLE (ENGLISH): IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE SERINE PROTEASE DERIVES DE IMIDAZO[1,5A]PYRIDINE
INVENTOR(S): OTTENHEYM, Henricus, Carl, Joseph; ADANG, Anton, Egbert, Peter; PETERS, Jacobus, Albertus, Maria
PATENT ASSIGNEE(S): AKZO NOBEL N.V.; OTTENHEYM, Henricus, Carl, Joseph; ADANG, Anton, Egbert, Peter; PETERS, Jacobus, Albertus, Maria
LANGUAGE OF PUBL.: German
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9638470	A1	19961205
DESIGNATED STATES	AU BR CA CN CZ HU JP KR MX NO NZ PL RU SG TR US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1996-EP2298	A	19960529
PRIORITY INFO.:	AT 1995-952001448.4		19950602

ABEN The invention relates to an imidazo[1,5a]pyridine derived serine protease inhibitor comprising a unit having general formula (I) wherein R1 is hydrogen, lower alkyl or an acyl group; R2 is hydrogen or lower alkyl; R3 and R4 are independently hydrogen, lower alkyl or together form =CH-NR5R6, R5 and R6 being lower alkyl. The compounds are serine protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

ABFR Cette invention concerne un inhibiteur de serine protease derive de imidazo[1,5a]pyridine, lequel inhibiteur comprend une unite correspondant a la formule generale (I) ou R1 represente hydrogene, alkyle inferieur ou un groupe acyle; R2 represente hydrogene ou alkyle inferieur; R3 et R4 representent independamment hydrogene, alkyle inferieur ou forment ensemble =CH-NR5R6, R5 et R6 representant un alkyle inferieur. Ces composes sont des inhibiteurs de serine protease et peuvent

etre utilises dans le traitement et la prevention de thromboses et de maladies associees a la
thrombine.

L104 ANSWER 165 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996030035 PCTFULL ED 20020514
TITLE (ENGLISH): 'beta'-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE **PEPTIDES** OR PROTEINS
TITLE (FRENCH): IMITATEURS DE FEUILLETS 'beta' ET LEUR EMPLOI COMME INHIBITEURS DE **PEPTIDES** OU DE PROTEINES BIOLOGIQUEMENT ACTIFS
INVENTOR(S): KAHN, Michael
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; KAHN, Michael
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9630035	A1	19961003
DESIGNATED STATES	AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1996-US4044	A	19960325
PRIORITY INFO.:	US 1995-8/410,518		19950324
	US 1995-8/549,006		19951027

ABEN There are disclosed 'beta'-sheet mimetics and methods relating to the same for imparting or stabilizing the 'beta'-sheet structure of a **peptide**, protein or molecule. In one aspect, the 'beta'-sheet mimetics are covalently attached at the end or within the length of the **peptide** or protein. The 'beta'-sheet mimetics have utility as inhibitors of one or more of proteases, kinases, CAAX, **peptides** binding to SH2 domains and MHC-I and/or MHC-II presentation of **peptides** to T cell receptors in warm-blooded animals.

ABFR La presente invention concerne des mimetiques de feuillets 'beta' et des procedes s'y rapportant permettant de communiquer ou stabiliser la structure en feuillets 'beta' d'un **peptide**, d'une proteine ou d'une molecule. Dans l'une des variantes, les mimetiques de feuillets 'beta' sont fixes par covalence a l'extremite du **peptide** ou de la proteine, ou entre ses extremites. Ces imitateurs de feuillets 'beta' conviennent comme inhibiteurs d'une ou plusieurs proteases, kinases, CAAX, de **peptides** se liant a des domaines SH2 et de la presentation MHC-I et/ou MHC-II de **peptides** a des recepteurs de cellules T chez les animaux a sang chaud.

L104 ANSWER 166 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996025427 PCTFULL ED 20020514
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE SERINES PROTEASES
INVENTOR(S): GREEN, Donovan, St. Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph
PATENT ASSIGNEE(S): ELLERMAN PHARMACEUTICALS LIMITED; GREEN, Donovan, St. Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9625427	A1	19960822
DESIGNATED STATES	AU CA JP NZ US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1996-GB352	A	19960215
PRIORITY INFO.:	GB 1995-9502985.6		19950216

ABEN **Peptide** inhibitors of serine proteases, especially thrombin, in which the P1-P2 natural amide linkage is replaced by another bond. Exemplary thrombin inhibitors are of the formula: X-(aa3)-(aa2)-'psi'-(aa1)-Z wherein X is H or a substituent on the N-terminal amino group, aa3 is a hydrophobic amino acid such as Phe, aa2 is Pro, aa1 is Arg or an Arg **analogue** such as methoxypropylglycyl, Z is -COOH or a heteroatom acid group, such as boronate, or a derivative of either, and 'PSI' is a non-amide linkage, typically containing up to 5 in-chain atoms, such as -CO2-, -CH2O-, NHCO- or -CH2-CH2-.

ABFR On decrit des inhibiteurs peptidiques de serines proteases, notamment la thrombine, dans lesquels la liaison amide naturelle P1-P2 est remplacee par une autre liaison. A titre d'exemple, on decrit des inhibiteurs de thrombine possedant la formule X-(aa3)-(aa2)-'PSI'-(aa1)-Z dans laquelle X represente H ou un substituant sur le groupe amino N-terminal, aa3 represente un acide amine hydrophobe tel que Phe, aa2 represente Pro, aa1 represente Arg ou un **analogue** de Arg tel que methoxypropylglycyle, Z represente -COOH ou un groupe acide d'heteroatomes, tel qu'un boronate, ou un derive de l'un ou de l'autre, et 'PSI' represente une liaison non amide, contenant typiquement jusqu'a 5 atomes en chaine, tels que -CO2-, -CH2O-, NHCO- ou -CH2-CH2-.

L104 ANSWER 167 OF 189 PCTFULL COPYRIGHT 2002 Univentic
ACCESSION NUMBER: 1996013274 PCTFULL ED 20020514
TITLE (ENGLISH): PROCESS FOR PRODUCTION OF INHIBITED FORMS OF ACTIVATED BLOOD FACTORS
TITLE (FRENCH): PROCEDE DE PRODUCTION DE FORMES INHIBEES DE FACTEURS SANGUINS ACTIVES
INVENTOR(S): KING, Robert, S.
PATENT ASSIGNEE(S): COR THERAPEUTICS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9613274	A1	19960509
DESIGNATED STATES	CA JP MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1995-US13940	A	19951027
PRIORITY INFO.:	US 1994-8/330,978		19941028

ABEN A process, as shown in the figure, for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated

blood factor.

ABFR L'invention concerne un procede, comme illustre dans la figure, qui permet d'obtenir une preparation des plus pures d'une forme inhibee d'un facteur de coagulation sanguine, consistant a produire une preparation partiellement purifiee contenant le facteur en question, a traiter cette preparation partiellement purifiee pour transformer en une seule etape le facteur de coagulation en une forme inhibee et, ensuite, a purifier le facteur active inhibe qui en resulte.

L104 ANSWER 168 OF 189 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1996004373 PCTFULL ED 20031614

TITLE (ENGLISH): RECOMBINANT PRODUCTION OF BIOLOGICALLY ACTIVE **PEPTIDES** AND PROTEINS

TITLE (FRENCH): PRODUCTION PAR RECOMBINAISON DE **PEPTIDES** ET PROTEINES BIOLOGIQUEMENT ACTIFS

INVENTOR(S): WILLIAMS, Jon, I.; PIERCE, James, C.; ANDERSON, G., Mark; KARI, Prasad

PATENT ASSIGNEE(S): MAGAININ PHARMACEUTICALS, INC.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9604373	A2	19960215
DESIGNATED STATES	AU CA JP KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1995-US10219	A	19950726
PRIORITY INFO.:	US 1994-8/282,030		19940729

ABEN The present invention relates to the recombinant production of amphiphilic **peptides** with biologically and therapeutically significant activities. In one embodiment, this invention relates to recombinantly producing an amphiphilic **peptide** by providing a protease-deficient microbial host transformed with an expression vector containing DNA that encodes the amphiphilic **peptide** under the control of a regulatory sequence operable in the microbial host and expressing the amphiphilic **peptide** in the tranformed microbial host. In another embodiment, this invention relates to providing an E. coli protease-deficient K-12 cell transformed with a vector that expresses a cleavable fusion protein comprising at least part of a carbohydrate binding protein and the amphiphilic **peptide** in the cell, expressing the fusion protein in the cell, and cleaving the fusion protein to obtain the amphiphilic **peptide** substantially free of carbohydrate binding protein residues. The biologically active amphiphilic **peptide** so produced can be further treated chemically or enzymatically to obtain a chemically distinct amphiphilic **peptide** with improved biological and therapeutic properties.

ABFR L'invention concerne la production par recombinaison de **peptides** amphiphiles qui presentent des activites biologiques et therapeutiques significatives. Une variante de cette invention concerne la production par recombinaison d'un **peptide** amphiphile, qui consiste a produire un hote microbien presentant une deficience en protease, transforme a l'aide d'un vecteur d'expression contenant un ADN codant ce **peptide** amphiphile sur commande d'une sequence regulatrice qu'on peut activer dans

l'hote microbien, et a exprimer ce **peptide** amphiphile dans
l'hote microbien transforme. Une autre
variante de l'invention consiste a prendre une cellule K-12 d'E. coli,
presentant une deficience en
protease, transformee a l'aide d'un vecteur qui exprime une proteine de
fusion qu'on peut couper et
qui comprend au moins une partie d'une proteine se liant a un glucide et
le **peptide** amphiphile
present dans la cellule, a exprimer cette proteine de fusion dans la
cellule et a la couper pour
donner un **peptide** amphiphile pratiquement depourvu de residu
de la proteine se liant a un glucide.
Le **peptide** amphiphile biologiquement actif ainsi obtenu peut
alors etre traite par voie chimique ou
enzymatique, ce qui permet d'obtenir un **peptide** amphiphile
chimiquement different dote de proprietes
biologiques et therapeutiques ameliorees.

L104 ANSWER 169 OF 189 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996000541 PCTFULL ED 20020514
TITLE (ENGLISH): AN EXTERNAL URINARY CATHETER AND A HOSE CONNECTOR FOR CONNECTION THEREWITH
TITLE (FRENCH): CATHETER EXTERNE POUR LES URINES ET RACCORD DE CONDUITE DESTINE A CE CATHETER
INVENTOR(S): JENSEN, Thomas, Dam
PATENT ASSIGNEE(S): COLOPLAST A/S; JENSEN, Thomas, Dam
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9600541	A1	19960111
DESIGNATED STATES	AM AT AU BB BG BR BY CA CH CN CZ DE DK DK EE ES FI FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1995-DK234	A	19950612
PRIORITY INFO.:	DK 1994-774/94		19940629

ABEN An external catheter comprises a sheath essentially formed as a shaft and a constricted
drainage tube part (1) integrated therewith for connection with a hose connector (5) which is
connected to a draining hose. In order to facilitate the mounting of the drainage tube part (1) on
the hose connector (5), an end portion of the drainage tube part at the orifice thereof is divided
into at least two sections (2-3).
ABFR Un catheter externe pour les urines comprend une gaine venue d'une piece avec une partie
resserree (1) formant un tube de drainage, ce systeme etant raccorde par un raccord (5) a une
conduite de drainage. Pour faciliter le montage de la partie resserree (1) formant un tube de
drainage sur le raccord (5), une portion terminale du tube de drainage au niveau de son orifice est
divisee en deux sections (2-3) au moins.

L104 ANSWER 170 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 459670 EUROPATFULL EW 199617 FS PS
TITLE: NOVEL INHIBITORS OF THROMBIN.

NEUE THROMBININHIBITOREN.
NOUVEAUX INHIBITEURS DE THROMBINE.

INVENTOR(S): MARAGANORE, John, M., 84 Patrick Road, Tewksbury, MA 01876, US;
FENTON, John, W., II, P.O. Box 37 Route 66, Malden Bridge, NY 12115, US;
KLINE, Toni, 47 Hayes Street, Cambridge, MA 02139, US

PATENT ASSIGNEE S: BIOGEN, INC., 14 Cambridge Center, Cambridge Massachusetts 02142, US;
HEALTH RESEARCH INCORPORATED, 66 Hackett Boulevard, 3rd Floor, Albany NY 12208, US

PATENT ASSIGNEE NO: 1149451; 822424

AGENT: VOSSIUS & PARTNER, Postfach 86 07 67, D-81634 Muenchen, DE

AGENT NUMBER: 100311

OTHER SOURCE: EPB19960309 EP 0439070 B1 960424

SOURCE: Wila-EPS-1996-H17-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R LU; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 469070	B1	19960424
'OFFENLEGUNGS' DATE:		19920610
APPLICATION INFO.:		19900817
PRIORITY APPLN. INFO.:		19890818
		19900706
RELATED DOC. INFO.:	WO 90-US4642	900817 INTAKZ
	WO 9102750	910307 INTPNR

REFERENCE PAT. INFO.: EP 276014 A; EP 291981 A; EP 293986 A; EP 333366 A; EP 341607 A; EP 352742 A; WO 79-00638 A

REF. NON-PATENT-LIT.: Chemical Abstracts, volume 107, no. 11, 14 September 1987, (Columbus, Ohio, US), Krstenansky, John L. et al.: "Anticoagulant peptides. Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin", see page 733, abstract 97113c, & J. Med. Chem. 1987, 30(9), 1688-169 Chemical Abstracts, volume 108, no. 19, 9 May 1988, (Columbus, Ohio, US), Owen, Thomas J. et al.: "N-Terminal requirements of small peptide anticoagulants based on hirudin.", see page 701, abstract 167961z, & J. Med. Chem. 1988, 31(5), 1009-101 The Journal of Biological Chemistry, Vol. 264, No. 15, May 1989 John M. Maraganore et al.: "Anticoagulant Activity of Synthetic Hirudin Peptides" Thrombosis and Haemostasis, Vol. 63, No. 2, 1990 John L. Krstenansky et al.: "Development of MDL 28,051, a Small Stable Antithrombin AgentBased on a Functional Domain of the Leech Protein, Hirudin" Blood, Vol. 75, No. 2, January 1990 Joseph A. Jakubowski et al.: "Inhibition of Coagulation and Thrombin-Induced Platelet Activities by a Synthetic Dodecapeptide Modeled on the Carboxy-Terminus of Hirudin"

L104 ANSWER 171 OF 189 USPATFULL

ACCESSION NUMBER: 95:71454 USPATFULL

TITLE: Method of treatment of neurodegeneration with calpain inhibitors

INVENTOR(S): Bartus, Raymond T., Laguna Hills, CA, United States
Eveleth, David D., Irvine, CA, United States

Power, James D., Atlanta, GA, United States
PATENT ASSIGNEE(S): Cortex Pharmaceuticals, Irvine, CA, United States (U.S. corporation)
Georgia Tech Research Corporation (GTRC), Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5444042		19950822
APPLICATION INFO.:	US 1994-207881		19940307 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-816120, filed on 27 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-682925, filed on 9 Apr 1991, now abandoned which is a continuation of Ser. No. US 1990-635952, filed on 28 Dec 1990		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Geisner, William H.		
ASSISTANT EXAMINER:	Gitomer, Ralph		
LEGAL REPRESENTATIVE:	Knobbe Martens Olson & Bear		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	4963		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method of treating a neurodegenerative pathology in a human patient. This method includes selecting a patient for monitoring for the presence of a neurodegenerative pathology associated with enhanced Calpain activity and monitoring the patient for indicia of the onset or existence of such a pathology. In response to the detection of any such indicium of the presence or onset of the pathology, a therapeutically efficacious amount of a **Peptide** Ketoamide compound, or a pharmaceutically acceptable salt or derivative thereof, together with a pharmaceutically acceptable carrier is administered. The invention also provides additional methods of treatment and pharmaceutical compositions using **Peptide** Ketoamides, **Peptide** Ketoacids and **Peptide** Ketoesters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 172 OF 189 USPATFULL
ACCESSION NUMBER: 95:69093 USPATFULL
TITLE: Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
INVENTOR(S): Edgington, Thomas S., La Jolla, CA, United States
Colman, Robert W., Moylan, PA, United States
Kappelmayer, Janos, Debrecen, Hungary
Edmunds, Jr., L. Henry, Bryn Mawr, PA, United States
Bernabei, Alvise, Philadelphia, PA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
Temple University - Of the Commonwealth Systems of Higher Education, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5437864		19950801
APPLICATION INFO.:	US 1992-977281		19921116 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-165939, filed on 9 Mar 1988, now patented, Pat. No. US 5223427 which		

is a continuation-in-part of Ser. No. US 1987-67103, filed on 25 Jun 1987, now patented, Pat. No. US 5110730 which is a continuation-in-part of Ser. No. US 1987-31147, filed on 31 Mar 1987, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nubel, Christine M.
ASSISTANT EXAMINER: Cunningham, T.
LEGAL REPRESENTATIVE: Spensley Horn Jubas & Lubitz
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 3505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TFS-6B4 may be used in the claimed methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 173 OF 189 USPATFULL
ACCESSION NUMBER: 95:64843 USPATFULL
TITLE: Fibrinolytic and anti-thrombotic cleavable dimers
INVENTOR(S): Dawson, Keith, Marlow, United Kingdom
Hunter, Michael G., Aylesbury, United Kingdom
Czaplewski, Lloyd G., Didcot, United Kingdom
PATENT ASSIGNEE(S): British Bio-Technology Limited, Oxford, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5434073		19950718	
	WO 9109125		19910627	
APPLICATION INFO.:	US 1992-854596		19920603	(7)
	WO 1990-GB1911		19901207	
			19920603	PCT 371 date
			19920603	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-27722	19891207

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen G.
LEGAL REPRESENTATIVE: Allegretti & Witcoff, Ltd.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Relatively inactive fusion proteins are activatable by enzymes of the clotting cascade to have fibrinolytic and/or clot formation **inhibition** activity. For example, a fusion protein comprising two hirudin or streptokinase molecules, linked by a cleavable linkage sequence, may be cleaved to yield anti-thrombotic hirudin or fibrinolytic streptokinase by thrombin or **Factor Xa**. Fibrinolytic or clot formation **inhibition** activity is therefore directed to the site of clot formation. Cleavable streptokinase/hirudin heterodimers are claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 174 OF 189 USPATFULL
ACCESSION NUMBER: 95:64711 USPATFULL
TITLE: Inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Concord, MA, United States
Fenton, II, John W., Malden Bridge, NY, United States
Kline, Toni, Cambridge, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5433940		19950718	
	WO 9102750		19910307	
APPLICATION INFO.:	US 1992-834259		19920210	(7)
	WO 1990-US4642		19900817	
			19920210	PCT 371 date
			19920210	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1990, now patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Prickril, Benet
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18.ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 175 OF 189 USPATFULL
ACCESSION NUMBER: 95:54207 USPATFULL
TITLE: Inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Tewksbury, MA, United States
Jablonski, Jo-Ann M., Middleborough, MA, United States
Bourdon, Paul R., Somerville, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5436934		19950420	
APPLICATION INFO.:	US 1992-924549		19920731	(7)

RELATED APPLN. INFO.: Division of Ser. No. US 1991-652929, filed on 9 Feb 1991, now patented, Pat. No. US 5241913, issued on 31 Aug 1993 which is a continuation-in-part of Ser. No. US 1990-549388, filed on 6 Jul 1990, now patented, Pat. No. US 5196404, issued on 23 Mar 1993 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Jill
ASSISTANT EXAMINER: Balatbat, Carol A.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Marks, Andrew S.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula: ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a guanidinium- or Amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.4 is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 8.5; and X, R.sub.2, R.sub.3, R.sub.5, R.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18.ANG. and 42.ANG. in length which connects the Y to the ABEAM. This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 176 OF 189 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 95:548594 SCISEARCH
THE GENUINE ARTICLE: RT259
TITLE: **PEPTIDE**-DERIVED TRANSITION-STATE ANALOG INHIBITORS OF THROMBIN - SYNTHESIS, ACTIVITY AND **SELECTIVITY**
AUTHOR: JETTEN M (Reprint); PETERS G A M; VISSER A; GROOTENHUIS P D J; VANNISPEN J W; OTTENHEIJM H C J
CORPORATE SOURCE: NV ORGANON, 5340 BH OSS, NETHERLANDS
COUNTRY OF AUTHOR: NETHERLANDS
SOURCE: BIOORGANIC & MEDICINAL CHEMISTRY, (AUG 1995) Vol. 3, No. 8, pp. 1099-1114.
ISSN: 0968-0896.
DOCUMENT TYPE: Article; Journal
LANGUAGE: ENGLISH
REFERENCE COUNT: 48

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB In a study to combine the transition state **analogue** concept with the principle of catalytic site spanning, a series of **peptide** -derived transition state **analogue** (TSA) **inhibitors** of thrombin has been synthesized and tested. In the sequence H-D-Phe-Pro-Arg-Gly-OH (3) the Arg-Gly amide bond has been replaced by three classes of transition state **analogues**, being the ketomethylene, the hydroxyethylene and the hydroxymethylene amide bond replacements. Compound 11a, in which the amide bond has been replaced by the ketomethylene group, was found to be the most potent thrombin **inhibitor** of the series studied. Subsequently, penta- and hexapeptide sequences with good affinity for thrombin were developed, i.e. H-D-Phe-Pro-Arg-Gly-Phe-OH (16) and H-D-Phe-Pro-Arg-Gly-Phe-Lys-OH (26).

In these sequences the Arg-Gly amide bond was then replaced by the ketomethylene group. The resulting compounds 43a and 47a, respectively, were evaluated in vitro as **inhibitors** of thrombin and **factor Xa**. Compound 47a was found to be the most potent thrombin **inhibitor** of the series studied (K-i = 2.4 nM). The combination of the transition state **analogue** concept and the principle of **peptide** elongation (tetrapeptide→hexapeptide) yields thrombin **inhibitors** of high potency and **selectivity**. The effects of these two alterations reinforce each other indicating a synergistic effect. This might be rationalized by entropy factors.

L104 ANSWER 177 OF 189 USPATFULL
ACCESSION NUMBER: 94:109013 USPATFULL
TITLE: Aprotinin **analogues** and a process for the production thereof
INVENTOR(S): Norris, Kjeld, Hellerup, Denmark
Petersen, Lars C., Horsholm, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5378090		19941213	
	WO 8910374		19891102	
APPLICATION INFO.:	US 1990-598737		19901119	(7)
	WO 1989-DK96		19890425	
			19901119	PCT 371 date
			19901119	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1988-215488	19880426

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Delson, Steve T., Agris, Cheryl H.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 758
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel aprotinin **analogues** having a selected inhibition profile against serine proteases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 178 OF 189 USPATFULL
ACCESSION NUMBER: 94:106771 USPATFULL
TITLE: Asp-Pro-Arg .alpha.-keto-amide enzyme inhibitors
INVENTOR(S): Webb, Thomas R., Encinitas, CA, United States
Miller, Todd A., Encinitas, CA, United States
Vlasuk, George P., Carlsbad, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5371071		19941206	
APPLICATION INFO.:	US 1992-962301		19921016	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Weber, Jon P.

LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Asp-Pro-Arg alpha-keto-amide derivatives, and their pharmaceutically acceptable salts and compositions, for use as antithrombotic agents in mammals are disclosed. The method of use of these inhibitor compounds for treatment or prevention of conditions of abnormal thrombus formation in mammals is also disclosed. Further disclosed are alpha-hydroxy amide compounds used as intermediates in the preparation of the keto-amide compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 179 OF 189 USPATFULL
ACCESSION NUMBER: 94:93075 USPATFULL
TITLE: Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
INVENTOR(S.): Roy, Soumitra, San Francisco, CA, United States
Venar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5346991		19940913
APPLICATION INFO.:	US 1991-714819		19910613 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Winter, Daryl B.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 180 OF 189 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 339942 EUROPATFULL EW 199944 FS OS STA B
TITLE: Aprotinin **analogues** and process for the production thereof.
Aprotinin-Analoge und Verfahren zu ihrer Herstellung.
Analogues d'aprotinin et procede pour leur production.
INVENTOR(S): Norris, Kjeld, Anlmanns Alle 34, DK-2900 Hellerup, DK;
Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm, DK
PATENT ASSIGNEE(S): NOVO-NORDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK
PATENT ASSIGNEE NO: 1008511
AGENT: Brown, John David et al, FORRESTER & BOEHMERT Widenmayerstrasse 4/I, D-8000 Muenchen 22, DE

AGENT NUMBER: 28911
OTHER SOURCE: ESP1999046 EP 0339942 A2 891102
SOURCE: Wila-EPS-1989-H44-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Verbeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 339942	A2	19891102
'OFFENLEGUNGS' DATE:			19891102
APPLICATION INFO.:	EP 1989-304132		19890425
PRIORITY APPLN. INFO.:	DK 1988-2254		19880426

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 339942 EUROPATFULL EW 199412 FS PS STA B
TITLE: Aprotinin **analogues** and process for the production thereof.
Aprotinin-Analoge und Verfahren zu ihrer Herstellung.
Analogues d'aprotinin et procede pour leur production.
INVENTOR(S): Norris, Kjeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK; Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm, DK
PATENT ASSIGNEE(S): NOVO NORDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK
PATENT ASSIGNEE NO: 231781
AGENT: Thalsoe-Madsen, Kine Birgit et al, c/o Novo Nordisk A/S Novo Alle, DK-2880 Bagsvaerd, DK
AGENT NUMBER: 61401
OTHER SOURCE: EPB1994021 EP 0339942 B1 940323
SOURCE: Wila-EPS-1994-H12-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Verbeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND	DATE		
	EP 339942	B1	19940323		
'OFFENLEGUNGS' DATE:			19891102		
APPLICATION INFO.:	EP 1989-304132		19890425		
PRIORITY APPLN. INFO.:	DK 1988-2254		19880426		
REFERENCE PAT. INFO.:	EP 132732	A		EP 238993	A
	EP 244627	A		EP 307592	A

REF. NON-PATENT-LIT.: SCIENCE, vol. 235, 13th March 1987, pages 1370-1373; C.B. MARKS et al.: "Mutants of bovine pancreatic trypsin inhibitor lacking cysteines 14 and 38 can fold properly" BIOCHEMISTRY, vol. 16, no. 8, 19th April 1977, pages 1531-1541, The American Chemical Society; N.H.Tan et al.: "Synthesis and characterization of a pancreatic Trypsin inhibitor homologue and a model inhibitor"

L104 ANSWER 181 OF 189 USPATFULL
ACCESSION NUMBER: 98:72061 USPATFULL
TITLE: Inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Tewksbury, MA, United States
Gabriel, Jo-Ann M., Middleborough, MA, United States
Bourdon, Paul R., Somerville, MA, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5240913		19930831
APPLICATION INFO.:	US 1991-652929		19910208 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-549389, filed on 6 Jul 1990 which is a continuation-in-part of Ser. No. US 1989-395482, filed on 18 Aug 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Perkins, Susan M.		
LEGAL REPRESENTATIVE:	Pierri, Margaret A., Marks, Andrew S., Miraglia, Loretta A.		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1254		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unsubstituted, monosubstituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.4 is any amino acid comprising a side chain group characterized by the capacity to accept a hydrogen bond at a pH of between about 5.5 and 9.5; and X, R.sub.2, R.sub.3, R.sub.5, R.sub.6 and Y are defined as above. Preferred thrombin inhibitors are further characterized by a anion binding exosite associating domain (ABEAM) and a linker portion of between 18 .ANG. and 42 .ANG. in length which connects the Y to the ABEAM. This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 182 OF 189 USPATFULL

ACCESSION NUMBER:	93:52505 USPATFULL
TITLE:	Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
INVENTOR(S):	Edgington, Thomas S., La Jolla, CA, United States Morrissey, James H., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5227427		19930629
APPLICATION INFO.:	US 1988-165939		19880309 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-33047, filed on 31 Mar 1987 And Ser. No. US 1987-67103, filed on 25 Jun 1987		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine		
ASSISTANT EXAMINER:	Cunningham, T.		
LEGAL REPRESENTATIVE:	Bingham, Douglas A.		

NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Murine hyoridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 183 OF 189 USPATFULL
ACCESSION NUMBER: 93:50487 USPATFULL
TITLE: Directed evolution of novel binding proteins
INVENTOR(S): Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PATENT ASSIGNEE(S): Protein Engineering Corp., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5223409		19930629
APPLICATION INFO.:	US 1991-664989		19910301 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-487063, filed on 3 Mar 1990, now abandoned And a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Cooper, Iver P.
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 15410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 184 OF 189 USPATFULL
ACCESSION NUMBER: 93:22694 USPATFULL

TITLE: Inhibitors of thrombin
INVENTOR(S): Maraganore, John M., Concord, MA, United States
Fenton, II, John W., Malden Bridge, NY, United States
Klimas, Toni, New York, NY, United States
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
Health Research, Inc., Albany, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5196404		19930323
APPLICATION INFO.:	US 1990-549386		19900706 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-395482, filed on 17 Aug 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Lester L.
ASSISTANT EXAMINER: Perkins, Susan M.
LEGAL REPRESENTATIVE: Haley, Jr., James F., Marks, Andrew S., Pierri, Margaret A.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 185 OF 189 ADISALERTS COPYRIGHT 2002 (ADIS)
ACCESSION NUMBER: 1993:57169 ADISALERTS
DOCUMENT NUMBER: 800204109
TITLE: Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation
ADIS TITLE: Antithrombotics: pharmacodynamics.; Inhibition of thrombin-induced platelet aggregation after thrombolysis; Review (127 references)
AUTHOR: Puri R N; Colman R W
CORPORATE SOURCE: Temple University School of Medicine, Philadelphia, Pennsylvania, USA
SOURCE: Blood Coagulation and Fibrinolysis (Jun 1, 1993), Vol. 4, pp. 465-478
DOCUMENT TYPE: General Review
REFERENCE: Ischaemic Heart Disease (Summary): Alert no. 7, 1993; Antithrombotics (Summary): Alert no. 7, 1993
FILE SEGMENT: Summary
LANGUAGE: English
WORD COUNT: 584

L104 ANSWER 186 OF 189 USPATFULL
ACCESSION NUMBER: 91:46449 USPATFULL
TITLE: Serine protease inhibitors
INVENTOR(S): Glover, George I., Creve Coeur, MO, United States
Sorbstean, Charles S., University City, MO, United States
PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5157019		19921020
APPLICATION INFO.:	US 1991-729002		19910701 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-203821, filed on 1 Jun 1988, now abandoned which is a continuation of Ser. No. US 1987-6725, filed on 6 Feb 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-840810, filed on 18 Mar 1986, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Y. Christina		
LEGAL REPRESENTATIVE:	Bennett, Dennis A.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1964		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **peptides** which exhibit inhibitory activity toward serine proteases and methods for preparing and using same are disclosed. In one aspect, the present invention provides **peptides** comprising a generic inhibitory core having a functional site recognition sequence fused to the N-terminus. The functional site recognition sequence is adapted to provide enhanced **selectivity** and/or potency for a target protease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 187 OF 189 USPATFULL

ACCESSION NUMBER:	91:86794 USPATFULL
TITLE:	Affinity matrices of modified polysaccharide supports
INVENTOR(S):	Hou, Kenneth C., Glastonbury, CT, United States Liao, Tung-Ping D., Missouri City, TX, United States Rohan, Robert, Columbia, CT, United States
PATENT ASSIGNEE(S):	Cuno Inc., Meriden, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5059654		19911022
APPLICATION INFO.:	US 1989-311498		19890216 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-154815, filed on 11 Feb 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-130186, filed on 8 Dec 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-13512, filed on 27 Jan 1987, now abandoned which is a continuation-in-part of Ser. No. US 1984-656922, filed on 2 Oct 1984, now patented, Pat. No. US 4639513 which is a continuation-in-part of Ser. No. US 1984-576448, filed on 2 Feb 1984, now patented, Pat. No. US 4663163 which is a continuation-in-part of Ser. No. US 1983-466114, filed on 14 Feb 1983, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nutter, Nathan M.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	3381		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a modified polysaccharide material which comprises: (1) polysaccharide covalently bonded to a synthetic polymer; (2) the synthetic polymer being made from (a) a polymerizable compound which is capable of being covalently coupled directly or indirectly to

said polysaccharide, and (b) one or more polymerizable compounds containing (i) a chemical group capable of causing the covalent coupling of the compound (b) to an affinity ligand or a biologically active molecule or (ii) a hydrophobic compound.

The invention is also directed to devices for the chromatographic separation of at least two components of a mixture comprising the modified polysaccharide material of the invention, wherein the device is configured for radial or tangential flow.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 188 OF 189 USPATFULL
ACCESSION NUMBER: 91:46695 USPATFULL
TITLE: Factor VII/VIIA active site inhibitors
INVENTOR(S): Edgington, T. Scott, La Jolla, CA, United States
Pepe, Michael G., San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5023236		19910611
APPLICATION INFO.:	US 1989-320559		19890313 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-178495, filed on 7 Apr 1988, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lee, Lester L.
LEGAL REPRESENTATIVE: Greenlee and Associates
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
LINE COUNT: 1349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes a class of compounds that inhibit the specific proteolytic activity of the bimolecular complex 1[TF:VII/VIIa] that initiates the blood coagulation systems. Both reversible and irreversible inhibitors are disclosed.

The invention encompasses the use of inhibitors of the active site of the factor VII and VIIa component of [TF:VII/VIIa] as diagnostic reagents, as analytical reagents, and as therapeutic drugs.

The invention includes the compounds based on the following general formula for both reversible and irreversible selective inhibition of [TF:VII/VIIa]. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L104 ANSWER 189 OF 189 USPATFULL
ACCESSION NUMBER: 82:6872 USPATFULL
TITLE: Substrates for the quantitative assay of enzymes and such assay
INVENTOR(S.: Yaron, Arieh, Rehovot, Israel
Carmel, Amos, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co., Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4314936		19820209
APPLICATION INFO.:	US 1980-211794		19801201 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1979-48260, filed on 13 Jun 1979, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1978-54940	19780616
	IL 1980-60888	19800821

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Phillips, Delbert R.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB According to the present invention there are provided novel substrates for the determination of enzymes, and especially of the **peptide** hydrolases such as angiotensin-converting enzyme, trypsin and similar enzymes, and aminopeptidase-P, and to a process for the determination of these enzymes, which comprises contacting a biological fluid containing said enzyme with said substrate, which is cleaved, resulting in a pronounced fluorescence which is measured, thus giving a quantitative measure of the enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

```
=> S (factor (w) Xa) (s) (inhibitor or inhibition) (p) peptide (s) analogue?
L105          10 FILE USPATFULL
L106          54 FILE PCTFULL
L107          17 FILE EUROPATFULL
L108           0 FILE JAPLUS
L109          10 FILE MEDLINE
L110          10 FILE EMBASE
L111           6 FILE STNGUIDE
L112           7 FILE BIOSIS
L113           0 FILE DRUGU
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L114           5 FILE BIOTECHNO
L115           0 FILE USPAT2
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L116           3 FILE PASCAL
L117           0 FILE TOXCENTER
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L118           4 FILE ESBIOBASE
L119           3 FILE IFIPAT
L120           5 FILE WPIDS
L121           1 FILE LIFESCI
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L122           1 FILE BABS
L123           0 FILE JICST-EPLUS
L124           0 FILE CANCERLIT
L125           1 FILE BIOBUSINESS
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'XA) (S) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'PEPTIDE (S) ANALOGUE?'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L126           0 FILE CASREACT
L127           0 FILE AGRICOLA
L128           0 FILE CABA
L129           0 FILE CEN
L130           0 FILE INVESTEXT
L131           1 FILE PROMT
L132           1 FILE ADISALERTS
L133           0 FILE PHIN
L134           0 FILE SYNTHLINE
L135           0 FILE AQUASCI
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HIBITION) (P) '
L136           0 FILE BIOTECHDS
L137           0 FILE VETU

TOTAL FOR ALL FILES
L138         139 (FACTOR (W) XA) (S) (INHIBITOR OR INHIBITION) (P) (PEPTIDE (S)
                 ANALOGUE?)

=> dup rem l138
DUPLICATE IS NOT AVAILABLE IN 'INVESTEXT, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L138
L139          100 DUP REM L138 (39 DUPLICATES REMOVED)

=> d l139 1-100 ibib abs

L139   ANSWER 1 OF 100   PCTFULL   COPYRIGHT 2002 UniventioDUPLICATE 1
ACCESSION NUMBER:       2002058734 PCTFULL  ED 20020809  EW 200231
```

TITLE ENGLISH: COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS

TITLE FRENCH: COMBINAISONS D'INHIBITEUR S D'ABSORPTION DES STEROLS ET DE MODIFICATEUR(S) SANGUIN(S) POUR LE TRAITEMENT DES TROUBLES VASCULAIRES

INVENTOR(S): KOSOGLOU, Teddy; REISS, Ridyard, Joseph; STRONY, John; VELTRI, Enrico, P.

PATENT ASSIGNEE(S): SCHERING CORPORATION

AGENT: SANNONI, Ann, Marie

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002056734	A2	20020801

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US2013 A 20020125

PRIORITY INFO.: US 2001-60/264,396 20010126
US 2001-60/264,600 20010126
US 2001-60/264,275 20010126
US 2001-60/324,103 20010921

ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

ABFR L'invention concerne des compositions, des combinaisons therapeutiques et des procedes reposant sur l'utilisation: (a) d'au moins un inhibiteur d'absorption des sterols; et (b) d'au moins un modificateur sanguin. Ces compositions, combinaisons therapeutiques et procedes peuvent etre utiles pour le traitement des troubles vasculaires et pour la reduction du degre de concentration plasmique des sterols

L139 ANSWER 2 OF 100 USPATFULL

ACCESSION NUMBER: 2002:273409 USPATFULL

TITLE: Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES
Kosoglou, Teddy, Jamison, PA, UNITED STATES
Picard, Gilles J., Brussels, BELGIUM

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

NUMBER	KIND	DATE	
PATENT INFORMATION: US 2002151536	A1	20021017	
APPLICATION INFO.: US 2002-57322	A1	20020125	(10)

NUMBER	DATE
PRIORITY INFORMATION: US 2001-264396P	20010126 (60)
US 2001-324934P	20010921 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-1530

NUMBER OF CLAIMS: 101

EXEMPLARY CLAIM: 1
LINE COUNT: 5004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 3 OF 100 USPATFULL
ACCESSION NUMBER: 2002:272691 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer
INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002150922	A1	20021017	
APPLICATION INFO.:	US 2001-998598	A1	20011116	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252322P	20001120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 9233
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L139 ANSWER 4 OF 100 USPATFULL
ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jines, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20021[illegible]237	A1	20020919	
APPLICATION INFO.:	US 2001-867701	A1	20010529	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207494P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 5 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002077155 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): KERATINOCYTE GROWTH FACTOR-2
TITLE (FRENCH): FACTEUR DE CROISSANCE DES KERATINOCYTES-2
INVENTOR(S): RUBEN, Steven, M.; JIMENEZ, Pablo; DUAN, D., Roxanne; RAMPY, Mark, A.; MENDRICK, Donna; ZHANG, Jun; NI, Jian; MOORE, Paul, A.; COLEMAN, Timothy, A.; GRUBER, Joachim, R.; DILLON, Patrick, J.; GENTZ, Reiner, L.
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., for all designates States except US; RUBEN, Steven, M., for US only; JIMENEZ, Pablo, for US only; DUAN, D., Roxanne, for US only; RAMPY, Mark, A., for US only; MENDRICK, Donna, for US only; ZHANG, Jun, for US only; NI, Jian, for US only; MOORE, Paul, A., for US only; COLEMAN, Timothy, A., for US only; GRUBER, Joachim, R., for US only; DILLON, Patrick, J., for US only; GENTZ, Reiner, L., for US only
AGENT: STEPPE, Eric, K.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002077155	A2	20021003
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US131	A	20020104
PRIORITY INFO.:	US 2001-60/259,853		20010103
	US 2001-60/286,368		20010426
	US 2001-60/331,169		20011109

ABEN This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present

invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as KGF-2 also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

ABFR La presente invention concerne des polynucleotides, des polypeptides codes par ces polynucleotides nouvellement identifies, l'utilisation de ces polynucleotides et polypeptides, ainsi que la production de ces polynucleotides et polypeptides. Plus precisement, le polypeptide de la presente invention est un facteur de croissance des keratinocytes, parfois signale ci-dessous sous le nom generique de ≤ KGF-2 ≥ et egalement connu sous le nom generique de facteur de croissance des fibroblastes 12 (FGF-12). La presente invention concerne egalement l'utilisation therapeutique du KGF-2 pour promouvoir ou accelerer la cicatrisation. La presente invention concerne egalement de nouvelles formes mutantes du KGF-2 presentant une activite amelioree, une plus grande stabilite, un meilleur rendement ou une meilleure solubilite.

L139 ANSWER 6 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002063017 PCTFULL ED 20020827 EW 200233
TITLE (ENGLISH): INTEGRIN-BINDING CHIMERAS
TITLE (FRENCH): CHIMERES POUVANT SE LIER A L'INTEGRINE
INVENTOR(S): LU, Xinjie; KAKKAR, Vijay, Vir
PATENT ASSIGNEE(S): TRIGEN LIMITED, for all designates States except US; LU, Xinjie, for US only; KAKKAR, Vijay, Vir, for US only
AGENT: HARRISON GODDARD FOOTE
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002063017	A2	20020815
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-GB500	A	20020205
PRIORITY INFO.:	US 2001-60/267,234		20010205

ABEN Products which contain two interlinked functional moieties of which one is an integrin-binding protein (e.g. a snake venom protein) or a homologue thereof. The products comprise a first portion which is an integrin-binding protein, a homologue thereof having a binding activity or a fragment of either which has integrin-binding activity, and, ligated to the first portion, a second portion which has a different function.

ABFR L'invention concerne des produits qui contiennent deux fragments fonctionnels entrelaces dont l'un est une proteine de liaison a l'integrine (p. ex. une proteine du venin du serpent) ou un homologue de ladite proteine. Ces produits comprennent une premiere partie qui est une proteine de liaison a l'integrine, un homologue de ladite proteine ayant une activite de liaison, ou un fragment de l'un ou l'autre ayant une activite de liaison a l'integrine; et une seconde partie liee a la premiere partie et ayant une fonction differente.

L139 ANSWER 7 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002059733 PCTFULL ED 20020809 EW 200231

TITLE (ENGLISH): COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

TITLE (FRENCH): COMBINAISONS DE CHELATEUR(S) DES ACIDES BILIAIRES ET D'INHIBITEUR(S) D'ABSORPTION DES STEROLS, ET TRAITEMENTS POUR TROUBLES VASCULAIRES

INVENTOR(S): DAVIS, Harry, R.; KOSOGLOU, Teddy

PATENT ASSIGNEE(S): SCHERING CORPORATION

AGENT: CANNONI, Ann, Marie

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002058739	A2	20020801
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US2010	A	20020125
PRIORITY INFO.:	US 2001-60/264,600		20010126
	US 2001-60/303,842		20010921

ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

ABFR L'invention concerne des compositions, des combinaisons therapeutiques et des procedes reposant sur l'utilisation: (a) d'au moins un chelateur des acides biliaires; et (b) d'au moins un inhibiteur d'absorption des sterols d'azetidinone ou de beta-lactamine a substitution. Ces compositions, combinaisons therapeutiques et procedes peuvent etre utiles pour le traitement des troubles vasculaires, du diabete ou de l'obesite et pour la reduction du degre de concentration plasmique des sterols.

L139 ANSWER 8 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002058732 PCTFULL ED 20020809 EW 200231

TITLE (ENGLISH): COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

TITLE (FRENCH): COMBINAISONS D'ACTIVATEUR(S) DU RECEPTEUR ACTIVE PAR LE PROLIFERATEUR DE PEROXYSOME ET D'INHIBITEUR(S) D'ABSORPTION DES STEROLS, ET TRAITEMENTS POUR TROUBLES VASCULAIRES

INVENTOR(S): KOSOGLOU, Teddy; DAVIS, Harry, R.; PICARD, Gilles, Jean Bernard

PATENT ASSIGNEE(S): SCHERING CORPORATION

AGENT: CANNONI, Ann, Marie

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002058732	A2	20020801
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA		

UZ VN YU ZA ZM SH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN
GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US31094 A 20020129
PRIORITY INFO.: US 2001-60/264,396 20010126
US 2001-60/313,809 20010821

ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted b-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

ABFR L'invention concerne des compositions, des combinaisons therapeutiques et des procedes reposant sur l'utilisation: (a) d'au moins un activateur du recepteur active par le proliferateur de peroxysome; et (b) d'au moins un inhibiteur d'absorption des sterols d'azetidinone ou de beta-lactamine a substitution. Ces compositions, combinaisons therapeutiques et procedes peuvent etre utiles pour le traitement des troubles vasculaires, du diabete ou de l'obesite et pour la reduction du degre de concentration plasmique des sterols.

L139 ANSWER 9 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002058731 PCTFULL ED 20020809 EW 200231
TITLE (ENGLISH): COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS
TITLE (FRENCH): COMBINAISONS D'INHIBITEUR(S) DE L'ABSORPTION DE STEROLS ET D'AGENTS CARDIO-VASCULAIRES POUR LE TRAITEMENT D'AFFECTIONS VASCULAIRES
INVENTOR(S): KOSOGLOU, Teddy; REISS, Rudyard, Joseph; STRONY, John; VELTRI, Enrico, P.; HAUER, William
PATENT ASSIGNEE(S): SCHERING CORPORATION
AGENT: CANNONI, Ann, Marie
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002058731	A2	20020801

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS
JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO
NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA
UG VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN
GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US1196 A 20020105
PRIORITY INFO.: US 2001-60/264,396 20010126
US 2001-60/264,609 20010126
US 2001-60/264,275 20010126
US 2001-60/313,342 20010821

ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

ABFR L'invention concerne des methodes, des compositions, et des combinaisons therapeutiques contenant: (a) au moins un inhibiteur de l'absorption de sterols et (b) au moins un agent cardio-vasculaire different de l'inhibiteur de l'absorption de sterols, utilisables pour traiter les affections vasculaires, l'obesite, et le diabete, et pour reduire le niveaux plasmatique des sterols.

L139 ANSWER 10 OF 100 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002059696 PCTFULL ED 20020809 EW 200231
TITLE (ENGLISH): THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA
TITLE (FRENCH): UTILISATION DE COMPOSES D'AZETIDINONE SUBSTITUEE POUR LE TRAITEMENT DE LA SITOSTEROLEMIE
INVENTOR(S): DAVIS, Harry, R.
PATENT ASSIGNEE(S): SCHERING CORPORATION
AGENT: CANNONI, Ann, Marie
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002059696	A2	20020801
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US1195	A	20020125
PRIORITY INFO.:	US 2001-60/264,645		20010126

ABEN The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.

ABFR L'invention concerne des composes inhibiteurs de l'absorption de sterols, des compositions pharmaceutiques, des combinaisons therapeutiques, ainsi que leur utilisation en association a d'autres agents hypolipidemiants pour traiter ou prevenir la sitosterolemie et/ou reduire la concentration de sterol(s) autres que le cholesterol dans le plasma ou les tissus d'un mammifere. Par ailleurs, l'invention concerne des methodes de traitement ou de prevention des maladies vasculaires et des accidents vasculaires.

L139 ANSWER 11 OF 100 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002058685 PCTFULL ED 20020809 EW 200231
TITLE (ENGLISH): COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS
TITLE (FRENCH): COMBINAISONS D'ACIDE NICOTINIQUE ET DE DERIVES DE CE DERNIER, INHIBITEUR(S) D'ABSORPTION DE STEROLS ET TRAITEMENTS DE CONDITIONS VASCULAIRES
INVENTOR(S): DAVIS, Harry, R.; KOSOGLOU, Teddy
PATENT ASSIGNEE(S): SCHERING CORPORATION
AGENT: CANNONI, Ann, Marie
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002058685	A2	20020801
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA		

UZ VN YU ZA ZM GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN
GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US1014 A 20020115
PRIORITY INFO.: US 2001-60 264,275 20010126
US 2001-60 316,842 20010901

ABEN The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

ABFR L'invention concerne des procedes, compositions et combinaisons therapeutiques renfermant a) au moins un element parmi l'acide nicotinique et des derives de ce dernier et b) au moins un inhibiteur d'absorption de sterols azetidinone substitue ou β-lactame substitue pouvant etre utile pour traiter des conditions vasculaires, le diabete, l'obesite et pour abaisser la concentration plasmique de sterols.

L139 ANSWER 12 OF 100 PCTFULL

ACCESSION NUMBER: 2002057273 PCTFULL ED 20020801 EW 200230
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR
TITLE (FRENCH): INHIBITEURS DE LA SERINE PROTEASE COMPRENANT UN ACCEPTEUR DE LIAISON HYDROGENE
INVENTOR(S): DEADMAN, John, Joseph; SPENCER, John; GREENIDGE, Paulette, Angela; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; SCULLY, Michael, Finbarr
PATENT ASSIGNEE(S): TRIGEN LIMITED, for all designates States except US; DEADMAN, John, Joseph, for US only; SPENCER, John, for US only; GREENIDGE, Paulette, Angela, for US only; GOODWIN, Christopher, Andrew, for US only; KAKKAR, Vijay, Vir, for US only; SCULLY, Michael, Finbarr, for US only
AGENT: HARRISON GODDARD FOOTE
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002057273	A1	20020725

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH
GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN
TD TG

APPLICATION INFO.: WO 2002-GB224 A 20020118
PRIORITY INFO.: GB 2001-0101537.9 20010120
US 2001-60/267,172 20010206

ABEN Compounds, useful as protease inhibitors, of the formula (I): where: Ar is a ring or ring system, for example a benzene ring, and may be substituted by one or more moieties in addition to X and LJ; X is a functional group which is a hydrogen-bond acceptor, e.g. a nitro or boronate group BY<sp>1</sp>Y<sp>2</sp>; L is a linker, most preferably (CR<sp>5</sp>R<sp>6</sp>)-S-; J is a moiety containing a

basic
nitrogen atom but not containing an amino acid residue, preferably amidino, quanidino,
amino, carboxamido, hydroxylamino, or imidazolyl, or an N-substituted analogue
thereof.

ABFR L'invention concerne des composes utilises comme inhibiteurs de protease representes par la formule (I). Dans cette formule, Ar represente un noyau ou un systeme cyclique, par exemple, un noyau benzenique,
et peut etre substitue par au moins une fraction en plus de X et LJ; X represente un groupe fonctionnel accepteur de liaison hydrogene,
par exemple, un groupe nitro ou boronate BY<sp>1</sp>Y<sp>2</sp>; L represente
un liant, de preference (CR<sp>5</sp>R<sp>6</sp>)n-3-; J represente une fraction contenant un atome d'azote basique mais ne contenant pas de residu d'acide amine, et contenant de preference amidino,
guanidino, amino, carboxamido, hydroxylamino, ou imidazolyl, ou un analogue
de ceux-ci substitue par un N.

L139 ANSWER 13 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001047582 PCTFULL ED 20020704 EW 200225
TITLE (ENGLISH): EXPANDABLE STENT WITH SLIDING AND LOCKING RADIAL ELEMENTS
TITLE (FRENCH): EXTENSEUR DILATABLE COMPORTANT DES ELEMENTS DE COULISSEMENT ET DE VERROUILLAGE RADIAL
INVENTOR(S): STEINKE, Thomas, A.; KOENIG, Donald, H.
PATENT ASSIGNEE(S): MDS, INC., for all designates States except US; STEINKE, Thomas, A., for US only; KOENIG, Donald, H., for US only
AGENT: ALTMAN, Daniel, E.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002047582	A2	20020620
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US48316	A	20011213
PRIORITY INFO.:	US 2000-09/739,552		20001214

ABEN The present invention provides a lumen support stent with a clear through-lumen
for use in a body lumen. The stent is formed from at least one series of sliding and
locking radial elements and at least one ratcheting mechanism comprising an
articulating element and a plurality of stops. The ratcheting mechanism permits
one-way sliding of the radial elements from a collapsed diameter to an expanded
diameter, but inhibits radial recoil from the expanded diameter.

ABFR L'invention concerne un extenseur de support conçu pour etre mis en application dans une lumiere anatomique et comportant un passage depourvu d'obstacle. Cet extenseur est constitue par au moins
une serie d'elements de coulissement et de verrouillage

radial et par au moins un mecanisme d'encliquetage comprenant un element d'articulation et une pluralite de buteez. Ce mecanisme d'encliquetage permet a ces elements de coulisser dans un sens radial unique depuis un diametre d'affaissement a un diametre de dilatation, mais empeche le retrecissement radial depuis le diametre de dilatation..

L139 ANSWER 14 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002044736 PCTFULL ED 20020624 EW 200233
TITLE (ENGLISH): DIAGNOSIS AND TREATMENT OF DISEASE
TITLE (FRENCH): DIAGNOSTIC ET TRAITEMENT DE MALADIE
INVENTOR(S): TAZI-AHNINI, Rachid; BAVIK, Claes; WARD, Simon; DUFF, Gordon; CORK, Michael
PATENT ASSIGNEE(S): MOLECULAR SKINCARE LIMITED, for all designates States except US; TAZI-AHNINI, Rachid, for US only; BAVIK, Claes, for US only; WARD, Simon, for US only; DUFF, Gordon, for US only; CORK, Michael, for US only
AGENT: KHOO, Chong-Yee
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002044736	A2	20020606

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-GB5303 A 20011130
PRIORITY INFO.: GB 2000-0029225.0 20001130
GB 2000-0029879.4 20001207

ABEN We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual.

ABFR L'invention concerne un methode de diagnostic d'une maladie, ou de susceptibilite a une maladie, associee a une adhesion cellule-cellule anormale entre des cellules epitheliales, la methode consistant a detecter, chez un individu, une mutation dans un acide nucleique codant pour une proteine d'adhesion, une protease, ou un inhibiteur de protease.

L139 ANSWER 15 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002039997 PCTFULL ED 20020613 EW 200321
TITLE (ENGLISH): ACE-2 MODULATING COMPOUNDS AND METHODS OF USE THEREOF
TITLE (FRENCH): COMPOSES MODULANT ACE-2 ET PROCEDES D'UTILISATION ASSOCIES
INVENTOR(S): ACTON, Susan, L.; COAIN, Timothy, D.; GOULD, Alexandra, E.; DALES, Natalie, A.; GUAN, Bing; BROWN, James, A.; PATANE, Michael; KADAMBI, Vivek, J.; SOLOMON, Michael; STRICKER-KRONGRAD, Alain
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC., for all designates States except US; ACTON, Susan, L., for US only; COAIN, Timothy, D., for US only; GOULD, Alexandra, E., for US only; DALES, Natalie, A., for US only; GUAN, Bing, for US only; BROWN, James, A., for US only; PATANE, Michael, for US only; KADAMBI, Vivek, J., for US only;

SOLOMON, Michael, for US only; STRICKER-KRONGRAD, Alain, for US only

AGENT: HANLEY, Elisabeth, A.
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002038994	A2	20020523

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US45703	A	20011031
PRIORITY INFO.:	US 2000-244,704,216		20001101
	US 2001-847,970,382		20010529
	US 2001-60/331,741		20011019

ABEN ACE 2 modulating compounds for the treatment of body disorders are disclosed. Methods of using the compounds and pharmaceutical compositiosn containing the compounds are also claimed.

ABFR L'invention concerne des composes modulant ACE-2, destines au traitement de problemes de poids. L'invention concerne egalement des procedes d'utilisation de ces composes et des compositions pharmaceutiques contenant lesdits composes.

L139 ANSWER 16 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002029062 PCTFULL ED 20020627 EW 200215
TITLE (ENGLISH): CYTOKINE PROTEINS
TITLE (FRENCH): PROTEINES CYTOKINE
INVENTOR(S): FAGAN, Richard, Joseph; PHELPS, Christopher, Benjamin; GUTTERIDGE, Alex
PATENT ASSIGNEE(S): IMPHARMATICA LIMITED, for all designates States except US; FAGAN, Richard, Joseph, for US only; PHELPS, Christopher, Benjamin, for US only; GUTTERIDGE, Alex, for US only
AGENT: MERCER, Christopher, Paul
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002029062	A2	20020411

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-GB4412	A	20011004
PRIORITY INFO.:	GB 2000-0024283.4		20001004

ABEN This invention relates to novel proteins, termed the CC1 and CC2 polypeptides, herein identified as cytokines and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

ABFR La presente invention concerne de nouvelles proteines, denommees polypeptides CC1 et CC2, identifiees comme etant des cytokines, ainsi que l'utilisation de ces proteines et de sequences d'acide nucleique de

genes codants dans le diagnostic, la prevention et le traitement de maladie.

L139 ANSWER 17 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 994893 EUROPATFULL EW 200201 FS PS
TITLE: SELECTIVE FACTOR XA INHIBITORS CONTAINING A FUSED AZEPINONE STRUCTURE.
SELEKTIVE INHIBITOREN DES FAKTORS X, EINE AZEPINONSTRUKTUR ENTHALTEND.
INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE.
INVENTOR(S): SCARBOROUGH, Robert, M., 2644 Belmont Canyon Road, Belmont, CA 94002, US
PATENT ASSIGNEE(S): COR THERAPEUTICS, INC., 256 East Grand Avenue, Suite 80, South San Francisco, CA 94080, US
PATENT ASSIGNEE NO: 1193100
AGENT: Doireau, Marc et al., Cabinet Ores 6, avenue de Messine, 75008 Paris, FR
AGENT NUMBER: 44329
OTHER SOURCE: EPBBL002001 EP 0994893 B1 0063
SOURCE: Wila-EPS-2002-H01-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 994893	B1	20020102
'OFFENLEGUNGS' DATE:		20000426
APPLICATION INFO.:	EP 1998-939911	19980911
PRIORITY APPLN. INFO.:	US 1997-82316	19970911
	US 1997-907779	19970811
RELATED DOC. INFO.:	WO 98 US16704	980811 INTAKZ
	WO 9907730	990218 INTPNR
REFERENCE PAT. INFO.:	WO 97-05160 A	

REF. NON-PATENT-LIT.: J A POBL ET AL.: "Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 15, 1994, pages 1795-1800, XP000196070 Amsterdam J A POBL ET AL.: "Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY., vol. 39, 1996, pages 494-502, XP000749701 EASTON US

L139 ANSWER 18 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 922004 EUROPATFULL EW 200233 FS PS
TITLE: ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES.
ANTIKOAGULIEREND WIRKENDE PEPTIDYL-ARGININ ALDEHYD DERIVATE.
DERIVES DE PEPTIDYL-ARGININE ALDEHYDE ANTICOAGULANTS.
INVENTOR(S): BAJUSZ, Sandor, Derek u. 16/a, H-1016 Budapest, HU; JUHASZ, Attila, Petnehazy u. 23, H-1139 Budapest, HU; BARABAS, Eva, Pusztaszeri ut 6, H-1025 Budapest, HU;

FEHER, Andras, Tuzko u. 6, H-1118 Budapest, HU;
SZABO, Gabriella, Vadi ut 9, H-1132 Budapest, HU;
SZELL, Erzsebet, Heves u. 64, H-1106 Budapest, HU;
VEGHELYI, Ivan, Labanc u. 6/b, H-1021 Budapest, HU;
LAVICH, Emilia, Frankovics M. u. 33, H-1158 Budapest, HU;
KASZAS, Eva, Nyar u. 69, H-1045 Budapest, HU;
LANDA, Jozsef, Amfiteatrum u. 11, H-1031 Budapest, HU;
MORAVCSIK, Imre, Mester u. 38, H-1095 Budapest, HU;
SZEKER, Agnes, Deak F. u. 91, H-1041 Budapest, HU;
TASCHLER, Zsuzsanna, Amfiteatrum u. 27, H-1031 Budapest, HU;
TOTH, Gabor, Veres P. u. 74, H-1163 Budapest, HU;
MOHAI, Zsuzsanna, Baratka u. 48, H-1173 Budapest, HU;
SZALKAY, Anna Maria, Szoedliget u. 10, H-1151 Budapest, HU;
MAKK, Klara, Liget u. 26, H-2623 Kismaros, HU

PATENT ASSIGNEE(S): GYOGYSZERKUTATO INTEZET KFT., Berlini u. 47-49, H-1045 Budapest, HU
PATENT ASSIGNEE NO: 1668100
AGENT: Beszedes, Stephan G., Dr., Patentanwalt, Muenchener Strasse 90a, 85221 Dachau, DE
AGENT NUMBER: 1931
OTHER SOURCE: BEPB2002057 EP 0922054 B1 0025
SOURCE: Wila-EPS-2002-H33-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 922054	B1	20020814
'OFFENLEGUNGS' DATE:		19990616
APPLICATION INFO.:		19970605
PRIORITY APPLN. INFO.:		19960605
RELATED DOC. INFO.:	WO 97-HU29	970605 INTAKE
	WO 9746576	971211 INTPNR
REFERENCE PAT. INFO.:	EP 19589 A	EP 479489 A
	US 4703036 A	

L139 ANSWER 19 OF 100 IFIPAT COPYRIGHT 2002 IFI
AN 10203477 IFIPAT;IFIUDB;IFICDB
TITLE: COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS
INVENTOR(S): Kosoglou; Teddy, Jamison, PA, US
Hess; Rudyard J., Flemington, NJ, US
Strony; John T., Lebanon, NJ, US
Veltri; Enrico P., Princeton, NJ, US
PATENT ASSIGNEE(S): Schering Corporation
AGENT: SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 20021476184	A1	20021010
APPLICATION INFORMATION:	US 2002-56690		20020125

	NUMBER	DATE
	US 2001-264276P	20010126 (Provisional)
	US 2001-264396P	20010126 (Provisional)

US 2001-264690P20010126 (Provisional)
US 2001-324123P20010921 (Provisional)
FAMILY INFORMATION: US 7302147184 20021119
DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 46
AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.
CLMN 46

L139 ANSWER 20 OF 100 USPATFULL
ACCESSION NUMBER: 2001:63240 USPATFULL
TITLE: Pharmaceutical preparation for treating blood coagulation disorders
INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224862	B1	20010501
APPLICATION INFO.:	US 2000-521219		20000308 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-245339, filed on 5 Feb 1999 Division of Ser. No. US 1998-165745, filed on 6 Oct 1998, now patented, Pat. No. US 6039945 Division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb 1999

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-513	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 21 OF 100 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001063290 PCTFULL ED 20020822
TITLE (ENGLISH): SCMP-7 AS MARKER FOR DIAGNOSIS OF BREAST CANCER
TITLE (FRENCH): SCMP-7 EN TANT QUE MARQUEUR POUR LE DIAGNOSTIC DU CANCER DU SEIN
INVENTOR(S): BOYD, Robert, Simon; STAMPS, Alasdair, Craig; TERRETT, Jonathan, Alexander; TYSON, Kerry, Louise
PATENT ASSIGNEE(S): OXFORD GLYCOSCIENCES (UK) LTD.; BOYD, Robert, Simon; STAMPS, Alasdair, Craig; TERRETT, Jonathan, Alexander; TYSON, Kerry, Louise

DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001063090	A1	20010830

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-GB734 A 20010221
PRIORITY INFO.: GB 2000-0004576.5 20000225

ABEN The present invention provides the use of a protein found in breast cancer cell membranes, known as BCMP 7, in the diagnosis, screening, treatment and prophylaxis of breast cancer, as well as compositions comprising BCMP 7, including vaccines and antibodies that are immunospecific for BCMP 7.

ABFR La presente invention concerne l'utilisation d'une proteine presente dans des membranes cellulaires de cancer du sein, connue en tant que BCMP 7, dans le diagnostic, le criblage, le traitement et la prophylaxie du cancer du sein. L'invention concerne egalement des compositions contenant BCMP 7 et des vaccins et anticorps immunospecifiques a BCMP 7.

L139 ANSWER 22 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001062085 PCTFULL ED 20020822
TITLE (ENGLISH): PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR
TITLE (FRENCH): FORMES PROTEGEES D'AGENTS PHARMACOLOGIQUEMENT ACTIFS ET UTILISATIONS CORRESPONDANTES
INVENTOR(S): LAI, Ching-San; WANG, Tingmin; VASSILEV, Vassil, P.
PATENT ASSIGNEE(S): MEDINOX, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001062085	A1	20010830

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US5977 A 20010223
PRIORITY INFO.: US 2000-09/515,043 20000225

ABEN In accordance with the present invention, there are provided conjugates of dithiocarbamates ("DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein.

ABFR La presente invention se rapporte a des conjugues de dithiocarbamates ("DC") et a des agents pharmacologiquement actifs (par exemple, des AINS). Lesdits conjugues fournissent une nouvelle classe d'agents pharmacologiquement actifs (par exemple, d'agents anti-inflammatoires) qui provoquent une apparition bien moindre d'effets secondaires en raison des effets protecteurs conferes par la modification des agents pharmacologiquement actifs decrits ci-dessus.

L139 ANSWER 23 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001057210 PCTFULL ED 20020827

TITLE (ENGLISH): USE OF DENDROASPIN AS A VEHICLE FOR NON-DENDROASPIN DOMAINS

TITLE (FRENCH): UTILISATION DE DENDROASPINE EN TANT QU'EXCIPIENT POUR DOMAINES EXEMPTS DE DENDROASPINE

INVENTOR(S): LY, Minjie; KARKAR, Vijay, Vir

PATENT ASSIGNEE(S): TRIGEN LIMITED

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001042305 A2		20010614
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-GB4639	A	20001205
PRIORITY INFO.:	GB 1999-0029625.2		19991206

ABEN The use of dendroaspin as a scaffold for one or more non-wild-type dendroaspin domains, the dendroaspin scaffold being modified in that the native RGD motif has been deleted or has been replaced by (i) an amino acid sequence having no integrin-binding activity or (ii) an integrin-binding amino acid sequence other than RGD which contains aspartic acid (D) or glutamic acid (E).

ABFR L'invention concerne l'utilisation de dendroaspine en tant que structure pour au moins un domaine de dendroaspine qui n'est pas du type sauvage, la structure de dendroaspine etant modifiee du fait que le motif endogene RGD a ete elimine ou remplace (i) par une sequence d'acides amines ne possedant pas d'activite de liaison aux integrines ou (ii) par une sequence d'acides amines se liant aux integrines qui differe de RGD et renferme de l'acide aspartique (D) ou de l'acide glutamique (E).

L139 ANSWER 24 OF 100 PCTFULL COPYRIGHT 2001 Univentio

ACCESSION NUMBER: 2001049675 PCTFULL ED 20020827

TITLE (ENGLISH): DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS

TITLE (FRENCH): DIHYDROBENZOPYRANNES, DIHYDROBENZOTHIOPYRANNES ET TETRAHYDROQUINOLINES DESTINES AU TRAITEMENT DES TROUBLES INDUITS PAR COX-2

INVENTOR(S): ROGIER, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, John, J.

PATENT ASSIGNEE(S): PHARMACIA CORPORATION; ROGIER, Donald, J., Jr.; CARTER, Jeffrey, S.; TALLEY, John, J.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001049675	A1	20010712
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US34525	A	20001219
PRIORITY INFO.:	US 1999-60/174,281		19991203

ABEN A class of dihydrobenzopyrans, dihydrobenzothiopyrans, tetrahydroquinolines, tetrahydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders.

Compounds of particular interest are defined by Formula (I) wherein X, A1, A2, A3, A4, B, R'', R1 and R2 are as described in the specification.

ABFR L'invention concerne une categorie de dihydrobenzopyrannes, dihydrobenzothiopyrannes, tetrahydroquinolines, tetrahydronaphthalenes, et leurs analogues, destines a etre utilises dans le traitement des troubles induits par la cyclooxygenase-2. Les composes presentant un interet particulier sont representes par la formule (I), ou X, A1, A2, A3, A4, B, R'', R1 et R2 sont tels que definis dans le descriptif.

L139 ANSWER 25 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20010216661 PCTFULL ED 20020822
TITLE (ENGLISH): BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX
TITLE (FRENCH): INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa
INVENTOR(S): FRESKGAARD, Per-Ola; JAKOBSEN, Palle
PATENT ASSIGNEE(S): NOVO NORDISK A/S; FRESKGAARD, Per-Ola; JAKOBSEN, Palle
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001021661	A1	20010329
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-DK516	A	20000919
PRIORITY INFO.:	DK 1999-PA 1999 01333		19990920
	US 1999-60/159,773		19991015

ABEN A novel bivalent serine protease inhibitor (I) of coagulation factor VIIa and factor Xa comprises: (i) a first serine protease inhibitor binding to factor VIIa; (ii) a linker moiety; and (iii) a second serine protease inhibitor binding to factor Xa. Also claimed are a method for inhibiting the two different serine proteases factor VIIa and factor Xa simultaneously and selectively when the two serine proteases becomes localised on the membrane protein tissue factor. The compounds and method are useful for prevention or treatment of FVIIa/TF-related diseases or disorders such as deep venous thrombosis, arterial thrombosis, post surgical thrombosis, coronary artery bypass graft (CABG), percutaneous transdermal coronary angioplastry (PTCA), stroke, tumour metastasis, inflammation, septic chock, hypotension, ARDS, pulmonary embolism, disseminated intravascular coagulation (DIC), vascular restenosis, platelet deposition, myocardial infarction, angiogenesis, or the prophylactic treatment of mammals with atherosclerotic vessels at risk for thrombosis.

ABFR

L139 ANSWER 26 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20010321259 PCTFULL ED 20020820
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS
TITLE (FRENCH): PROCEDES ET COMPOSITIONS DE TRAITEMENT DES PATHOLOGIES APPARENTEES AUX PLAQUETTES
INVENTOR(S): HANSON, Stephen, R.
PATENT ASSIGNEE(S): EMORY UNIVERSITY
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001021259	A2	20010329
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US25781	A	20000921

PRIORITY INFO.: US 1999-60/154,909 19990921

ABEN The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

ABFR

L139 ANSWER 27 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: [illegible] PCTFULL ED [illegible]

TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS USING MPL PATHWAY INHIBITORY AGENTS

TITLE (FRENCH): PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES LIES AUX PLAQUETTES AU MOYEN D'AGENTS INHIBITEURS DE TRAJET DE MPL

INVENTOR(S): HANSON, Stephen, R.

PATENT ASSIGNEE(S): EMORY UNIVERSITY

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001021163	A2	20010329
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 2000-US26025	A	20000921
PRIORITY INFO.:	US 1999-60/154,909		19990921

ABEN The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

ABFR

L139 ANSWER 28 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001010892 PCTFULL ED 20020828

TITLE (ENGLISH): FVIIa ANTAGONISTS

TITLE (FRENCH): ANTAGONISTE DU FVIIa

INVENTOR(S): DENNIS, Mark, S.

PATENT ASSIGNEE(S): GENENTECH, INC.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001010892	A2	20010215
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US21946	A	20000804
PRIORITY INFO.:	US 1999-60/147,627		19990806
	US 1999-60/150,315		19990823

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

ABFR

L139 ANSWER 29 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: [illegible] PCTFULL ED 20010808
TITLE (ENGLISH): BASB118 POLYPEPTIDE AND POLYNUCLEOTIDE FROM MORAXELLA CATARRHALIS
TITLE (FRENCH): POLYPEPTIDE BASB118 ET POLYNUCLEOTIDE DE MORAXELLA CATARRHALIS
INVENTOR(S): THONNARD, Joelle
PATENT ASSIGNEE(S): SMITHKLINE BEECHAM BIOLOGICALS S.A.; THONNARD, Joelle
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001009334	A1	20010208

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2000-EP7360 A 20000731
PRIORITY INFO.: GB 1999-9918308.1 19990803
ABEN The invention provides BASB118 polypeptides and polynucleotides encoding BASB118 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
ABFR

L139 ANSWER 30 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001007918 PCTFULL ED 20010808
TITLE (ENGLISH): CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES
TITLE (FRENCH): ALLO-ANTICORPS CATALYTIQUES DU FACTEUR VIII
INVENTOR(S): KAVERI, Srinivas; LACROIX-DESMAZES, Sebastien; KAZATCHKINE, Michel
PATENT ASSIGNEE(S): INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); BAYER PHARMA; KAVERI, Srinivas; LACROIX-DESMAZES, Sebastien; KAZATCHKINE, Michel
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001007918	A1	20010201

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2000-EP6870 A 20000718
PRIORITY INFO.: EP 1999-99401841.4 19990721
ABEN The present invention relates to a method of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-catalysed Factor

VIII degradation inhibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.

ABFR

L139 ANSWER 31 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: [illegible]
TITLE (ENGLISH): FVIIa ANTAGONISTS
TITLE (FRENCH): ANTAGONISTES DE FVIIa
INVENTOR(S): DENNIS, Mark, S.; EIGENBROT, Charles; LAZARUS, Robert, A.
PATENT ASSIGNEE(S): GENENTECH, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001001749	A2	20010111

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US18394	A	20000630
PRIORITY INFO.:	US 1999-60/142,211		19990702

ABEN This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

ABFR

L139 ANSWER 32 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 20010011150 PCTFULL ED 20020829
TITLE (ENGLISH): DIAGNOSTIC TEST FOR THROMBOTIC OR THROMBOEMBOLIC DISEASE
TITLE (FRENCH): EXAMEN DIAGNOSTIQUE POUR LA THROMBOSE OU LA THROMBOEMBOLIE
INVENTOR(S): MORRIS, Timothy, A.
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA; MORRIS, Timothy, A.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001001150	A2	20010104

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US17477	A	20000630
PRIORITY INFO.:	US 1999-60/141,734		19990630

ABEN Thrombotic or thromboembolic disease is detected or monitored by

determining the presence or amount B in a physiological sample.
ABFR

L139 ANSWER 33 OF 100 EUROPATFULL COPYRIGHT 2001 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1074-42 EUROPATFULL EW 200106 FS OS
TITLE: Catalytic anti-factor VIII allo-antibodies.
Katalytische gegen Faktor VIII spezifische AlloantiKoerper.
Catalytic anti-factor VIII allo-antibodies.
INVENTOR(S): Kaveri, Srinivas, 15, rue Lucien et Edouard Gerber, 92140 Malakoff, FR;
Lacroix-Desmazes, Sebastien, 33, rue de St-Cloud, 92410 Ville D'Avray, FR;
Kazatchkine, Michel, 1, rue Le Goff, 75005 Paris, FR
PATENT ASSIGNEE(S): INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), 101, rue de Tolbiac, 75654 Paris Cedex 13, FR;
Bayer Pharma, 13, rue Jean Jaures, 92807 Puteaux Cedex, FR
PATENT ASSIGNEE NO: 248440; 1666151
AGENT: Portal, Gerard et al., Cabinet Beau de Lomenie 158, rue de l'Universite, 75340 Paris Cedex 07, FR
AGENT NUMBER: 48943
OTHER SOURCE: BEPA2001012 EP 1074842 A1 0020
SOURCE: Wila-EPZ-2001-H06-T2a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1074842	A1	20010207

'OFFENLEGUNGS' DATE: 20010207
APPLICATION INFO.: EP 1999-401841 19990721

L139 ANSWER 34 OF 100 EUROPATFULL COPYRIGHT 2001 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 833848 EUROPATFULL EW 200137 FS PS STA E
TITLE: FACTOR IX BINDING PEPTIDES, DERIVED FROM FACTOR VIII AND THEIR USE AS INHIBITORS OF BLOOD COAGULATION.
FAKTOR IX BINDENDE PEPTIDE ABGELEITET VON FAKTOR VII UND IHRE VERWENDUNG ALS INHIBITOREN DER BLUTGERINNUNG.
PEPTIDES LIANT LE FACTEUR IX DERIVES DU FACTEUR VIII ET LEUR UTILISATION COMME INHIBITEURS DE LA COAGULATION DU SANG.
INVENTOR(S): MERTENS, Koenraad, Domela Nieuwenhuislaan 14, 2314 ES Leiden, NL;
LENTING, Petrus Johannes, Stormbootweg 8, 1035 TW Amsterdam, NL
PATENT ASSIGNEE(S): Stichting Sanquin Bloedvoorziening, Plesmanlaan 125, 1066 CX Amsterdam, NL
PATENT ASSIGNEE NO: 1530 30
AGENT: Smulders, Theodorus A.H.J., Ir. et al., Vereenigde Postbus 87930, 2508 DH Den Haag, NL
AGENT NUMBER: 21191
OTHER SOURCE: BEPB2001041 EP 0833849 B1 0017
SOURCE: Wila-EPS-2001-H37-T1

DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT Internationale Anmeldung

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 813384-	B1	20010912
'OFFENLEGUNGS' DATE:			19980408
APPLICATION INFO.:	EP 1996-917727		19960613
PRIORITY APPLN. INFO.:	EP 1995-201564		19950613
RELATED DOC. INFO.:	WO 96-NL236		960613 INTAKC
	WO 9641816		961227 INTPNR
REFERENCE PAT. INFO.:	WO 93-15610 A		WO 96-00572 A

REF. NON-PATENT-LIT.: JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 10, 11 March 1994, MD US, pages 7150-7155, XP000617254 P. LENTING ET AL: "Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII" cited in the application ANNUAL REPORT DR KARL LANDSTEINER FOUNDATION, AMSTERDAM NL, pages 1-2, XP000617255 J. VAN DE LOO ET AL: "Identification and characterization of the binding site of a murine monoclonal antibody that inhibits factor VIII function" cited in the application NATURE, vol. 312, pages 337-342, XP002017256 G. VEHAR ET AL: "Structure of human factor VIII" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 3, 25 January 1990, MD US, pages 1484-1489, XP000617257 F. WALKER ET AL: "Identification of the binding site for activated protein C on the light chain of factors V and VIII" JOURNAL OF BIOLOGICAL CHEMISTRY 271 (4). 1996. 1935-1940. ISSN: 0021-9258, 26 January 1996, XP002017258 LENTING P J ET AL: "The sequence Glu-1811-Lys-1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX."

L139 ANSWER 35 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 692029 EUROPATFULL EW 200142 FS PS STA R
TITLE: YEAST CELLS ENGINEERED TO PRODUCE PHEROMONE SYSTEM PROTEIN SURROGATES, AND USES THEREFOR.
HEFE ZELLEN SO KONSTRUIERT, DASS SIE PROTEINSURROGATE DES PHEROMENSYSTEMS PRODUZIEREN UND ANWENDUNGEN DAFUER.
CELLULES DE LEVURE TRAITEES POUR PRODUIRE DES SUBSTITUTS DE PROTEINES DU SYSTEME DE PHEROMONES, ET LEURS EMPLOIS.

INVENTOR(S): FOWLKES, Dana, Merriman 90 Green Street, Apartment 2, New York, NY 10012, US;
BROACH, Jim 360 East 88th Street, Apartment 2A, New York, NY 10128, US;
MANFREDI, John 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
KLEIN, Christine 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
MURPHY, Andrew, J., 17 Windsor Place, Montclair, NJ 07043, US;
PAUL, Jeremy, 197 Route 9W, Palisades, NY 10964, US;
TRUEHEART, Joshua, 212 South Broadway, South Nyack, NY 10960, US

PATENT ASSIGNEE(S): Canus Pharmaceutical Corporation, 7th floor, 180 Varick Street, New York, NY 10128, US
PATENT ASSIGNEE NO: 1860160
AGENT: Price, Vincent Andrew et al., FRY HEATH & SPENCE The Old

College 53 High Street, Horley Surrey RH6 7BN, GB
AGENT NUMBER: 74513
OTHER SOURCE: BEPB.001051 EP 0692025 B1 20010117
SOURCE: Wila EPS-2001-H42-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EP B1 EUROPAEISCHE PATENTSCHRIFT 'Internationale Anmeldung'
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 692025	B1	20010117

'OFFENLEGUNGS' DATE: 19960117
APPLICATION INFO.: EP 1994-912292 19940323
PRIORITY APPLN. INFO.: US 1993-41431 19930331
US 1994-190328 19940131
RELATED DOC. INFO.: WO 94-US3143 940323 INTAKC
WO 9423025 941013 INTPNR
REFERENCE PAT. INFO.: WO 93-05244 A
REF. NON-PATENT-LIT.: SCIENCE vol. 250, October 1990, LANCASTER, PA US pages 121 - 123 KLIM KING ET AL. 'Control of yeast mating signal transduction by a mammalian beta2-adrenergic receptor and Gs alpha subunit' CELL vol. 66, 20 September 1991, CAMBRIDGE, MA US pages 1197 - 1206 D. J. LEW ET AL. 'Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast' CELL vol. 65, 17 May 1991, CAMBRIDGE, MA US pages 691 - 699 YUE XIONG ET AL. 'Human D-type cyclin' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 89, October 1992, WASHINGTON US pages 9410 - 9414 M. WITHEWAY ET AL. 'Dominant negative selection of heterologous genes: Isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell cycle arrest' JOURNAL OF CELLULAR BIOCHEMISTRY vol. 18B, February 1994 page 224 J. MANFREDI ET AL. 'Autocrine stimulation of yeast through human G-coupled receptors' A. KOFF ET AL.,: 'HUMAN CYCLIN E, A NEW CYCLIN THAT INTERACTS WITH TWO MEMBERS OF THE CDC2 GENE FAMILY' CELL vol. 66, 1991, pages 1217 - 1228 D.A. HUGHES ET AL.,: 'COMPLEMENTATION OF BYR1 IN FISSION YEAST BY MAMMALIAN MAP KINASE REQUIRES COEXPRESSION OF RAF KINASE' NATURE vol. 364, 1993, pages 344 - 352

L139 ANSWER 36 OF 100 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 2002040828 MEDLINE
DOCUMENT NUMBER: 21619700 PubMed ID: 11769093
TITLE: [Research on synthetic peptides of biological interest]. Szintetikus peptidek a gyogyszerkutatasban.
AUTHOR: Bajusz S
CORPORATE SOURCE: Gyogyszerkutato Intezet Kft., Budapest, Pf. 82.-1325.
SOURCE: ACTA PHARMACEUTICA HUNGARICA, (2001) 71 (1) 13-24.
Journal code: 0414322. ISSN: 0001-6659.
PUB. COUNTRY: Hungary
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Hungarian
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200201
ENTRY DATE: Entered STN: 20020124
Last Updated on STN: 20020129
Entered Medline: 20020125

AB Research on synthetic **peptides** at the Institute for Drug Research (IDR) is exemplified by an overview of the projects that resulted in significant results. The first synthesis of oxytocin, a pituitary

hormone, in 1953 launched the research on synthetic **peptides** all over the world. This synthesis was reproduced by Bodanszky at the IDR in 1954, then, after some improvements, the process was presented to Richter to produce synthetic oxytocin for therapeutic purposes. Significant result was the first synthesis of the 39-member whole molecule of human ACTH, another pituitary hormone. A short SAR study on luteinizing hormone-releasing hormone (LHRH) led to an interesting analog, Glt-8-LHRH, and somewhat later, to the D-Glt-6-LHRH **analogues**, of which SB-75 become marketed under the name Detrorelix. Studies on the brain **peptides**, enkephalins, resulted in GYKI-14,238, the first analog that showed analgesic activity upon systemic administration and whose human efficacy could also be proven during clinical examination. Significant results were also achieved in the research on anticoagulant **peptides**. The first highly potent **peptide** aldehyde **inhibitor** of thrombin, GYKI-14,166, was identified at the IDR as well as its stable analog, GYKI-14,766. This compound was selected for detailed preclinical study, licensed to Eli Lilly Company, got the generic name efegatran, and entered clinical trials. The first non-covalent **peptide inhibitor** of thrombin, GYKI-14,525, was also identified at the IDR. Thus IDR really provided the prototype of original thrombin **inhibitors** in the mid 70's, and **analogues** were prepared in many laboratories through two decades. IDR's current research program's objective includes a quest for **peptide** originals that can inhibit both thrombin and **factor Xa** in solution and also within plasma clots in which these enzymes are entrapped. Structures with such inhibitory profile were identified among the efegatran-related alpha-hydroxy acid and ethoxycarbonyl-amino acid derivatives. The follow-up molecules are even more promising as antithrombotics, and may also be useful for treatment of disseminated intravascular coagulation, an often fatal syndrome, so we continue working on this project.

L139 ANSWER 37 OF 100 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 2000:953223 PROMT
TITLE: Tick Anticoagulant Peptides Have Inhibitory Activity.
SOURCE: Blood Weekly, (9 Nov 2000) .
ISSN: 1065-6073.
PUBLISHER: Charles W. Henderson
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 412
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB 2000 NOV 9 - (NewsRx.com) --
THIS IS THE FULL TEXT: COPYRIGHT 2000 Charles W. Henderson

Subscription: $995.00 per year. Published weekly. P.O. Box 930409, Birmingham, AL 35283-0409.

L139 ANSWER 38 OF 100 USPATFULL
ACCESSION NUMBER: 2000:174602 USPATFULL
TITLE: Pharmaceutical preparation for treating blood coagulation disorders
INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6165974		20001226
APPLICATION INFO.:	US 1999-245339		19990205 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-165745, filed on 6 Oct 1999, now patented, Pat. No. US 6039945 which is a		

division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb 1999

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 39 OF 100 USPATFULL
ACCESSION NUMBER: 2000:101870 USPATFULL
TITLE: Pharmaceutical preparation for treating blood coagulation disorders
INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6099837		20000808
APPLICATION INFO.:	US 1999-244762		19990205 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-165745, filed on 6 Oct 1998 which is a division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122		

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 40 OF 100 USPATFULL

ACCESSION NUMBER: 2000:34192 USPATFULL
TITLE: Pharmaceutical preparation for treating blood coagulation disorders
INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6039948		20000321
APPLICATION INFO.:	US 1998-165745		19981006 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866112		

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 41 OF 100 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2000052034 PCTFULL ED 20020515
TITLE (ENGLISH): INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
TITLE (FRENCH): INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT D'INFECTIONS VIRALES
INVENTOR(S): SHAPIRO, Leland
PATENT ASSIGNEE(S): THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000052034	A2	20000908
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK EA FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US5558	A	20000303
PRIORITY INFO.:	US 1999-60/123,167		19990305
	US 1999-60/137,795		19990603

ABEN A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP)

activity is disclosed, which
consists of administering to a subject suffering or about to suffer from viral infection a
therapeutically effective amount of a compound having a serine protease inhibitory or serpin
activity. Among compounds are α1-antitrypsin (AAT), peptide derivatives from the
carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such
compounds. The preferred viral infections include retroviral infection such as human
immunodeficiency virus (HIV) infection.

ABFR L'invention concerne une nouvelle methode de traitement et de prevention d'une infection
virale. L'invention concerne, en particulier, une methode destinee a combattre une infection virale
favorisee par une activite de serine proteolytique (SP), consistant a administrer a un sujet
souffrant ou susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace
d'un compose presentant une activite d'inhibition de serine protease ou serpin. Parmi les composes
se trouvent l'antitrypsine α1 (AAT), des derives peptidiques de l'extremite carboxyterminale
de l'AAT, et des composes synthetiques artificiels imitant l'action de ces composes. Parmi les
infections virales preferees se trouvent les infections retrovirales telles que l'infection du virus
de l'immunodeficience humaine (VIH).

L139 ANSWER 42 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	2000051625 PCTFULL ED 20020515
TITLE (ENGLISH):	INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF HERPES VIRUSES
TITLE (FRENCH):	INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT DE VIRUS DE L'HERPES
INVENTOR(S):	SHAPIRO, Leland
PATENT ASSIGNEE(S):	THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000051625	A1	20000908
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US5557	A	20000303
PRIORITY INFO.:	US 1999-60/123,167		19990305
	US 1999-60/153,942		19990915

ABEN Novel compositions and methods of treating and preventing a viral infection are provided. A
method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed,
which involves administering to a subject suffering or about to suffer from a viral infection a
therapeutically effective amount of a substance having serine protease inhibitory activity or serpin
activity. Among the substances found to be useful are
α1-antitrypsin (AAT), peptide

derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such
substances. The invention is particularly well suited for checking a viral infection mediated by
members of herpesviridae family.

ABFR L'invention concerne de nouvelles compositions et methodes de traitement et de prevention d'une
infection virale. L'invention concerne une methode visant a bloquer une infection virale favorisee
par une activite proteolytique de serine (SP), consistant a administrer a un sujet souffrant ou
susceptible de souffrir d'une infection virale une quantite therapeutiquement efficace d'une
substance presentant une activite d'inhibition de serine protease ou serpin. Parmi les substances
utiles se trouvent l'antitrypsine α1 (AAT), des derives peptidiques de l'extremite
carboxyterminale de l'AAT et des medicaments synthetiques imitant l'action de ces substances.
L'invention est particulierement appropriee dans le depistage d'une infection virale a mediation de
membres de la famille des Herpesviridae.

L139 ANSWER 43 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	2000051623 PCTFULL ED 20000915
TITLE (ENGLISH):	INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF NITRIC OXIDE-INDUCED CLINICAL CONDITIONS
TITLE (FRENCH):	INHIBITEURS D'ACTIVITE DE SERINE PROTEASE, METHODES ET COMPOSITIONS DE TRAITEMENT DES ETATS CLINIQUES DUS AU BIOXYDE D'AZOTE
INVENTOR(S):	SHAPIRO, Leland
PATENT ASSIGNEE(S):	THE TRUSTEES OF UNIVERSITY TECHNOLOGY CORPORATION
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000051623	A2	20000908
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US5556	A	20000303
PRIORITY INFO.:	US 1999-60/123,167		19990305
	US 1999-60/156,523		19990929

ABEN A novel method of treating and preventing diseases is provided. In particular, compositions and
methods of blocking diseases associated with aberrant levels of nitric oxide and facilitated by a
serine proteolytic (SP) activity are disclosed, which consist of administering to a subject a
therapeutically effective amount of a compound having a serine protease inhibitory activity. Among
effective compounds are α1-antitrypsin and synthetic drugs mimicking some or all of the
actions of α1-antitrypsin.

ABFR L'invention concerne une nouvelle methode de traitement et de prevention de maladies.
L'invention concerne en particulier des compositions et des methodes destinees a bloquer des

maladies associees a des niveaux anormaux de monoxyde d'azote et favorisees par une activite
proteolytique de serine (SP), consistant a administrer a un sujet une quantite therapeutiquement
efficace d'un compose presentant une activite d'inhibition de serine protease. Parmi les composes
efficaces se trouvent l'antitrypsine α1 et des medicaments synthetiques imitant certaines ou
toutes les actions de l'antitrypsine α1.

L139 ANSWER 44 OF 100 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2000050450 PCTFULL ED 20000915
TITLE (ENGLISH): MITE PROTEIN
TITLE (FRENCH): PROTEINE D'ACARIEN
INVENTOR(S): MATTSSON, Jens
PATENT ASSIGNEE(S): STATENS VETERINAERMEDICINSKA ANSTALT; MATTSSON, Jens
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000050450	A1	20000831
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-SE346	A	20000222
PRIORITY INFO.:	SE 1999-9900674-4		19990225

ABEN The present invention relates to a novel major mite antigen, which according to the invention
has been isolated and sequenced for the first time. More specifically, said antigen is a protein
originating from the mite i(Sarcoptes scabiei). Thus, the invention relates to said antigen as well
as to the encoding nucleic acid as defined in the claims. Further, the invention also relates to
advantageous uses of the novel protein and/or functional fragments thereof, e.g. in immunological
testing, such as in ELISA methods, as well as in the preparation of vaccines.

ABFR La presente invention concerne un nouvel antigene acarien majeur qui selon la presente
invention a ete isole et sequence pour la premiere fois. De maniere plus specifique, ledit antigene
est une proteine issue de l'acarien i(Sarcoptes scabiei.) L'invention concerne par consequent ledit
antigene ainsi que l'acide nucleique de codage tel qu'il est defini dans les revendications. En
outre, l'invention concerne egalement les utilisations interessantes de la nouvelle proteine et/ou
de ses fragments fonctionnels, par exemple dans les analyses immunologiques telles que les procedes
ELISA, ainsi que dans la preparation de vaccins.

L139 ANSWER 45 OF 100 PCTFULL COPYRIGHT 2001 Univentio
ACCESSION NUMBER: 2000039310 PCTFULL ED 20000915
TITLE (ENGLISH): RUBREDOXIN FUSION PROTEINS, PROTEIN EXPRESSION SYSTEM AND METHODS
TITLE (FRENCH): PROTEINES HYBRIDES DE RUBREDOXINE, SYSTEME ET METHODES D'EXPRESSION DE PROTEINE
INVENTOR(S): PRZYBYLA, Alan; MENON, Nanda

PATENT ASSIGNEE(S): THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.; PRZYBYLA, Alan; MENON, Nanda
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000039310	A1	20000706
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US31176	A	19991229
PRIORITY INFO.:	US 1998-60/114,034		19981229

ABEN A recombination fusion protein is presented which comprises rubredoxin as the fusion partner. The fusion protein optionally includes an intervening spacer region between the rubredoxin constituent and the fused polypeptide of interest that can contain a proteolytic cleavage site for release of the polypeptide of interest. The fusion protein can contain one or more sites for affinity purification. The invention also includes methods and materials for making and using the rubredoxin fusion protein. Also provided are antigenic compounds and compositions, including vaccines, comprising a rubredoxin as a carrier molecule linked to an antigen or hapten.

ABFR Cette invention a trait a une nouvelle proteine hybride de recombinaison comprenant de la rubredoxine comme partenaire de fusion. Cette proteine hybride peut, eventuellement, comprendre une region d'espacement intervenante entre le constituant rubredoxine et le polypeptide fusionne etudie, pouvant comporter un site de clivage proteolytique pour la liberation dudit polypeptide. Cette proteine hybride peut contenir un ou plusieurs sites pour purification par affinite. L'invention concerne egalement des methodes et des substances permettant de produire et d'utiliser la proteine hybride rubredoxine. Elle porte, en outre, sur des composes et des compositions antigeniques, notamment des vaccins, renfermant la rubredoxine comme molecule porteuse liee a un antigene ou a un haptene.

L139 ANSWER 46 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000036646 PCTFULL ED 20020515
TITLE (ENGLISH): HETEROCYCLIC COMPOUNDS REGULATING CLOTTING
TITLE (FRENCH): COMPOSES HETEROCYCLIQUES REGULANT LA COAGULATION
INVENTOR(S): JAKOBSEN, Palle; HORNEMANN, Anne, Marie; PERSSON, Egon
PATENT ASSIGNEE(S): NOVO NORDISK A/S
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000036646	A1	20000622
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX		

NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML
MR NE SN TD TG

APPLICATION INFO.: WO 1999-DK646 A 19991123
PRIORITY INFO.: DK 1998-DA 1998 01560 19981126

ABEN The invention relates to the use of heterocyclic compounds with formulas (I) and (II), and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for treatment of coagulation-related diseases. The compounds are inhibitors of TF-FVIIa activity and thus show anticoagulant activity. The invention also relates to methods of treatment. The invention furthermore relates to novel compounds with the formula (I) or (II).

ABFR La presente invention concerne l'utilisation de composes heterocycliques representes par les formules (I) et (II), et de leurs sels acceptables sur le plan pharmaceutique, dans la fabrication dune preparation pharmaceutique destinee au traitement des maladies liees a la coagulation. Ces composes sont des inhibiteurs de l'activite de TF-FVIIa et ont par consequent une activite anticoagulante. En outre, cette invention concerne des methodes de traitement, ainsi que de nouveaux composes representes par les formules (I) ou (II).

L139 ANSWER 47 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000015658 PCTFULL ED 20020515
TITLE (ENGLISH): FACTOR VIIa INHIBITORS
TITLE (FRENCH): INHIBITEURS DU FACTEUR VIIa
INVENTOR(S): SAFAR, Pavel; SAFAROVA, Alena; WILDGOOSE, Peter
PATENT ASSIGNEE(S): AVENTIS PHARMA DEUTSCHLAND GMBH
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000015658	A1	20000323
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-EP6449	A	19990903
PRIORITY INFO.:	EP 1998-98117506.0		19980915

ABEN The present invention relates to novel compounds, their preparation, their use and pharmaceutical compositions containing the compounds which have a strong antithrombotic effect through reversible inhibition of activated blood coagulation factor VIIa (FVIIa).

ABFR L'invention porte sur de nouveaux composes, leur preparation, leurs utilisations, et sur des preparations pharmaceutiques les contenant presentant une forte activite antithrombotique en tant qu'inhibiteurs reversible du facteur VIIa d'activation de la coagulation du sang (FVIIa).

L139 ANSWER 48 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000004392 PCTFULL ED 20020515

TITLE (ENGLISH): ARRAYS OF PROTEINS AND METHODS OF USE THEREOF
TITLE (FRENCH): GROUPEMENTS DE PROTEINES ET PROCEDES D'UTILISATION DE CEUX-CI
INVENTOR(S): WAGNER, Peter; AULT-RICHE, Dana; NOCK, Steffen; ITIN, Christian
PATENT ASSIGNEE(S): CYSMYX, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000004382	A1	20000127
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US15971	A	19990714
PRIORITY INFO.:	US 1998-09/115,455		19980714

ABEN Protein arrays for the parallel, i(in vitro) screening of biomolecular activity are provided.
Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different
proteins, such as different members of a single protein family, are immobilized on one or more
organic thin films on the substrate surface. The protein arrays are particularly useful in drug
development, proteomics, and clinical diagnostics.

ABFR L'invention concerne des groupements de proteines permettant de mettre en oeuvre un criblage
i(in vitro) en parallele d'activite biomoleculaire. Des procedes d'utilisation des groupements de
proteines sont egalement decrits. Dans les groupements, plusieurs proteines differentes telles que
des membres differents d'une seule famille de proteines, sont immobilisees sur un ou plusieurs films
minces organiques a la surface du substrat. Les groupements de proteines sont particulierement
utiles dans le developpement de medicaments, la proteomique et le diagnostic clinique.

L139 ANSWER 49 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 987274 EUROPATFULL EW 200012 FS OS
TITLE: Factor VIIa Inhibitors.
Faktor VIIa Inhibitore.
Inhibiteurs du facteur VIIa.
INVENTOR(S): Safar, Pavel, 12431 N. Forest Lake Way, Tucson AZ 85737, US;
Safarova, Alena, 12431 N. Forest Lake Way, Tucson AZ 85737, US;
Wildgoose, Peter, Hintergasse 13, 61440 Oberursel, DE
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland GmbH, Brueningstrasse 50, 65929 Frankfurt am Main, DE
PATENT ASSIGNEE NO: 2370600
OTHER SOURCE: EPPA 000020 EP 0987274 A1 0029
SOURCE: Wila-EPE-2000-H12-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R

SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 863871	A1	19980916
'OFFENLEGUNGS' DATE:			19980916
APPLICATION INFO.:	EP 1998-117506		19980911

L139 ANSWER 50 OF 100 EUROPATFULL COPYRIGHT 2004 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 863871 EUROPATFULL EW 200010 FS PS
TITLE: ANTICOAGULANT PEPTIDE ALDEHYDE DERIVATIVES.
PEPTID-ALDEHYDDERIVATE ALS ANTIKOAGULIERENDE MITTEL.
DERIVES D'ALDEHYDE PEPTIDIQUES ANTICOAGULANTS.
INVENTOR(S): BAJUSZ, Sandor, Derek u. 16/a, H-1016 Budapest, HU;
JUHASZ, Attila, Fetnehazy u. 23, H-1139 Budapest, HU;
BARABAS, Eva, Pusztaszeri ut 6, H-1035 Budapest, HU;
FEHER, Andras, Tuzko u. 6, H-1118 Budapest, HU;
SZABO, Gabriella, Vaci ut 8, H-1132 Budapest, HU;
SZELL, Erzsebet, Heves u. 64, H-1106 Budapest, HU;
VEGHELYI, Iren, Labanc u. 6/b, H-1021 Budapest, HU;
LAVICH, Emilia, Frankovics M. u. 33, H-1150 Budapest, HU;
KASZAS, Eva, Nyar u. 69, H-1045 Budapest, HU;
LANGO, Jozsef, Amfiteatrum u. 11, H-1031 Budapest, HU;
MORAVCSIK, Imre, Mester u. 38, H-1095 Budapest, HU;
SZEKER, Agnes, Deak F. u. 81, H-1041 Budapest, HU;
TASCHLER, Zsuzsanna, Amfiteatrum u. 27, H-1031 Budapest, HU;
TOTH, Gabor, Veres P. u. 74, H-1163 Budapest, HU;
MOHAI, Zsuzsanna, Baratka u. 48, H-1173 Budapest, HU;
SZALKAY, Anna, Maria, Szoedliget u. 10, H-1151 Budapest, HU;
MAKK, Klara, Liget u. 26, H-2623 Kismaros, HU
PATENT ASSIGNEE(S): GYOGYSZERKUTATO INTEZET KFT., Berlini u. 47-49, H-1045 Budapest, HU
PATENT ASSIGNEE NO: 1668100
AGENT: Beszedes, Stephan G., Dr. et al., Patentanwalt Postfach 11 68, 85201 Dachau, DE
AGENT NUMBER: 1932
OTHER SOURCE: BEPB2000011 EP 0863871 B1 0019
SOURCE: Wila-EPS-2000-H10-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 863871	B1	20000308
'OFFENLEGUNGS' DATE:			19980916
APPLICATION INFO.:	EP 1997-901209		19970605
PRIORITY APPLN. INFO.:	HU 1996-1527		19960605
RELATED DOC. INFO.:	WO 97-HU27	970605	INTAPZ
	WO 9746523	971211	INTPNR

REF. NON-PATENT-LIT.: JONES D.M. ET AL.: "Design and synthesis of thrombin inhibitors" LETT.PEPT.SCI., vol. 2, no. 3/4, 1995, pages 147-154, XP002041031 SHUMAN R.T. ET AL.: "Structure-Activity Study of Tripeptide Thrombin Inhibitors Using Alpha-Alkyl Amino Acids and other

Conformationally Constrained Amino Acids" J.MED.CHEM., vol. 39, 1996, pages 4446-4453, XP002041082 BAJUSZ S. ET AL.: "Active Site-Directed Thrombin Inhibitors: Alpha-Hydroxyacyl-prolyl-arginals. New Orally active Stable Analogs of D-Phe-Pro-Arg H" BIOORGANIC & MEDICAL CHEMISTRY, vol. 3, no. 9, 1995, pages 1079-1089, XP002041081 cited in the application

L139 ANSWER 51 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 830371 EUROPATFULL EW 200051 FS PS
TITLE: IMIDAZO(1,5A)PYRIDINE DERIVED SERINE PROTEASE INHIBITORS.
AUS IMIDAZO-(1,5A)-PYRIDIN STAMMENDE INHIBITOREN VON SERINPROTEASEN.
INHIBITEURS DE SERINE PROTEASE DERIVES DE IMIDAZO(1,5A)PYRIDINE.
INVENTOR(S): OTTENHEYM, Henricus Carl Joseph, Gagelveld 5, 6596 CC Milsbeek, NL;
ADANG, Antonius Egbert Peter, Le Sage ten Broeklaan 77, 5615 JR Eindhoven, NL;
PETERS, Jacobus Albertus Maria, Meerval 23, 5345 DB Oss, NL
PATENT ASSIGNEE(S): Akzo Nobel N.V., Velperweg 76, 6824 BM Arnhem, NL
PATENT ASSIGNEE NO: 200754
AGENT: Hogenbirk, Marijke et al., P.O. Box 20, 5340 BH Oss, NL
AGENT NUMBER: 96991
OTHER SOURCE: BEPB2000060 EP 0830371 B1 0019
SOURCE: Wila-EPS-2000-H51-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 830371	B1	20001220
'OFFENLEGUNGS' DATE:		19980325
APPLICATION INFO.:		19960529
PRIORITY APPLN. INFO.:		19950602
RELATED DOC. INFO.:	WO 96-EP2238	960529 INTAKZ
	WO 9638470	961205 INTPNR
REFERENCE PAT. INFO.:	EP 236483 A	

REF. NON-PATENT-LIT.: LIEBIGS ANNALEN DER CHEMIE, no. 9, September 1983, WEINHEIM DE, pages 1623-1637, XP002014819 C KLEIN ET AL.: "Umwandlung von omega-Guanidino- und omega-Ureido-alpha-aminosaeuren in alpha-Ketosaeuren und deren heterocyclische Folgeprodukte " cited in the application TETRAHEDRON, vol. 48, no. 24, 12 June 1992, OXFORD GB, pages 5191-5198, XP002014820 R GONZALEZ-MUNIZ ET AL.: "Synthesis of 2-substituted 8-amino-3-oxoindolizidine-2-carboxylic acid derivatives as peptide conformation mimetics"

L139 ANSWER 52 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 528963 EUROPATFULL EW 200021 FS PS
TITLE: IMPROVED INHIBITORS OF THROMBIN.
VERBESSERTE THROMBININHIBITOREN.

INHIBITEURS AMELIORES DE THROMBINE.

INVENTOR(S): MARAGANORE, John, M., 17 Highland Street, Concord, MA 01742, US;
JABLONSKI, Jo-Ann, M., 9 Summer Street, Middleborough, MA 02346, US;
BOURDON, Paul, R., 17 1/2 Vinal Avenue, Somerville, MA 02143, US

PATENT ASSIGNEE(S): BIOGEN, INC., 14 Cambridge Center, Cambridge Massachusetts 02142, US

PATENT ASSIGNEE NO: 1048451

AGENT: VOSSIUS & PARTNER, Postfach 86 07 67, 81634 Muenchen, DE

AGENT NUMBER: 106311

OTHER SOURCE: BEPBL000129 EP 0529031 B1 00126

SOURCE: Wila-EPB-2000-H21-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R MC; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 529031	B1	20000524

'OFFENLEGUNGS' DATE: 19930303

APPLICATION INFO.: EP 1992-905748 19920203

PRIORITY APPLN. INFO.: US 1991-650929 19910203

RELATED DOC. INFO.: WO 92-US836 920203 INTAKZ
WO 9213952 920820 INTPNR

REFERENCE PAT. INFO.: EP 19589 A
WO 91-02750 A
EP 118280 A

REF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, (Easton, PA, US), J.M. MARAGANORE et al.: "Design and characterization of Hirulogs: A novel class of Bivalent peptide inhibitors of thrombin" pages 7095-7101, see abstract, page 7099, left-hand column, lines 11-13 Scand. J. Haematol., vol. 31, 1983, (Copenhagen, DK), G.F. HANDELAND et al.: "Simplified assay for antithrombin III activity using chromogenic peptide substrate", pages 427-436, see abstract; page 435, left-hand column, paragraphs 2-3

L139 ANSWER 53 OF 100 USPATFULL DUPLICATE 3

ACCESSION NUMBER: 1999:33980 USPATFULL

TITLE: Inhibitors of factor Xa

INVENTOR(S): Brunck, Terence Kevin, San Diego, CA, United States
Webb, Thomas Roy, Encinitas, CA, United States
Ripka, William Charles, San Diego, CA, United States

PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5883077		19990316
APPLICATION INFO.:	US 1993-163964		19931215 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cecilia J.

ASSISTANT EXAMINER: Lukton, David

LEGAL REPRESENTATIVE: Lyon & Lyon LLP

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 1521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds, their salts and compositions related thereto having activity against mammalian **factor Xa** are disclosed. The novel compounds include **peptide** aldehyde **analogues** having substantial potency and specificity as **inhibitors** of mammalian **factor Xa** are further disclosed. The compounds are thought useful as **inhibitors** of **factor xa** in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 54 OF 100 USPATFULL

ACCESSION NUMBER:	1999:15483 USPATFULL		
TITLE:	Pharmaceutical preparation for treating blood coagulation disorders		
INVENTOR(S):	Turecek, Peter, Weidling, Austria Schwarz, Hans-Peter, Vienna, Austria Eibl, Johann, Vienna, Austria		
PATENT ASSIGNEE(S):	Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5866122		19990202	
APPLICATION INFO.:	US 1997-821763		19970320	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Weddington, Kevin E.
LEGAL REPRESENTATIVE:	Foley & Lardner
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	1609

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 55 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	1999066919 PCTFULL ED 20020515
TITLE (ENGLISH):	THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR
TITLE (FRENCH):	METHODES THERAPEUTIQUES UTILISANT DES DERIVES DE BISULFURE DE DITHIOCARBAMATES ET COMPOSITIONS UTILISEES
INVENTOR S :	LAI, Ching-San; VASSILEV, Vassil
PATENT ASSIGNEE(S):	MEDINOX, INC.; LAI, Ching-San; VASSILEV, Vassil
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9966919	A1	19991229
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK		

EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 1999-US14037 A 19990622
PRIORITY INFO.: US 1998-09/103,639 19980623

ABEN The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

ABFR La presente invention porte sur un nouveau dithiocarbamate bisulfure dimere utilise dans divers traitements therapeutiques, soit seul, soit en combinaison avec d'autres agents actifs. Selon un procede, le derive de bisulfure d'un dithiocarabamate est administre conjointement avec un agent qui desactive (ou inhibe la production) d'especes induisant l'expression de la synthase de l'oxyde nitrique de facon a reduire la production de ces especes tout en reduisant, en meme temps, les taux d'oxyde nitrique chez le sujet. Selon une autre realisation, on reduit chez un sujet les taux d'ions ferriques libres en administrant un derive de bisulfure d'un dithiocarbamate de facon a pieger des ions ferriques libres, par exemple, chez des sujets soumis a une chimiotherapie a l'anthracycline. Selon une autre realisation, on reduit les taux de cyanure chez un sujet en administrant un derive de bisulfure de dithiocarbamate de facon a fixer le cyanure chez le sujet. La presente invention porte egalement sur des compositions et des formulations utilisees dans ces procedes therapeutiques.

L139 ANSWER 56 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999048878 PCTFULL ED 20020515
TITLE (ENGLISH): HETEROCYCLIC COMPOUNDS REGULATING CLOTTING
TITLE (FRENCH): COMPOSES HETEROCYCLIQUES REGULATEURS DE COAGULATION
INVENTOR(S): PERSSON, Egon; JAKOBSEN, Palle; WORSAAE, Helle
PATENT ASSIGNEE(S): NOVO NORDISK A/S
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9948878	A1	19990930

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-DK138 A 19990317
PRIORITY INFO.: DK 1998-0413/98 19980324
DK 1998-0464/98 19980402
DK 1998-PA 1998 01559 19981126

ABEN The use of compounds of general formula (I) as factor VII-tissue factor inhibitors as well as novel benzoaxin derivatives are disclosed. The compounds of general formula (I) and pharmaceutical acceptable salts thereof have been shown to be inhibitors of factor VIIa-tissue factor activity. The compounds show anticoagulant properties. The compounds are useful for the treatment of deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors. Methods for inhibiting clotting activity are disclosed.

ABFR L'invention se rapporte a l'utilisation de composes representes par la formule (I) en tant qu'inhibiteurs du complexe facteur VII-facteur tissulaire ainsi qu'a de nouveaux derives benzoxazines. On a montre que les composes representes par la formule (I) et leurs sels pharmaceutiquement acceptables sont des inhibiteurs de l'activite du facteur VIIa-facteur tissulaire. Ces composes possedent des proprietes anticoagulantes. Lesdits composes s'averent utiles au traitement des anomalies des facteurs de coagulation sanguine ou des effets d'inhibiteurs sur les facteurs de coagulation sanguine. L'invention se rapporte egalement a des procedes d'inhibition de l'activite de coagulation.

L139 ANSWER 57 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999040907 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
TITLE (FRENCH): PROCEDES D'APPORT REGULE DE DISULFURE DE CARBONE DANS LE TRAITEMENT D'ETATS INFLAMMATOIRES
INVENTOR(S): LAI, Ching-San
PATENT ASSIGNEE(S): MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9940907	A1	19990819

DESIGNATED STATES AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US2679 A 19990208
PRIORITY INFO.: US 1998-60/074,741 19980213

ABEN In accordance with the present invention, it is described for the first time that CS2 is capable of directly inhibiting the activity of NFκB, without the need for any other active

agents to be present. It is assumed, therefor, that the inhibitory effect of, for example, pyrrolidine dithiocarbamate and other dithiocarbamates on NFκB may simply be attributed to CS2 released upon i(in vivo) hydrolysis of dithiocarbamates rather than as a result of the action of the parental compound per se. Dithiocarbamates may therefore be considered as pro-drugs for CS2 for the treatment of inflammatory conditions mediated via NFκB pathways. Thus, in accordance with the present invention, there are provided methods for the treatment of inflammatory conditions mediated by NFκB pathways, as well as novel compositions useful for such methods.

ABFR Selon la presente invention, on decrit pour la premiere fois que du disulfure de carbone CS2 peut inhiber directement l'activite de NFκB (facteur nucleaire kappa B) sans que la presence d'autres agents ne soit necessaire. On en a deduit, par consequent, que l'on pouvait attribuer l'effet inhibiteur sur le facteur NFκB, par exemple du dithiocarbamate de pyrrolidine et d'autres dithiocarbamates, plutot au CS2, libere lors d'une hydrolyse i(in vivo) de dithiocarbamates, qu'au resultat de l'action du compose parenteral en lui-meme. On peut donc considerer des dithiocarbamates comme des promedicaments de CS2, dans le traitement d'etats inflammatoires induits par des mecanismes d'action du facteur NFκB. Ainsi, selon l'invention, on decrit des procedes de traitement d'etats inflammatoires induits par des mecanismes d'action du facteur NFκB, de meme que des nouvelles compositions utiles dans de tels procedes.

L139 ANSWER 58 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	1999040787 PCTFULL ED 20020515
TITLE (ENGLISH):	MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME
TITLE (FRENCH):	AGENTS MODIFIES, ACTIFS SUR LE PLAN PHARMACOLOGIQUE, ET PROCEDES THERAPEUTIQUES AMELIORES ET METTANT EN OEUVRE CES AGENTS
INVENTOR(S):	LAI, Ching-San
PATENT ASSIGNEE(S):	MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9940787	A1	19990819

DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SL UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 1999-US2679 A 19990209
PRIORITY INFO.:	US 1998-60/074,694 19980213

ABEN In accordance with the present invention, there are provided modified forms of pharmacologically active agents (e.g., anti-inflammatory agents) which provide increased prolonged circulating levels of the active agent, thereby allowing administration of reduced levels of the

agent to the recipient. This not only reduces the cost of drug, it also reduces the level to which
the recipient is exposed to potentially harmful agents. Invention compounds provide a new class of
pharmacologically active agents which cause a much lower incidence of side effects due to the
benefits obtained by modifying the pharmacologically active agents as described herein.

ABFR Selon la presente invention, des formes modifiees d'agents actifs sur le plan pharmacologique
(par exemple des agents anti-inflammatoires) apportent des concentrations circulatoires accrues/a
effet prolonge de l'agent actif, permettant ainsi d'administrer des concentrations reduites de cet
agent a un receveur, ce qui diminue non seulement le cout du medicament mais egalement la
concentration en agents potentiellement nocifs, a laquelle le receveur est expose. Les composes de
l'invention constituent une nouvelle classe d'agents actifs, sur le plan pharmacologique, provoquant
une frequence moins grande d'effets secondaires, par suite de l'effet benefique obtenu par
modification pharmacologique de ces agents actifs.

L139 ANSWER 59 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999027962 PCTFULL ED 20020515
TITLE (ENGLISH): USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION
TITLE (FRENCH): UTILISATION D'UN ANTAGONISTE DU RECEPTEUR DU FIBRINOGENE POUR LA PREVENTION DE LA COAGULATION INTRAVASCULAIRE DISSEMINEE
INVENTOR(S): WIEMANN, Gundula
PATENT ASSIGNEE(S): WIEMANN, Gundula
LANGUAGE OF PUBL.: German
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9927962	A1	19990610
DESIGNATED STATES	CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1998-EP7833	A	19981202
PRIORITY INFO.:	DE 1997-197 53 393.3		19971202

ABEN The present invention relates to the use of fibrinogen receptor-antagonists for preventing
disseminated intravascular coagulation (DIC) related to sepsis or systemic inflammatory response
syndrome (SIRS) in humans.

ABFR La presente invention concerne l'utilisation d'antagoniste du recepteur du fibrinogene pour la
prevention de la coagulation intravasculaire disseminee (DIC) en relation avec la septicemie ou le
syndrome de reaction inflammatoire systemique (SIRS) chez l'homme.

L139 ANSWER 60 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1999017784 PCTFULL ED 20020515
TITLE (ENGLISH): TREATING OCCLUSIVE PERIPHERAL VASCULAR DISEASE AND CORONARY DISEASE WITH COMBINATIONS OF HEPARIN AND AN ADENOSIDE A2 AGONIST, OR WITH ADENOSINE
TITLE (FRENCH): TRAITEMENT DE LA VASCULOPATHIE PERIPHERIQUE OBLITERANTE ET DE LA CORONARITE AU MOYEN DE COMBINAISONS D'HEPARINE ET D'UN AGONISTE A2 ADENOSINE, OU AU MOYEN D'ADENOSINE
INVENTOR(S): BARRON, Hal, V.; BOTVINICK, Elias
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION
LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9917784	A1	19990415

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1998-US21153	A	19981007
PRIORITY INFO.:	US 1997-08/946,196		19971007
	US 1998-09/167,816		19981007

ABEN Compositions and methods for treatment of occlusive peripheral vascular disease and coronary disease are disclosed. The compositions and methods allow treatment of diseases associated with occlusion of coronary vessels, for example, by promoting growth of new blood vessels, i(i.e.), angiogenesis and/or by recruitment of collaterals. The methods involve the co-administration of an adenosine A2 receptor agonist, i(e.g.) adenosine, and heparin and/or a heparin-like substance over a period of several days. In particular, this invention is applicable to improving collateral coronary circulation in patients suffering from myocardial infarction.

ABFR Cette invention concerne des compositions et des procedes permettant de traiter la vasculopathie peripherique obliterante et la coronarite. Les compositions et les procedes permettent de traiter des maladies associees a l'occlusion des vaisseaux coronaires, par exemple, au moyen de l'activation de la croissance de nouveaux vaisseaux sanguins (c'est-a-dire par angiogenese et/ou par recrutement d'arteres collaterales). Le procede consiste a coadministrer un agoniste du recepteur A2 adenosine, par exemple de l'adenosine et de l'heparine et/ou une substance similaire a l'heparine sur une periode de plusieurs jours. D'une maniere plus specifique, cette invention peut s'appliquer pour ameliorer la circulation des arteres coronaires collaterales chez des patients atteints d'infarctus du myocarde.

L139 ANSWER 61 OF 100 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 915154 EUROPATFULL EW 199919 FS OS
TITLE: Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor.
Hefe Zellen so konstruiert, dass sie Proteinsurrogate des Pheromonsystems produzieren und Anwendungen dafuer.
Cellules de levure traitees pour produire des substituts de proteines du systeme de pheromones, et leurs emplois.

INVENTOR(S): Fowlkes, Dana Merriman, 90 Green Street, Apartment 2, New York, NY 10012, US;
Broach, Jim, 360 East 88th Street, Apartment 2A, New York, NY 10128, US;
Manfredi, John, 666 Greenwich Street, Apartment 556, New York, NY 10014, US;
Klein, Christine, 666 Greenwich Street, Apartment 556, New York, NY 10014, US;

Murphy, Andrew J., 17 Windsor Place, Montclair, NJ 07043, US;
Paul, Jeremy, 197 Route 9W, Palisades, NY 10964, US;
Trueheart, Joshua, 212 South Broadway, South Nyack, NY 1096 , US

PATENT ASSIGNEE(S): Cadus Pharmaceuticals, Inc., 7th floor, 180 Varick Street, New York, NY 10014, US
PATENT ASSIGNEE NO: 1860561
AGENT: Brice, Vincent Andrew et al, PRY HEATH & SPENCE The Old College 53 High Street, Horley Surrey RH6 7BN, GB
AGENT NUMBER: 795.3
OTHER SOURCE: ESP1999034 EP 0915154 A1 990512
SOURCE: Wila-EPS-1999-H19-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 915154	A1	19990512
'OFFENLEGUNGS' DATE:		19990512
APPLICATION INFO.:	EP 1998-202997	19940323
PRIORITY APPLN. INFO.:	US 1993-41431	19930331
	US 1994-190308	19940131
RELATED DOC. INFO.:	EP 692035 DIV	

L139 ANSWER 62 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 694830 EUROPATFULL EW 199924 FS PS
TITLE: INHIBITORS OF THROMBOSIS.
INHIBITOREN GEGEN THROMBOSE.
INHIBITEURS DE LA THROMBOSE.
INVENTOR(S): VLASUK, George Phillip, 3024 Garbose Street, Carlsbad, CA 92009, US;
WEBB, Thomas Roy, 2250 Colony Terrace, Encinitas, CA 92024, US;
PEARSON, Daniel Andrew, 149 Beals Road, Bedford, NH 03110, US;
ABELMAN, Matthew Mark, 873 Stevens Avenue, 3312, Solana Beach, CA 92075, US
PATENT ASSIGNEE(S): CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US
PATENT ASSIGNEE NO: 1501290
AGENT: Irvine, Jonquil Claire et al, J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, GB
AGENT NUMBER: 74183
OTHER SOURCE: EPB1999035 EP 0694830 B1 990616
SOURCE: Wila-EPS-1999-H24-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 694830	B1	19990616
'OFFENLEGUNGS' DATE:		19951206
APPLICATION INFO.:	EP 1994-909618	19940214
PRIORITY APPLN. INFO.:	US 1993-17125	19930212

	US 1994-195995	19940211
RELATED DOC. INFO.:	WO 94-US1612	940214 INTAKZ
	WO 9417781	940818 INTPNR
REFERENCE PAT. INFO.:	WO 93-14778 A	WO 93-18756 A
	US 4994068 A	

L139 ANSWER 63 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER:	6647-6 EUROPATFULL EW 199912 FS PS
TITLE:	ARGININE KETO-AMIDE ENZYME INHIBITORS. INHIBITOREN DES ARGININ-KETOAMID-ENZYMS. CETO-AMIDE D'ARGININE COMME INHIBITEURS ENZYMATIQUES.
INVENTOR(S):	WEBB, Thomas, Roy, 2250 Colony Terrace, Encinitas, CA 92024, US; MILLER, Todd, Anthony, 1710 South El Camino Real, E-208, Encinitas, CA 92024, US; VLASUK, George, Phillip, 3024 Garboso Street, Carlsbad, CA 92009, US; ABELMAN, Matthew, Mark, 873 Stevens Avenue, 3312, Solana Beach, CA 92075, US
PATENT ASSIGNEE(S):	CORVAS INTERNATIONAL, INC., 3030 Science Park Road, San Diego CA 92121-1102, US
PATENT ASSIGNEE NO:	1501290
AGENT:	Viering, Jentschura & Partner, Postfach 22 14 43, 80504 Muenchen, DE
AGENT NUMBER:	100645
OTHER SOURCE:	EPB1999017 EP 0664786 B1 990324
SOURCE:	Wila-EPS 1999-H12-T1
DOCUMENT TYPE:	Patent
LANGUAGE:	Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES:	R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE:	EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 664786	B1	19990324
'OFFENLEGUNGS' DATE:		19950802
APPLICATION INFO.:	EP 1993-904369	19931018
PRIORITY APPLN. INFO.:	US 1992-962301	19921016
RELATED DOC. INFO.:	WO 93-US10015	931018 INTAKZ
	WO 9408941	940428 INTPNR
REFERENCE PAT. INFO.:	EP 195013 A	WO 92-11850 A
	WO 90-12140 A	US 3966701 A
	US 4161522 A	US 4171299 A
	US 4478745 A	US 5221752 A

REF. NON-PATENT-LIT.: J. AM. CHEM. SOC., vol.112, 1990 pages 7053 - 7054 N. FUSETANI, S. MATSUNAGA 'Cyclotheonamides, Potent Thrombin Inhibitors from a Marine Sponge'

L139 ANSWER 64 OF 100 MEDLINE DUPLICATE 4

ACCESSION NUMBER:	2000014946 MEDLINE
DOCUMENT NUMBER:	20014045 PubMed ID: 10543068
TITLE:	Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor.
AUTHOR:	De Filippis V; Russo I; Vindigni A; Di Cera E; Salmaso S; Fontana A
CORPORATE SOURCE:	CRIBI Biotechnology Center and Department of Pharmaceutical Sciences, University of Padua, Italy.
CONTRACT NUMBER:	HL49413 (NHLBI) HL58141 (NHLBI)

SOURCE: PROTEIN SCIENCE, 1999 Oct; 8 (10): 2213-7.
Journal code: 9211750. ISSN: 0961-8368.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200002
ENTRY DATE: Entered STN: 20000229
Last Updated on STN: 20000229
Entered Medline: 20000211

AB Hirudin is an anticoagulant polypeptide isolated from a medicinal leech that inhibits thrombin with extraordinary potency (Kd = 0.2-1.0 pM) and selectivity. Hirudin is composed of a compact N-terminal region (residues 1-47, cross-linked by three disulfide bridges) that binds to the active site of thrombin, and a flexible C-terminal tail (residues 48-64) that interacts with the exosite I of the enzyme. To minimize the sequence of hirudin able to bind thrombin and also to improve its therapeutic profile, several N-terminal fragments have been prepared as potential anticoagulants. However, the practical use of these fragments has been impaired by their relatively poor affinity for the enzyme, as given by the increased value of the dissociation constant (Kd) of the corresponding thrombin complexes (Kd = 30-400 nM). The aim of the present study is to obtain a derivative of the N-terminal domain 1-47 of hirudin displaying enhanced inhibitory potency for thrombin compared to the natural product. In this view, we have synthesized an **analogue** of fragment 1-47 of hirudin HM2 in which Val1 has been replaced by tert-butylglycine, Ser2 by Arg, and Tyr3 by beta-naphthylalanine, to give the BugArgNal **analogue**. The results of chemical and conformational characterization indicate that the synthetic **peptide** is able to fold efficiently with the correct disulfide topology (Cys6-Cys14, Cys16-Cys28, Cys22-Cys37), while retaining the conformational properties of the natural fragment. Thrombin **inhibition** data indicate that the effects of amino acid replacements are perfectly additive if compared to the singly substituted **analogues** (De Filippis V, Quarzago D, Vindigni A, Di Cera E, Fontana A, 1998, Biochemistry 37:13507-13515), yielding a molecule that inhibits the fast or slow form of thrombin by 2,670- and 6,818-fold more effectively than the natural fragment, and that binds exclusively at the active site of the enzyme with an affinity (Kd,fast = 15.4 pM, Kd,slow = 220 pM) comparable to that of full-length hirudin (Kd,fast = 0.2 pM, Kd,slow = 5.5 pM). Moreover, BugArgNal displays absolute selectivity for thrombin over the other physiologically important serine proteases trypsin, plasmin, **factor Xa**, and tissue plasminogen activator, up to the highest concentration of **inhibitor** tested (10 microM).

L139 ANSWER 65 OF 100 USPATFULL DUPLICATE 5
ACCESSION NUMBER: 1999:39504 USPATFULL
TITLE: Inhibitors of factor Xa
INVENTOR(S): Brunck, Terence Kevin, San Diego, CA, United States
Webb, Thomas Roy, Encinitas, CA, United States
Ripka, William Charles, San Diego, CA, United States
PATENT ASSIGNEE(S): Corvas International, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739112		19980414
APPLICATION INFO.:	US 1995-465115		19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-168964, filed on 15 Dec 1993 which is a continuation-in-part of Ser. No. US 1992-991204, filed on 15 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia J.		
ASSISTANT EXAMINER:	Duketon, David		

LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 14466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds, their salts and compositions related thereto having activity against mammalian **factor Xa** are disclosed. The novel compounds include **peptide** aldehyde **analogues** having substantial potency and specificity as **inhibitors** of mammalian **factor Xa** are further disclosed. The compounds are thought useful as **inhibitors** of **factor Xa** in vitro or as a therapeutic agent for the prevention and treatment of conditions characterized by abnormal thrombosis in mammals. Intermediates useful for the preparation of the novel compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L139 ANSWER 66 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998055453 PCTFULL ED 20020514
TITLE (ENGLISH.): CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR
TITLE (FRENCH): CONJUGUES DE DITHIOCARBAMATES COMPRENANT DES AGENTS PHARMACOLOGIQUEMENT ACTIFS ET UTILISATIONS DESDITS CONJUGUES
INVENTOR(S): LAI, Ching-San
PATENT ASSIGNEE(S): MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9855453	A1	19981210
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US10095	A	19980519
PRIORITY INFO.:	US 1997-8/869,158		19970604

ABEN In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or DC) and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

ABFR L'invention concerne des conjugues d'accepteurs de monoxyde d'azote dithiocarbamates ou DC, par exemple, et des agents pharmacologiquement actifs AINS, par

exemple. Les conjugues de
l'invention donnent une nouvelle categorie d'agents pharmacologiquement
actifs (agents
anti-inflammatoires, par exemple) qui ont une incidence d'effets
secondaires beaucoup moindre en
raison de l'effet de protection produit par la modification de ces
agents pharmacologiquement
actifs. En outre, les conjugues de l'invention sont plus efficaces que
les agents
pharmacologiquement actifs puisse que ses cellules ou des tissus places
au contact desdits agents
sont proteges contre les effets potentiellement deteriorants de la
surproduction de monoxyde d'azote
ainsi induite par la coproduction d'accepteurs de monoxyde d'azote (des
dithiocarbamates, par
exemple), a laquelle s'ajoute celle d'un agent libre pharmacologiquement
actif lorsque le conjugue
est clive.

L139 ANSWER 67 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998011066 PCTFULL ED 20020514
TITLE (ENGLISH): POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
TITLE (FRENCH): MACROMOLECULES CONTENANT DU POLYDITHIOCARBAMATE, ET LEUR UTILISATION DANS DES APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES
INVENTOR(S): LAI, Ching-San
PATENT ASSIGNEE(S): MEDINOX, INC.; LAI, Ching-San
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9811066	A1	19980319
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US15324	A	19970828
PRIORITY INFO.:	US 1996-60/025,967		19960910
	US 1997-8/899,087		19970723

ABEN In accordance with the present invention, there is provided a new class of drugs for
therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury.
Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a
macromolecule (e.g., albumin protein) either by using cross-linking reagents or by non-specific
binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new
class of drugs for therapeutic treatment of such indications as cerebral stroke and other
ischemia/reperfusion injury. In accordance with another aspect of the present invention,
combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of
formation (either directly or indirectly) of species which induce the expression of inducible nitric
oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase
expression. In accordance with yet another aspect of the present

invention, magnetic resonance
imaging methods have been developed for the measurement of cerebral and cardiac blood flow and
infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing
complexes of a composition comprising a dithiocarbamate and a macromolecule as contrast agents.

ABFR L'invention concerne une nouvelle classe de medicaments destines au traitement therapeutique de
certains troubles, tels qu'une apoplexie ou d'autres accidents causes par une ischemie ou une
reperfusion. Des dithiocarbamates sont lies a la surface d'une macromolecule (par exemple, une
proteine d'albumine), soit au moyen de reactifs reticules, soit par liaison non specifique, de facon
a produire des compositions contenant des macromolecules de polydithiocarbamate, qui representent
une nouvelle classe de medicaments servant au traitement therapeutique de certains troubles, tels
qu'une apoplexie ou d'autres accidents causes par une ischemie ou une reperfusion. Dans un autre
mode de realisation, des procedes therapeutiques combinatoires ont ete elabores pour inactiver ou
inhiber in vivo (soit directement soit indirectement) la formation d'especes induisant l'expression
de synthase d'oxyde nitrique inductible et pour reduire le niveau d'oxyde nitrique produit en
consequence de l'expression de synthase .NO. Dans un autre mode de realisation, des procedes
d'imagerie par resonance magnetique ont ete mis au point pour mesurer le debit sanguin du cerveau et
du coeur et le volume de l'infarctus lors de troubles ischemiques ou de crise cardiaque. De tels
procedes ont recours a des complexes contenant du fer d'une composition renfermant un
dithiocarbamate et une macromolecule comme agents de contraste.

L139 ANSWER 68 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998005333 PCTFULL ED 20020514
TITLE (ENGLISH): USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS
TITLE (FRENCH): UTILISATION DE MIMETIQUES DE FEUILLETS BETA COMME INHIBITEURS DE PROTEASE ET DE KINASE OU COMME INHIBITEURS DE FACTEURS DE TRANSCRIPTION
INVENTOR(S): KAHN, Michael; QABAR, Maher, Nicola; McMILLAN, Michael, Kim; OGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; URBAN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; KAHN, Michael; QABAR, Maher, Nicola; McMILLAN, Michael, Kim; OGBU, Cyprian, Okwara; EGUCHI, Masakatsu; KIM, Hwa-Ok; BOATMAN, Patrick, Douglas, Jr.; URBAN, Jan; MEARA, Joseph, Patrick; BABU, Suresh; FERGUSON, Mark, D.; LUM, Christopher, Todd
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9805333	A1	19980212
DESIGNATED STATES	AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR		

GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US13618 A 19970805
PRIORITY INFO.: US 1996-8/692,420 19960805
US 1996-8/725,073 19961002
US 1997-8/797,915 19970210
US 1997-60/043,367 19970519

ABEN 'beta'-sheet mimetics and methods relating to the same are disclosed. The 'beta'-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors. Methods of the invention include administration of a 'beta'-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase and/or transcription factor.

ABFR L'invention concerne des mimetiques de feuillets beta et des procedes les concernant. Les mimetiques de feuillets beta sont utiles comme inhibiteurs de protease et de kinase ainsi que comme inhibiteurs de facteurs de transcription. Des procedes de l'invention comprennent l'administration d'un mimetique de feuillets beta ou l'utilisation dudit mimetique pour fabriquer un medicament destine au traitement d'une variete d'etats pathologiques associes a la protease, a la kinase et/ou au facteur de transcription cibles.

L139 ANSWER 69 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998001428 PCTFULL ED 20020514
TITLE (ENGLISH): AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
TITLE (FRENCH): AMIDINOINDOLES, AMIDINOAZOLES ET LEURS ANALOGUES AGISSANT EN TANT QU'INHIBITEURS DU FACTEUR Xa ET DE LA THROMBINE
INVENTOR(S): DOMINGUEZ, Celia; HAN, Qi; DUFFY, Daniel, Emmett; PARK, Jeongsook, Maria; QUAN, Mimi, Lifen; ROSSI, Karen, Anita; WEXLER, Ruth, Richmond
PATENT ASSIGNEE(S): THE DU PONT MERCK PHARMACEUTICAL COMPANY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9801428	A1	19980115
DESIGNATED STATES	AM AU AZ BR BY CA CN CZ EE HU IL JP KG KR KZ LT LV MD MX NO NZ PL RO RU SG SI SK TJ TM UA VN AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1997-US11325	A	19970630
PRIORITY INFO.:	US 1996-8/676,766		19960708
	US 1997-60/049,519		19970613

ABEN The present application describes amidinoindoles, amidinoazoles, and analogs thereof of formula (I): wherein W, W1, W2, and W3 are selected from CH and N, provided that one of W1 and W2 is C(=NH)NH2) and at most two of W, W1, W2, and W3 are N and one of Ja and Jb is substituted by -(CH2)n-Z-A-B, which are useful as inhibitors of factor Xa or thrombin.

ABFR La presente demande concerne des amidinoindoles, des amidinoazoles et leurs analogues repondant a la formule (I), ou W, W1, W2 et W3 sont choisis parmi CH et N, a condition que l'un des elements W1 et W2 soit C(=NH)NH2), que deux au plus des elements W, W1, W2 et W3 soient N, et que l'un des

elements Ja et Jb soit substitue par -(CH2)n-Z-A-B, et pouvant etre utiles en tant qu'inhibiteurs du facteur Xa ou de la thrombine.

L139 ANSWER 71 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1998000442 PCTFULL ED 20020514
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE LA SERINE PROTEASE
INVENTOR(S): DEADMAN, John, Joseph; ELGENDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir
PATENT ASSIGNEE(S): THROMBOSIS RESEARCH INSTITUTE; DEADMAN, John, Joseph; ELGENDY, Said; GREEN, Donovan; SKORDALAKES, Emmanuel; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9800442	A1	19980108
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-GB1574	A	19970611
PRIORITY INFO.:	GB 1996-9613719.5		19960629

ABEN Bifunctional serine protease inhibitors and methods of preparing boron-containing peptides are provided. The serine protease inhiitors comprise a catalytic site-directed moiety, which binds to and inhibits the active site of a serine protease, and an exosite associating moiety, which are joined by a connector moiety. The catalytic site directed moiety and the exosite associating moiety are capable of binding simultaneously to a molecule of the serine protease.

ABFR L'invention concerne des inhibiteurs bifonctionnels de la serine protease et des procedes de preparation de peptides contenant du bore. Ces inhibiteurs comprennent une fraction catalytique dirigee qui se lie au site actif d'une serine protease et l'inhibe, et une fraction se liant a un exosite, ces deux fractions etant reunies par une fraction de couplage. La fraction dirigee catalytique et la fraction se liant a un exosite sont capables de se lier simultanement a une molecule de la serine protease.

L139 ANSWER 71 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 818744 EUROPATFULL EW 199803 FS OS
TITLE: Process for selecting candidate drug compounds.
Verfahren zur Auswahl von Kandidat-Drogenverbindungen.
Procede de selection des compositions medicamenteuses potentielles.
INVENTOR(S): Young, Stephen Clinton, 9 Cranbourne Road, Heaton Moor, Stockport, Cheshire SK4 4DL, GB;
Murray, Christopher, 1 Wheatfield Close, Titherington, Macclesfield, Cheshire SK10 2TT, GB

PATENT ASSIGNEE S.: Proteus Molecular Design Limited, Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL, GB
PATENT ASSIGNEE NO: 906234
AGENT: Cockbain, Julian, Dr., Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street, London EC4V 4EL, GB
AGENT NUMBER: 32641
OTHER SOURCE: ESP1998004 EP 0818744 A2 980114
SOURCE: Wila-EPZ-1998-H03-T2a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 818744	A2	19980114
'OFFENLEGUNGS' DATE:			19980114
APPLICATION INFO.:	EP 1997-304412		19970624
PRIORITY APPLN. INFO.:	GB 1996-14303		19960708
	GB 1996-16562		19960807

L139 ANSWER 72 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 703923 EUROPATFULL EW 199841 FS PS
TITLE: FACTOR VII-DERIVED PEPTIDES.
FAKTOR VII-PEPTIDE.
PEPTIDES DERIVES DU FACTEUR VII.
INVENTOR(S): STEPHENS, Ross Wentworth, Silurveien 19, N-0380 Oslo, NO;
OPNING, Lars, Thomas Heftyes gate 47B, N-0267 Oslo, NO;
SAKARIASSEN, Kjell Steinar, Kygd Alle 33B, N-0262 Oslo, NO
PATENT ASSIGNEE(S): NYCOMED IMAGING AS, Nycoveien 1-2, 0401 Oslo 4, NO
PATENT ASSIGNEE NO: 1564564
AGENT: Matthews, Derek Peter et al, Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street, London EC4V 4EL, GB
AGENT NUMBER: 60131
OTHER SOURCE: EPB1998055 EP 0703923 B1 981007
SOURCE: Wila-EPS-1998-H41-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 703923	B1	19981007
'OFFENLEGUNGS' DATE:			19960403
APPLICATION INFO.:	EP 1994-918437		19940617
PRIORITY APPLN. INFO.:	GB 1993-12601		19930618
	GB 1994-9335		19940510
RELATED DOC. INFO.:	WO 94-GB1315	940617	INTAKZ
	WO 95000541	950105	INTPNR
REFERENCE PAT. INFO.:	EP 446787 A		WO 90-03390 A
	WO 93-09804 A		

L139 ANSWER 73 OF 100 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1998-594555 [50] WPIDS

DOC. NO. CPI: C1998-178350
TITLE: New di aza cyclic **peptide** mimetic **analogues** are selective **inhibitors** of **factor Xa** or **factor Xa**/prothrombinase complex, useful for treating e.g. angina and as diagnistic agents.
DERWENT CLASS: B04 B13 B04
INVENTOR(S): SCARBOROUGH, R M; SU, T; ZHU, B
PATENT ASSIGNEE(S): (CORT-N) CORTECH THERAPEUTICS INC
COUNTRY COUNT: 73
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9846627	A1	19981022	(199850)*	EN	72

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AU 9868963	A	19981111	(199912)	
EP 977773	A1	20000209	(200012)	EN
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE				
MX 9909143	A1	20000201	(200123)	
NZ 500352	A	20011026	(200176)	
US 6369063	B1	20020409	(200227)	
JP 2002514214 W		20020514	(200236)	82

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9846627	A1		WO 1998-US7160	19980413
AU 9868963	A		AU 1998-68963	19980413
EP 977773	A1		EP 1998-914658	19980413
			WO 1998-US7160	19980413
MX 9909143	A1		MX 1999-9143	19991006
NZ 500352	A		NZ 1998-500352	19980413
			WO 1998-US7160	19980413
US 6369063	B1	Provisional	US 1997-72094P	19970414
			US 1998-58821	19980413
JP 2002514214 W			JP 1998-544068	19980413
			WO 1998-US7160	19980413

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9868963	A	Based on	WO 9846627
EP 977773	A1	Based on	WO 9846627
NZ 500352	A	Based on	WO 9846627
JP 2002514214 W		Based on	WO 9846627

PRIORITY APPLN. INFO: US 1997-72094P 19970414; US 1998-58821 19980413

AN 1998-544068 [50] WPIDS
AB WO 9846627 A UPAB: 19981217
Diaza cyclic **peptide** mimetic **analogues** of formula (I), their salts and optical isomers are new. R1 = H, alkyl, cycloalkyl, 1-3C alkylaryl, 1-3C alkyl-cycloalkyl or aryl; R2 =H; or R1+R2 = carbocyclic ring; m = 0-2; n =0-6; k, p, s = 0-1; q = 0-3; r,t = 0-4; A = R3, NR3R4, N(R5)C(=NR6)NR3R7, C(=NR6)NR3R8, N(R5)C(=NR6)R7, C(=NR6)R8 or SC(=NR6)NR3R9; R3-R6 = H, OH, alkyl, aryl or 1-4C alkylaryl; R7 = H, alkyl, aryl or 1-4C alkylaryl; or R7+R5 or R7+R6 = 5-6 membered ring; R8 =

H, alkyl, aryl or 1-4C alkylaryl; or R8+R6 = 5-6 membered ring; Q = bond, S, SO, O, SO2NH, NHSO2, CO, CONH, 1-6C alkyl, 3-8C cycloalkyl, 2-6C alkenyl, 2-6C alkenylaryl, aryl or a 5-10 membered heterocyclic ring system containing 1-4 of N, O or S; D = bond, CO, SO2, CO2, NR9SO2 or NR9CO; R9 = H, OH, alkyl, aryl or 1-4C alkylaryl; E = bond, cycloalkyl, aryl or a 5-10 membered heterocyclic ring system containing 1-4 of N, O or S; J = as A, provided that if G is R5, then E must contain at least one N; F = bond, cycloalkyl, 2-6C alkenyl, 2-6C alkenylaryl, aryl or 5-10 membered heterocyclic ring containing 1-4 of N, O or S; T = R28, NR28R29, N:R27)C(=NR31)NR28R32, C(=NR31)N(R28)(R33 , N:R30)C(=NR31)R32, C(=NR31)R33 or SO2=NR31)NR28R33; R28-R31 = H, OH, alkyl, aryl or 1-4C alkylaryl; R32 = H, alkyl, aryl or 1-4C alkylaryl; or R32+R30 or R32+R31 = 5-6 membered ring; R33 = H, alkyl, aryl or 1-4C alkylaryl; or R33+R31 = 5-6 membered ring; X, Y = O or H2; W = H, B(OR16)OR17, CO2 or a cyclic boronyl group of formula (a) or (b); R16, R17 = H, 1-3C alkyl or aryl; Z = H, COOR18, CONR18, CF3, CF2CF3 or a heterocyclic group of formula (c) or (d); R18, R19 = H, alkyl, aryl or 1-4C alkylaryl; U, V = O, S, N or NH, provided that at least one is NH; R20 = H, alkyl, 2-6C alkenyl, 3-6C alkylaryl, 2-6C alkenylaryl, 3-6C alkylheterocyclo, 2-6C alkenylheterocyclo, CF3 or CF2CF3; J = S, SO, SO2, O or NR21; R21 = H, 1-6C alkyl or benzyl; L = CH:R22)-(CH2)dCH(R23); C(R24):C(R25); o-phenylene substituted by R24 and R25; or 5-10C heterocyclic ring substituted by R24 and R25 and containing 1-4 of N, S or O; d = 0-2; R22, R23 = H, alkyl, aryl, alkylaryl, COOR26, CONR26R27, CN or CF3; R24, R25 = H, alkyl, aryl, alkylaryl, 1-4C alkoxy, halo, NO2, NR26R27, NR26COR27, OR26, OCOR26, COOR26, CONR26R27, CN, CF3, SO2NR26R27 or alkyl-OR26; R26, R27 = H, alkyl, 1-3C alkylaryl or aryl; unless specified otherwise, alkyl moieties have 1-6C and cycloalkyl moieties 3-8C.

USE - (I) are potent and highly selective **inhibitors** of **factor Xa** or **factor Xa** /prothrombinase complex and are potent and specific **inhibitors** of blood coagulation in mammals. (I) are useful for treating unstable or refractory angina, myocardial infarction, transient ischaemic attacks, thrombotic or embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis or reperfused coronary arteries, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy (all claimed). (I) are also useful for inhibiting the coagulation of biological samples (claimed) and as diagnostic agents.

Dwg.0/0

L139 ANSWER 74 OF 100 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1998-544554 [50] WPIDS
DOC. NO. CPI: C1998-170349
TITLE: New di aza cyclic **peptide** mimetic **analogues** - are selective **inhibitors** of **factor Xa** or **factor Xa**/prothrombinase complex, useful for treating e.g. angina and as diagnostic agents.
DERWENT CLASS: B02 B03 B04
INVENTOR(S): SCARBOROUGH, R M; SU, T; ZHU, B
PATENT ASSIGNEE S.: (COR T) COR THERAPEUTICS INC
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9846726	A1	19981022	(199850)*	EN	70

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

AU 9868962 A 19981111 (199912)
EP 977772 A1 20000209 (200010) EN
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6034068 B1 20000307 200015
MX 9909138 A1 20000201 200123
JP 2001523226 W 20011120 200204 80
NZ 500353 A 20020201 200214

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9846626	A1		WO 1998-US7159	19980413
AU 9868962	A		AU 1998-68962	19980413
EP 977772	A1		EP 1998-914697	19980413
			WO 1998-US7159	19980413
US 6034068	B1	Provisional	US 1997-69322P	19970414
			US 1998-58565	19980413
MX 9909138	A1		MX 1999-9138	19991006
JP 2001523226	W		JP 1998-544067	19980413
			WO 1998-US7159	19980413
NZ 500353	A		NZ 1998-500353	19980413
			WO 1998-US7159	19980413

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9868962	A	Based on	WO 9846626
EP 977772	A1	Based on	WO 9846626
JP 2001523226	W	Based on	WO 9846626
NZ 500353	A	Based on	WO 9846626

PRIORITY APPLN. INFO: US 1997-69322P 19970414; US 1998-58565 19980413

AN 1998-394554 [50] WPIDS

AB WO 9846626 A UPAB: 19981217

Diaza cyclic **peptide** mimetic **analogues** of formula (I) and their salts and optical isomers are new. R1 = H, alkyl, cycloalkyl, 1-3C alkylaryl, 1-3C alkyl-cycloalkyl or aryl; R2 =H; or R1+R2 = carbocyclic ring; m = 0-2; n = 0-6; k, p, s = 0-1; q = 0-3; r, t = 0-4; A = R3, NR3R4, N(R5)C(=NR6)NR3R7, C(=NR6)NR3R8, N(R5)C(=NR6)R7, C(=NR6)R8 or SO(=NR6)NR3R8; R3-R6 = H, OH, alkyl, aryl or 1-4C alkylaryl; R7 = H, alkyl, aryl or 1-4C alkylaryl; or R7+R5 or R7+R6 = 5-6 membered ring; R8 = H, alkyl, aryl or 1-4C alkylaryl; or R8+R6 = 5-6 membered ring; Q = bond, alkyl, cycloalkyl, 2-6C alkenyl, 2-6C alkenylaryl, aryl or a 5-10 membered heterocyclic system containing 1-4 of N, O or S; D = bond, CO, SO2, OCO, NR9SO2 or NR9CO; R9 = H, OH, alkyl, aryl or 1-4C alkylaryl; X, Y = O or H2; K = OR29 or NR29R30; R29-R30 = H, alkyl, 0-3C alkylaryl, 0-3C alkyl cycloalkyl, 0-3C alkyl heterocycle; or R29+R30 = 5-10 membered heterocyclic ring system containing 1-4 of N, O or S; E = bond, 3-8C cycloalkyl, aryl or a 5-10 membered heterocyclic ring system containing 1-4 of N, O or S; G = as for A, provided that if G is R3, then E must contain at least one N; W = H, B(OR16)OR17, COOR or a cyclic boronyl group of formula (a) or (b); R17, R16 = H, 1-3C alkyl or aryl; Z = H, COOR18, CONR18R19, CF3, CF2CF3 or a heterocyclic group of formula (c) or (d); R18, R19 = H, alkyl, aryl or 1-4C alkylaryl; U, V = O, S, N or NH, provided that at least one is NH; R10 = H, alkyl, 2-6C alkenyl, 0-6C alkylaryl, 2-6C alkenylaryl, 0-6C alkylheterocyclo, 2-6C alkenylheterocyclo, CF3 or CF2CF3; T = S, SO, SO2, O or NR21; R21 = H, alkyl or benzyl; L = CH(NR22)(CH2)dCH(R23); C(R24)=C(R25); o-phenylene substituted by R24 and

R25; or 6-10C heterocycle substituted by R24 and R25 and containing 1-4 of N, S or O; d = 0-2; R22, R23 = H, alkyl, aryl, alkylaryl, COOR26, CONR26R27, CN or CF3; R24, R25 = H, alkyl, aryl, alkylaryl, 1-4C alkoxy, halo, NO2, NR26R27, NR26COR27, OR26, COOR26, COOR26, CONR26R27, CN, CF3, SO2NR26R27 or alkyl-OR26; R26, R27 = H, alkyl, 1-3C alkylaryl or aryl; unless specified otherwise alkyl moieties have 1-6C and cycloalkyl moieties 3-6C.

USE - (I) are potent and highly selective **inhibitors** of **factor Xa** or **factor Xa** /prothrombinase complex and are potent and specific **inhibitors** of blood coagulation in mammals. (I) are useful for treating unstable or refractory angina, myocardial infarction, transient ischaemic attacks, thrombotic or embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy (all claimed). (I) are also useful for inhibiting the coagulation of biological samples (claimed) and as diagnostic agents.

Dwg.0/0

L139 ANSWER 75 OF 100 MEDLINE DUPLICATE 6

ACCESSION NUMBER: 1998128583 MEDLINE
DOCUMENT NUMBER: 98128583 PubMed ID: 9454596
TITLE: Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.
AUTHOR: Ostrem J A; al-Obeidi F; Safar P; Safarova A; Stringer S K; Patek M; Cross M T; Spochamore J; LoCascio J C; Kasireddy P; Thorpe D S; Sepetov N; Lebl M; Wildgoose P; Strop P
CORPORATE SOURCE: Selectide Corporation, Tucson, Arizona 85737, USA.. jim.ostrem@hmrag.com
SOURCE: BIOCHEMISTRY, (1998 Jan 27) 37 (4) 1053-9. Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199803
ENTRY DATE: Entered STN: 19980319
Last Updated on STN: 20000303
Entered Medline: 19980306

AB A series of low molecular weight **peptide inhibitors** of **factor Xa**, unrelated to any previously described, was identified by screening a combinatorial **peptide** library composed of L-amino acids. The minimal inhibitory sequence is a tripeptide, L-tyrosinyl-L-isoleucyl-L-arginyl, which competitively inhibits the hydrolysis of small chromogenic substrates by **factor Xa** but binds in an orientation which prevents a productive nucleophilic attack by serine 195 of the catalytic triad on the carbonyl carbon of the carboxyterminal arginine. The initial leads identified in an octamer combinatorial **peptide** library ranged in potency from 4 to 15 microM. These **peptides** were modified into **peptide** mimetics with a greater than 1000-fold increase in potency while retaining unusual selectivity for **factor Xa** over the related serine proteases thrombin, factor VIIa/tissue factor, plasmin, activated protein C, kallikrein, and trypsin. One of the most potent **analogues**, SEL 2711, with a Ki of 0.003 microM for **factor Xa** and 40 microM for thrombin, is active in in vitro and ex vivo coagulation assays, suggesting the potential application of these **inhibitors** in anticoagulant therapy.

L139 ANSWER 76 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1997046576 PCTFULL ED 20000514
TITLE (ENGLISH): ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES
TITLE (FRENCH): DERIVES DE PEPTIDYL-ARGININE ALDEHYDE ANTICOAGULANTS
INVENTOR(S): BAJUSZ, Sssndor; JUHASZ, Attila; BARABAS, Eva; FEHER, Andrsss; SZABO, Gabriella; SZELL, Erzsebet; VEGHELYI, Iren; LAVICH, Emilia; KASZAS, Eva; LANGO, J¾zsef; MORAVCSIK, Imre; SZEKERE, Agnes; TASCHLER, Zsuzsanna; TOTH, Gssbor; MOHAI, Zsuzsanna; SZALKAY, Anna Mssria; MARK, Klssra
PATENT ASSIGNEE S): GYOGYSZERKUTATO INTEZET KFT.; BAJUSZ, Sssndor; JUHASZ, Attila; BARABAS, Eva; FEHER, Andrsss; SZABO, Gabriella; SZELL, Erzsebet; VEGHELYI, Iren; LAVICH, Emilia; KASZAS, Eva; LANGO, J¾zsef; MORAVCSIK, Imre; SZEKERE, Agnes; TASCHLER, Zsuzsanna; TOTH, Gssbor; MOHAI, Zsuzsanna; SZALKAY, Anna Mssria; MARK, Klssra
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9746576	A1	19971211
DESIGNATED STATES	AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-HU28	A	19970605
PRIORITY INFO.:	HU 1996-P 96 01526		19960605

ABEN The invention relates to new peptidyl-arginine aldehyde derivatives of general formula (I):
Q-D-Xaa-Pro-Arg-H, wherein Q represents an acyl group of formula Q'-O-CO-, where Q' represents an
alkyl group with 1-3 carbon atoms, D-Xaa represents 3-cyclobutyl-D-alanyl- or
3-cyclo-pentyl-D-alanyl- group, Pro stands for L-prolyl- group, and Arg stands for L-arginyl- group,
and acid-addition salts thereof formed with an organic or inorganic acid and pharmaceutical
compositions containing the same. The compounds of formula (I) have valuable therapeutic,
particularly anticoagulant, properties together with inhibiting platelet functions and thrombosis
development.

ABFR L'invention concerne des nouveaux derives de peptidyl-arginine aldehyde de formule generale (I)
Q-D-Xaa-Pro-Arg-H, et leurs sels d'addition d'acide formes avec un acide organique ou inorganique.
Dans ladite formule (I), Q represente un groupe acyle de formule Q'-O-CO-, ou Q' represente un
groupe alkyle a 1 a 3 atomes de carbone, D-Xaa represente un groupe 3-cyclobutyl-D-alanyl- ou
3-cyclo-pentyl-D-alanyl-, Pro represente un groupe L-propyl-, et Arg un groupe L-arginyl-. Elle
porte aussi sur des compositions pharmaceutiques les contenant. Les composes de formule (I)
presentent des proprietes therapeutiques precieuses, en particulier anticoagulantes, inhibent les
fonctions des plaquettes et le developpement de la thrombose.

L139 ANSWER 77 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1997046523 PCTFULL ED 20020514
TITLE (ENGLISH): ANTICOAGULANT PEPTIDE ALDEHYDE DERIVATIVES
TITLE (FRENCH): DERIVES D'ALDEHYDE PEPTIDIQUES ANTICOAGULANTS

INVENTOR(S): BAJUSZ, Sssndor; JUHASZ, Attila; BARABAS, Eva; FEHER, Andrsss; SZABO, Gabriella; SZELL, Erzsebet; VEGHELYI, Iren; LAVICH, Emilia; KASZAS, Eva; LANGO, J¾zsef; MORAVCSIK, Imre; SZEKER, Agnes; TASCHLER, Zsuzsanna; TOTH, Ssabor; MOHAI, Zsuzsanna; SZALKAY, Anna, Mssria; MAKK, Klssra

PATENT ASSIGNEE(S): GYOGYSZERKUTATO INTEZET RT.; BAJUSZ, Sssndor; JUHASZ, Attila; BARABAS, Eva; FEHER, Andrsss; SZABO, Gabriella; SZELL, Erzsebet; VEGHELYI, Iren; LAVICH, Emilia; KASZAS, Eva; LANGO, J¾zsef; MORAVCSIK, Imre; SZEKER, Agnes; TASCHLER, Zsuzsanna; TOTH, Ssabor; MOHAI, Zsuzsanna; SZALKAY, Anna, Mssria; MAKK, Klssra

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9746523	A1	19971211

DESIGNATED STATES: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-HU27 A 19970605

PRIORITY INFO.: HU 1996-P 96 01527 19960605

ABEN This invention relates to new peptide aldehyde derivatives of general formula (I):
D-Xaa-Pro-Arg-H, wherein Xaa represents a 2-cycloheptyl-2-hydroxyacetyl or
2-cyclopentyl-2-hydroxyacetyl group, Pro represents an L-prolyl residue and Arg represents an
L-arginyl residue, their acid-addition salts formed with an organic or inorganic acid and
pharmaceutical compositions containing the same. The compounds of general formula (I) of the
invention have valuable therapeutic, particularly anticoagulant, antiplatelet and antithrombotic,
properties.

ABFR L'invention concerne des nouveaux derives d'aldehyde peptidiques de formule generale (I)
D-Xaa-Pro-Arg-H, et leurs sels d'addition d'acide formes avec un acide organique ou inorganique.
Dans ladite formule (I), Xaa represente un groupe 2-cycloheptyl-2-hydroxyacetyl ou
2-cyclopentyl-2-hydroxyacetyl, Pro represente un reste L-prolyl et Arg represente un reste
L-arginyl. L'invention porte aussi sur des compositions pharmaceutiques contenant ces derniers. Les
composes de formule generale (I) presentent des proprietes therapeutiques precieuses, notamment
anticoagulantes, antiplaquettaires et antithrombotiques.

L139 ANSWER 78 OF 100 PCTFULL COPYRIGHT 2002 Univertio

ACCESSION NUMBER: 1997043436 PCTFULL ED 20020514

TITLE (ENGLISH): A PROCESS FOR PRODUCING A RECOMBINANT POLYPEPTIDE INVOLVING THE ADDITION OF AN INHIBITOR OF METAL-DEPENDENT PROTEASES OR CHYMOTRYPSINS TO THE CELL CULTURE MEDIUM

TITLE (FRENCH): PROCEDE POUR PRODUIRE UN POLYPEPTIDE RECOMBINE COMPRENANT L'ADDITION D'UN INHIBITEUR DE PROTEASES METAL-DEPENDANTES OU DE CHYMOTRYPSINES AU MILIEU DE CULTURE CELLULAIRE

INVENTOR(S): ADAMSON, Lars; WALUM, Erik; DIXELIUS, Johan; LIMA LIE, Kristina

PATENT ASSIGNEE(S): PHARMACIA & UPJOHN AB; ADAMSON, Lars; WALUM, Erik; DIXELIUS, Johan; LIMA LIE, Kristina
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9743436	A1	19971120

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1997-SE783	A	19970513
PRIORITY INFO.:	SE 1996-9601855-1		19960514
	US 1996-60/018,874		19960529

ABEN The present invention relates to a process for reducing the detrimental influence of certain proteases on recombinant human protein and polypeptide molecules, by adding an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium. The invention also relates to a cell culture medium for cultivating cells expressing and secreting a biologically active recombinant human polypeptide containing an inhibitor of metal-dependent proteases or chymotrypsins, or a combination thereof. The invention further relates to use of recombinant factor VIII which has been produced in a cell culture medium according to the present process for the manufacture of a medicament for administration to a patient having the symptoms of hemophilia A. Also, the invention relates to a method for treatment of hemophilia A by administration of a therapeutically effective amount of recombinant factor VIII which has been produced in a cell culture medium according to the present process.

ABFR Procede pour reduire l'influence nocive de certaines proteases sur les molecules de proteines et de polypeptides humains recombines, par l'adjonction d'un inhibiteur de proteases metal-dependantes ou de chymotrypsines au milieu de culture cellulaire. L'invention concerne egalement un milieu de culture cellulaire pour cultiver des cellules exprimant et secretant un polypeptide humain recombine, biologiquement actif et contenant un inhibiteur de proteases metal-dependantes ou de chymotrypsines, ou une combinaison des deux. L'invention porte en outre sur l'utilisation du facteur recombine VIII produit dans un milieu de culture conforme au procede decrit, pour la fabrication d'un medicament pouvant etre administre a un patient presentant les symptomes de l'hemophilie A. Une methode de traitement de l'hemophilie A comprenant l'administration d'une quantite therapeutiquement active de facteur recombine VIII produit dans un milieu de culture conforme au procede decrit est egalement proposee.

L139 ANSWER 79 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1997011880 PCTFULL ED 20020514
TITLE (ENGLISH): COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS

TITLE FRENCH.: METHODES THERAPEUTIQUES COMBINEES EMPLOYANT DES ENTRAINEURS DE MONOXYDE D'AZOTE

INVENTOR(S): LAI, Ching-San
PATENT ASSIGNEE(S): MEDINOX, INC.; LAI, Ching-San

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9718805	A1	19970529
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1996-US18124	A	19961112
PRIORITY INFO.:	US 1995-8/561,594		19951121

ABEN In accordance with the present invention, there are provided combinational therapeutic methods for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide production is inhibited), the present invention employs a combination of inactivation (or inhibition) and scavenging approach whereby the stimulus of nitric oxide synthase expression is inactivated, or the production thereof is inhibited, and overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complexes render the stimulus of nitric oxide synthase expression inactive (or inhibit the production thereof), and nitric oxide harmless. The resulting complexes are eventually excreted in the urine of the host. Further in accordance with the present invention, there are provided compositions and formulations useful for carrying out the above-described methods.

ABFR Methodes therapeutiques combinees d'inactivation ou d'inhibition de formation (soit directe soit indirecte) d'especes encourageant l'expression de la monoxyde d'azote synthase, et la reduction des niveaux de monoxyde d'azote produits du fait de l'expression de la monoxyde d'azote synthase. Contrairement a la methode par inhibition decrite dans les procedes existants precedemment (c'est-a-dire, lorsque la fonction des enzymes responsables pour la production de monoxyde d'azote est inhibee), la presente invention emploie une combinaison d'inactivation (ou d'inhibition) et d'entrainement par laquelle le stimulus de l'expression de monoxyde d'azote synthase est inactive, ou sa production est inhibee, et le surplus de monoxyde d'azote est lie in vivo a un entraineur de monoxyde d'azote adapte. Les complexes ainsi produits rendent le stimulus d'expression du monoxyde d'azote synthase inactif (ou inhibent sa production), et rendent le monoxyde d'azote inoffensif. Les complexes ainsi produits sont finalement excretes dans l'urine de

l'hote. Sont decrites egalement
des compositions et preparations utiles a la mise en oeuvre des procedes
decrits plus haut.

L139 ANSWER 90 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 502[illegible] EUROPATFULL EW 199730 FS PS
TITLE: ACTIVATABLE FIBRINOLYTIC AND ANTI-THROMBOTIC PROTEINS.
AKTIVIERBARE FIBRINOLYTISCHE UND ANTITHROMBOTISCHE PROTEINE.
PROTEINES FIBRINOLYTIQUES ET ANTITHROMBOTIQUES ACTIVABLES.
INVENTOR(S): DAWSON, Keith Martyn., 30 Barnards Hill, Marlow, Bucks SL7 2NZ, GB;
EDWARDS, Richard Mark, 7 Ludlow Drive, Thame, Oxon OX9 3XS, GB;
FORMAN, Joan Mabel, 6 Margaret Road, Oxford OX3 8NG, GB
PATENT ASSIGNEE(S): BRITISH BIOTECH PHARMACEUTICALS LIMITED, Watlington Road, Cowley Oxford, OX4 5LY, GB
PATENT ASSIGNEE NO: 97061.
AGENT: Walls, Alan James et al, British Biotech Pharmaceuticals Ltd., Watlington Road, Oxford OX4 5LY, GB
AGENT NUMBER: 37214
OTHER SOURCE: EPB1997047 EP 0502968 B1 970723
SOURCE: Wila-EPS-1997-H30-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 502968	B1	19970723
'OFFENLEGUNGS' DATE:		19920916
APPLICATION INFO.:		19901207
PRIORITY APPLN. INFO.:		19891207
RELATED DOC. INFO.:	WO 90-GB1912	901207 INTAKZ
	WO 9109113	910627 INTPNR

REFERENCE PAT. INFO.:

EP 211399	A	EP 227938	A
EP 242009	A	EP 297882	A
EP 304013	A	EP 319944	A
EP 323143	A	EP 330700	A
EP 338541	A	WO 89-01036	A
WO 89-06239	A	WO 90-10081	A
WO 90-13640	A	WO 91-08297	A

REF. NON-PATENT-LIT.: Biochemistry, vol. 29, 1990, American Chemical Society, D.C. Davidson et al.: "plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens", pages 3585-3590 Chemical Abstracts, vol. 103, 1985, Columbus, Ohio, US); J.Y. Chang: "Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate", see page 412 Archives of Biochemistry and Biophysics, vol. 271, no. 2, June 1989, Academic Press, Inc.; T. White-Fillet-Smith et al.: "Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system", pages 390-399 Proc. Natl. Acad. Sci. USA, vol. 79, October 1982; T. Miyata et al.: "Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine 600 by threonine in the active site", pages 6132-6136

L139 ANSWER 81 OF 100 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1997-340537 [31] WPIDS
DOC. NO. CPI: C1997-109336
TITLE: New peptide analogues derived from imidazolyl-boronic acid - useful as trypsin-like serine protease inhibitors, especially for treatment of thrombosis or as anticoagulants.
DERWENT CLASS: B03
INVENTOR(S): CACCIOLA, J; DOMINGUEZ, C; FEVIG, J M
PATENT ASSIGNEE(S): (DUPO) DUPONT MERCK PHARM CO
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 5639739	A	19970617	(199731)*		12

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5639739	A	US 1995-409573	19950324

PRIORITY APPLN. INFO: US 1995-409573 19950324
AN 1997-340537 [31] WPIDS
AB US 5639739 A UPAB: 19970731
Imidazolyl-substituted boronic acid derivative **peptide analogues** of formula (I) and their salts are new. R1 = CO-CH((CH2)nR4)-NR5R6, CO-CR8R9-(CH2)p-R4 or CO-CR8R9-W-(CH2)r-R4; R2 = CH2-C(R12)2-aryl or (1-aryl-(3-6C) cycloalkyl)-methyl; R3 = H; or R1R3N-CHR8-CO = 1-(R1)-pyrrolidin-2-ylcarbonyl; R4 = aryl or 3-8C cycloalkyl; R5 = H or -(alkyl)-aryl; R6 = COR7, COOR7, CONR5R7, SO2R7 or SO2NR5R7; R7 = alkyl or (alkyl)-aryl; R8, R9 = H, alkyl, aryl or (alkyl)-aryl, or R8 + R9 = 3-7C cycloalkyl; R12 = 1-5C alkyl or 1-5C perfluoroalkyl; aryl = phenyl (optionally substituted by 1-3 of F, Cl, Br, I, alkyl, methylenedioxy, NO2, CF3, S(O)r-alkyl, CN, OH, NH2, mono- or di-alkylamino, NHCO-alkyl, (CH2)p-COO-alkyl and phenyl); T = NH2; Y1,Y2 = OH, or BY1Y2 = a cyclic ester derived from pinanediol, pinacol, 1,2-ethanediol, 1,2- or 1,3-propanediol, 2,3-butanediol, 1,2-diisopropylethanediol, 5,6-decanediol or 1,2-dicyclohexylethanediol; n = 0 or 1; p = 0-3; r = 0-2; s = 1-4; t = 1-3; alkyl moieties have 1-4C unless specified otherwise.
USE - (I) inhibit trypsin-like serine proteases e.g. Factors II, X, VII, XII, kallikrein, tissue plasminogen activators, urokinase-like plasminogen activator, plasmin, complement system enzymes, acrosin (required for fertilisation) or pancreatic trypsin, especially thrombin, factor X and factor VII. They are useful for treatment of aberrant proteolysis e.g. consumptive coagulopathy, inflammation, pancreatitis, hereditary angioedema or especially thrombosis (including arterial thrombosis associated with myocardial infarction and other clotting disorders); and as anticoagulants in the processing of blood for therapeutic or diagnostic purposes or for the production of blood products or fragments. (I) are especially used for treatment of thrombosis by inhibiting trypsin-like serine proteases of the coagulation cascade. The dosage of (I) is 0.01-10 mg/kg, orally, parenterally or intravenously.
ADVANTAGE - (I) have potent trypsin-like protease inhibiting activity i.e. Ki values of < 20 nM for **inhibition** of the human blood coagulation proteases thrombin, **Factor Xa** and Factor VIIa; and may be effective against clotting disorders against which conventional anticoagulants (e.g. heparin) are ineffective.
Dwg.0/0

L139 ANSWER 82 OF 100 MEDLINE DUPLICATE 7

ACCESSION NUMBER: 1999102699 MEDLINE
DOCUMENT NUMBER: 99102699 PubMed ID: 9841205
TITLE: New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.
AUTHOR: Lee S L; Alexander R S; Smallwood A; Trievel R; Mersinger L; Weber P C; Kettner C
CORPORATE SOURCE: Chemical and Physical Sciences, DuPont Merck Pharmaceutical Company, P. O. Box 80500, Wilmington, Delaware 19880-0500, USA.
SOURCE: BIOCHEMISTRY, (1998 Oct 20) 36 (43) 13180-6.
Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: PDB-1AUJ
ENTRY MONTH: 199911
ENTRY DATE: Entered STN: 19991224
Last Updated on STN: 20000303
Entered Medline: 19991117

AB Highly effective thrombin **inhibitors** have been obtained by preparing boronic acid **analogues** of m-cyano-substituted phenylalanine and its incorporation into **peptides**. The cyano group enhances binding by several orders of magnitude. For example, Ac-(D)Phe-Pro-boroPheOH binds to thrombin with a Ki of 320 nM and the Ki of Ac-(D)Phe-Pro-boroPhe(m-CN)-OH is 0.79 nM. Protein crystal structure determination of trypsin complexed to H-(D)Phe-Pro-boroPhe(m-CN)-OH indicates that the aromatic side chain is bound in the P1 binding site and that the cyano group can act as a H-bond acceptor for the amide proton of Gly219. Enhanced binding for **inhibitors** containing the m-cyano group was observed for coagulation **factor Xa** and for the factor VIIa.tissue factor complex [Ki values of Ac-(D)Phe-Pro-boroPhe(mCN)-OH are 760 and 9.3 nM, respectively]. This result is consistent with the sequence homology of these two enzymes in the P1 binding site. Two enzymes lacking the strict homology in the P1 binding site, pancreatic kallikrein and chymotrypsin, did not exhibit significantly enhanced binding.

L139 ANSWER 83 OF 100 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 8
ACCESSION NUMBER: 97147964 EMBASE
DOCUMENT NUMBER: 1997147964
TITLE: Peptide argininol 'inverse substrates' of anisic acid: Novel inhibitors of the trypsin-like serine proteinases.
AUTHOR: Lynas J.F.; Walker B.
CORPORATE SOURCE: B. Walker, Centre Peptide/Protein Engineering, School of Biology/Biochemistry, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, United Kingdom. brian.walker@qub.ac.uk
SOURCE: Bioorganic and Medicinal Chemistry Letters, (1997) 7/9 (1133-1138).
Refs: 14
ISSN: 0960-894X CODEN: BMCLE8
PUBLISHER IDENT.: S 0960-894X(97)00174-1
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB **Peptides** containing a C-terminal argininol residue linked, via an ester bond, to anisic acid have been synthesized as putative **inhibitors** of trypsin-like serine proteinases. The most potent **analogue**, Boc-Ile-Glu-Gly-Arg-.PSI.-CH2-O -CO-C6H4-OMe, that was

modelled on a known recognition sequence for the clotting enzyme **factor Xa**, was found to inactivate the protease with a second-order rate constant of .approx. 4.5 x 105 M-1.min-1.

L139 ANSWER 84 OF 100 MEDLINE
ACCESSION NUMBER: 97404080 MEDLINE
DOCUMENT NUMBER: 97404081 PubMed ID: 9262116
TITLE: Current status on new anticoagulant and antithrombotic drugs and devices.
COMMENT: Comment in: Curr Opin Pulm Med. 1997 Jul;3(4):265-7
AUTHOR: Walenga J M; Fareed J
CORPORATE SOURCE: Loyola University Medical Center, Department of Pathology, Maywood, IL 60153, USA.
SOURCE: CURRENT OPINION IN PULMONARY MEDICINE, (1997 Jul) 3 (4) 291-302. Ref: 96
Journal code: 9503765. ISSN: 1070-5287.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199709
ENTRY DATE: Entered STN: 19971013
Last Updated on STN: 19971013
Entered Medline: 19970926

AB Several new drugs for the management of thromboembolic disorders have recently become available. Low-molecular-weight heparins are being evaluated for the prophylaxis of medical and surgical deep venous thrombosis and pulmonary embolism; for the treatment of pre-existing thrombosis; and for cases of coronary syndrome (unstable angina, myocardial infarction), thrombotic and ischemic stroke, interventional cardiology, pregnancy, cancer, and transplantation-associated thrombosis. A chemically synthesized heparin pentasaccharide, which has purely anti-**factor Xa** activity and does not induce thrombocytopenia, is also in clinical trial. Thrombin **inhibitors**, such as hirudin and argatroban, are a practical anticoagulant substitute where heparin cannot be used. They are also useful for the management of coronary syndrome and as adjunct therapy. The antiplatelet agent ticlopidine and its **analogue**, clopidogrel, which does not produce blood dyscrasia, are effective for the secondary prevention of thrombotic stroke and the management of combined arterial thrombotic syndromes. Glycoprotein-targeting antibodies, synthetic derivatives, and **peptides** (some of which are orally bioavailable) have added a new dimension to the management of arterial thrombosis and high-risk patients having angioplasty. Plasma-derived agents, such as antithrombin III, are available for the management of thrombophilia and disseminated intravascular coagulation. Compression devices and the foot pump, alone and in combination with pharmacologic agents, have been used successfully. Combination therapy using various agents in different proportions have also been found useful. Although there is much enthusiasm in this quickly developing area and clinical trials are demonstrating the antithrombotic efficacy of the new drugs, safety considerations require additional clinical validation. Long-term outcomes and costs also need to be addressed objectively.

L139 ANSWER 85 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996038470 PCTFULL ED 20020314
TITLE (ENGLISH): IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE SERINE PROTEASE DERIVES DE IMIDAZO[1,5A]PYRIDINE
INVENTOR(S): OTTENHEYM, Henricus, Carl, Joseph; ADANG, Anton, Egbert, Peter; PETERS, Jacobus, Albertus, Maria
PATENT ASSIGNEE(S): AKZO NOBEL N.V.; OTTENHEYM, Henricus, Carl, Joseph;

ADANS, Anton, Egbert, Peter; PETERS, Jacobus, Albertus, Maria
LANGUAGE OF PUBL.: German
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9638470	A1	19961205
DESIGNATED STATES	AU BR CA CN CZ HU JP KR MX NO NZ PL RU SG TR US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1996-EP2298	A	19960529
PRIORITY INFO.:	AT 1995-95201448.4		19950602

ABEN The invention relates to an imidazo[1,5a]pyridine derived serine protease inhibitor comprising a unit having general formula (I) wherein R1 is hydrogen, lower alkyl or an acyl group; R2 is hydrogen or lower alkyl; R3 and R4 are independently hydrogen, lower alkyl or together form =CH-NR5R6, R5 and R6 being lower alkyl. The compounds are serine protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

ABFR Cette invention concerne un inhibiteur de serine protease derive de imidazo[1,5a]pyridine, lequel inhibiteur comprend une unite correspondant a la formule generale (I) ou R1 represente hydrogene, alkyle inferieur ou un groupe acyle; R2 represente hydrogene ou alkyle inferieur; R3 et R4 representent independamment hydrogene, alkyle inferieur ou forment ensemble =CH-NR5R6, R5 et R6 representant un alkyle inferieur. Ces composes sont des inhibiteurs de serine protease et peuvent etre utilises dans le traitement et la prevention de thromboses et de maladies associees a la thrombine.

L133 ANSWER 86 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996030035 PCTFULL ED 20020514
TITLE (ENGLISH): 'beta'-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS
TITLE (FRENCH): IMITATEURS DE FEUILLETS 'beta' ET LEUR EMPLOI COMME INHIBITEURS DE PEPTIDES OU DE PROTEINES BIOLOGIQUEMENT ACTIFS
INVENTOR(S): KAHN, Michael
PATENT ASSIGNEE(S): MOLECUMETICS LTD.; KAHN, Michael
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9630035	A1	19961003
DESIGNATED STATES	AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1996-US4044	A	19960325
PRIORITY INFO.:	US 1995-8/411,518		19950324
	US 1995-8/549,096		19951027

ABEN There are disclosed 'beta'-sheet mimetics and methods relating to the same for imparting or stabilizing the 'beta'-sheet structure of a peptide, protein or molecule. In one aspect, the 'beta'-sheet mimetics are covalently attached at the end or within the

length of the peptide or
protein. The 'beta'-sheet mimetics have utility as inhibitors of one or more of proteases, kinases,
CAAX, peptides binding to SH2 domains and MHC-I and/or MHC-II presentation of peptides to T cell
receptors in warm-blooded animals.

ABFR La presente invention concerne des mimetiques de feuillets 'beta' et des procedes s'y
rapportant permettant de communiquer ou stabiliser la structure en feuillets 'beta' d'un peptide,
d'une proteine ou d'une molecule. Dans l'une des variantes, les mimetiques de feuillets 'beta' sont
fixes par covalence a l'extremite du peptide ou de la proteine, ou entre ses extremites. Ces
imitateurs de feuillets 'beta' conviennent comme inhibiteurs d'une ou plusieurs proteases, kinases,
CAAX, de peptides se liant a des domaines SH2 et de la presentation MHC-I et/ou MHC-II de peptides a
des recepteurs de cellules T chez les animaux a sang chaud.

L139 ANSWER 87 OF 100 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996025427 PCTFULL ED 20020514
TITLE (ENGLISH): SERINE PROTEASE INHIBITORS
TITLE (FRENCH): INHIBITEURS DE SERINES PROTEASES
INVENTOR(S): GREEN, Donovan, St. Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph
PATENT ASSIGNEE(S): ELLEMAN PHARMACEUTICALS LIMITED; GREEN, Donovan, St. Clair; ELGENDY, Said, Mohammed, Anwr, Ahmed; PATEL, Geeta; SCULLY, Michael, Finbarr; GOODWIN, Christopher, Andrew; KAKKAR, Vijay, Vir; DEADMAN, John, Joseph
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9625427	A1	19960822
DESIGNATED STATES	AU CA JP NZ US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1996-GB352	A	19960215
PRIORITY INFO.:	GB 1995-9502985.6		19950216

ABEN Peptide inhibitors of serine proteases, especially thrombin, in which the P1-P2 natural amide
linkage is replaced by another bond. Exemplary thrombin inhibitors are of the formula:
X-(aa3)-(aa2)-'psi'-(aa1)-Z wherein X is H or a substituent on the N-terminal amino group, aa3 is a
hydrophobic amino acid such as Phe, aa2 is Pro, aa1 is Arg or an Arg analogue such as
methoxypropylglycyl, Z is -COOH or a heteroatom acid group, such as boronate, or a derivative of
either, and 'PSI' is a non-amide linkage, typically containing up to 5 in-chain atoms, such as
-CO-, -CH2O-, NHCO- or -CH2-CH2-.

ABFR On decrit des inhibiteurs peptidiques de serines proteases, notamment la thrombine, dans
lesquels la liaison amide naturelle P1-P2 est remplacee par une autre liaison. A titre d'exemple, on
decrit des inhibiteurs de thrombine possedant la formule
X-(aa3)-(aa2)-'PSI'-(aa1)-Z dans laquelle X
represente H ou un substituant sur le groupe amino N-terminal, aa3 represente un acide amine
hydrophobe tel que Phe, aa2 represente Pro, aa1 represente Arg ou un analogue de Arg tel que

methoxypropylglycyle, Z represente -COOH ou un groupe acide d'heteroatomes, tel qu'un boronate, B, un derive de l'un ou de l'autre, et 'PGI' represente une liaison non amide, contenant typiquement jusqu'a 5 atomes en chaine, tels que -CO2-, -CH2O-, NHCO- ou -CH2-CH2 .

L139 ANSWER 98 OF 100 POTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996010639 POTFULL ED 20020514
TITLE (ENGLISH): ALPHA-1-ANTITRYPSIN AND ANTITHROMBINE-III VARIANTS
TITLE (FRENCH): VARIANTES DE L''alpha'-1-ANTITRYPSINE ET DE L'ANTITHROMBINE III
INVENTOR(S): HOPKINS, Paul, C., B.; CARRELL, Robin; CROWTHER, Damian; STONE, Stuart
PATENT ASSIGNEE(S): PPL THERAPEUTICS (SCOTLAND) LTD.; HOPKINS, Paul, C., B.; CARRELL, Robin; CROWTHER, Damian; STONE, Stuart
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9610639	A1	19960411
DESIGNATED STATES	AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1995-GB2155	A	19950912
PRIORITY INFO.:	GB 1994-9419804.1		19940930
	GB 1995-9502138.2		19950203

ABEN Serine protease inhibitors (serpins) are provided which: (a) are substantially incapable of inhibiting activated protein C; (b) do not require activation by heparin; and (c) comprise a target sequence capable of interacting with the proteolytic active site of thrombin thereby to inhibit the proteolytic activity of thrombin. Preferred serpins are muteins or variants of 'alpha'1-antitrypsin, modified by inclusion of a thrombin-specific target sequence derived from antithrombin-III (AT-III). Such serpins have the specificity and irreversibility of action of AT-III, but do not have to be co-administered with heparin.

ABFR On decrit des innibiteurs de serine protease (serpines) qui: a) sont en pratique incapables d'inhiber la proteine C activee, b) n'exigent pas d'activation par l'heparine, et c) comprennent une sequence cible pouvant interagir avec le site actif proteolytique de la thrombine pour inhiber l'activite proteolytique de cette derniere. Les serpines preferees sont des muteines ou des variantes de l''alpha'-1-antitrypsine, modifiees par l'inclusion d'une sequence cible, specifique de la thrombine, derivee de l'antithrombine-III (AT-III). Ces serpines presentent la specificite et l'irreversibilite propres a l'action de l'AT-III, mais elles n'exigent pas d'etre co-administrees avec de l'heparine.

L139 ANSWER 99 OF 100 POTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 1996014378 POTFULL ED 20020514
TITLE (ENGLISH): RECOMBINANT PRODUCTION OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS
TITLE (FRENCH): PRODUCTION PAR RECOMBINAISON DE PEPTIDES ET PROTEINES BIOLOGIQUEMENT ACTIFS
INVENTOR(S): WILLIAMS, Jon, I.; PIERCE, James, C.; ANDERSON, S.,

Mark; KARI, Prasad
PATENT ASSIGNEE S.: MAGAININ PHARMACEUTICALS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9604373	A2	19960215
DESIGNATED STATES	AU CA JP KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1995-US10219	A	19950726
PRIORITY INFO.:	US 1994-282,010		19940729

ABEN The present invention relates to the recombinant production of amphiphilic peptides with biologically and therapeutically significant activities. In one embodiment, this invention relates to recombinantly producing an amphiphilic peptide by providing a protease-deficient microbial host transformed with an expression vector containing DNA that encodes the amphiphilic peptide under the control of a regulatory sequence operable in the microbial host and expressing the amphiphilic peptide in the tranformed microbial host. In another embodiment, this invention relates to providing an E. coli protease-deficient K-12 cell transformed with a vector that expresses a cleavable fusion protein comprising at least part of a carbohydrate binding protein and the amphiphilic peptide in the cell, expressing the fusion protein in the cell, and cleaving the fusion protein to obtain the amphiphilic peptide substantially free of carbohydrate binding protein residues. The biologically active amphiphilic peptide so produced can be further treated chemically or enzymatically to obtain a chemically distinct amphiphilic peptide with improved biological and therapeutic properties.

ABFR L'invention concerne la production par recombinaison de peptides amphiphiles qui presentent des activites biologiques et therapeutiques significatives. Une variante de cette invention concerne la production par recombinaison d'un peptide amphiphile, qui consiste a produire un hote microbien presentant une deficience en protease, transforme a l'aide d'un vecteur d'expression contenant un ADN codant ce peptide amphiphile sur commande d'une sequence regulatrice qu'on peut activer dans l'hote microbien, et a exprimer ce peptide amphiphile dans l'hote microbien transforme. Une autre variante de l'invention consiste a prendre une cellule K-12 d'E. coli, presentant une deficience en protease, transformee a l'aide d'un vecteur qui exprime une proteine de fusion qu'on peut couper et qui comprend au moins une partie d'une proteine se liant a un glucide et le peptide amphiphile present dans la cellule, a exprimer cette proteine de fusion dans la cellule et a la couper pour donner un peptide amphiphile pratiquement depourvu de residu de la proteine se liant a un glucide. Le peptide amphiphile biologiquement actif ainsi obtenu peut alors etre traite par voie chimique ou enzymatique, ce qui permet d'obtenir un peptide amphiphile chimiquement different dote de proprietes biologiques et therapeutiques ameliorees.

L139 ANSWER 41 OF 100 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 1996000541 PCTFULL ED 20020514
TITLE (ENGLISH): AN EXTERNAL URINARY CATHETER AND A HOSE CONNECTOR FOR CONNECTION THEREWITH
TITLE (FRENCH): CATHETER EXTERNE POUR LES URINES ET RACCORD DE CONDUITE DESTINE A CE CATHETER
INVENTOR(S): JENSEN, Thomas, Dam
PATENT ASSIGNEE(S): COLOPLAST A/S; JENSEN, Thomas, Dam
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9600541	A1	19960111

DESIGNATED STATES: AM AT AU BB BG BR BY CA CH CN CZ DE DK DK EE ES FI FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:	WO 1995-DK234	A	19950612
PRIORITY INFO.:	DK 1994-774/94		19940629

ABEN An external catheter comprises a sheath essentially formed as a shaft and a constricted drainage tube part (1) integrated therewith for connection with a nose connector (5) which is connected to a draining hose. In order to facilitate the mounting of the drainage tube part (1) on the hose connector (5), an end portion of the drainage tube part at the orifice thereof is divided into at least two sections (2-3).

ABFR Un catheter externe pour les urines comprend une gaine venue d'une piece avec une partie resserree (1) formant un tube de drainage, ce systeme etant raccorde par un raccord (5) a une conduite de drainage. Pour faciliter le montage de la partie resserree (1) formant un tube de drainage sur le raccord (5), une portion terminale du tube de drainage au niveau de son orifice est divisee en deux sections (2-3) au moins.

L139 ANSWER 91 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 489070 EUROPATFULL EW 199617 FS PS
TITLE: NOVEL INHIBITORS OF THROMBIN.
NEUE THROMBININHIBITOREN.
NOUVEAUX INHIBITEURS DE THROMBINE.
INVENTOR(S): MARAGANORE, John, M., 94 Patrick Road, Tewksbury, MA 01876, US;
FENTON, John, W., II, P.O. Box 37 Route 66, Maiden Bridge, NY 12116, US;
KLINE, Toni, 47 Hayes Street, Cambridge, MA 02139, US
PATENT ASSIGNEE(S): BIOGEN, INC., 14 Cambridge Center, Cambridge Massachusetts 02142, US;
HEALTH RESEARCH INCORPORATED, 66 Hackett Boulevard, 3rd Floor, Albany NY 12209, US
PATENT ASSIGNEE NO: 1149451; 520424
AGENT: VOSSIUS & PARTNER, Postfach 86 07 67, D-81634 Muenchen, DE
AGENT NUMBER: 101311
OTHER SOURCE: EPB19960626 EP 0489070 B1 960424
SOURCE: Wila-EPS-1996-H17-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R IT; R LI; R LU; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT *Internationale Anmeldung

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	BE 899870	B1	19960424
'OFFENLEGUNGS' DATE:			19920610
APPLICATION INFO.:	BE 1990-912754		19900917
PRIORITY APPLN. INFO.:	US 1989-395482		19890818
	US 1990-549388		19900706
RELATED DOC. INFO.:	WO 90-US4642	900817	INTAKZ
	WO 9102750	910307	INTPNR

REFERENCE PAT. INFO.: BE 876014 A; EP 291931 A; BE 891492 A; EP 333356 A; EP 341607 A; EP 357242 A; WO 79-00638 A

REF. NON-PATENT-LIT.: Chemical Abstracts, volume 107, no. 11, 14 September 1987, (Columbus, Ohio, US), Krstenansky, John L. et al.: "Anticoagulant peptides. Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin", see page 733, abstract 97113c, & J. Med. Chem. 1987, 30(9), 1688-169 Chemical Abstracts, volume 108, no. 19, 9 May 1988, (Columbus, Ohio, US), Owen, Thomas J. et al.: "N-Terminal requirements of small peptide anticoagulants based on hirudin", see page 701, abstract 167961z, & J. Med. Chem. 1988, 31(5), 1009-101 The Journal of Biological Chemistry, Vol. 264, No. 15, May 1989 John M. Maraganore et al.: "Anticoagulant Activity of Synthetic Hirudin Peptides" Thrombosis and Haemostasis, Vol. 63, No. 2, 1990 John L. Krstenansky et al.: "Development of MDL 26,050, a Small Stable Antithrombin AgentBased on a Functional Domain of the Leech Protein, Hirudin" Blood, Vol. 75, No. 2, January 1990 Joseph A. Jakubowski et al.: "Inhibition of Coagulation and Thrombin-Induced Platelet Activities by a Synthetic Dodecapeptide Modeled on the Carboxy-Terminus of Hirudin"

L139 ANSWER 92 OF 100 ADISALERTS COPYRIGHT 2002 (ADIS)

ACCESSION NUMBER: 1996:39037 ADISALERTS

DOCUMENT NUMBER: 300416693

TITLE: Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis
ADIS TITLE: Bivalirudin, CVS 995, desirudin: pharmacodynamics.; Antithrombotic effects, comparison with tick anticoagulant peptide and nadroparin calcium; Animal study

AUTHOR: Biemond B J; Friederich P W; Levi M; Vlasuk G P; Buller H R; et al

CORPORATE SOURCE: University of Amsterdam, Amsterdam, The Netherlands; Corvas International, San Diego, California, USA

SOURCE: Circulation (Jan 1, 1996), Vol. 93, pp. 153-160

DOCUMENT TYPE: (Animal)

REFERENCE: Antithrombotics (Summary): Alert no. 2, 1996

FILE SEGMENT: Summary

LANGUAGE: English

WORD COUNT: 656

L139 ANSWER 93 OF 100 MEDLINE DUPLICATE 9

ACCESSION NUMBER: 96049146 MEDLINE

DOCUMENT NUMBER: 96049146 PubMed ID: 7592953

TITLE: Peptide-derived transition state analogue inhibitors of

thrombin; synthesis, activity and selectivity.
AUTHOR: Jetten M; Peters C A; Visser A; Brootenhuis P D; van Nispen J W; Ottenheijm H C
CORPORATE SOURCE: N.V. Organon, Oss, The Netherlands.
SOURCE: BIOORGANIC AND MEDICINAL CHEMISTRY, (1995 Aug) 3 8 1099-114.
Journal code: 9413298. ISSN: 0968-0896.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199512
ENTRY DATE: Entered STN: 19960124
Last Updated on STN: 19960124
Entered Medline: 19951218

AB In a study to combine the transition state **analogue** concept with the principle of catalytic site spanning, a series of **peptide** -derived transition state **analogue** (TSA) **inhibitors** of thrombin has been synthesized and tested. In the sequence H-D-Phe-Pro-Arg-Gly-OH (2) the Arg-Gly amide bond has been replaced by three classes of transition state **analogues**, being the ketomethylene, the hydroxyethylene and the hydroxymethylene amide bond replacements. Compound 13a, in which the amide bond has been replaced by the ketomethylene group, was found to be the most potent thrombin **inhibitor** of the series studied. Subsequently, penta- and hexapeptide sequences with good affinity for thrombin were developed, i.e. H-D-Phe-Pro-Arg-Gly-Phe-OH (16) and H-D-Phe-Pro Arg-Gly-Phe-Lys-OH (26). In these sequences the Arg-Gly amide bond was then replaced by the ketomethylene group. The resulting compounds 43a and 47a, respectively, were evaluated in vitro as **inhibitors** of thrombin and **factor Xa**. Compound 47a was found to be the most potent thrombin **inhibitor** of the series studied (Ki = 29 nM). The combination of the transition state **analogue** concept and the principle of **peptide** elongation (tetrapeptide--hexapeptide) yields thrombin **inhibitors** of high potency and selectivity. The effects of these two alterations reinforce each other indicating a synergistic effect. This might be rationalized by entropy factors.

L139 ANSWER 94 OF 100 MEDLINE DUPLICATE 10
ACCESSION NUMBER: 95369143 MEDLINE
DOCUMENT NUMBER: 95369143 PubMed ID: 7641602
TITLE: Novel antithrombotic drugs in development.
AUTHOR: Verstraete M; Zoldhelyi P
CORPORATE SOURCE: Center for Molecular and Vascular Biology, University of Leuven, Belgium.
SOURCE: DRUGS, (1995 Jun) 49 (6) 856-84. Ref: 229
Journal code: 7600076. ISSN: 0012-6667.
PUB. COUNTRY: New Zealand
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199509
ENTRY DATE: Entered STN: 19950930
Last Updated on STN: 19950930
Entered Medline: 19950920

AB Platelet activation plays a critical role in thromboembolic disorders, and aspirin remains a keystone in preventive strategies. This remarkable efficacy is rather unexpected, as aspirin selectively inhibits platelet aggregation mediated through activation of the arachidonic-thromboxane pathway, but not platelet aggregation induced by adenosine diphosphate (ADP), collagen and low levels of thrombin. This apparent paradox has stimulated investigations on the effect of aspirin on eicosanoid-independent effects of aspirin on cellular signalling. It has also

fostered the search for antiplatelet drugs inhibiting platelet aggregation at other levels than the acetylation of platelet cyclo-oxygenase, such as thromboxane synthase **inhibitors** and thromboxane receptor antagonists. The final step of all platelet agonists is the functional expression of glycoprotein GP IIb/IIIa on the platelet surface, which ligates fibrinogen to link platelets together as part of the aggregation process. Agents that interact between GPIIb/IIIa and fibrinogen have been developed, which block GPIIb/IIIa, such as monoclonal antibodies to GPIIb/IIIa, and natural and synthetic **peptides** disintegrins containing the Arg-Gly-Asp (RGD) recognition sequence in fibrinogen and other adhesion macromolecules. Also, some non-**peptide** RGD mimetics have been developed which are orally active prodrugs. Stable **analogues** of prostacyclin, some of which are orally active, are also available. Thrombin has a pivotal role in both platelet activation and fibrin generation. In addition to natural and recombinant human antithrombin III, direct antithrombin III-independent thrombin **inhibitors** have been developed as recombinant hirudin, hirulog, argatroban, borarginine derivatives and single stranded DNA oligonucleotides (aptanes). Direct thrombin **inhibitors** do not affect thrombin generation and may leave some 'escaping' thrombin molecules unaffected. **Inhibition** of **factor Xa** can prevent thrombin generation and disrupt the thrombin feedback loop that amplifies thrombin production.

L139 ANSWER 95 OF 100 MEDLINE DUPLICATE 11
ACCESSION NUMBER: 97023654 MEDLINE
DOCUMENT NUMBER: 97023654 PubMed ID: 8869014
TITLE: New developments in antiplatelet and antithrombotic therapy.
AUTHOR: Verstraete M
CORPORATE SOURCE: Center for Molecular and Vascular Research, University of Leuven, Belgium.
SOURCE: EUROPEAN HEART JOURNAL, (1995 Nov) 16 Suppl L 16-23. Ref: 76
Journal code: 8006263. ISSN: 0195-668X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199701
ENTRY DATE: Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19970109

AB Several agents which inhibit platelet aggregation (aspirin, ticlopidine, dipyridamole), and anticoagulants (vitamin K antagonists, unfractionated heparin, low molecular weight heparins and heparinoids) are in clinical use. The search for more effective antiaggregating agents has resulted in the development of clopidogrel, a chemical **analogue** of ticlopidine with minimal bone-marrow suppressing effects, thromboxane synthase **inhibitors** and receptor blockers, and antagonists of platelet receptor glycoproteins Ib and IIb/IIIa. In addition there is increasing therapeutic experience with chimeric monoclonal antibodies against the platelet receptors, glycoprotein IIb/IIIa, and, to a minor extent, with synthetic **peptides** or non-**peptide** **inhibitors** against the same receptors. Although new anticoagulants have become available, their efficacy has only been tested in animal models of thrombosis: tissue factor pathway **inhibitor**, **factor Xa inhibitors** (recombinant tick anticoagulant **peptide**, antistasin, natural pentasaccharide and DX-9065a), recombinant thrombomodulin and recombinant protein C have been tested in this manner. Considerable clinical progress has been made with direct thrombin **inhibitors**, such as recombinant hirudin and hirulog which appear to be effective antithrombotic agents in patients.

There is also clinical experience with argatroban, an arginine derivative which is a competitive antagonist to thrombin. However, PPACK, a tripeptide synthetic compound which irreversibly blocks the active catalytic site of thrombin, has not been investigated in the clinical setting.

L139 ANSWER 96 OF 100 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 339942 EUROPATFULL EW 199444 FS DS STA B
TITLE: Aprotinin analogues and process for the production thereof.
Aprotinin-Analoge und Verfahren zu ihrer Herstellung.
Analogues d'aprotinin et procede pour leur production.
INVENTOR(S): Norris, Kjeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK;
Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm, DK
PATENT ASSIGNEE(S): NOVO-NORDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK
PATENT ASSIGNEE NO: 1099510
AGENT: Brown, John David et al, FORRESTER & BOEHMERT
Widenmayerstrasse 4/I, D-8000 Muenchen 22, DE
AGENT NUMBER: 08811
OTHER SOURCE: ESP1989046 EP 0339942 A2 891102
SOURCE: Wila-EPZ-1989-H44-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 339942	A2	19891102

'OFFENLEGUNGS' DATE: 19891102
APPLICATION INFO.: EP 1989-304122 19890425
PRIORITY APPLN. INFO.: DK 1988-2254 19880426

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 339942 EUROPATFULL EW 199412 FS PS STA B
TITLE: Aprotinin analogues and process for the production thereof.
Aprotinin-Analoge und Verfahren zu ihrer Herstellung.
Analogues d'aprotinin et procede pour leur production.
INVENTOR(S): Norris, Kjeld, Ahlmanns Alle 34, DK-2900 Hellerup, DK;
Petersen, Lars Christian, Havrevej 4, DK-2960 Horsholm, DK
PATENT ASSIGNEE(S): NOVO NORDISK A/S, Novo Alle, DK-2880 Bagsvaerd, DK
PATENT ASSIGNEE NO: 231781
AGENT: Thalsoe-Madsen, Kine Birgit et al, c/o Novo Nordisk A/S
Novo Alle, DK-2880 Bagsvaerd, DK
AGENT NUMBER: 61421
OTHER SOURCE: EPB1994031 EP 0339942 B1 940323
SOURCE: Wila-EPS 1994-H12-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 339942	B1	19940323

'OFFENLEGUNGS' DATE: 19891102

APPLICATION INFO.: EP 1999-304122 19990425
PRIORITY APPLN. INFO.: DK 1998-2254 19980426
REFERENCE PAT. INFO.: EP 132732 A EP 238993 A
EP 244627 A EP 307942 A
REF. NON-PATENT-LIT.: SCIENCE, vol. 225, 13th March 1987, pages 1370-1373; C.B. MARKS et al.: "Mutants of bovine pancreatic trypsin inhibitor lacking cysteines 14 and 38 can fold properly" BIOCHEMISTRY, vol. 16, no. 8, 19th April 1977, pages 1531-1541, The American Chemical Society; N.H.Tan et al.: "Synthesis and characterization of a pancreatic Trypsin inhibitor homologue and a model inhibitor"

L139 ANSWER 97 OF 100 MEDLINE DUPLICATE 12
ACCESSION NUMBER: 94355559 MEDLINE
DOCUMENT NUMBER: 94355559 PubMed ID: 8075912
TITLE: Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system.
AUTHOR: Claeson G
CORPORATE SOURCE: Thrombosis Research Institute, London, UK.
SOURCE: BLOOD COAGULATION AND FIBRINOLYSIS, (1994 Jun) 5 (3) 411-36. Ref: 214
Journal code: 9102551. ISSN: 0957-5235.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199410
ENTRY DATE: Entered STN: 19941013
Last Updated on STN: 20000303
Entered Medline: 19941006

AB The synthesis of **peptides** as imitations of the thrombin cleavage site of fibrinogen has led to sequences with affinity for the enzyme. These **peptides** were first developed as chromogenic and fluorogenic substrates for thrombin. The same idea was also used to generate **peptide** substrates for other serine proteases in blood coagulation and fibrinolysis. Amidolytic methods based upon the substrates have revolutionized assays of proenzymes, enzymes, cofactors and **inhibitors** in research as well as in clinical laboratories. Like peptidomimetics based only on Arg (P1 of the natural substrate) or Arg **analogues**, these amino acid sequences also have been developed as active site directed **inhibitors** of thrombin and of **factor Xa**. A further interesting development is the synthesis of bivalent thrombin **inhibitors** which, like hirudin, bind to the thrombin active centre as well as to its anionic exosite. Recently, also, it has been shown that the positively charged side chain of P1 Arg is not an absolute necessity for binding a **peptide** to the active site of thrombin. Several of the new thrombin **inhibitors** show interesting properties for pharmaceutical development and some of them are on clinical trials.

L139 ANSWER 98 OF 100 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 1993-320447 [40] WPIDS
DOC. NO. CPI: C1993-143581
TITLE: Human factor X to human factor Xa conversion inhibition for treating thrombosis - by contacting with reagent binding sialic acid alpha-2 linked to galactose or galactosamine residues, or cleaving glycosylation moieties e.g. neuraminidase.
DERWENT CLASS: B04 D16
INVENTOR(S): SINHA, U; WILF, D L
PATENT ASSIGNEE(S): (CORT-N) COR THERAPEUTICS INC
COUNTRY COUNT: 41

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9318782	A1	19930930	(199343)*	EN	34
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE					
W: AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE US VN					
AU 9339177	A	19931011	(199407)		
EP 631501	A1	19950104	(199506)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
JP 07507769	W	19950831	(199543)		9
EP 631501	A4	19951227	(199627)		
IL 105064	A	19970415	(199736)		
AU 681074	B	19970821	(199742)		
AU 9745309	A	19980212	(199814)		
US 5798332	A	19980825	(199841)		
AU 717123	B	20000316	(200024)		
EP 631501	B1	20000830	(200042)	EN	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
US 6117836	A	20000912	(200046)		
DE 69329383	E	20001005	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9318782	A1		WO 1993-US2203	19930311
AU 9339177	A		AU 1993-39177	19930311
EP 631501	A1		EP 1993-908307	19930311
			WO 1993-US2203	19930311
JP 07507769	W		JP 1993-516612	19930311
			WO 1993-US2203	19930311
EP 631501	A4		EP 1993-908307	
IL 105064	A		IL 1993-105064	19930316
AU 681074	B		AU 1993-39177	19930311
AU 9745309	A	Div ex	AU 1993-39177	19930311
			AU 1997-45309	19971119
US 5798332	A	Cont of	US 1992-854109	19920320
			US 1994-302226	19940906
AU 717123	B	Div ex	AU 1993-39177	19930311
			AU 1997-45309	19971119
EP 631501	B1		EP 1993-908307	19930311
			WO 1993-US2203	19930311
US 6117836	A	Cont of	US 1992-854109	19920320
			WO 1993-US2203	19930311
		Div ex	US 1994-302226	19940906
			US 1994-307609	19941202
DE 69329383	E		DE 1993-629383	19930311
			EP 1993-908307	19930311
			WO 1993-US2203	19930311

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9339177	A	Based on	WO 9318782
EP 631501	A1	Based on	WO 9318782
JP 07507769	W	Based on	WO 9318782
AU 681074	B	Previous Publ.	AU 9339177
		Based on	WO 9318782
AU 717123	B	Div ex	AU 681074
		Previous Publ.	AU 9745309
EP 631501	B1	Based on	WO 9318782
US 6117836	A	Div ex	US 5798332

		Based on	WO 9318782
DE 69329333	E	Based on	EP 631511
		Based on	WO 9318782

PRIORITY APPLN. INFO: US 1992-854109 19920320; US 1994-302226 19940916; US 1994-307619 19941202

AN 1993-320447 [40] WPIDS

AB WO 9318782 A UPAB: 19931129

The inhibition comprises contacting human Factor X with a reagent capable of specifically binding sialic acid residues that are alpha2-6 linked to galactose or galactosamine residues (SA/Gal/GalNAc binding reagent) in an amt. and for a time sufficient to complex to Factor X.

The SA/Gal/GalNAc binding reagent may be pref. a lectin, e.g. Sambucus nigra agglutinin (SNA), an antibody or a peptide derived from Factor IXa/VIIIa or tissue factor/Factor VIIa.

Pref. a complex comprises a SA/Gal/GalNAc binding reagent and human Factor X.

Pref. preventing or treating (i) thrombosis, (ii) inflammation, (iii) restenosis or (iv) complications of transplantation in a human subject comprises administering a SA/Gal/GalNAc binding reagent.

Pref. **inhibition** comprises contacting human Factor X with (i) a glycosylation moieties cleavable reagent from the Factor X, or (ii) a reagent capable of binding to the glycosylation moieties of the activation **peptide** of Factor X, or (iii) soluble **analogue**(s) of SA/Gal/GalNac, and the contact is under conditions which may normally, in the absence of the soluble **analogue**, effect the conversion of Factor X to **Factor Xa**.

Pref. inhibition in a living organism comprises administering as inhibitor of glycosylation.

USE - The inhibition may be used for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin e.g. restenosis and inflammation. They may also be used for inhibition of Factor X activation in cardiopulmonary by-pass, in harvesting organs, in prepn. of blood prods. or samples, in transport and implantation of organs and in treatment of adult respiratory distress syndrome. The reagents may also be used for producing antibodies which may be used to monitor therapy.

Dwg.0/1

L139 ANSWER 99 OF 100 MEDLINE DUPLICATE 13

ACCESSION NUMBER:	90036406 MEDLINE
DOCUMENT NUMBER:	90036406 PubMed ID: 2509406
TITLE:	The inhibition of the enzymic activity of blood coagulation and fibrinolytic serine proteases by a new leupeptin-like inhibitor, and its structural analogues, isolated from Streptomyces griseus.
AUTHOR:	Chi C W; Liu H Z; Liu C Y; Chibber B A; Castellino F J
CORPORATE SOURCE:	Department of Chemistry and Biochemistry, University of Notre Dame, Indiana 46556.
CONTRACT NUMBER:	HL-13423 (NHLBI) HL-19982 (NHLBI)
SOURCE:	JOURNAL OF ANTIBIOTICS, (1989 Oct) 42 (10) 1506-12. Journal code: 0151115. ISSN: 0021-8820.
PUB. COUNTRY:	Japan
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals
ENTRY MONTH:	199912
ENTRY DATE:	Entered STN: 19900328 Last Updated on STN: 21000303 Entered Medline: 19991201

AB A group of leupeptin **analogues** was found in Streptomyces griseus strain 254, isolated from a soil sample from Fujian Province, China. The **inhibitors** excreted in the culture filtrate were purified by adsorption on macroporous resin, followed by sequential ion exchange

chromatography on DEAE-52 cellulose, CM-52 cellulose and affinity chromatography with immobilized trypsin. The preparation thus obtained was further purified by preparative HPLC. Several major components were found and characterized, which possessed different inhibitory properties toward trypsin. Based upon amino acid and mass spectrophotometric analysis, these **peptides** were placed in four major structural categories, viz., R-Val-Val-argininal, R-Leu-Leu-argininal, R-Ile-Ile-argininal and R-Thr-Thr-argininal, this latter component representing a newly identified leupeptin **analogue**. The structural variability of the R-group was partly responsible for the multiplicity of the peaks obtained with HPLC. All **peptides** displayed varying degrees of inhibitory activity toward proteases involved in blood coagulation and fibrinolysis, including plasmin, **factor Xa**, activated protein C and thrombin. Among these **peptide inhibitors**, the molecule containing threonine showed the strongest inhibitory activity.

L139 ANSWER 100 OF 100 BABS COPYRIGHT 2002 BEILSTEIN CRS MDLI
ACCESSION NUMBER: 6056113 BABS
TITLE: Peptide Argininol "Inverse Substrates" of Anisic Acid: Novel Inhibitors of the Trypsin-like Serine Proteinases
AUTHOR(S): Lynas, John F.; Walker, Brian
SOURCE: Bioorg.Med.Chem.Lett. (1997), 7(9), 1133-1138
CODEN: BMCLE8
DOCUMENT TYPE: Journal
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 6056113 BABS
AB **Peptides** containing a C-terminal argininol residue linked, via an ester bond, to anisic acid have been synthesized as putative **inhibitors** of trypsin-like serine proteinases.The most potent **analogue**, Boc-Ile-Glu-Gly-Arg-$Q-(CH2-O)-CO-C6H4OMe, that was modelled on a known recognition sequence for the clotting enzyme **factor Xa**, was found to inactivate the protease with a second-order rate constant of ca. 4.5x10-5& M--1&.min--1&.

=>